0001079973-22-001171.txt : 20220927 0001079973-22-001171.hdr.sgml : 20220927 20220927145011 ACCESSION NUMBER: 0001079973-22-001171 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BION ENVIRONMENTAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000875729 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 841176672 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19333 FILM NUMBER: 221270504 BUSINESS ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 BUSINESS PHONE: (212) 758-6622 MAIL ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 FORMER COMPANY: FORMER CONFORMED NAME: RSTS CORP DATE OF NAME CHANGE: 19930328 10-K 1 bnet_10k-063022.htm FORM 10-K
0000875729 false 2022 FY No No Yes Yes 0000875729 2021-07-01 2022-06-30 0000875729 2022-06-30 0000875729 2022-08-01 0000875729 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2020-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2020-06-30 0000875729 us-gaap:CommonStockMember 2020-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000875729 bnet:SubscriptionsReceivableMember 2020-06-30 0000875729 us-gaap:RetainedEarningsMember 2020-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2020-06-30 0000875729 2020-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2020-07-01 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 bnet:RibbonwireMember 2021-07-01 2022-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2022-06-30 0000875729 srt:MaximumMember 2022-06-30 0000875729 bnet:CenterpointMember 2022-06-30 0000875729 us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 us-gaap:WarrantMember 2020-07-01 2021-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2022-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2020-07-01 2021-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2022-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2020-07-01 2021-06-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-06-30 0000875729 bnet:BassaniMember 2021-06-30 0000875729 bnet:SmithMember 2021-06-30 0000875729 bnet:ConsultantsMember 2022-06-30 0000875729 bnet:ConsultantsMember 2021-06-30 0000875729 bnet:SmithMember 2022-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2022-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2020-07-01 2021-06-30 0000875729 bnet:PennvestLoanMember 2022-06-30 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-01 2022-06-15 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 bnet:The2020ConvertibleObligationsMember 2021-07-01 2022-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-07-01 2021-06-30 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-06-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2021-06-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2021-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2021-06-30 0000875729 bnet:September2015ConvertibleNotesMember 2021-07-01 2022-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 srt:ScenarioForecastMember srt:MinimumMember 2023-04-30 0000875729 srt:ScenarioForecastMember srt:MaximumMember 2023-04-30 0000875729 srt:ScenarioForecastMember 2023-04-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2020-07-01 2021-06-30 0000875729 srt:MinimumMember 2022-04-30 0000875729 srt:MaximumMember 2022-04-30 0000875729 srt:PresidentMember us-gaap:CommonStockMember 2021-07-01 2022-06-30 0000875729 srt:PresidentMember 2022-06-30 0000875729 us-gaap:RestrictedStockMember 2021-06-30 0000875729 us-gaap:RestrictedStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:WarrantMember 2020-07-01 2021-06-30 0000875729 us-gaap:WarrantMember 2021-06-30 0000875729 bnet:AnInvestorMember 2021-07-01 2022-06-30 0000875729 srt:PresidentMember 2020-07-01 2021-06-30 0000875729 bnet:WarrantsRelatedToTheConversionOfDeferredCompensationAndAccountsPayableIntoUnitsMember srt:PresidentMember 2021-06-30 0000875729 bnet:TwoConsultantsMember 2020-07-01 2021-06-30 0000875729 bnet:TwoConsultantsMember 2021-06-30 0000875729 bnet:SaleOfUnitsInExchangeForSalaryMember srt:PresidentMember 2020-07-01 2021-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2021-06-30 0000875729 srt:PresidentMember 2021-07-01 2022-06-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-06-30 0000875729 bnet:Plan2006Member 2022-02-01 2022-02-11 0000875729 2022-04-01 2022-04-29 0000875729 bnet:SchaferMember 2022-04-01 2022-04-29 0000875729 bnet:NorthropMember 2022-04-01 2022-04-29 0000875729 bnet:BassaniMember 2022-04-01 2022-04-29 0000875729 bnet:SmithMember 2022-04-01 2022-04-29 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000875729 us-gaap:OptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:OptionMember 2020-07-01 2021-06-30 0000875729 bnet:Project3GMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:WeightedAverageMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:WeightedAverageMember 2020-07-01 2021-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-07-01 2021-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-07-01 2021-06-30 0000875729 2019-07-01 2020-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2021-06-30 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2021-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2021-06-30 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2022-06-30 0000875729 2022-04-30 2022-05-01 0000875729 bnet:SmithMember 2021-07-01 2022-06-30 0000875729 bnet:SmithMember 2020-07-01 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember srt:ScenarioForecastMember 2023-03-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2020-07-01 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-06-30 0000875729 2022-01-01 2022-01-28 0000875729 2022-03-02 2022-03-21 0000875729 us-gaap:SubsequentEventMember 2022-07-01 2022-07-05 0000875729 2022-03-02 2022-03-23 0000875729 2022-06-01 2022-06-06 0000875729 us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0000875729 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-07-01 2022-07-31 0000875729 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2022-07-01 2022-07-31 0000875729 us-gaap:SubsequentEventMember bnet:RestrictedAndLegendedSharesMember 2022-07-01 2022-07-31 0000875729 us-gaap:SubsequentEventMember 2022-07-31 0000875729 us-gaap:SubsequentEventMember bnet:TwoNonAffiliatedPurchasersMember 2022-07-01 2022-07-31 0000875729 us-gaap:SubsequentEventMember 2022-07-01 2022-09-27 0000875729 us-gaap:SubsequentEventMember 2022-09-27 0000875729 us-gaap:SubsequentEventMember bnet:ConsultantsMember 2022-08-01 2022-08-08 0000875729 us-gaap:SubsequentEventMember bnet:ThreeEmployeesAndContractorsMember 2022-08-01 2022-08-08 0000875729 us-gaap:SubsequentEventMember bnet:NonAffilatedConsultantMember 2022-09-01 2022-09-09 0000875729 us-gaap:SubsequentEventMember 2022-09-30 0000875729 us-gaap:SubsequentEventMember 2022-08-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure bnet:Decimal

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   

 

For the Fiscal Year Ended: June 30, 2022

     
    OR
     
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   

 

For the transition period from: __________ to __________

 

 

Commission File No. 000-19333

 

BION ENVIRONMENTAL TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Colorado   84-1176672
(State or Other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification Number)

 

9 East Park Court

Old Bethpage, New York 11804

(Address of Principal Executive Offices, Including Zip Code)

 

Registrant’s Telephone Number, including area code: (516) 586-5643

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class   Name of Exchange on Which Registered
None   N/A

 

Securities Registered Pursuant to Section 12(g) of the Act:

 

Common Stock, No Par Value

(Title of Class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

  YES   NO

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

  YES   NO

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

  YES   NO

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit).

  YES   NO

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

 

 

 
 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act)

☐  YES   NO

 

The aggregate market value of the approximately 30,000,000 shares of voting stock held by non-affiliates of the Registrant as of June 30, 2022 approximated $35.5 million.  As of August 1, 2022, the Registrant had 44,120,320 shares of common stock issued and 43,416,011 shares of common stock outstanding.

 

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None

 

 

 
 

FORWARD-LOOKING STATEMENTS

 

THE RISK FACTORS BELOW ARE FURTHER HEIGHTENED BY THE COVID-19 PANDEMIC AND RESULTING ECONOMIC DOWNTURN AND OTHER RELATED CRISES AS DISCUSSED BELOW.

 

This Annual Report on Form 10-K (and the documents incorporated herein by reference) contain forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe," or "continue," or the negative thereof or variations thereon and/or references to goals, targets, projections or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect.

 

Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, the following (not set forth in any order that ranks priority or magnitude):

 

  · failure of the political, legal, regulatory and economic climate to support funding of environmental clean-up and enforcement of environmental rules and regulations;

 

  ·

changes in the public's perceptions of large scale livestock agriculture/CAFOs, consumption of meat and dairy, environmental protection and other related issues; cybercrimes/ hacking (actual and potential) of the Company’s online presence and limited operational computer systems; the Company’s <biontech.com domain was hacked/stolen during 2021 and the Company migrated to the bionenviro.com domain name. The Company initiated litigation seeking its recovery and other relief, recovered and subsequently sold the <biontech.com> domain. See Item 3 “Legal Proceedings” and Note 9 to Financial Statements, “Litigation ” ;

 

  · the Company's extremely limited financial and management resources which need to be augmented and limited ability to raise additional needed funds and/or hire needed personnel;

 

  · unsatisfactory wrap-up of the business activities of Bion PA-1 LLC (“PA1”) and/or resolution of PA-1’s negotiations with the Pennvest Infrastructure Authority (“Pennvest”) regarding PA1’s Pennvest Loan (presently in default) and the Kreider 1 System (see “Part I, Items 1 and Item 7 and “Notes to Financial Statements” below);

 

  · continued delays in (and/or failure of) development of markets (or other means of monetization) for nutrient reductions and other environmental benefits from agriculture and CAFOs and related waste treatment facilities; including failure of markets for nutrient (nitrogen and phosphorus) reductions to develop sufficient breadth and depth;

 

  · potential delays in constructing the Company’s Initial System, the Dalhart Project other Gen3Tech system installation and/or further delays in the Kreider 2 project and other potential Projects (capitalized items defined in the Item 1 narrative below);

 

  · the ability of the Company to implement its business strategy;

 

  · the extent of the Company's success in the development of of Gen3Tech joint ventures (“JVs”) and development/operation of Projects and retrofit/remediation of existing livestock facilities(“Retrofits”) and/or reaching the goals and targets set forth below, especially in light of the fact that at this date the Company has not yet developed its first Gen3Tech JV project and that the resources (CAPEX/personnel/expertise) required for development and operation of such projects will need to be sourced from outside the Company which has very limited resources in each listed category.;

 

  · dependence upon key personnel and the ability of the Company to keep its existing personnel and their accumulated expertise including the substantial risk of illness or death of one or more key personnel (most of whom are over 70 years of age and/or have existing health vulnerabilities that are exacerbated by the COVID-19 pandemic) and the need to obtain the services of additional personnel as employees and/or consultants as the Company’s business progresses;

 

  · engineering, mechanical or technological difficulties with operational equipment including potential mechanical failure or under-performance of equipment; operating variances from expectations;

 

  · the substantial capital expenditures required for the Company’s proposed JVs and development/construction of the Company's proposed Projects and facilities and the related need to fund such capital requirements through commercial banks and/or public or private securities markets;

 

  · the need to develop and re-develop technology and related applications;

 

 

1 
 

 

  · operating hazards attendant to the environmental clean-up, CAFO and renewable energy production, fertilizer and/or food retailing and biofuel industries;

 

  · seasonal and climatic conditions;

 

  · decreased availability and increased cost of material and equipment (including those caused by the COVID-19 pandemic);

 

  · the strength and financial resources of the Company's potential competitors;

 

  · general economic, Covid-19 pandemic (see Item 7. “Management's Discussion And Analysis Of Financial Condition and Results Of Operations” and Note 1 to Financial Statements, “Covid-19 pandemic related matters”) and capital market conditions;

 

  · industry risks, including environmental related problems;

 

  · delays in anticipated permit approval and/or start-up dates;

 

  · the limited liquidity of the Company's equity securities; limited availability of capital on acceptable terms for small public companies like Bion in the current financial markets; and

 

  · the Company’s limited ability to comply with current and rapidly evolving ESG (environmental, social and governance) related items to date (which is due in large part to the Company’s small size and the fact that the Company has engaged in almost no new hiring ‘in house’ during the past decade combined with the Company’s limited financial capacity and the particular industry segments in which the Company is working) may inhibit the Company’s ability to raise capital and increase its shareholder base.

 

We do not undertake and specifically disclaim any obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

 

 

2 
 

PART I

 

 

ITEM 1.  BUSINESS.

 

GENERAL

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers (and other stakeholders) through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. 

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – including primarily nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.

 

During the first half of 2022 Bion began marketing our sustainable beef opportunity to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2023, Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will treat the waste stream and recover/refine valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity, organic fertilizer and potentially other products. We anticipate converting the Ribbonwire LOI into a definitive agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors during the current fiscal year.

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

Our business plan is focused on executing multiple agreements and letters of intent related to the “Bion Beef Opportunity” and commencing development of multiple sustainable beef joint venture projects over the next twelve-eighteen (12-18) months while moving forward with the Initial Project (see below) and the Dalhart Project. Bion also intends to pursue other opportunities in the livestock industry enabled by our Gen3Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and food distribution and retail industry. We believe that this interest, combined with consumer interest in ‘sustainable products’ and the growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, provides Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.

During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2nd quarter in 2023 which will support development of the Dalhart Project (and other projects) during 2023 and thereafter.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

 

3 
 

Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation (see below and Notes to Financial Statements , ii) development/construction of the Dalhart Project, iii) developing applications and markets for its sustainable (conventional and organic) animal protein products and its low carbon organic fertilizer products , iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their harvest and production techniques, meat industry leaders have also announced their willingness to move forward with initiatives in this area. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2025) and 25% in five (5) years (end of 2027) (approximately 2,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2023. Our first commercial project is likely to be the Dalhart Project but we anticipate commencing additional sustainable beef projects during 2023 as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development/under construction during 2023 in three (3) different JVs with the initial barns being populated with livestock by fall/winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and populated by 2027-28 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

During this five (5) year period, the Company also anticipates having additional Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

4 
 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During July 2022, the Company entered into a letter of intent with Ribbonwire Ranch (Dalhart, Texas) (“Ribbonwire LOI”) setting forth the parties’ intention to negotiate a joint venture agreement (“JVA”) and enter into a joint venture (“JV”) to develop and operate an initial 15,000 head integrated, sustainable beef facility on RWR property (“Dalhart Project”) including:

 

a)innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,
b)‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,
c)a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonium bicarbonate recovery) for the production of ammonium bicarbonate fertilizer for use in organic crop production (plus residual organic solids and clean water),
d)which will produce verifiably sustainable beef products with USDA certified branding.

 

5 
 

The Dalhart Project will include expansion capability up to 60,000 head of cattle, in aggregate, located at/around/contiguous to the initial facilities on Ribbonwire property.

The opportunity presented by the Ribbonwire LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation in Dalhart, TX a reality as soon as possible.

To place the Ribbonwire LOI and the Dalhart Project in the context of Company’s business plan (and our prior public disclosure), if the contemplated venture moves forward on the timelines set forth in the Ribbonwire LOI, active development of the Dalhart Project will commence early in the second quarter of 2023.

 

Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the Dalhart Project). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site targeted to commence during January 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart Project.

 

As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until sometime during January 2023. 3G1 has been moving forward with the development process of the Initial Project. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2023 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

 

6 
 

Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

i.Proof of Gen3Tech platform scalability

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

ii.   Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

iii.Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

iv.Produce sustainable beef products for initial test marketing efforts.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($665,375)) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced Gen3Tech Initial Project. This Purchase Order encompasses the core of Bion’s Gen3Technology.

 

On March 21, 2022 the Company received progress notice re completion of certain work in process and an invoice from Buflovak for the next 25% payment ($665,375) which was paid during the 2022 fiscal year. On June 6, 2022, the Company received progress notice re completion of certain work in process and an invoice from Buflovak for the third 25% payment ($665,375) which was paid on July 5, 2022 bringing the aggregate payments to $1,996,125 as of the date of this report.  Buflovak has worked with the Company on design and testing of its Gen3Tech over several years. 3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.

 

The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our solid ammonium bicarbonate fertilizer product line), Bion expects to be ready to move forward with its plans for development of much larger facilities including the Dalhart Project including final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-12 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility will include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project. 

 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food & Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which is likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Organic Fertilizer Listing/Certification Process” below.

 

 

7 
 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers is choosing seemingly sustainable food product offerings, and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Gen3Tech Beef Business Model

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and initially enjoyed steady sales growth until sales began flattening over the past 12-18 months. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence) plus a patina of initiatives invoking the vague term ‘regenerative’ agriculture. However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, segment which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad technical and economic challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost and timeline for availability remain very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium verifiably sustainable beef products that address these consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or sustainable organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, while providing the superior taste and texture those consumers have grown to prefer.

 

While the beef industry has largely continued historic practices, the dairy industry has housed milk cows in barns and has been processing cow waste through anaerobic digesters (ADs) to generate energy for years. In recent years the renewable biogas (RNG) from the dairy ADs  has become increasingly lucrative due to related environmental credits .

 

 

8 
 

 

Bion‘s sustainable beef business model, based on our Gen3Tech platform, will develop and operate large scale facilities that: a) utilize custom designed barns which enable a more controlled and monitored husbandry environment (and photovoltaic solar electricity generation utilizing the rooftops), b) with continual manure transfer to ADs, c) which produce RNG and related environmental revenues, and d) then channel the AD waste (including CO2 recovered from the RNG processing/cleanup) through a series of patented technologies to refine the waste into its various components. The diagram below depicts a simplified facility schematic/flow chart:

 

 

This overall business model unites several interrelated businesses driven by Bion’s technology and augments and aggregates multiple revenue streams as described below. See “Technology and Technology Platform” below for descriptions of the 4 major categories of products/revenue streams which Bion anticipates from its Gen3Tech beef facilities: a) premium ‘sustainable branded’ beef, b) renewable energy and energy/environmental/carbon-related credits, c) organic fertilizer products and d) nutrient credits.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water and air, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility (see diagram above) will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss to the atmosphere, as well as odors, thereby improving animal health and human working conditions while preventing air/soil/water pollution. The manure will be collected and moved directly to customized anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

Waste treatment and resource recovery will be provided by Bion’s Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

 

9 
 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their harvest and production techniques, meat industry leaders have also announced their willingness to move forward with initiatives in this area. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2025) and 25% in five (5) years (end of 2027) (approximately 2,000,000 cattle annually). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2023. Our first commercial project is likely to be the Dalhart Project but we anticipate commencing additional sustainable beef projects during 2023 as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development/under construction during 2023 in three (3) different JVs with the initial barns being populated with livestock by fall/winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules -- with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3%% of the US beef market) and 30-45 Modules constructed and populated by 2027-28 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

Some portion of which sustainable beef will likely be organic (see below).

 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

10 
 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year. 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Organic Fertilizer Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021), the Iowa Organic Program (“IOP”)(filed during March 2022) and the California Department of Food & Agriculture (“CDFA”)(filed during May 2022) and are each in the review process. The review processes are requiring extended periods of time and multiple procedural steps with each entity in part due to the novel nature of Bion’s Gen3Tech and our solid ammonium bicarbonate product in the context of organic certifications. The OMRI application has proceeded through multiple stages of review and rebuttal/appeal without receiving a positive result to date. The Company anticipates has recently filed a new appeal to the most recent determinations. The Company’s CDFA has received initial comments regarding our solid ammonium bicarbonate product line and we anticipate providing CDFA with the requested updated information and clarifications during the next 60 days. The Company’s product line is novel in part due to the fact that there is not a formal listing category for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this matter with one or more listings/certifications of this product line well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

 

11 
 

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates that if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’. The Covid-19 pandemic has delayed legislative efforts in Pennsylvania needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.

 

 

12 
 

Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

 

13 
 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Technology and Technology Platform 

 

Bion has invested decades of work and substantial capital on the development of our technology and technology platform since 1989. The predecessor to Bion’s Gen3Tech platform, our patented second-generation technology (“2G Tech”), was proven at commercial scale and was reviewed and qualified for federal loan guarantees under USDA’s Technical Assessment program. Bion’s 2G Tech dairy project (“Kreider 1” or “KF1”), located at Kreider Farms in Pennsylvania (“PA”) received the first verified /measurable nutrient reduction credits from a non-point source livestock facility in the U.S. and its nutrient reductions were verified by the Pennsylvania Department of Environmental Protection (“DEP”) during 2012.

 

 

14 
 

A key attribute of Bion’s 2G Tech (now supplanted by our Gen3Tech) was that nutrient and other pollution reductions could be measured, providing a level of verification on par with a municipal wastewater treatment plant, which created the opportunity for the nutrient reductions to be used as “qualified offsets” to EPA-mandated requirements. While it was an engineering success, Kreider 1 has failed financially because the 2G Tech platform was almost wholly dependent for revenue from anticipated demand for nutrient credits, based on PA’s mandated nitrogen reductions under the Chesapeake Bay Strategy and their proposed nutrient trading program that did not materialize. Bion began development of its Gen3Tech platform when it became apparent there was significant opposition to the trading program (and private sector participation in clean water activities, generally) from entrenched clean water interests. The Company is no longer implementing Projects based on its 2G Tech and the Kreider 1 project has been shut down.

 

Bion’s Gen3Tech was developed to avoid the dependence of our 2G Tech systems on the sale of water quality trading credits in order to develop profitable projects. The Gen3Tech platform has been designed to maximize revenues from co-products, including biogas and fertilizer products, achieve premium pricing from USDA PVP-certified ‘environmentally sustainable’ retail branding of the animal protein products it supports, as well as generate verified credits for still-developing water quality trading programs. The first patent on the Gen3Tech was filed in 2015 for an ammonia recovery process that produces ammonium bicarbonate (a commercial fertilizer) without external chemical additives, thereby providing the basis for organic certification. A Notice of Allowance from the US Patent and Trademark Office (“USPTO”) was received during August 2018 related to this patent application and the patent was subsequently issued. Since July 2017 Bion has filed for extensions of this patent application to provide broadened protections and to cover improvements to the process developed in the interim. During August 2020 the Company received a Notice of Allowance’ for our third patent related to our Gen3Tech and additional related applications are pending and/or planned (See “Patents”.) The Gen3Tech platform incorporates Bion’s patented and proprietary technology while utilizing existing commercial evaporation and distillation process equipment (with decades of reliability and service history) that is customized for Bion’s specific applications.

 

Gen3Tech Platform 

 

Our Gen3Tech platform is the basis for a JV business model with four primary distinct revenue streams: 1) pipeline quality renewable natural gas and related carbon and other environmental credits, 2) premium organic fertilizer products, 3) nutrient reduction credits, and 4) premium pricing/license fees for verifiably sustainable, USDA PVP-certified ‘Environmentally Sustainable’ branded meat at the retail level. Carbon and nutrient credit revenues will be supported by third-party verification of the waste treatment processes that simultaneously capture methane and nutrients, while producing renewable energy and fertilizer products from them with relatively limited incremental cost to Bion. The same verified data will also provide the backbone for the USDA PVP-certified sustainable brand, again with limited incremental cost.

 

  1) Renewable energy- and carbon-related credits:

 

Bion’s Gen3Tech platform utilizes anaerobic digestion (“AD”) customized to maximize recovery of biogas (methane) (and ammonia nitrogen components) from the waste stream. At sufficient scale, methane produced from AD can be cost-effectively conditioned/cleaned, compressed and injected into a pipeline. The US Renewable Fuel Standard (“RFS”) program and state programs in California and elsewhere provide ongoing renewable energy credits for the production of biogas and its subsequent use as a renewable transportation fuel. The CO2 recovered in the gas cleaning process will be recycled for use in the production of organic fertilizer products along with the ammonia-rich digestate. Gen3Tech facilities will also generate photovoltaic (solar) electricity from modules placed on the roofs of the barns (approximately 12 acres of rooftop per 15,000 head of cattle module). Additional renewable energy-related credit programs are being developed that Bion believes will impact these revenues, including a Carbon Intensity (CI) score that measures the amount of carbon produced per unit of energy produced.

 

  2) Organic Fertilizer products:

 

The Gen3Tech platform has been designed to produce multiple fertilizer products from the ammonia-rich digestate, including: i) ammonium bicarbonate liquid, ii) ammonium bicarbonate in solid crystal form and iii) soil amendment products that will contain the remaining nitrogen, phosphorus and other micronutrients captured from the livestock waste stream. Bion believes each product will qualify for organic certification. The Company has filed an application the initial version of its crystal product which is in the review process. Additional applications may be filed in subsequent periods.

 

Ammonium bicarbonate, manufactured using chemical processes, has a long history of use as a fertilizer. Bion’s Gen3Tech recovers solid ammonium bicarbonate products containing 18-22 percent nitrogen in a crystalline form that is easily transported, is water soluble and provides a readily available nitrogen source for crops. This product line will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

 

15 
 

The ammonium bicarbonate products produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic fertilizers. The reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Analysis (LCA) of carbon impacts from synthetic fertilizer production is not available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid.

 

The Company’s initial low concentration ammonium bicarbonate liquid product completed its OMRI application and review process with approval during May 2020. Applications to OMRI, the California Department of Food and Agriculture (“CDFA”) and the Iowa Organic Program have been filed by the Company for its initial solid concentrated ammonium bicarbonate nitrogen and are currently being reviewed.

 

To provide a first level degree of clarity regarding organic approvals and the processes/procedures involved, Bion believes that the initial OMRI approval is of importance, because our solid organic products are produced by using the very same technology platform (our Gen3Tech). Note that there are different layers to the U.S. organic program and that fertilizers do not get ‘certified’ as organic, per se. Rather, they are evaluated to determine if they are acceptable for ‘use in organic production’.

 

The National Organic Program (“NOP”) was established by Congress in 2001 under the USDA’s Agricultural Marketing Service. The NOP develops and enforces uniform national standards for organically-produced agricultural end products – meat/dairy/milk, fruits, vegetables – sold in the United States. Operating as a public-private partnership, NOP accredits private companies and helps train their inspectors (USDA-accredited Certifiers) to certify that farms and businesses meet the national organic standards. For example, in a potential Midwest organic beef project, each element in the supply chain must provide their certifying agent’s certification that the specific product, such as organic corn, has been produced in accordance with their organic plan. The end product - the beef - would be USDA-certified as organic by an accredited Certifier after a review of ALL the farming practices and inputs (which would include Bion’s ammonium bicarbonate fertilizer).

 

OMRI enables a national listing thru one application versus the alternative of using certifiers to secure listings in individual states and regions. To those who wish to sell organic fertilizers into national distribution channels, an OMRI listing provides nearly uniform acceptance in the U.S. The OMRI listing Bion received in May was for our initial commercial product, a low-concentration liquid ammonia. It is valid ONLY for that particular product. For future Bion product offerings using the same technology platform, Bion will either need to file for specific state approval, or file for a national listing, or a combination of the two. Bion may elect to use an individual state listing initially to be followed by an OMRI application if and when the need for a regional or national listing arises.

 

The overarching standard of organic production, per NOP guidelines, is that a “product shall have been produced and handled without the use of synthetic chemicals…” That is rule Number One. At NOP, the term "synthetic" means “a substance that is formulated or manufactured by a chemical process or by a process that chemically changes a substance extracted from naturally occurring plant, animal, or mineral sources, except that such term shall not apply to substances created by naturally occurring biological processes.” In evaluating and approving Bion’s liquid ammonia for OMRI listing, Bion’s patented ammonia recovery system was not deemed synthetic. That is an important distinction for future Bion product filings based upon the same patented process.

 

The Company believes that organic approvals for its products will: a) provide access to substantially higher value markets compared to synthetic nitrogen products, and/or b) allow its products to be utilized in growing of organic feed grains to be consumed by livestock raised in JVs which will be sold as organic. Based on preliminary market surveys to date, we believe that existing competing organic fertilizer products in both liquid and granular form are being sold presently at price points significantly greater than Bion’s projected cost and projected pricing. We also believe that livestock products from animals raised with feed grains grown using Bion organic ammonium bicarbonate fertilizer products (and that otherwise qualify) will receive organic approvals. It is anticipated that the Company will continue to seek approvals for such products during the balance of the current fiscal year and will commence JVs that undertake initial production and marketing of such products during the 2023 calendar year.

 

 

16 
 

 

  3) Nutrient credits:

 

Bion believes that nutrient reduction (and other similar) credits and/or other methods of monetizing environmental benefits from the capture and re-purposing of the nutrients (largely nitrogen and phosphorus) from the livestock waste stream, will become available in multiple states over the next several years. The passage in the Pennsylvania (“PA”) Senate of key legislation – SB 575 – in June 2019 that would have established a competitively-bid market for nutrient credits in PA, is indicative of the trends. Despite the fact that the bill was not considered in the House, due to the Covid-19 pandemic (a re-introduced bill will have to be considered again in the current and/or future sessions, Bion anticipates that after passage of a similar bill in the future, PA will establish a competitively-bid market for nutrient credits within twelve months after legislative passage and being signed into law by the Governor. See “Policy Change is Coming” and “Kreider Poultry Joint Venture and Pennsylvania and Chesapeake Bay Initiatives” below for discussion of the history and status of matters in PA.

 

Note, however, that the Covid-19 pandemic and resultant social and economic crises and budgetary constraints have delayed policy initiatives related to these matters at both the state and federal levels. As a result, it is not currently possible to reasonably project a timetable for adoption of the policy changes discussed herein.

 

  4) Sustainable Branding:

 

Consumers have demonstrated a willingness to pay a premium for their safe and sustainable food choices. Based on Bion’s recognition of the potential opportunities created by such willingness, beginning in 2015, Bion worked with the USDA’s Process Verified Program (“PVP”) – the ‘gold standard’ in food verification and branding – to establish a USDA PVP-certified sustainable brand. Bion received conditional approval from the PVP related to its Kreider 1 project (utilizing 2G Tech). It is our intention to submit an application for the Gen3Tech platform when the initial Gen3Tech Project is operational and seek an approval for certification based on third-party-verified reductions in nutrient impacts, greenhouse gases and pathogens in the waste stream (and other attributes), based on our Gen3Tech platform. PVP certification incorporated as part of a recognizable brand (together with point-of-sale information) will provide consumers with products and brands that can be trusted. Bion believes that such a brand and livestock product line will command a pricing premium for Bion’s livestock JVs and their customers.

 

Food safety and sustainability are issues of growing importance in the U.S. and worldwide. Bion’s branding initiative reflects trends already underway in the livestock industry. Driven by growing consumer demand, large food retailers (such as Walmart and Costco) and restaurant chains (including Chipotle and McDonalds) are increasingly demanding greater responsibility and improved sustainability in food production practices from their suppliers. The Global Roundtable for Sustainable Beef (“Roundtable”) was created to advance a sustainable global beef value chain that is “environmentally sound, socially responsible and economically viable”. The Roundtable represents members from across the supply chain, including U.S., Canadian and Australian cattlemen’s associations, Cargill, JBS, Elanco, McDonalds and A&W.

 

Large institutional investors have begun to pressure the livestock industry. Ceres and several other large activist institutional investors have already expressed concerns about carbon footprint, water quality, antibiotic usage and animal welfare in letters to management of their investment holdings in the food production industry. The Collier Farm Animal Investment Risk & Return (“FAIRR”) Initiative was recently launched to highlight the environmental, social, and governance (“ESG”) risks associated with large-scale livestock production.

 

In past years, the UN FAO has issued several highly critical reports of the livestock industry, more recently focused on its impacts on climate change. While some of their early reports were based on incomplete data and faulty methodologies and have since been somewhat quietly ‘retracted’, a wide array of activist groups, including climate, animal rights, and anti-factory farming advocates, have seized on them to create a global “anti-meat” messaging campaign. Their messaging is predicated on the (incorrect) notion that agriculture, and the livestock sector specifically, is the largest contributor to climate change, greater than the energy and transportation sectors. While this fact has been publicly ‘debunked’, the anti-meat campaign has been joined and amplified by various other stakeholders, governments, and more recently, competitors in the alternative protein space, such as plant-based and cellular meats.

 

Over the last few years, most large meat and dairy product retailers have announced ‘sustainability’ initiatives, although the definition of sustainability is often unclear. Based on recent statements from the industry regarding sustainability policy, many that identify goals that are 10 to 30 years in the future, Bion believes that sustainability on the production side will look a lot like what the Company’s Gen3Tech platform can provide today. The Gen3Tech platform can deliver verifiable metrics that demonstrate meaningful improvements in sustainability for livestock production that are unmatched in the industry today, including a dramatically reduced carbon and nutrient footprint; lower negative impacts to water, soil and air; increased pathogen destruction; and other environmental and public health impacts. The Covid-19 pandemic has further heightened consumer awareness and concerns related to a) environmental sustainability, b) food safety, c) sourcing and traceability and d) humane treatment of both animals and workers.

 

 

17 
 

The more the livestock industry’s supply chain practices become transparent and known by consumers, the more consumers are seeking alternatives. Bion’s ‘Sustainable’ branding program is designed to address a wide array of consumer concerns including: a) ‘where does your food come from?’ (animal heritage information); b) climate change (carbon) and other key environmental impacts (air/water/soil); c) antibiotic use/ standards; d) animal welfare/ humane treatment; e) laborer welfare/ working conditions. These issues can be addressed with the consumer through general advertising and/or at the point of sale with a QR code on the packaging that links back to product-specific data. The verification processes that will be employed by Bion’s Gen3Tech platform support block chain traceability, providing accountability throughout that part of the supply chain addressed by Bion’s platform and enabling any quality issues to be quickly identified by lot and location, minimizing risk to its consumers. In essence, Bion’s comprehensive technology platform will enable its livestock JVs and other adopters to be not only the provider of the product the consumer wants, but also the businesses that shares their consumers’ values.

 

Technology Applications/Business Opportunities

 

For the past decade, Bion has been focused on developing its Gen3Tech platform and creating applications for its patented and proprietary waste management technology platform to pursue JVs and other business opportunities in three broad categories:

 

a)       Development of new state-of-the-art large scale waste treatment facilities (now utilizing our Gen3Tech) as JVs (or through other contractual arrangements and licensing), which may be developed in conjunction with new CAFOs in strategic locations (some of which were previously impracticable due to environmental impacts) and/or to treat the waste streams from one or more existing large livestock facilities (“Projects”). Some of these Projects may be either a) Integrated Projects as described below, b) ‘central processing facilities’ which receive the waste from multiple livestock facilities, c) Retrofit Projects or d) hybrids with elements of each of these types. Each version will be able to realize revenue from multiple revenue streams potentially generated by our Gen3Tech.

The “Sustainable Beef” and “Sustainable Organic Beef” opportunities (discussed both above and below) would be examples of this category. Bion anticipates that some of our Gen3Tech projects will involve swine and poultry. Some Projects may be international.

 

b)       Installation of Bion systems to retrofit and environmentally remediate existing large CAFOs (“Retrofits” and “Retrofit Projects”) in selected markets where:

 

a) government policy supports such efforts (such as the Chesapeake Bay watershed, Great Lakes Basin states, and/or other states and watersheds facing EPA ‘total maximum daily load’ (“TMDL”) issues), and/or

b) where CAFO’s need our technology to obtain permits to expand or develop without negative environmental consequences.

The Kreider Poultry JV project (“Kreider 2” or Kreider Poultry”) (discussed below) is an example of such a Retrofit Project.

c)    Licensing and/or joint venturing of Bion’s technology and applications, primarily targeted outside North America.

 

In both categories a) and b) above, the Company intends to directly participate (whether by joint venture agreement or other contractual arrangements) in the revenues of the Retrofits and Projects.

 

The opportunities described in categories a) and b) above each require substantial political and regulatory (federal, state and local) efforts on the part of the Company and a substantial part of Bion’s efforts are focused on such political and regulatory matters. Bion currently intends to pursue the international opportunities primarily through the use of consultants with existing relationships in target countries.

 

At this time, our primary focus is on categories a) and b) above, using our Gen3Tech to develop new (or expanded) large-scale Projects with strategic partners (including the Kreider 2 Project) on a joint venture (or other participating contractual form) basis. Bion’s business model opens up the opportunity for JVs in various forms, based upon the revenue generated by our Gen3Tech platform from nutrient reductions, fertilizer co-products and renewable natural gas (which revenue streams will be secured through long term take-off agreements for each of these co-products) providing initial support for financing of required capital expenditures (whether equity or debt). We anticipate that these revenue streams will be supplemented by revenue realized from long-term premium pricing resulting from the sustainable branding opportunity. We believe that, over time, the branding opportunity may provide the single largest contribution to the overall economic opportunity enabled by Bion’s Gen3Tech platform and business model.

 

 

18 
 

Initial Project: Gen3Tech Demonstration Facility

 

During the 2021 fiscal year, Bion completed a series of core optimization trials of its Gen3Tech platform that were required to move forward with its initial commercial scale Gen3Tech project. See discussion of the Initial Project above.

 

Sustainable/Organic Corn-Finished Beef Opportunity

 

The Dalhart Project discussed above is the first Bion Gen3Tech project in this category.

 

The U.S. is the largest producer of beef (and veal) in the world, accounting for 11.5 million tons out of 61.5 million tons produced worldwide in 2020. Per capita beef consumption in the U.S. was approximately 70 pounds in 2020, up from 55 pounds in 2011. Annual cash receipts for all U.S. ‘cattle and calves’ were lower at approximately $62 billion in 2020, with 2021 receipts anticipated to be higher (and back in line with recent years) at $66 billion. Retail sales of fresh beef in the U.S. in 2020 were $30.2 billion. In 2020, there were approximately 93.8 million cattle and calves in the U.S., with 14.7 million on feed. Of those cattle on feed, 81.4 percent were in feedlots with a capacity over 1,000 head.

 

Beef production is the most challenged sector of the livestock industry, due to its size and inability, as currently structured, to respond to growing consumer concerns related to sustainability and food safety. The beef industry is highly fragmented, and it is designed to produce multiple levels of commodity products (without any significant pricing premiums) that are graded based on marbling (fat) that determines taste and tenderness. Further, during its several decades of growth, the industry has avoided significant environmental regulation, and instead, has externalized its environmental costs by returning its waste to crop fields, where much of it is ‘flushed’ downstream. Today, however, consumer demand is shifting to products that are more sustainable, regarding carbon footprint, impacts to air and water, and other metrics. The result has been an opening for disruptive startups, including Beyond Meat and Impossible Foods, that are backed by large institutional investors and offer plant-based (in part) meat substitutes. The CEO of Impossible Foods has made bold claims that the $100B-plus (U.S. alone) meat industry will be obsolete in 15 years. Bion disagrees --- but such competition provides and highlights opportunities for us.

 

The Company doesn’t think the consumer wants to ‘blow up’ the beef industry, which is responsible for the best and safest beef available in the world today (as well as the livelihoods of almost 800,000 farming, ranching and other families supported by the beef industry in the U.S). Nor do market studies bear out the concept that consumers want to replace the current supply chain. Rather, the studies indicate that consumers want the supply chain to be more sustainable---and still taste good. Bion believes that strong demand exists for a verified sustainable beef product that is real meat, with the taste and texture of traditional corn-fed beef, but which addresses consumers’ sustainability concerns. Bion’s technology platform is designed to produce such an environmentally sustainable beef (and other meat) product. Bion previously achieved conditional approval (for its 2G Tech pending resubmission and final inspections) for USDA brand certification that would initially include verified reductions in carbon, nutrients, and pathogens. The Company is confident that its Gen3Tech will support a PVP brand for products of sustainable and organic beef JVs.

 

Market studies indicate there is potentially a large, currently unserved, market for sustainable/organic corn-finished beef; and further, that this is a long term and growing trend. Bion believes its 30 years of experience and expertise in livestock waste management, coupled with its state-of-the-art Gen3Tech platform and first-mover advantage, put the Company and its selected JV partners in a unique position to develop the most environmentally and economically sustainable animal protein production facilities possible today. The Company is unaware of any other technology and/or business model that can offer the same level of comprehensive treatment of livestock waste, produce high value coproducts, and deliver a sustainable brand that can provide an industry response to counter today’s anti-meat messaging, along with the inroads in the animal protein market being made by alternative protein competitors.

 

‘Sustainable’ and ‘organic’ are two separate and distinct designations and represent different markets and consumers. While the markets and consumer demographics may overlap, it is assumed for purposes of Bion’s analysis and planning that the market for sustainable beef will be larger but command a smaller pricing premium; while the market for organic will be smaller but command a substantially larger premium and be somewhat costlier to produce. Note that in the sustainable and organic markets targeted by Bion, ‘corn-finished’ is a constant. Bion believes, and the market has demonstrated, that delivering the same taste and texture that consumers expect in American beef and other meat products is a key to successful market acceptance, within both the sustainable and sustainable organic markets. The success of grass-fed/organic ground beef vs that of grass-fed/organic steaks demonstrates that palatability, as well as price, is a key criterion in whether a consumer chooses sustainability. Bion’s Gen3Tech platform supports production of beef products that check all the boxes: sustainable, expected taste/texture, and affordable.

 

 

 

19 
 

Bion believes there is an opportunity, without the need to ‘reinvent’ the beef production supply chain, to provide at least a premium segment of the market with an affordable product that satisfies consumers’ sustainability concerns. Further, we believe that the opportunity is large in scope and of sufficient duration and potential economic upside to warrant the investment of significant capital and resources. Our anticipated project development timeline can potentially allow us and our JV partners to be first to market with a sustainable/organic beef product at scale. The ability to deliver a large supply of a consistent product will be critical to the large retail distribution partners Bion will seek to include in its JVs. Our first-mover advantage should allow us to capture a significant portion of the early adopters in what market studies indicate is a potentially large, and essentially unserved, market.

 

In parallel with the beef demonstration project described above, we continue to move forward with preliminary pre-development work on a JV to build a large-scale state-of-the-art beef cattle feeding operations in the Midwest U.S. Such projects will be developed to produce a supply of corn-fed beef that is a mixture of both USDA PVP-certified sustainable and sustainable-organic brands. The Ribbonwire LOI and Dalhart Project (discussed above), representing the first fruition of this initiative, will most likely be our first large scale sustainable/organic beef JV with development commencing during the 2023 calendar year.

 

Bion intends to pursue its ‘beef opportunity’ in a series of large-scale JV projects, which will be based on construction of modules housing approximately 15,000 head each, for differing aggregate totals depending on multiple geographic and economic factors. Bion anticipates that these JVs would be comprised of parties that could include a) Bion, b) capital market/financing providers, and c) strategic industry partners who would be equity participants and/or offtake customers for the products of the ventures. The supply chain for each JV would vary and might include participating a) organic corn producers, b) cow-calf operators, c) cattle feedlot operators, d) slaughter/processing plants, and e) retail distribution partners--- each subject to negotiated standards and controls. Bion’s model will potentially enable segment of the supply chain to generate greater profitability as part of an integrated program, rather than the present fragmented industry model, for essentially performing the same basic services. One example of such synergies/integration might involve providing an organic corn producer with sufficient ammonium bicarbonate fertilizer to support a higher yield per acre, in return for a share of the excess yield value and a production purchase commitment.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verifying, and sustainability technologies in other perishable categories like produce and dairy due to their harvest and production techniques, meat industry leaders have announced their willingness to move forward with initiatives in this area. Bion predicts that within five years, consumers will be able to track and verify claims including sustainability on 25% of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % in three (3) years (end of 2025) and 25% in five (5) years (end of 2027) (approximately 2,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that of the market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2023. Our first commercial project is likely to be the Dalhart Project but we anticipate commencing additional sustainable beef projects during 2023 as well. Our current target is to have at least three (3) 15,000 head modules (“Modules”) in development/under construction during 2023 in three (3) different JVs with the initial barns being populated by winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process -- each of which JVs will be pursuing development of multiple Modules -- with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and populated by 2027-28 (approximately 6%-8% of the US beef market) with further expansion thereafter. During this period, Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

Retrofit Gen3Tech Project: Kreider Poultry JV (“Kreider 2”)

 

The JV Kreider 2 Gen3Tech project is intended to treat the waste from Kreider Farms’ approximately six million egg layer chickens (with capacity for an additional three million layers)(and potentially 1,600 dairy cows). The Project will be designed for an initial capacity of 450 tons per day of waste and will remove nitrogen and phosphorus from the waste stream that will be converted into high-value coproducts instead of polluting local and downstream waters. The Project is planned to be built in multiple phases and may be expanded to include a ‘central processing facility’ with modules that will accept transported waste from the region on a fee basis.

 

Bion has a long-standing relationship with Kreider Farms, including a 2016 joint venture agreement related to these potential facilities. Kreider has already made a significant investment in upgrading its poultry facilities to maximize the treatment and recovery efficiencies that can be achieved with Bion’s technology. Note, however, that the Kreider 2 project is dependent, in part, on development of a substantial competitively-bid market for long-term commercial sale of the nutrient reduction credits produced at Kreider 2 (or another form of payment for ecosystem services). If/when a viable competitive procurement program for nutrient credits or similar program is implemented in PA, we intend to move forward on the development of the initial portions of the Kreider 2 Project during the subsequent year. Certain matters related to Kreider 2 are discussed at “Kreider Poultry Joint Venture and Pennsylvania and Chesapeake Bay Initiatives”.

 

Policy Change is Coming

 

Because Bion believes that policy change is coming, we continue to work with an array of stakeholders, including national representatives of the livestock industry, to support establishing new market driven strategies to allow the private sector, including the livestock industry, to provide low-cost large-scale verifiable solutions to our Nation’s clean water challenges. There are many states that face similar (or worse) to Pennsylvania’s livestock waste-related pollution issues, and they will be forced to adopt new strategies, as well. When competitively-bid markets for nutrient reductions (and/or other means to monetize environmental benefits) become fully established, Bion anticipates a robust opportunity to use its Gen3Tech-based platforms to retrofit both existing CAFOs and equip new large-scale livestock facilities (“Projects”) which will generate the supplemental revenue needed to profitably afford technology implementation from sales of verified nutrient reduction credits.

 

 

20 
 

Bion's Gen3Tech can provide a solution to a significant portion to the livestock problem discussed above because it prevents the uncontrolled release to the environment of most of the nutrients from the CAFO waste stream, while treating the waste stream and recovering a substantial portion of those nutrients for value-added commercial utilization. Our technology platform largely eliminates ammonia emissions, other substantial greenhouse gas emissions, odors and other harmful air pollutants. Additionally, the platform destroys virtually all pathogens in the waste stream that have been linked to foodborne illnesses and growing antibiotic resistance. Similar to point-source treatment, such as provided by an industrial or municipal wastewater treatment plants, the performance of Bion’s technology platform can be precisely monitored, measured and quantified (in contrast to the modeled, in-exact - and so far, disappointing - results from modeled BMPs). Third-party data from our facilities can provide the basis for verified environmental credits, and related revenues, as well as sustainable branding claims.

 

In contrast, the current clean water strategy being utilized in the U.S. is clearly failing, because it doesn’t adequately address waste from agriculture. About half of U.S. crops are now fertilized with raw, untreated manure. However, approximately 75 percent of the nitrogen in that manure is not utilized by the plants being fertilized but rather ‘escapes’ to contaminate the environment through various pathways. Because livestock waste is one of the largest contributors to nutrient problems in our watersheds, livestock waste treatment can be the source of the low-cost solution for such problems – if the waste is treated upstream at (or close to) the source of production. Manure control technologies, applied to large scale facilities where concentration and scale enable cost-effective cleanup, can potentially offer the lowest cost nutrient solutions available in most watersheds today. More than 80 percent of U.S. livestock production takes place on large-scale facilities, where cost-effective treatment can be implemented. There is no longer any real question regarding whether such facilities need to be cleaned up. The actual question for public policy concerns developing sources of new revenues which will enable the livestock industry to offset the implementation costs for the cleanup.

 

Despite trends toward concentration in segments over the last several decades, the U.S. animal-protein industry remains (in large part) a fragmented, low-margin commodity business without effective integrated efforts toward either environmentally or economically sustainable production. Cleaning it up will have to be orderly and contain a path to sustainability that does not cause U.S. food costs to spike or bankrupt the industry. This will require treatment sufficient to remove the volume of nutrients in excess of crop requirements. Because the global export market represents a significant part of the U.S. livestock production industry, direct increases in federal regulation without offsetting revenues would likely create costs that could not be absorbed by the industry in a manner that would allow it to remain competitive in international markets. Selective state regulation would have a similar chilling effect within the U.S., since regulated producers in one state would be unable to compete with unregulated producers in adjoining states. Subsidies and/or new revenue sources are required.

 

Bion believes that reallocating some part of the approximately $110 billion in existing U.S. taxpayer-funded clean water spending to lower-cost alternative solutions in agriculture (including competitively-bid nutrient reduction procurement) is inevitable. It will provide the taxpayer with accelerated and substantially lower-cost verified air and water quality solutions compared to current strategy. If Bion’s technology is implemented in appropriate situations, it will provide the livestock industry with the recurring revenues that are needed to offset the costs of technology adoption without major disruption to the industry. To date, a wide range of entrenched interests have opposed and fought policy change that might reallocate clean water spending to more cost-effective alternatives; but this common-sense approach is being accepted by a widening group of stakeholders.

 

NOTE, THAT THE COVID-19 PANDEMIC AND RESULTANT ECONOMIC CRISES AND BUDGETARY CONSTRAINTS APPEAR TO HAVE DELAYED POLICY INITIATIVES RELATED TO THESE MATTERS AT BOTH THE STATE AND FEDERAL LEVELS. AS A RESULT, IT IS NOT CURRENTLY POSSIBLE TO REASONABLY PROJECT A TIMETABLE FOR ADOPTION OF THE POLICY CHANGES DISCUSSED HEREIN.

 

However, Bion believes that some opportunity exists at the federal level in the projected infrastructure spending to create funding for climate and environmental initiatives. For example, the recently passed Inflation Reduction Act includes provisions that may provide up to a 30% federal tax credit to partially offset costs of adoption of environmental technologies such as AD and Bion’s Gen3Tech waste treatment technology. Such an incentive, if available (of which there is no assurance), would materially impact JV project economics (including the Dalhart Project and the Kreider 2 project).

 

Note that a bipartisan 2013 Pennsylvania legislative study projected that creating a competitive bidding program to procure verified nitrogen reductions to meet federal Chesapeake Bay mandates, regardless of source, could reduce the state’s tax- and ratepayer-funded compliance costs by up to 80 percent (approximately $1.5B annually). The legislative study was updated in 2018 to reflect new policies. The updated report projects savings of up to 90 percent. As discussed in the original study, much of the savings were due to low-cost high-impact manure control projects (Bion’s technology figured prominently in the report).  Senate Bill 575, which was supported by legislative leadership, national livestock interests and other key stakeholders (and is consistent with US EPA policies), which would have established a competitive procurement program and unlock some of these opportunities in PA was passed during June 2019 by the Pennsylvania Senate voted 33 to 17 but one effect of the Covid-19 pandemic crisis has been that PA funding for new initiatives is largely ‘on hold’ at the present time. Bion anticipates that after passage of a similar bill in the future (of which there is no assurance), PA will establish a competitively-bid market for nutrient credits within twelve months after legislative passage and being signed into law by the Governor. See “Pre-Gen3Tech: Chesapeake Bay Watershed: Kreider Farms Projects/Pennsylvania Initiatives” below for discussion of the history and status of matters in PA.

 

 

21 
 

In a 2017 Letter of Expectation to PA’s Department of Environmental Protection, US EPA demonstrated its support of a procurement strategy to engage the private sector - as long as the Credits are verified. It is noteworthy that US EPA and national livestock industry representatives agree on this strategy. Such a procurement strategy is also consistent with USDA and EPA support of ‘Private Partnerships’ and OMB’s guidance that supports acquiring verified results vs. financing projects with uncertain outcomes and taxpayer risks. We believe that such strategies being developed in Pennsylvania and the Chesapeake Bay, if implemented, are likely to serve as a model for the 40 other states now seeking solutions to similar water quality problems. Today, most states face a similar issue---unfunded federal clean water mandates. Pennsylvania’s proposed competitive bidding program provides an opportunity to significantly reduce the cost to PA (and a model for other states to utilize in the future) in meeting such mandates.

 

Going Concern:

 

The Company’s audited financial statements for the years ended June 30, 2022 and 2021 were prepared assuming the Company will continue as a going concern. The Company has net income of $8,292,000 for the year ended June 30, 2022.  The Company has incurred net losses of approximately $3,451,000 for the year ended June 30, 2021. The Report of the Independent Registered Public Accounting Firm on the Company’s consolidated financial statements as of and for the year ended June 30, 2022 includes a “going concern” explanatory paragraph which means that there are factors that raise substantial doubt about the Company’s ability to continue as a going concern. The Company has incurred net losses from operations of approximately $2,550,000 and $2,828,000 for the years ended June 30, 2022 and 2021, respectively.  At June 30, 2022, the Company has working capital and a stockholders’ deficit of approximately $1,364,000 and $932,000, respectively. Management’s plans with respect to these matters are described in this section and in our consolidated financial statements (and notes thereto), and this material does not include any adjustments that might result from the outcome of this uncertainty. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.  

PRINCIPAL PRODUCTS AND SERVICES

 

The Company’s primary focus is on implementing its Gen3Tech in JVs (as described above). Therefore, the category ‘PRINCIPAL PRODUCTS AND SERVICES’ is not fully appropriate for the Company’s business. While the Company may implement some Gen3Tech systems on a contractual basis, our business does not primarily involve sale of our systems or long term direct operations/management of our systems. The discussion below should be read in the context this business focus (described in detail above and below).

 

Bion has invested over $100 million in its business since 1989, much of which has been expended development of its technologies and technology platform, policy change initiatives and other activities. Our 2G Tech (now supplanted by our Gen3Tech) was proven at commercial scale and has been reviewed and qualified for federal loan guarantees under USDA’s Technical Assessment program. The 2G Tech platform (as will our Gen3Tech going forward) provided verified nutrient credits from wet livestock waste (dairy, beef, and swine) that can be used to offset US EPA-mandated TMDL requirements. The Company intends to implement its first Gen3Tech systems during the current fiscal year. Our Gen3Tech and Gen3Tech platform provide the basis for our planned JVs and Projects and therefore constitute our ‘principal products’.

 

Each Bion system (whether prior 2G Tech or current Gen3Tech) is comprised of several process units combined in a ‘process train’, much like a municipal wastewater treatment plant. The platform utilizes a combination of mechanical, biological, and thermal processes and can be configured in a variety of ways, based on the needs and economics of the location, to provide the level of environmental treatment required, while separating and aggregating the various components of the waste stream for processing and recovery. A key attribute of the Bion platform is that the performance of the systems can be measured, quantified and verified through a proprietary data collection system, providing a level of oversight and verification similar to waste water treatment facilities. In addition to providing third-party verification of reductions for regulatory/credit purposes, the same data can also be used to support the claims of a USDA-certified sustainable branding.

 

Bion’s waste treatment solutions are scalable, proven in commercial operations (2G Tech) and the verified results have been accepted by EPA (for use as a “qualified offset”), USDA and other regulatory agencies. Bion’s core processes are protected by five United States patents. Additionally, Bion has two United States patent applications pending and has three international patent applications currently pending. We do not know of any other cost-effective technology that provides Bion Gen3Tech platform’s system’s level of treatment of livestock waste (dairy, beef, poultry and swine) or which can provide the full set of ‘sustainability benefits’ anticipated to be provided by the Company’s JVs. Note that while revenues from Bion’s 2G platform were 90 percent dependent on developing markets for nutrient reductions, our Gen3Tech platform will generate revenues from multiple co-product streams to supplement revenues from nutrient reductions.

 

 

22 
 

Bion’s Gen3Tech platform has been developed over the past six years to maximize co-product recovery values from large scale facilities (or multiple modular facilities) while maintaining/improving the level of environmental remediation produced by our 2G systems. The 3G systems will recover nitrogen from the CAFO waste stream for production of nitrogen-rich products that Bion believes will qualify for certification for use as fertilizer in growing organic crops (the first approval was received during the 2020 fiscal year) for livestock and human consumption and/or for other uses. Further, the Gen3Tech platform will recover methane that can be conditioned/cleaned to pipeline quality gas (with the CO2 recovered from the cleaning process re-cycled and utilized in the fertilizer production process) and will qualify for various credits and subsidies as clean, renewable natural gas.  These two revenue streams will supplement revenues from the sale of USDA PVP-certified, verifiably sustainable branded meat products.  In some locations, revenues may also be realized from nutrient credits and other environmental services.

 

Building upon our 2G Tech and Bion's over 20 years of experience providing waste treatment services to the livestock industry, commencing with our first generation technology applications, the Company is also pursuing the Retrofit opportunities related to environmental remediation of existing CAFOs in appropriate situations (see discussion of Kreider Poultry venture herein).  Our technology has evolved and been upgraded over the decades to meet changing standards and requirements. Bion's Gen3Tech platform creates potentially profitable business opportunities to provide waste treatment services and systems and/or renewable energy production capability to existing large livestock operations (of which there are many), and potentially to smaller facilities through aggregation of waste streams. However, this is not our primary focus. Candidates for these solutions include individual CAFO facilities that face impending regulatory action, CAFOs that wish to expand or relocate, and operations located in regions that suffer severe and immediate environmental issues, such as the Chesapeake Bay watershed, Great Lakes region and/or the San Joaquin Valley, where financial incentives (such as nutrient reduction credit trading programs) are (or may become) available that encourage voluntary reductions of nutrient releases and/or atmospheric emissions from agricultural sources.

 

Sustainable/Organic Corn-Fed Beef Opportunity

 

The Company believes that one of its major opportunities will be in JVs to pursue the Sustainable Beef Opportunity and the Sustainable/Organic Corn-Fed Beef Opportunity in the Midwest as discussed at some length above. It is the Company’s current intention to initiate several JVs pursuing this opportunity as developer of, technology provider to, and direct participant. See discussion above.

 

While it is not possible at this time to firmly predict where the initial JVs and/or Project will be developed or the order in which JVs and Projects will be developed, the Dalhart Project (see discussion above) will most likely be the Company’s first large scale Gen3Tech commercial project. All potential JVs and/or Projects are in very early pre-development stages and may never progress to actual development or may be developed after other JVs and/or Projects not yet under active consideration.

 

The Company's successful accomplishment of its business activities is dependent upon many factors (see 'Forward-Looking Statements' above) including without limitation the following, none of which can be assured at this date:

 

  Successful development and completion of the Initial Project (at least phase 1) and the first large scale Gen3Tech commercial Project(s) to demonstrate the commercial economics of its Gen3Tech platform;

 

  Successful development of the first Integrated Project to demonstrate the operation of a fully-integrated, environmentally-compliant Integrated Project at a profitable level;

 

  Establishment of a substantial and liquid market for nutrient reductions and other environmental attributes generated from the Company’s future facilities;

 

  Establishment of marketing relationships needed for realization of full value from the saleable co-products including sustainable and organic meat products and organic nitrogen fertilizer products;

 

  Successful completion of organic certifications and USDA PVP-certified sustainable brand;

 

  Our ability to raise sufficient funds to allow us to finance our activities, JVs, and Projects; and

 

  Regulatory and enforcement policies at the Federal, State and local levels.

 

 

23 
 

 

Kreider Poultry Joint Venture and Pennsylvania and Chesapeake Bay Initiatives

 

Bion’s activities in Pennsylvania (“PA”) commenced with the Kreider 1 2G Tech dairy system in the Chesapeake Bay watershed. This retrofit installation was designed and intended primarily to reduce nitrogen and phosphorus releases and ammonia emissions from the dairy waste streams to generate tradable nutrient reduction credits as part of a nutrient credit trading program through the PA Department of Environmental Protection (‘PADEP’). While this project was not a commercial success (due to PA’s failure to implement a viable long-term credit trading market), it demonstrated that Bion’s manure treatment technology can generate low-cost verified credits and provided the basis of a 2013 PA Legislative Budget and Finance Committee report (updated in 2018) that supports the use of manure technologies to provide low-cost alternatives to meet Bay mandates.

 

It is possible that the Kreider 2 poultry waste treatment Project, which is in its early development and pre-permitting phase, will be one of our first large scale JV Projects if a workable market for nutrient reduction credits develops in PA, of which there is no assurance. See “Retrofit Gen3Tech Project: Kreider Poultry JV (“Kreider 2”)” above. The Kreider 2 Project will utilize our Gen3Tech platform to treat the waste stream from Kreider Farm’s large poultry operations (possibly together with waste from other nearby poultry operations and/or other waste streams) (and the dairy waste stream previously treated in the Kreider 1 system) to generate renewable energy, marketable nutrient reduction credits and co-products (including nitrogen in organic and/or non-organic forms). It is targeted to treat the waste stream from approximately 9 million birds, in modules, when fully developed. Estimated capital costs (‘capex’) are currently estimated in the $60 million range (with the caveat that no site has yet been chosen, technology development is not complete and the final design work has not yet begun) and has the potential to generate gross revenues of up to $50 million annually from the multiple revenue streams based on current projected yields and prices, none of which are assured. Note that tech and system design work is continuing and the Company anticipates reduce reductions of both capex and operating costs.

 

To date the market for long-term nutrient reduction Credits in Pennsylvania has been very slow to develop and the Company’s activities have been negatively affected by such lack of development.  However, Bion is confident that if and when these markets are established, the Credits it produces will be competitive in the credit trading markets, based on its cost to remove nitrogen from the livestock waste stream, compared to the cost to remove nitrogen through various other treatment activities.

 

Several independent studies have calculated the average cost to remove nitrogen through various sector practices. Reports prepared for the PA Senate (2008), Chesapeake Bay Commission (2012) and PA legislature (2013; described below), as well as the Maryland Chesapeake Bay Financing Strategy Report (2015), demonstrate that the cost to remove nitrogen (per pound on average) from agriculture is $44 to $54, municipal wastewater: $28 to $43, and storm water: $386 to $633. Pursuant to the PA legislative study, by replacing sector allocation (for all sectors) with competitive bidding, up to 80 percent savings could be achieved in PA’s Chesapeake Bay compliance costs ($1.5 billion annually) by 2025. If the legislative study had focused on the cost differentials of competitive bidding compared only with storm water, the relative savings would be substantially greater.

 

Since these studies were completed, most of the larger (Tier 1) municipal wastewater treatment plants in PA have been upgraded, at a cost of approximately $2.5 billion (vs initial 2004 PA DEP cost estimates of $376 million). US EPA is now focused on PA’s storm water allocation (3.5 million pounds) and has this sector on ‘backstop level actions’, the highest level of EPA-oversight and the final step before sanctions. In the same 2004 PA DEP cost estimate that led to the more than a $2 billion underestimate/miscalculation in municipal wastewater plant upgrade costs, the estimate for storm water cost was $5.6 billion. In April 2017, US EPA sent a Letter of Expectation to PA DEP, expressing the agency’s support for the use of nutrient credit trading and competitive bidding to engage the private-sector to lower costs. The letter specifically encouraged the use of credit trading to offset the state’s looming storm water obligations.

 

Bion anticipates that it will be able to profitably develop the Kreider 2 project if it is able sell nutrient credits generated at the Kreider 2 facilities (and subsequent projects) at prices are in the range of $6-$12 (or higher) per lb. of nitrogen reduction under long-term contracts, of which there is no assurance. Bion further believes that with the studies and information now available to other states that are (or will shortly be) facing these same decisions, a cost-benefit analysis will make it clear from the outset that competitive bidding for nutrient reduction credits from alternative approaches can provide dramatically lower-cost solutions than traditional strategies.

 

The Kreider 2 poultry waste treatment facility in PA may be one of our initial Gen3Tech Projects. Bion intends that it will select a site for the Kreider 2 Project and/or its initial Integrated Project (and possibly additional Projects) after PA adopts a competitively-bid nutrient reduction Credit purchase program (see discussion above and below).

 

CORPORATE BACKGROUND

 

The Company is a Colorado corporation organized on December 31, 1987. Our principal executive offices are now located at the residence of our Office Manager at 9 East Park Court, Old Bethpage, New York 11804, at which location most of the Company’s physical records and central computer reside. Our primary telephone number is 516-586-5643. We have no additional offices at this time as all employees and primary consultants work from their home offices.

 

 

24 
 

HISTORY AND DEVELOPMENT OF OUR BUSINESS

 

Substantially all of our business and operations to date has been conducted through wholly-owned subsidiaries, Bion Technologies, Inc. (a Colorado corporation organized September 20, 1989), Bion Integrated Projects Group, Inc. ("Projects Group") (formerly Bion Dairy Corporation through August 2008 and originally Bion Municipal, Inc., a Colorado corporation organized July 23, 1999) and Bion Services Group, Inc. ("Services Group") (formerly Bion International, Inc., a Colorado corporation organized July 23, 1999) and BionSoil, Inc. (a currently inactive Colorado corporation organized June 3, 1996).  Bion is also the parent of Bion PA 2 LLC (a Colorado entity organized June 24, 2010) (“PA2”) and Bion 3G-1, LLC (a Colorado entity organized on September 23, 2021). In January 2002, Bion entered into a series of transactions whereby the Company became a 57.7% (now 58.9%) owner of Centerpoint Corporation (a Delaware corporation organized August 9, 1995) ("Centerpoint"). Bion was formerly the parent of Bion PA 1 LLC (a Colorado entity organized August 14, 2008) (“PA1”) which was dissolved on December 29, 2021 (See “Pennvest Loan and Bion PA1 LLC Dissolution” herein).

 

Although we have been conducting business since 1989, we determined that we needed to redefine how we could best utilize our technology during 2003 and again in 2015.  From 2003 through early 2008, we primarily worked on technology improvements and applications and in furtherance of our business model of Integrated Project development.  During 2008 we re-commenced pursuing active commercial transactions involving installation of our 2G Tech for CAFO waste treatment and related environmental remediation and initiation of pre-development modeling and pre-development work to prepare for our initial Integrated Projects. Commencing during 2015, the Company focused its efforts largely on the development of our Gen3Tech platform which was largely completed during 2021. We are now focused primarily on development of JVs and Projects based on implementation of our Gen3Tech platform (and business model) in the industry segments discussed above.

 

Our original systems were wastewater treatment systems for dairy farms and food processing plants.  The basic design was modified in late 1994 to create Nutrient Management Systems ("NMS") that produced organic soil products as a byproduct of remediation of the waste stream when installed on large dairy or swine farms.  Through June 30, 2002, we sold and subsequently installed, in the aggregate, approximately 30 of these first iteration of Bion’s systems in 7 states, of which we believe a few may still in operation in 3 states.  We discontinued marketing of our first-generation NMS systems during fiscal year 2002 and turned control and ownership of the first-generation systems over to the farms on which they were installed over the following two years.  We were unable to produce a business model based on the first-generation systems that would generate sufficient revenues to create a profitable business.  While continuing to market and operate the first-generation systems, during the second half of calendar year 2000, we began to focus our activities on developing the next generation of the Bion technology. We no longer operate or own any of the first-generation NMS systems.

 

As a result of our research and development efforts, the core of our current technology was re-developed during fiscal years 2001-2004.  We designed and tested Systems that used state-of-the-art, computerized, real-time monitoring and system control with the potential to be remotely accessed for both reporting requirements and control functions.  These Systems were smaller and faster than our first-generation NMS systems.  The initial versions of our second generation of Bion Systems were designed to harvest solids used to produce organic fertilizer and soil amendments or additives (the "BionSoil(R) products") in a few weeks as compared to six to twelve months with our first-generation systems.

 

During 2003-4 we designed, installed and began testing a commercial scale, second generation Bion System as a temporary modification or retrofit to a waste lagoon on a 1,250-milking cow dairy farm in Texas, known as the DeVries Dairy.  In December 2004, Bion published an independently peer-reviewed report, a copy of which may be found on our website, www.biontech.com, with data from the DeVries project demonstrating a reduction in nutrients (nitrogen and phosphorus) of approximately 75% and air emissions of approximately 95%.  More specifically, those published results indicated that the Bion System produced a 74% reduction of nitrogen and a 79% reduction of phosphorus.  The air results show that the Bion System limited emissions from the waste stream as follows: (in pounds per 1,400-pound dairy cow per year):

 

Ammonia 0.20  
Hydrogen Sulfide  0.56  
Volatile Organic Compounds    0.08  
Nitrogen Oxides 0.17  

 

These emissions represented a reduction from published baselines of 95%-99%.

 

 

25 
 

Through 2007 the demonstration project at the DeVries Dairy in Texas also provided Bion with the opportunity to explore mechanisms to best separate the processed manure into streams of coarse and fine solids, with the coarse cellulosic solids/biomass supporting generation of renewable energy and the fine solids potentially becoming the basis of organic fertilizer products and/or a high-protein animal feed ingredients. On-going research was also carried out on various aspects of nutrient releases and atmospheric emissions.

 

Bion discontinued operation of the DeVries demonstration research system during 2008.

 

During the 2005-2008 period, Bion focused on completing development of its 2G Tech platform and business model.  As such, we did not pursue near term sales and revenue opportunities, such as retrofitting existing CAFO's with interim versions of our waste management solutions, because such efforts would have diverted scarce management and financial resources and negatively impacted our ability to complete development of an integrated technology platform in support of large-scale sustainable Projects.

 

From 2009 through 2015 (when development of our Gen3Tech platform began), Bion  actively pursued business opportunities in three broad areas 1) Bion systems to retrofit of existing CAFO’s (some of which may  generate verified nutrient credits and revenues from the production of renewable energy and byproducts) (“Retrofits”), and 2) development of new state-of-the-art large scale waste treatment facilities, potentially in conjunction with new CAFOs developed in strategic locations that were not previously possible due to environmental constraints in strategic locations (“Projects”) (some of these may be “closed loop’ Integrated Projects that were not previously possible due to environmental constraints as described below), and 3) licensing and/or joint venturing of Bion’s technology (primarily) outside North America. Bion is now primarily pursuing JVs related to these opportunities within the United States and internationally based on our Gen3Tech as described above.

 

Pre-Gen3Tech: Chesapeake Bay Watershed: Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution/Kreider Farms Projects/Pennsylvania Initiatives

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

 

26 
 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. The remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form 10-K Annual Reports for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

Chesapeake Bay Watershed: Kreider Farms Projects/Pennsylvania Initiatives

 

The urgency and priority of the need to clean up nutrient (primarily nitrogen and phosphorus) pollution to the Chesapeake Bay was clearly demonstrated with promulgation of President Obama's 2009 Executive Order concerning clean-up of the Chesapeake Bay and the EPA’s publication and issuance during December 2010 of the Chesapeake Bay Total Maximum Daily Load (TMDL) standard (http://www.epa.gov/reg3wapd/tmdl/ChesapeakeBay/tmdlexec.html) for nutrient pollution in Chesapeake Bay tributaries. In May 2010, the EPA published their overall strategy for remediating the Chesapeake Bay, and they have committed to reducing nitrogen and phosphorus flows to the Bay sufficiently to enable 60% of the Bay watershed segments to meet water quality standards by 2025.  At that time, 89 of the 92 Bay and tidal watershed segments were not in compliance with water quality standards (97% were out of compliance).  The EPA and associated state agencies also committed to short-term 3-year compliance milestones to enhance accountability and corrective actions, along with a host of definable and measurable goals, enhanced partnerships, and major environmental initiatives.  Based on these actions, greater compliance has been required commencing with the 2016 ‘water year’.  EPA documents defined the overall mission as requiring an approximately 65-million-pound annual reduction from existing nitrogen (N) loading to the Chesapeake Bay by 2025, of which 35 million pounds was allocated to Pennsylvania. Importantly, the 3-year compliance milestones were established as a part of the compliance program to add both short- and long-term accountability to state actions associated with reduced nutrient and sediment flows to the Chesapeake Bay. According to the EPA’s Interim Evaluation of Pennsylvania’s Milestone Progress published in June 2015, PA was 14.6 million pounds behind its 2014-2015 milestone commitments for nitrogen, a remarkably large deficit given the previously stated 2-million-pound deficit from the 2012-2013 water year.  EPA has placed PA’s agriculture and urban/suburban sectors under a “Backstop Actions Level”, the highest level of EPA oversight.  EPA has also stated that if load reductions remain off track, EPA may consider seeking additional (and expensive) pollutant reductions from the wastewater sector.  

 

In an effort to get back on track and hold off federal intervention, PA unveiled a purported “comprehensive strategy” to "reboot" the state's efforts to improve water quality in January 2016.  The reboot strategy relied upon a mix of enhanced farm compliance and enforcement activities along with the promotion of additional best management practices (BMP).  This proposed strategy has been met with skepticism about its efficacy/practicality and resistance within the agricultural community. While many of these reboot efforts are continuing today, the PADEP Secretary resigned in May 2016 and PA appears to have slowed implementation efforts recently while seeking alternative approaches to reduce PA’s nitrogen pollution to the Chesapeake Bay. The EPA has continued to reject PA’s proposed plans related to the Chesapeake Bay clean-up mandate as inadequate. Recent reports indicate that PA is in need of 32 million pounds of nitrogen reductions to meet its requirements. Litigation has been initiated against PA and the EPA by neighboring states to compel performance by PA and enforcement by the EPA. The recent PA budget spending package that was passed by the PA legislature in 2022 includes allocation of some PA’s remaining pandemic relief funding for clean water related to either the Chesapeake Bay compliance mandates or state water quality. However, it appears that the funds will likely be expended on existing unsuccessful programs and clean-up strategies.

 

 

27 
 

As a result of PA’s default of its Bay mandates, and the host of upcoming both short and long-term specific commitments and compliance deadlines, Bion believes that its long-term opportunity related to the Chesapeake Bay clean-up has potentially been significantly expanded and accelerated.

 

During 2008, Bion executed an agreement to install a Bion System at the Kreider Farms (“KF”) in Lancaster County, Pennsylvania to reduce nitrogen (including ammonia emissions which are re-deposited as nitrogen from the atmosphere) and phosphorus in the farm's effluent. Bion undertook this project (through PA1) due, in large part, to Pennsylvania's nutrient credit trading program, which was established to provide cost-effective reductions of the excess flow of nutrients (nitrogen and phosphorus) into the Chesapeake Bay watershed. Bion worked extensively with the Pennsylvania Department of Environmental Protection ('PADEP') over several years to establish nutrient credit calculation/ verification methodologies that were appropriate to Bion's 2G Tech and recognizes its 'multi-media' (both water and atmospheric) approach to nutrient reductions.  Pennsylvania's nutrient credit trading program allows for voluntary credit trading between a 'non-point source' (such as a dairy or other agricultural sources) and a 'point source' polluter, such as a municipal waste water treatment plant or a housing development. However, the market for long term Credits in PA has failed to develop any significant breadth or depth and no Credits were sold by PA1 from the Kreider 1 system.

 

The original Kreider agreements also provided for Bion to develop a waste treatment/renewable energy production facility to treat the waste from Kreider's approximately 6+ million chickens (planned to expand to approximately 9-10 million)(and potentially other poultry operations and/or other waste streams)('Kreider Renewable Energy Facility' or ' Kreider 2 Project'). On May 5, 2016, the Company executed a stand-alone joint venture agreement (‘JVA’) with Kreider Farms covering all matters related to development and operation of a system to treat the waste streams from Kreider's poultry facilities in Bion PA2 LLC ("PA2"). Bion anticipates that it will execute an updated JVA with Kreider Farms during the current fiscal year which will include utilization of Bion’s Gen3Tech and other matters. The Company continues its pre-development work related to the details of the Kreider 2 Project. For more information regarding the history and background of the Kreider 2 Project, please review our Forms 10-K for the years from 2008 through 2021.

 

The Company believes that Pennsylvania is potentially ‘ground zero’ in the long-standing clean water battle between agriculture and the further regulation of agriculture relative to nutrient impacts. The ability of Bion and other technology providers to achieve verified reductions from agricultural non-point sources can resolve the current stalemate and enable implementation of constructive solutions that benefit all stakeholders, providing a mechanism that ensures that taxpayer funds will be used to achieve the most beneficial result at the lowest cost, regardless of source. All sources, point and non-point, rural and urban, will be able to compete for tax payer-funded nitrogen reductions in a fair and transparent process; and since payment from the tax and rate payers would now be performance-based, these providers will be held financially accountable.

 

See the extended additional discussion regarding these matters in our Annual Reports on Form 10-K for the year ended June 30, 2021 and prior years.

 

RECENT FINANCINGS

 

Sales of Common Stock during 2022 and 2021 Fiscal Years

 

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662, net proceeds of $1,718,061 after commissions of $18,601.

 

During the year ended June 30, 2022, Smith elected to convert accounts payable of $17,711 into an aggregate of 35,424 units at $0.50 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2022, the Company issued 25,000 units at $1.10 per until for services of $27,500.

 

 

28 
 

During the year ended June 30, 2021, the Company entered into subscription agreements, under three different offerings, to sell units for $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2021 and pursuant thereto, the Company issued 3,720,000 units for total proceeds of $1,860,000, net proceeds of $1,699,000 after commissions of $161,000.

 

During the year ended June 30, 2021 300,000 shares of the Company’s restricted company stock were sold to an investor for $300,000.

 

During the year ended June 30, 2021, 129,364 shares of its unregistered common stock were issued as commissions.

 

During the year ended June 30, 2021, the Company issued 1,186,824 units to various employees/consultants upon the conversion of debt (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until June 30, 2023.

 

During the year ended June 30, 2021, Smith elected to convert deferred compensation, accrued interest and accounts payable of $124,698, $3,342 and $52,360 respectively into an aggregate of 360,805 units at $0.50 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, the Company issued 144,000 units to Smith for salary of $72,000, (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, 4,065,988 warrants were exercised to purchase 4,065,988 shares of the Company’s common stock at $0.75 per share for total proceeds of $3,049,491.

 

COMPETITION:

 

There are a significant number of competitors in the waste treatment industry who are working on animal related pollution issues. Probably the most efficient way to assess competition in this industry is to review the Newtrient, LLC catalogue which is produced by an organization created by the dairy industry to help farmers, technology providers, manure-based product developers and other stakeholders assess manure related challenges and opportunities. Many of the technologies reviewed by and organized by Newtrient in their catalog, such as Bion, address manure streams in addition to dairy. The potential competition has increased with the growing governmental and public concern focused on pollution due to CAFO wastes.  Waste treatment lagoons which depend on anaerobic microorganisms ("anaerobic lagoons") are the most common traditional treatment process for animal waste on large farms within the swine and dairy industries.  Additionally, many beef feedlots, poultry facilities and dairy farms simply scrape and accumulate manure for later field application. Both lagoon and scrape/pile manure storage approaches are coming under increasing regulatory pressure due to associated odor, nutrient management and water quality issues and are facing possible phase-out in some states.  Although we believe that Bion’s comprehensive solution is the most economically and technologically viable solution for the current problems, other alternative (though partial) solutions do exist, including, for example, synthetic lagoon covers (which are placed on the top of the water in the lagoon to trap the gases), methane digesters (a tank which uses anaerobic microorganisms to break down the waste to produce methane), multistage anaerobic lagoons and solids separators (processes which separate large solids from fine solids), as well as various thermal waste-to-energy technologies.  Additionally, many efforts are underway to develop and test new technologies.

 

Our ability to compete is dependent upon favorable regulatory conditions, our ability to obtain required approvals and permits from regulatory and other authorities and upon our ability to introduce and market our Systems in the appropriate industry and geographic segments.

 

There is also extensive competition in the sustainable beef and sustainable organic beef market segments and organic soil amendment/fertilizer and feed ingredient markets that are being targeted by Bion’s Gen3Tech JVs as discussed above. 

 

There are many companies that are already selling products to satisfy demand in the sectors of these markets we are trying to enter.  Many of these companies have established marketing and sales organizations and customer commitments, are supporting their products with advertising, sometimes on a national basis, and have developed brand name recognition and customer loyalty in many cases.

 

Because Bion systems offer a comprehensive waste treatment solution that is designed to produce/augment up to four separate and distinct revenue streams, the Company believes that it has the ability to be competitive in each of the sectors from which it derives revenue.

 

DEPENDENCE ON ONE OR A FEW MAJOR CUSTOMERS

 

In our JVs/Projects (including Integrated Projects) business segment, we will most likely be dependent upon one or a few major customers/partners/joint venturers since a relatively limited number of JVs and/or Projects (including Integrated Projects) will be developed by the Company. We anticipate initially developing, owning interests in, and operating only one or a small number of Projects commencing during 2023 and, thereafter, developing a limited number of Projects at a time. Thus, at least for the near future, our revenues will be dependent on a relatively small number of major Projects, participants and/or customers.

 

29 
 

 

PATENTS

 

We are the sole owner of five United States patents. Additionally, Bion has two United States patent applications pending and has three International patent applications currently pending.

 

Patent Numbers and date of issue:

 

United States Currently Issued:

 

(1)8,287,734:  Method for Treating Nitrogen in Waste Streams: (OCN) Jere Northrop & James W. Morris (Exp 3/20/31)

 

(2)10,106,447: Process to Recover Ammonium Bicarbonate from Wastewater: Morton Orentlicher & Mark M. Simon. (Exp. 9/14/2035)

 

(3)10,604,432: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon. (Exp 6/29/2037)

 

(4)10,793,458: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon. (Exp 9/14/2035)

 

(5)11,254,581: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Morton Orentlicher, Mark M. Simon & Steve Pagano. (Exp 9/14/2035)

 

We are also the sole owner of, or possess the contractual right to acquire exclusive patent rights to, a pending United States provisional patent application, a pending United States utility patent application and three international applications as set forth below:

 

United States Currently Pending:

 

(1)63/367,771 (provisional): Methods For Recovering Ammonium Compounds From A Waste Stream; Dominic Bassani & Steve Pagan. (Exp 7/06/2023)

 

(2)17/589,037: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

International Applications Currently Pending:

 

  (1) EP18943551: Process to recover ammonium bicarbonate from wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

  (2) CA3123802A1: Process to recover ammonium bicarbonate from wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

  (3) MX/a/2021/007358: Process to recover ammonium bicarbonate from wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

In addition to such factors as innovation, technological expertise and experienced personnel, we believe that a strong patent position is increasingly important to compete effectively in the businesses on which we are focused.  It is likely that we will file applications for additional patents in the future. There is, however, no assurance that any such patents will be granted.

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

 

30 
 

It may become necessary or desirable in the future for us to obtain patent and technology licenses from other companies relating to technologies that may be employed in future products or processes.  To date, we have not received notices of claimed infringement of patents based on our existing processes or products, but due to the nature of the industry, we may receive such claims in the future.

 

We generally require all of our employees and consultants, including our management, to sign a non-disclosure and invention assignment agreements upon employment with us.

 

RESEARCH AND DEVELOPMENT

 

Current research and development work is focused on completion of the development and ongoing improvement of our Gen3Tech (the initial version of which is ready for implementation in an appropriate Project) with emphasis on increased recovery of valuable by-products (including nutrients in organic and/or non-organic forms, production of renewable energy from by-products together with related renewable energy and/or environmental credits). Bion believes its Gen3Tech will produce significantly greater value from the CAFO waste stream through the recovery of a concentrated natural nitrogen fertilizer and pipeline-quality natural gas.

 

During the years ended June 30, 2022 and June 30, 2021, respectively, we expended approximately $178,000 and $547,000 (excluding non-cash stock-based compensation) on research and development activities related to our technology platform applications in support of large-scale, economically and environmentally sustainable Projects and Retrofits. Since the 2018 fiscal year, Bion’s research and development has been primarily focused on development work to complete and further refine development of our Gen3Tech which will have the capacity to process dry, poultry CAFO waste streams in addition to wet dairy/beef/swine CAFO waste streams and increase our ability to recover marketable by-products from the waste stream remediation including renewable natural gas and nitrogen products (organic and non-organic). Some work  has also involved modifying and adding unit processes to our Gen3Tech platform with the objective of reducing capital costs and operating costs, while generating commercial equivalent by-products (and therefore, potential revenue streams) and significantly increasing environmental efficiency. As a result of these efforts (including their continuation during the current period), Bion made new (and supplemental) patent filing(s) during the 2019-2021 fiscal years related to our Gen3Tech. The Company anticipates completion of its pilot system and pre-commercial testing for its Gen3Tech by end of the current calendar year to support design finalization for our initial Gen3Tech systems. Our technology focus is to separate and aggregate the various “assets” in the waste stream and then to re-assemble them to maximize their economic value. Our current research and development efforts have been focused on developments that will minimize water removal requirements thereby significantly reducing the associated energy costs. In addition, current efforts are focused on fertilizer and soil amendment products (organic and inorganic), water reuse, environmental and reduction credits (including but not limited to nutrient, carbon, sediment, water and pathogen reduction) while reducing capital costs and operating costs. Bion continues to focus on “normalizing” its technology platform for use on multiple species. This effort has required significant work and resource allocation on research regarding balancing the activities of each unit process so that its output enables the subsequent unit processes to maximize efficiency and discharge to the subsequent unit process in order to produce a feedstock cost effectively. The by-products of this series of unit processes (which include certain Bion proprietary elements) are then “reassembled” into products to maximize their economic value. To date, research and development results have supported our objectives.

  

Environmental Protection/Regulation and Public Policy

 

In regards to Retrofits and development of Projects, we will be subject to extensive environmental (and other) regulations related to CAFO's, biofuel production and end product (e.g. fertilizer) producers.  To the extent that we are a provider of systems and services to others that result in the reduction of pollution, we are not under direct enforcement or regulatory pressure.  However, we are involved in the business of CAFO waste treatment and are impacted by environmental regulations in at least four different ways:

 

•     Our marketing and sales success depends, to a substantial degree, on the pollution clean-up requirements of various governmental agencies, from the Environmental Protection Agency (EPA) at the federal level to state and local agencies;

•     Our System design and performance criteria must be responsive to the changes in federal, state and local environmental agencies' effluent and emission standards and other requirements;

•     Our System installations and operations require governmental permits and/or other approvals in many jurisdictions; and

•     To the extent we own or operate Projects (including Integrated Projects with CAFO facilities and ethanol plants), those facilities will be subject to environmental regulations.

 

Additionally, our activities are affected by many public policies and regulations (federal, state and local) related to other industries such as agriculture, food, energy, municipal waste and storm water treatment, watershed-wide mandates, and others. For example, the existing differences in the regulatory requirements for agriculture versus municipal wastewater clean-up currently in place have negatively impaired the development of viable markets for nutrient reduction credits.

 

 

31 
 

Bion system installations and operations may require verification and compliance with an assortment of voluntary regulatory programs, such as the USDA Organic and USDA Process Verified branding programs. Each of these programs has a series of compliance verification steps that need to be met in order to maintain proper standing for use of the USDA shield on packaging.

 

EMPLOYEES

 

As of September 1, 2022, we had 7 employees and primary consultants, all of whom are performing services for the Company on a full-time basis. The Company utilizes other consultants and professionals on an ‘as needed’ basis. Our future success depends in significant part on the continued service of our key personnel and the ability to hire additional qualified personnel. The competition for highly qualified personnel is intense, and there can be no assurance that we will be able to retain our key managerial and technical employees or that we will be able to attract and retain additional highly qualified technical and managerial personnel in the future. None of our employees is represented by a labor union, and we consider our relations with our employees to be good. None of our employees is covered by "key person" life insurance.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

Not applicable.

 

ITEM 2. PROPERTIES.

 

The Company maintains its corporate offices at 9 East Park Court, Old Bethpage, New York 11804, the home of its office manager/bookkeeper, and its main corporate telephone number is (516) 586-5643.

 

We are the sole owner of five United States patents. Additionally, Bion has two United States patent applications pending and has three International patent applications currently pending. (See Item 1, “Patents” above).

 

ITEM 3. LEGAL PROCEEDINGS.

 

The Company is currently involved in no litigation matters except:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subject disruption and expenses were incurred related to the matter including legal fees.

 

 

32 
 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

 

33 
 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. The remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

The Company currently is not involved in any other material litigation or similar events.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

None.

 

 

PART II

 

ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

(a)  Market Information

 

Our common stock is quoted on the Over-The-Counter Electronic Bulletin Board under the symbol "BNET."  The following quotations reflect inter dealer prices, without retail mark up, markdown or commissions and may not represent actual transactions.

 

   2022   2021 
Fiscal Year Ended June 30,  High   Low   High   Low 
                 
First Fiscal Quarter  $1.80   $1.15   $0.55   $0.42 
Second Fiscal Quarter  $1.66   $0.805   $0.52   $0.35 
Third Fiscal Quarter  $1.40   $0.8001   $1.73   $0.395 
Fourth Fiscal Quarter  $1.27   $0.80   $1.71   $1.25 

 

(b) Holders

 

The number of holders of record of our common stock at September 1, 2022 was approximately 1,400. Many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, so we are unable to estimate the number of stockholders represented by these record holders.

 

The transfer agent for our common stock is Equiniti, 3200 Cherry Creek Drive South, Suite 430, Denver, Colorado 80209.

 

(c) Dividends

 

We have never paid any cash dividends on our common stock. Our board of directors does not intend to declare any cash dividends in the foreseeable future, but instead intends to retain earnings, if any, for use in our business operations. The payment of dividends, if any, in the future is within the discretion of the board of directors and will depend on our future earnings, if any, our capital requirements and financial condition, and other relevant factors.

 

No preferred shares are outstanding at this time. During fiscal year 2022 the Company paid an aggregate dividend of $0 cash, respectively, on shares of Series B Preferred Stock and Series C Preferred Stock which were outstanding during the year. A dividend of $1,000 was accrued on Series B Preferred Stock during the 2022 fiscal year. From July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock was mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares have reached their maturity date and the Company approved the redemption of the Series B preferred stock during the quarter ended December 31, 2021 and the final 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

34 
 

 

(d)  Securities Authorized for Issuance Under Equity Compensation Plans

 

In June 2006 the Company adopted its 2006 Consolidated Incentive Plan, as amended ("Plan"), which terminated all prior plans and merged them into the Plan.  The Plan was ratified by the Company's shareholders in October 2006 (and has been amended multiple times since initial ratification).  Under the Plan, Directors may grant Shares, Options, Stand Alone Stock Appreciation Rights ("SAR's"), shares of Restricted Stock, shares of Phantom Stock and Stock Bonuses and other items with respect to a number of Common Shares that in the aggregate does not exceed 36,000,000 shares. The maximum number of Common Shares for which Incentive Awards, including Incentive Stock Options, may be granted to any one Participant shall not exceed 2,000,000 shares in any one calendar year; and the total of all cash payments to any one participant pursuant to the Plan in any calendar year shall not exceed $1,500,000. As of June 30, 2022 11,201,600 options have been granted and outstanding under the Plan (as amended), including all options granted under prior merged plans, and were merged into the 2021 Equity Incentive Plan.  As of June 30, 2021, the Company had no outstanding contingent Stock Bonuses. 

 

In December 2021 the Company adopted its 2021 Equity Incentive Plan, as amended ("2021 Equity Plan").  The 2021 Equity Plan was ratified by the Company's shareholders in April 2022.  Under the 2021 Equity Plan, Directors may grant Shares, Options, Stand Alone Stock Appreciation Rights ("SAR's"), shares of Restricted Stock, shares of Phantom Stock and Stock Bonuses and other items with respect to a number of Common Shares that in the aggregate does not exceed 30,000,000 shares. The maximum number of Common Shares for which Incentive Awards, including Incentive Stock Options, may be granted to any one Participant shall not exceed 2,500,000 shares in any one calendar year. As of June 30, 2022 nil options have been granted and outstanding under the 2021 Equity Plan.  As of June 30, 2022, the Company had no outstanding contingent Stock Bonuses. 

 

Equity Compensation Plan Information

 

The following table summarizes share and exercise price information about the Company’s 2006 equity compensation plans as of June 30, 2022:

 

2006 Equity Compensation Plan table

             
Plan category 

Number of securities to be issued upon the exercise of outstanding options, warrants

and rights 

   Weighted average exercise price of outstanding options, warrants and rights   Number of Securities remaining available for future issuance under equity compensation plans 
             
Equity compensation plans
approved by security holders
   27,068,281    0.78    8,931,719 
                
Equity compensation plans not
approved by security holders
   —      —      —   
                
Total   27,068,281    0.78    8,931,719 

 

(e) Recent Sales of Unregister Securities

 

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662, net proceeds of $1,718,061 after commissions of $18,601.

 

During the year ended June 30, 2022, 66,860 shares of its unregistered common stock were issued as commissions.

 

 

35 
 

During the year ended June 30, 2022, Mark Smith elected to convert accounts payable of $17,711 into an aggregate of 35,424 units at $0.50 per unit, pursuant to the 2006 Consolidated Incentive Plan with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2022, the Company issued 25,000 units at $1.10 per until for services of $27,500.

 

During the year ended June 30, 2021, the Company entered into subscription agreements, under three different offerings, to sell units for $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2021 and pursuant thereto, the Company issued 3,720,000 units for total proceeds of $1,860,000, net proceeds of $1,699,000 after commissions of $161,000.

 

During the year ended June 30, 2021 300,000 shares of the Company’s restricted company stock were sold to an investor for $300,000.

 

During the year ended June 30, 2021, 129,364 shares of its unregistered common stock were issued as commissions.

 

During the year ended June 30, 2021, the company issued 1,186,824 units to various employees/consultants upon the conversion of debt  pursuant to the 2006 Consolidated Incentive Plan with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until June 30, 2023.

 

During the year ended June 30, 2021, Mark Smith elected to convert deferred compensation, accrued interest and accounts payable of $124,698, $3,342 and $52,360 respectively into an aggregate of 360,805 units at $0.50 per unit, pursuant to the 2006 Consolidated Incentive Plan with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, the Company issued 144,000 units to Mr. Smith for salary of $72,000, pursuant to the 2006 Consolidated Incentive Plan with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, 4,065,988 warrants were exercised to purchase 4,065,988 shares of the Company’s common stock at $0.75 per share for total proceeds of $3,049,491.

             

ITEM 6. SELECTED FINANCIAL DATA.

 

N/A

 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

This Annual Report on Form 10-K (and the documents incorporated herein by reference) contain forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe," or "continue," or the negative thereof or variations thereon and/or references to “goals”, “targets”, “projections” or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect. “The Company's actual results of operations, most of which are beyond the Company's control, could differ materially. We wish to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

 

These factors include adverse economic conditions, entry of new and stronger competitors, inadequate capital and limited ability to obtain financing, needed personnel and equipment, unexpected costs, failure (or delay) to gain product certifications and/or regulatory approvals in the United States (or particular states) or foreign countries, loss (permanently or for any extended period of time) of the services of members of the Company’s small core management team (many of whom are age 70 or older) and failure to capitalize upon access to new markets. Additional risks and uncertainties that may affect forward looking statements about Bion's business and prospects include: i) the possibility that markets for nutrient reduction credits (discussed below) and/or other ways to monetize nutrient reductions and other environmental benefits will be slow to develop (or not develop at all), ii) PA1’s dissolution and its effect on how the Company is viewed, (if any), iii) the possibility that competitors will develop more comprehensive and/or less expensive environmental solutions, iv) delays in market awareness of Bion and our Systems, v) uncertainties and costs increases related to research and development efforts to update and improve Bion’s technologies and applications thereof, and/or vi) delays and/or costs exceeding expectations relating to Bion's development of the Initial Project, JVs and/or Projects and vii) failure of marketing strategies, each of which could have both immediate and long term material adverse effects by placing us behind our competitors and requiring expenditures of our limited resources.

 

 

36 
 

THESE RISKS, UNCERTAINTIES AND FACTORS BEYOND OUR CONTROL ARE MAGNIFIED DURING THE CURRENT UNCERTAIN PERIOD RELATED TO THE COVID-19 PANDEMIC AND THE UNIQUE ECONOMIC, FINANCIAL, GOVERNMENTAL AND HEALTH-RELATED CONDITIONS IN WHICH THE COMPANY, THE ENTIRE COUNTRY AND THE ENTIRE WORLD NOW RESIDE.  TO DATE THE COMPANY HAS EXPERIENCED DIRECT IMPACTS  IN VARIOUS AREAS INCLUDING WITHOUT LIMITATION: I) GOVERNMENT-ORDERED  SHUTDOWNS WHICH HAVE SLOWED THE COMPANY’S RESEARCH AND DEVELOPMENT PROJECTS AND OTHER INITIATIVES, II) SHIFTED FOCUS OF STATE AND FEDERAL GOVERNMENT WHICH IS LIKELY TO NEGATIVELY IMPACT THE COMPANY’S LEGISLATIVE INITIATIVES IN PENNSYLVANIA AND WASHINGTON DC, III) STRAINS AND UNCERTAINTIES IN BOTH THE EQUITY AND DEBT MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS WITH INVESTMENT BANKERS, BANKS AND POTENTIAL STRATEGIC PARTNERS MORE TENUOUS, IV) STRAINS AND UNCERTAINTIES IN THE AGRICULTURAL SECTOR AND MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS MORE DIFFICULT AS FUTURE INDUSTRY CONDITIONS ARE NOW MORE DIFFICULT TO ASSESS/PREDICT, V) CONSTRAINTS DUE TO PROBLEMS EXPERIENCED IN THE GLOBAL INDUSTRIAL SUPPLY CHAIN WHICH HAVE INCREASED ANTICIPATED PROJECT DEVELOPMENT COSTS, VI) DUE TO THE AGE AND HEALTH OF OUR CORE MANAGEMENT TEAM, MOST OF WHOM ARE AGE 70 OR OLDER AND HAVE HAD ONE OR MORE EXISTING HEALTH ISSUES, THE COVID-19 PANDEMIC PLACES THE COMPANY AT GREATER RISK THAN WAS PREVIOUSLY THE CASE (TO A HIGHER DEGREE THAN WOULD BE THE CASE IF THE COMPANY HAD A LARGER, DEEPER AND/OR YOUNGER CORE MANAGEMENT TEAM), AND VII) THERE ALMOST CERTAINLY WILL BE OTHER UNANTICIPATED CONSEQUENCES FOR THE COMPANY AS A RESULT OF THE CURRENT PANDEMIC EMERGENCY AND ITS AFTERMATH.

 

Bion disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and Notes to Consolidated Financial Statements filed with this Report.

 

BUSINESS OVERVIEW

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. 

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3 Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

 

37 
 

 

During the first half of 2022 Bion began marketing our sustainable beef opportunity to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will treat the waste stream and recover/refine valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity, organic fertilizer and potentially other products. We anticipate converting the Ribbonwire LOI into a definitive agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors during the current fiscal year.

Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and, in some cases, Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

Our business plan is focused on executing multiple agreements and letters of intent related to the “Bion Beef Opportunity” and commencing development of multiple sustainable beef joint venture projects over the next twelve-eighteen (12-18) months while moving forward with the Initial Project (see below) and the Dalhart Project. Bion also intends to pursue other opportunities in the livestock industry enabled by our Gen3Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and the growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, provides Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.

During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2nd quarter in fiscal 2023 which will support development of the Dalhart Project (and other projects) during fiscal 2023 and thereafter.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

 

Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation (see discussion herein below and Notes to Financial Statements , ii) development/construction of the Dalhart Project, iii) developing applications and markets for its sustainable (conventional and organic) animal protein products and its low carbon organic fertilizer products , iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

 

See discussion at Item 1 above.

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

 

38 
 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. PA1 believes that the remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

 

39 
 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Consolidated Financial Statements included therein.

 

COVID-19 PANDEMIC RELATED MATTERS:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated

 

CRITICAL ACCOUNTING POLICIES

 

Revenue Recognition

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Stock-based compensation

 

The Company follows the provisions of ASC 718, which generally requires that share-based compensation transactions be accounted and recognized in the consolidated statement of operations based upon their grant date fair values.

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. . As of June 30, 2022 and 2021, there are no derivative financial instruments.

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates. 

 

40 
 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheets at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

YEAR ENDED JUNE 30, 2022 COMPARED TO THE YEAR ENDED JUNE 30, 2021

Revenue

Total revenues were nil for both the years ended June 30, 2022 and 2021, respectively.

General and Administrative

Total general and administrative expenses were $2,348,000 and $2,078,000 for the years ended June 30, 2022 and 2021, respectively.

General and administrative expenses, excluding stock-based compensation charges of $269,000 and $850,000, were $2,079,000 and $1,228,000 for the years ended June 30, 2022 and 2021, respectively, representing an $851,000 increase. Salaries and related payroll tax expenses were $340,000 and $319,000, for the years ended June 30, 2022 and 2021, respectively, representing a $21,000 increase. Consulting costs were $561,000 and $391,000 for the years ended June 30, 2022 and 2021, respectively. The $170,000 increase in consulting costs is due to a general increase in the levels of Company’s business activity without a large increase in the Company’s personnel including the consulting engagement with William O’Neill, who is now the Company’s CEO, during the periods from July 1, 2021 through April 30, 2022 during which the Company paid $160,000 to secure his services ($25,000 was capitalized to the 3G project). Investor relations expenses were $395,000 and $149,000 for the years ended June 30, 2022 and 2021, respectively, and the $246,000 increase is due to the 2022 shareholder meeting and new contract with an investor relations firm and increased activity during the year ended June 30, 2022 due to the resumption of investor conferences. Legal costs were $291,000 and $8,000 for the years ended June 30, 2022 and 2021, respectively, due to the hiring of a law firm to represent the Company in a lawsuit for the hack and attempt to steal the Company’s domain, engaging a law firm on the dissolution of PA-1, legal work in relation to corporate structure matters and preparation for the 2022 shareholder meeting and other matters.

 

41 
 

General and administrative stock-based employee compensation for the years ended June 30, 2022 and 2021 consists of the following:

    Year
ended
June 30,
2022
    Year
ended
June 30,
2021
 
General and administrative:                
  Change in fair value from modification of option terms   $ —       $ 9,000  
  Change in fair value from modification of warrant terms     8,000       25,000  
  Fair value of stock options expensed under ASC 718     261,000       816,000  
      Total   $ 269,000     $ 850,000  

 

Stock-based compensation charges were $269,000 and $850,000 for the years ended June 30, 2022 and 2021, respectively. The fair value of stock options expensed for the years ended June 30, 2022 and 2021 was $261,000 and $816,000, respectively. The Company capitalized $136,000 in stock-based compensation to the 3G project as of June 30, 2022. The Company granted 730,000 options during the year ended June 30, 2022 which were fully vested at grant date, and 960,000 options during the period ended June 30, 2021, which were fully vested at grant date.

Depreciation

Total depreciation expense was $1,161 and $827 for the years ended June 30, 2022 and 2021, respectively.

Research and Development

Total research and development expenses were $201,000 and $749,000 for the years ended June 30, 2022 and 2021, respectively.

Research and development expenses, excluding stock-based compensation charges of $22,000 and $202,000, were $179,000 and $547,000 for the years ended June 30, 2022 and 2021, respectively, representing a $368,000 decrease largely resulting from completion of the bulk of the research and development work on our Gen3Tech as we shifted our efforts to work on the Initial Project. Salaries and related payroll tax expenses were $32,000 and $94,000 for the years ended June 30, 2022 and 2021, respectively, as more salary expense was allocated to administrative expense for the year ended June 30, 2022. Consulting costs were $80,000 and $214,000 for the years ended June 30, 2022 and 2021, respectively. The decrease in consulting is due to capitalizing costs on the 3G project in 2022.   The Company also incurred $55,000 and $48,000 for the years ended June 30, 2022 and 2021, respectively in legal costs related to patent applications and renewals. The Company incurred $6,000 and $144,000 for the years ended June 30, 2022 and 2021, respectively in the development of new technologies for its anaerobic digestate process.

Research and development stock-based employee compensation for the years ended June 30, 2022 and 2021 consists of the following:

   Year
ended
June 30,
2022
   Year
ended
June 30,
2021
 
Research and Development:          
  Fair value of stock options expensed under ASC 718  $22,000   $202,000 

 

Stock-based compensation charges were $22,000 and $202,000 for the years ended June 30, 2022 and 2021, respectively. The Company granted 730,000 and 960,000 fully vested options during the years ended June 30, 2022 and 2021, a portion of which were allocated to research and development.

Loss from Operations

As a result of the factors described above, the loss from operations was $2,550,000 and $2,828,000 for the years ended June 30, 2022 and 2021, respectively.

42 
 

Other (Income) Expense

 

Other (income) expense was ($10,841,000) and $623,000 for the years ended June 30, 2022 and 2021, respectively. The Company recognized a gain on the dissolution of PA1 of $10,235,000 and a gain of $902,000 for the sale of a domain name. Total interest expense of $302,000 and $658,000 was recorded during the years ended June 30, 2022 and 2021, respectively. Interest of $32,000 and nil was capitalized as part of the 3G project in property and equipment during the years ended June 30, 2022 and 2021, respectively.

 

Interest expense related to deferred compensation, loan payable and convertible notes prior to capitalization of $32,000 to the 3G project was $334,000 and $472,000 for years ended June 30, 2022 and 2021, respectively. The $138,000 decrease is due the dissolution of PA-1 and no interest related to the Pennvest loan during the last six months ended June 30, 2022. Interest expense related to investor warrant modifications was nil and $187,000 for year end June 30, 2022 and 2021.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was $1,500 and $2,800 for the years ended June 30, 2022 and 2021, respectively.

Net Income (Loss) Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net income (loss) attributable to Bion’s stockholders was $8,292,000 and ($3,448,000) for the years ended June 30, 2022 and 2021, respectively, and the net income (loss) per basic common share was $.20 and ($.10) for the years ended June 30, 2022 and 2021, respectively.

 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company's consolidated financial statements for the year ended June 30, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's consolidated financial statements as of and for the year ended June 30, 2022 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

 

Operating Activities

 

As of June 30,2022, the Company had cash of approximately $3,160,000. During the year ended June 30, 2022, net cash used in operating activities was $671,000, primarily consisting of cash operating expenses related to salaries and benefits, and other general and administrative costs such as insurance, legal, accounting, consulting and investor relations expenses as well as the purchase of property and equipment. Cash expenditures were offset by proceeds from financing activities, primarily the exercise of warrants. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.

 

Investing Activities

 

During the year ended June 30, 2022, the Company invested $2,062,000 in the purchase of property and equipment, primarily related to project construction in process. During the year ended June 30, 2022, the Company invested $666,375 in a non-cash purchase of equipment for accounts payable related to the June 6, 2022 notice of completion of certain work in process and an invoice from Buflovak for the next 25% payment on the January 28, 2022 purchase order related to the Initial Project. The $666,375 was included in construction in process and accounts payable at June 30, 2022 and was paid on July 5, 2022 bringing the aggregate payments to $1,999,125 as of the date of this report.

 

Financing Activities

During the year ended June 30, 2022, the Company received gross cash proceeds of $1,737,000 from the exercise of 2,315,550 warrants into shares of the Company’s common stock and paid approximately $19,000 in cash commissions related to the exercise of warrants.

As of June 30, 2022, the Company has debt obligations consisting of: a) deferred compensation of $595,000 and b) convertible notes payable – affiliates of $5,171,000.

 

 

43 
 

Plan of Operations and Outlook

 

As of June 30, 2022, the Company had cash of approximately $3,160,000.

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During fiscal years 2022 and 2021, the Company has faced progressively less difficulty in raising equity funding (but substantial equity dilution has resulted from the larger amounts of equity financing during the periods). However, the Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring all or part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company. During the year ended June 30, 2018 senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. As of June 30 2022, such deferrals/loans totaled approximately $5,765,000 (including accrued interest and deferred compensation converted into convertible obligations and convertible promissory notes but excluding conversions of deferred compensation into the Company's common stock by officers, employees and consultants that have already been completed). The extended constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company's effort to develop its business. The Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again in 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent increased success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project, JVs, Projects (including Integrated Projects) and CAFO Retrofit waste remediation systems (potentially including the Kreider 2 facility. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (debt and equity) during the next twelve months. However, as discussed above, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. During the year ended June 30, 2021 the Company raised gross proceeds of approximately $5,209,000 through the sale of its securities and paid commissions of approximately $165,000, and anticipates raising additional funds from such sales and transactions. During the year ended June 30, 2022 the Company raised gross proceeds for approximately $1,737,000 and paid commissions of approximately $18,600. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

Because the Company is not currently generating significant revenues, the Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project and subsequent Projects.

 

 

44 
 

As indicated above, the Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects and other activities, continue its technology development and/or to successfully develop its business.

 

See “Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution” above and the Company’s Forms 10-K for the year 2009-2021 for discussion and more details related to the dissolution of PA1, the Pennvest Loan and the Kreider 1 project.

 

There is extremely limited likelihood that funds required during the next twelve months or in the periods immediately thereafter will be generated from operations and there is no assurance that those funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company's existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for companies such as Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

CONTRACTUAL OBLIGATIONS

 

We have the following material contractual obligations (in addition to employment and consulting agreements with management and employees):

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The following table summarized the supplemental cash flow information for the year ended June 30, 2022:

Cash paid for noncancelable operating lease included in the operating cash flows  $60,000 
Right of use assets obtained in exchange for operating lease liabilities  $180,586 

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2022:

 

Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (21,136)
Total  $128,864 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2022 were 3 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

Through 3G1 the Company is in the process of developing the Initial Project. See discussion above and in the Notes to our Financial Statements. 

 

 

45 
 

OFF-BALANCE SHEETS ARRANGEMENTS

 

The Company does not have any off-balance sheets arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA

 

The consolidated financial statements are set forth on pages F-1 through F-32 hereto.

 


Item 9.

 

None.

 

Item 9A. Controls and Procedures.

 

Disclosure Controls and Procedures

 

As of June 30, 2022, under the supervision and with the participation of the Company’s President and Principal Financial Officer (the same person), management has evaluated the effectiveness of the design and operations of the Company’s disclosure controls and procedures. Based on that evaluation, the President and Principal Financial Office concluded that the Company’s disclosure controls and procedures were not effective as of June 30, 2022 as a result of the material weakness in internal control over financial reporting discussed below.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting that occurred during the last fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Securities Exchange Act of 1934 Rule 13a-15(f). Our Chief Executive Officer and Principal Financial Officer (the same person) conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO Framework”) and the related guidance provided in Internal Control Over Financial Reporting – Guidance for Smaller Public Companies, also issued by the Committee of Sponsoring Organizations.

 

Based on this evaluation, management has concluded that our internal control over financial reporting was not effective as of June 30, 2022. Our President and Principal Financial Officer concluded we have a material weakness due to our control environment, and one condition caused by this is an inadequate of segregation of duties as well as a lack of timely review and approval of related party transactions and a second condition is the a lack of timely review and approval of capitalized internal costs and interest. Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our internal control system. There is one person involved in the processing of the Company's accounting and banking transactions and a single person with overall supervision and review of the cash disbursements and receipts and the overall accounting process. Therefore, while there are some compensating controls in place, it is difficult to ensure effective segregation of accounting duties. While we strive to segregate duties as much as practicable, there is an insufficient volume of transactions to justify additional full time staff. As a result of this material weakness, we have implemented remediation procedures whereby in May 2006 we engaged an outside accounting and consulting firm with SEC and US GAAP experience to assist us with the preparation of our financial statements, evaluation of complex accounting issues and the implementation of systems to improve controls and review procedures over all financial statement and account balances. In December of 2021, there was a change made to a new outside accounting and consulting firm. We believe that this outside consultant's review improved our disclosure controls and procedures. If this review is effective throughout a period of time, we believe it will help remediate the segregation of duties material weakness. However, we may not be able to fully remediate the material weakness unless we hire more staff. We will continue to monitor and assess the costs and benefits of additional staffing.

This annual report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management’s report on internal control in this annual report.

 

 

46 
 

 

Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subject disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

 

47 
 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

Our directors, executive officers and significant employees/consultants, along with their respective ages and positions are as follows:

 

Name  Age   Position
        
Directors and Officers:        
         
Mark A. Smith   72   Executive Chairman, President, General Counsel, Chief Financial Officer and Director
Edward T. Schafer   76    Director
Jon Northrop   79   Secretary and Director
William O’Neill   63   Chief Executive Officer
Dominic Bassani   75   Chief Operating Officer

 

Mark A. Smith (72) currently serves Bion Environmental Technologies, Inc. as Executive Chairman, President, General Counsel, Chief Financial Officer and a director and has continually served in senior positions since late March 2003. Since that time, he has also served as sole director, President and General Counsel of Bion’s wholly-owned subsidiaries including Project Group and Services Group. Since mid-February 2003, Mr. Smith has served as sole director and President and General Counsel of Bion’s majority-owned subsidiary, Centerpoint Corporation. Mr. Smith also serves as Manager of Bion PA1, LLC and Bion PA2, LLC. Previously, from May 21, 1999 through January 31, 2002, Mr. Smith served as a director of Bion. From July 23, 1999, when he became President of Bion, until mid-2001 when he ceased to be Chairman, Mr. Smith served in senior positions with Bion on a consulting basis. Additionally, Mr. Smith was the president of RSTS Corporation prior to its acquisition of Bion Technologies, Inc. in 1992. Mr. Smith received a Juris Doctor Degree from the University of Colorado School of Law, Boulder, Colorado (1980) and a BS from Amherst College, Amherst, Massachusetts (1971). Mr. Smith has engaged in the private practice of law in Colorado since 1980. In addition, Mr. Smith has been active in running private family companies, Stonehenge Corporation (until 1994), LoTayLingKyur, Inc. (1994-2002) and LoTayLingKyur, LLC (2007-present). Until returning to Bion during March 2003, Mr. Smith had been in retirement with focus on charitable work and spiritual retreat. From July 2018 to March 2020 Mr. Smith served as a senior executive and director at Grow-Ray Technologies, Inc., a private LED lighting company based in Boulder, Colorado, on a consulting basis.

 

Edward T. Schafer (76) Edward Schafer previously served the Company’s senior management team as Executive Vice Chairman and has been a member of the Company’s Board of Directors since January 1, 2011. Mr. Schafer had served as a consultant to Bion since July 2010. Mr. Schafer served as a director of Continental Resources (NYSE-CLR) 2011-2016. He also chairs the Board of Directors of Dynamic Food Ingredients. In addition he has served on the Board of Governors of Amity Technology LLP since 2009. Mr. Schafer served as a trustee of the Investors Real Estate Trust (NASDAQGS-IRET) from September 2009 to October 2011. He also served as a trustee of the IRET from September 2006 through December 2007, when he resigned from the IRET’s Board to serve as Secretary of the U.S. Department of Agriculture under President George W. Bush.  Mr. Schafer, a private investor, is a two-term former Governor of North Dakota. He served as Chief Executive Officer of Extend America, a telecommunications company, from 2001 to 2006, and he has been a member of the Boards of RDO Equipment Co., a privately-owned agricultural and construction equipment company (August 2001 to July 2003) and the University of North Dakota Foundation (June 2005 to December 2007). Since 2019 Mr. Schafer has served on the Board of Directors of Cellular Biomedicine Group (NASDAQ: CBMG) and is Chairman of its Audit Committee. Mr. Schafer serves as a board member of the Center for Innovation at the University of North Dakota and is an adjunct professor at North Dakota State University. Mr. Schafer is a past chair of the Republican Governors Association, the Midwestern Governors’ Association, the Interstate Oil and Gas Compact, the Western Governors’ Association and served as the 29th United States Secretary of Agricultural from 2008 to 2009. Mr. Schafer holds a Master’s degree in Business Administration from the University of Denver. Mr. Schafer brings the following experience, qualifications, attributes and skills to the Company: general business management, budgeting and strategic planning experience from his service as Chief Executive Officer of Extend America and extensive government, regulatory, strategic planning, budgeting administrative and public affairs experience from his service as Governor of North Dakota and Secretary of the US Department of Agriculture.

 

Jon Northrop (79) has served as our Secretary and a Director since March of 2003. Since September 2001 he has been self employed as a consultant with a practice focused on business buyer advocacy. Mr. Northrop is one of our founders and served as our Chief Executive Officer and a Director from our inception in September 1989 until August 2001. Before founding Bion Technologies, Inc., he served in a wide variety of managerial and executive positions. He was the Executive Director of Davis, Graham & Stubbs, one of Denver’s largest law firms, from 1981 to 1989. Prior to his law firm experience, Mr. Northrop worked at Samsonite Corporation’s Luggage Division in Denver, Colorado, for over 12 years. His experience was in all aspects of manufacturing, systems design and implementation, and planning and finance, ending with three years as the Division’s Vice President, Finance. Mr. Northrop has a bachelor’s degree in Physics from Amherst College, Amherst, Massachusetts (1965), an MBA in Finance from the University of Chicago, Chicago, Illinois (1969), and spent several years conducting post graduate research in low energy particle physics at Case Institute of Technology, Cleveland.

 

 

48 
 

William O’Neill (63) has served as Chief Executive officer since May 1, 2022 (he previously held the same position for the period from November 2010 through May 2011). Mr. O’Neill currently also serves as a director of Wise Up Food, LLC, a privately-held company that provides a transparent supply chain and real sustainability information for food retailers (including restaurants) enabling consumers to make informed purchase decisions. He founded Wise Up Food during 2020 and served as its President until May 1, 2022 when his wife assumed that position. From February 2018 through May 2020 he was employed as Vice President Retail & Value-Added Business Teys, USA, as subsidiary of Teys, a large Australian beef packer. From April 2015 through February 2018 Mr. O’Neill served as Vice President Retail of Colorado Premium Foods. From 1990 through 2015 he held marketing and executive epositions with a variey of companies in the agriculture and food service businesses with an emphasis on developing/marketing products in the meat industry. Mr. O’Neill graduated from Gettysburg College in 1981 with a B.A. in economics.

 

Dominic Bassani (75) has served as Chief Operating Officer of Bion Environmental Technologies, Inc. since May 1, 2022 and served as Chief Executive Officer from April 2011. Previously he was a full-time consultant to the Company and served as the General Manager of Bion's Projects Group subsidiary from April 2003 through September 2006. From September 15, 2008 he has served as Director-Special Projects and Strategic Planning of the Company and our Projects Group subsidiary. He has been an investor in and consultant to Bion since December 1999. He is an independent investor and since 1990 has owned and operated Brightcap, a management consulting company that provides management services to early stage technology companies. He was a founding investor in 1993 in Initial Acquisition Corp. that subsequently merged in 1995 with Hollis Eden Corp. (HEPH), a biotech company specializing in immune response drugs. From early 1998 until June 1999 he was a consultant to Internet Commerce Corp. (re-named EasyLink Services International Corporation) (ESIC), a leader in business-to-business transactions using the Internet. He is presently an investor in numerous private and public companies primarily in technology related businesses. From 1980 until 1986, Mr. Bassani focused primarily on providing management reorganization services to manufacturing companies and in particular to generic pharmaceutical manufacturers and their financial sponsors.

 

Family Relationships

 

There are currently no family relationships among our Directors and Executive Officers.

 

Compliance with Section 16(a) of the Exchange Act

 

Section 16(a) of the Exchange Act requires our officers and directors, and stockholders owning more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission. The Company is not aware of any persons who failed to timely file reports under this section.

 

Involvement in Legal Proceedings

 

To the best of our knowledge, during the past five years, none of the following occurred with respect to our directors or executive officers:

 

(1)any bankruptcy petition filed by or against any business of which one of them was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

 

(2)any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

(3)being subject to any order, judgment or decree of any court of competent jurisdiction, permanently or temporarily inquiring, barring, suspending or otherwise limiting involvement in any type of business, securities or banking activities; and

 

(4)being found by a court of competent jurisdiction, the SEC or the CFTC to have violated Federal or state securities or commodities laws.

 

Audit Committee

 

The Company has no audit committee and is not now required to have one, or an audit committee financial expert.

 

Code of Ethics

 

To date, the Company has not adopted a code of business conduct and ethics applicable to its officers, directors or accounting officer.

 

 

49 
 

Advisory Group

 

The Company, which has only 7 full-time employees/consultants (all of whom are effectively ‘department heads’), has utilized many outside parties as consultants and contract workers for various roles to augment our management capabilities and expertise. Over the last year the Company has begun to establish a more formal ‘advisory’ relationship with some of these people to insure their availability for consultation by our senior management (separate from specific consulting engagements). At present, a) William Rupp (meat and beef industry), b) Matthew Lamb (agriculture/animal husbandry/dairy), c) Stanley Rapp (government affairs), d) Dennis Tristao (agricultural tech, engineering and agricultural/environmental policy) and e) Dennis Bracht (organic seed, corn/feed grain cultivation and related matters) have accepted roles as members of our Advisory Group. The Company anticipates that additional persons will be added to this group over time.

 

ITEM 11. EXECUTIVE COMPENSATION.

 

The Company does not have a compensation committee due to its small size and limited resources. The Board of Directors directly reviews and authorizes all compensation matters.

 

SUMMARY COMPENSATION TABLE

 

The following table sets forth the compensation paid to, or accrued for, each of our current executive officers during each of our last two fiscal years.

 

Summary Compensation

 

Name and Principal Position  Fiscal Year  

Salary

(1)

   Bonus   Stock Awards   Option Awards (2)  

Non-Equity Incentive Plan

Compen- sation

  

Nonqualified

Deferred Compensation Earnings

   Other Compen -sation   Total 
                                     
Mark A. Smith (3)  2022   $230,000   $—     $—      115,200    —      —      —     $345,200 
President and Chief  2021   $229,460   $—     $—      277,500    —      —      —     $506,960 
Financial Officer Since March 25, 2003,                                            
Director                                            
                                             
Brightcap/Dominic Bassani (4)  2022   $372,000   $—     $—      115,200    —      —      —     $487,200 
VP–Special Projects & Strategic  2021   $372,000   $—     $—      277,500    —      —      —     $649,500 
Planning and Chief Operating Officer                                            
                                             
William O’Neill  2022   $45,000   $—     $—      —      —      —      —     $45,000 
Chief Executive Officer (5)  2021   $—     $—     $—           —      —      —     $—   

 

1.Includes compensation paid by Bion Environmental Technologies, Inc. and our wholly owned subsidiaries.
2.Reflects the dollar amount expensed by the Company during the applicable fiscal year for financial statement reporting purposes pursuant to ASC 718.
3.Since October 2016, the Company approved a month-to-month contract extension with Smith which included a monthly deferred salary of $18,000 and the right to convert up to $300,000 of deferred compensation, at his sole election, at $0.75 per share until December 31, 2022. On May 1, 2022 Smith’s salary was changed to $25,000 a month with cash portion of $20,000 and $5,000 deferred compensation. Smith also has the right to convert his deferred compensation in whole or in part, at this sole election, at any time in an amount at "market" or into securities sold in the Company’s most current/recent private offering. During fiscal year 2021 the Company paid Smith $13,460 for payroll taxes on his deferred compensation conversions which was treated as salary.
4.On February 10, 2015, Bassani agreed to an extension to continue his employment through December 31, 2017 at an annual salary of $372,000 effective January 1, 2015. During October 2016, Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share which was expanded on April 27, 2017 to the right to convert up to $300,000). During February 2018, the Company agreed to the material terms of a binding two-year extension agreement, while a fully executed agreement is still being negotiated. Bassani’s annual salary will remain at $372,000 and the Company agreed to pay him $2,000 per month to be applied to life insurance premiums. The Company granted Bassani 2,000,000 fully vested options at $0.75 per share with an expiry date of December 31, 2024 which contain a 90% execution bonus and the options may be extended for an additional 5 years at $0.01 per share per extension year. On August 1, 2018, his agreement was extended and he agreed to provide services to the Company on a full-time basis through December 31, 2022 plus two years after that on a part-time basis. Currently Bassani receives $25,000 per month in cash and $6,000 per month is deferred.
5.On May 1, 2022 Bill O’Neill joined the Company with an annual salary of $420,000 which include $10,000 monthly deferred compensation to be paid at the discretion of the Board. There is an additional $1,500 per month health insurance allowance. Terms of the contract are thirty-seven months, with a re-evaluation after thirteen months. Bill O’Neil was previously paid as a contractor through Identifoods. Total payments to Identifoods for the years ended June 30, 2022 and June 2021, respectively, were $165,000 and $5,000.
6.Mr. Schafer's was moved to the Director’s Compensation table below as he no longer holds an executive position with the Company.

 

 

50 
 

 

Employment Agreements:

 

Mark A. Smith (“Smith”) has held the positions of Executive Chairman, Director, President and General Counsel of Company and its subsidiaries under various agreements and terms since March 2003 (details regard earlier years and periods between 2003 and 2011 may be found in the Company’s prior Forms 10-K and other SEC filings). During July 2011, the Company entered into an extension agreement pursuant to which Smith continued to hold his current positions in the Company through a date no later than December 31, 2012. Commencing January 1, 2012, Smith’s monthly salary was $20,000, which has been accrued and deferred. In addition, Smith has been issued 90,000 shares of the Company’s common stock in two tranches of 45,000 shares on each of January 15, 2013 and 2014, respectively. As part of the extension agreement, Smith was also granted 200,000 options, which vested immediately, to purchase common shares of the Company at a price of $3.00 per share and which options were originally to expire on December 31, 2019. Effective July 15, 2012, the Company entered into an extension agreement pursuant to which Smith will continue to hold his current positions in the Company through a date no later than June 30, 2014. Effective September 2012, Smith’s monthly salary became $21,000 (which is currently being deferred). In addition, Smith was issued 150,000 shares of the Company’s common stock in two tranches of 75,000 shares on each of January 15, 2014 and 2015, which shares vested immediately. As part of the extension agreement, Smith was also granted a bonus of $25,000 paid in warrants, which vested immediately, to purchase 250,000 shares of the Company’s common stock at a price of $2.10 per share and which warrants expire on December 31, 2018 and a contingent stock bonus of 100,000 shares payable on the date on which the Company’s stock price first reaches $10.00 per share (regardless of whether Smith is still providing services to the Company on such date). Mr. Smith has voluntarily reduced his monthly deferred salary accrual to $14,000 due to the Company’s financial situation. During September 2014, Smith agreed to continue his employment agreement through April 15, 2015 and also agreed to continue to defer his temporarily reduced salary of $14,000 per month.  On February 10, 2015, the Company executed an Extension Agreement with Smith pursuant to which Smith extended his employment with the Company to December 31, 2015 (with the Company having an option to extend his employment an additional six months).  As part of the Extension Agreement, the balance of Smith’s existing convertible note payable of $854,316 as of December 31, 2014, adjusted for conversions subsequent to that date, was replaced with a new convertible note with an initial principal amount of $760,519 with terms that i) materially reduced the interest rate by 50% (from 8% to 4%), ii) increased the conversion price by 11% (from $0.45 to $0.50), iii) set the conversion price at a fixed price so there can be no further reductions, iv) reduced the number of warrants received on conversion by 75% (from 1 warrant per unit to 1/4 per unit) and v) extended the maturity date to December 31, 2017 (which maturity date was subsequently extended to July 1, 2019).  Additionally, pursuant to the Extension Agreement, Smith: i) continued to defer his cash compensation ($18,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation,  ii) cancelled 150,000 contingent stock bonuses previously granted to him by the Company, iii) was granted 150,000 new options which vested immediately and iv) outstanding options and warrants owned by Smith (and his donees) were extended and had the exercise prices reduced to $1.50 (if above that price). Due to expiration of his most recent extension, Mr. Smith is currently serving the Company on a month-to –month basis. On April 29, 2022, Smith’s monthly salary was increased to $25,000, of which $5,000 is deferred each month

 

51 
 

 

Dominic Bassani (“Bassani”) has served in senior management positions with the Company (as a full-time consultant) since 2001 (see prior Forms 10-K for earlier years and other filings with the SEC). Since March 31, 2005, the Company has had various agreements with Brightcap, Bassani’s family consulting company, through which the services of Bassani were provided through 2011. On September 30, 2009 the Company entered into an extension agreement with Brightcap pursuant to which Bassani provided services to the Company through September 30, 2012 for $312,000 annually (currently deferred). The Board appointed Bassani as the Company's CEO effective May 13, 2011 in which position he served until May 2022. On July 15, 2011, Bassani, Brightcap and the Company agreed to an extension/amendment of the existing agreement with Brightcap which provided that Bassani serve as CEO through June 30, 2013 and would continue to provide full-time services to the Company in other capacities through June 30, 2014 at a salary of $26,000 per month. In addition Bassani was to be issued 300,000 shares of the Company’s common stock issuable in three tranches of 100,000 shares on each of January 15, 2015, 2016 and 2017, respectively. Bassani was also granted 725,000 options, which vested immediately, to purchase shares of the Company’s common stock at $3.00 per share which options expired on December 31, 2019. Effective July 15, 2012, Bassani, Brightcap and the Company agreed to a further extension/amendment of the existing agreement with Brightcap which provided that Bassani would continue to provide the services of CEO through June 30, 2014. Bassani continued to provide full-time services to the Company at a cash salary of $26,000 per month (which has been deferred) and Bassani would be issued 300,000 shares of the Company’s common stock issuable in two tranches of 150,000 shares on each of January 15, 2015 and 2016, respectively, which shares would be immediately vested upon issuance. As part of the extension agreement, Bassani was also granted a bonus of $5,000 paid in warrants, which vested immediately, to purchase 50,000 shares of the Company’s common stock at a price of $2.10 per share and which warrants expired on December 31, 2018. During September 2014, Bassani agreed to extend his employment agreement until April 15, 2015 and that previously issued and expensed share grants of 100,000 and 150,000 shares that were to be issued on January 15, 2015, would be deferred until January 15, 2016.  On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.)  As part of the agreement, the Company’s existing loan payable, deferred compensation and convertible note payable to Bassani, were restructured into two promissory notes as follows: a) The of sum of the cash loaned by Bassani to the Company of $279,000 together with $116,277 of unreimbursed expenses through December 31, 2014 were placed into a new promissory note with initial principal of $395,277 which was due and payable on December 31, 2015.  In connection with these sums and the new promissory note, Bassani was issued warrants to purchase 592,916 shares of the Company’s common stock at a price of $1.00 until December 31, 2020; and b) the remaining balances of the Company’s accrued obligations to Bassani ($1,464,545) were replaced with a new convertible promissory note with terms that compared with the largest prior convertible note obligation to Bassani:  i) materially reduced the interest rate by 50% (from 8% to 4%), ii) increased the conversion price by 11% (from $0.45 to $0.50), iii) set the conversion price at a fixed price so there can be no further reductions, iv) reduced the number of warrants received on conversion by 75% (from 1 warrant per unit to 1/4 per unit) and v) extended the maturity date to December 31, 2017 (See Notes to Financial Statements) (which maturity date was subsequently extended to July 1, 2019.  Additionally,  pursuant to the Extension Agreement, Bassani i) will continue to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation, ii) cancelled 250,000 contingent stock bonuses previously granted to him by the Company, iii) was granted 450,000 new options which vested immediately and iv) outstanding options and warrants owned by Bassani (and his donees) have been extended and had the exercise prices were reduced to $1.50 (if above that price). On May 5, 2013, the Board of Directors approved agreements with Bassani and Smith, with effective date of May 15, 2013, in which Bassani and Smith agreed to continue to defer their respective cash compensation through April 30, 2014 (unless the Board of Directors elected to re-commence cash payment on an earlier date) and extended the due dates of their respective deferred cash compensation until January 15, 2015. The Company provided Bassani and Smith with convertible promissory notes which reflected all the terms of these agreements to which future accruals were added as additional principal. These convertible promissory notes were altered as set forth in the paragraphs below. As part of the agreements, Bassani and Smith also forgave any possible obligations that Bion may have owed each of them in relation to unused vacation time for periods (over 10 years) prior to June 30, 2012. In consideration of these agreements, Bassani and Smith: a) have been granted 50% ‘execution/exercise’ bonuses (subsequently increased to 75%) to be effective upon future exercise of outstanding (or subsequently acquired) options and warrants owned by Bassani and Smith (and their respective donees) and in relation to contingent stock bonuses; b) their warrants and options, if due to expire prior to December 31, 2018, were extended to that date (and later further extended); and c) other modifications were made. Currently Bassani receives $25,000 per month in cash and $6,000 per month of deferred compensation.

 

 

52 
 

 

Effective January 1, 2011, the Company entered into an employment agreement with Edward Schafer (“Schafer”) pursuant to which for a period of three years, Schafer provided senior management services to the Company on an approximately 75% full time basis, initially as Executive Vice Chairman and as a director. Compensation for Schafer’s services were initially set at an annual rate of $250,000, which was to consist of $150,000 in cash compensation and $100,000 payable in the Company’s common stock. Commencing the month following the first calendar month-end after the Company has completed an equity financing in excess of $3,000,000 (net of commissions and other offering expenses), Schafer’s compensation was to be at an annual rate of $225,000, all of which would have been payable in cash. Effective July 15, 2012, the Company entered into a deferral/employment/ compensation agreement with Schafer pursuant to which Schafer provided senior management services to the Company on an approximately 75% full time basis, as Executive Vice Chairman and as a director. Basic compensation for Schafer’s services remained unchanged and Schafer was issued 100,000 options to purchase shares of the Company’s common stock at $2.10 per share until December 31, 2018, which options immediately vested and a contingent stock bonus of 25,000 shares payable on January 1 of the first year after the Company’s stock price first reaches $10.00 per share (regardless of whether Schafer is still providing services to the Company on such date). Since May 15, 2012 Schafer has deferred the cash portion of the compensation due him from the Company, in consideration of which he has been granted a 50% ‘execution/exercise’ bonus to be effective upon future exercise of outstanding (or subsequently acquired) options and warrants owned by Schafer (and his donees) and in relation to contingent stock bonuses. Effective January 1, 2014, Mr. Schafer agreed to continue his services to the Company as Director without periodic compensation in light of the Company’s financial situation. Mr. Schafer agreed not to receive any periodic compensation (cash or deferred) commencing January 1, 2014 and agreed to be compensated with bonuses from time-to-time as determined to be appropriate by the Board of Directors. No such bonuses have been declared to date. On February 10, 2015, the Company entered into an agreement with Schafer pursuant to which Schafer continued to provide services to the Company through December 31, 2015.  As part of the agreement, unreimbursed expenses of $15,956 due to Schafer at December 31, 2014 were replaced with a new promissory note with initial principal of $15,956 which was due and payable on December 31, 2015 and Schafer was issued warrants to purchase 7,978 shares of the Company’s common stock at a price of $1.00 until December 31, 2020. Schaefer’s deferred compensation for 2014 (and prior years) in the amount of $394,246 (including a sum of $120,000 for calendar year 2014) was placed in a convertible promissory note (See Notes to Financial Statements).  Additionally, pursuant to the agreement, i) the exercise period of outstanding options and warrants owned by Schafer were extended, ii) certain of Schafer’s outstanding options and warrants had the exercise prices reduced to $1.50 (if above that price), and iii) 25,000 contingent stock bonuses previously granted to Schafer have been cancelled by the Company. Effective June 30, 2016, Schafer and the Company determined that due to other obligations Schafer’s involvement with the Company during the 2016 fiscal year was less than anticipated and reduced his fiscal year 2016 compensation (all of which had been deferred) by $160,000 and agreed that future compensation will be determined periodically based on evaluation by the board of directors. Since 2018 Schaefer has no longer held any executive positions with the Company.

 

William O’Neill (“O’Neill”) has been hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $25,000 cash and $10,000 deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  As set forth in the Employment Agreement, the Company and Wise Up Foods LLC (an entity founded by O’Neill with which he continues to serve as a Director and of which O’Neill and his family members are majority owners) sets forth the intent to form “… a strategic alliance and committed to collaborate on projects each company has in their respective pipelines.  WUF and Bion will work together to use/create technology that will deliver the consumer verified sustainable results produced by Bion’s technology and technology platform.  The key to the strategic relationship is each company’s commitment to deliver real and verified results to the consumer – free of marketing hype and greenwashing…”.

 

Bassani, Smith and Schafer each agreed, effective June 30, 2017, to extend the maturity date of the outstanding convertible promissory notes set forth in the paragraphs above from December 31, 2017 to July 1, 2024 the last of which took place on February 6, 2020 when Bassani, Smith and Schafer (and a shareholder) each agreed to extend the maturity dates of their 2020 Convertible Obligations (“CVObligations”) (formerly convertible promissory notes) to July 1, 2024.

 

 

53 
 

 

 

Effective May 4, 2020 the Company agreed that all options and warrants owned (or subsequently acquired by conversion of CvObligations) by its officers, directors and key employees and consultants (including Jon Northrop (director), Bassani, Smith and Schafer) and their donees be amended to: a) lower the exercise price to $0.75 for any options/warrants with higher exercise prices and b) extend the expiration dates to December 31, 2024. Subsequently, it was agreed that if any of the CVObligations are converted, the warrants in units received will be exercisable through a date 3 years after conversion date.

Other Agreements

The Company has declared contingent deferred stock bonuses to its key employees and consultants at various times throughout the years. The stock bonuses were contingent upon the Company’s stock price exceeding a certain target price per share, and the grantees still being employed by or providing services to the Company at the time the target prices are reached. During the year ended June 30, 2017, pursuant to agreement with the employees and a consultant who had been granted the outstanding contingent stock bonuses, the Company cancelled all 117,500 outstanding contingent stock bonuses. In consideration for the cancellations, the Company granted 109,500 fully vested options to these employees and a consultant to purchase common stock of the Company at $1.00 per share until December 31, 2024 (including recent extensions).

 

 

54 
 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

 

The following table sets forth the number of shares of common stock covered by outstanding stock option awards that are exercisable and unexercisable, and the number of shares of common stock covered by unvested restricted stock awards for each of our named executive officers as of June 30, 2021.

 

Outstanding Equity Awards at Fiscal Year-End
 
    Option Awards    Stock Awards 
                                              
Name   

Number of

Securities

Underlying Unexercised

Options (#) Exercisable

    

Number of

Securities

Underlying

Unexercised

Options (#)Unexercisable

    

Equity

Incentive Plan

Awards:

Number of

Securities

Underlying

Unexercised

Unearned

Options (#)

    

Option

Exercise

 Price ($)

    

Option

Expiration

Date

    

Number of

Shares or

Units of

Stock That

Have Not

Vested (#)

    

Market

Value of

Shares or

Units of

Stock That

Have Not

Vested

    

Equity

Incentive Plan

Awards:

Number of

Unearned Shares,

Units or Other

Rights That Have

Not Vested

    

Equity

Incentive Plan

Awards:

Market or

Payout Value of

Unearned Shares,

Units or Other

Rights That Have

Not Vested

 
Mark A. Smith (1)   100,000    —      —      0.60    2024    —      —      —      —   
Mark A. Smith (1)   1,675,000    —      —      0.75    2024    —      —      —      —   
Mark A. Smith (2)   200,000    —      —      0.75    2024    —      —      —      —   
Mark A. Smith (1)   250,000    —      —      1.20    2026    —      —      —      —   
Mark A. Smith (1)   200,000    —      —      1.00    2025    —      —      —      —   
 Brightcap/ Dominic Bassani (1)   1,675,000    —      —      0.75    2024    —      —      —      —   
Brightcap/ Dominic Bassani (2)   2,000,000    —      —      0.75    2024    —      —      —      —   
Brightcap/ Dominic Bassani (1)   250,000    —      —      1.20    2026    —      —      —      —   
Brightcap/ Dominic Bassani (1)   200,000    —      —      1.00    2025    —      —      —      —   
 Edward Schafer (3)   25,000    —      —      0.60    2024    —      —      —      —   
Edward Schafer (3)   300,000    —      —      0.75    2024    —      —      —      —   
Edward Schafer (1)   600,000    —      —      0.75    2024    —      —      —      —   
Edward Schafer (2)   190,000    —      —      0.75    2024    —      —      —      —   
Edward Schafer (1)   50,000    —      —      1.20    2026    —      —      —      —   
Edward Schafer (1)   50,000    —      —      1.00    2025    —      —      —      —   

 

(1)  Options are subject to a 75% execution/exercise bonus upon notice of intent to exercise.

 

(2)  Options are subject to a 90% execution/exercise bonus upon notice of intent to exercise.

 

(3)  Options are subject to a 50% execution/exercise bonus upon notice of intent to exercise.

 

 

55 
 

 

Director Compensation

 

Members of the Board of Directors do not currently receive any cash compensation for their services as Directors, but are entitled to be reimbursed for their reasonable expenses in attending meetings of the Board. However, it is the Company's intention to begin to pay cash compensation to Board members at some future date (probably during the current fiscal year).

 

DIRECTOR COMPENSATION

 

The following table sets forth certain information regarding the compensation paid to directors during the fiscal year ended June 30, 2022:

 

Director Compensation
                                    
Name   Fees earned or paid in Cash ($)    Stock Awards ($)    Option Awards ($)(1)    Non-equity incentive plan compensation ($)    

Nonqualified deferred

 compensation earnings ($)

    All other compensation ($)    Total ($) 
                                    
Jon Northrop   —      —      28,800    —      —      —      28,800 
Edward Schafer   —      —      28,800    —      —      —      28,800 

 

(1)Reflects the dollar amount expensed by the Company during the applicable fiscal year for financial statement reporting purposes pursuant to ASC 718.

 

 

ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

As of August 1, 2022, the Registrant had 44,120,320 shares of common stock issued and 43,416,001 shares of common stock outstanding. (the balance of 704,309 shares are owned by Centerpoint, the Company's majority-owned subsidiary).

 

The following table sets forth certain information regarding the beneficial ownership of our common stock as of August 1, 2022 by:

 

  each person that is known by us to beneficially own more than 5% of our common stock;

 

  each of our directors;

 

  each of our executive officers and significant employees; and

 

  all our executive officers, directors and significant employees as a group.

 

Under the rules of the Securities and Exchange Commission, beneficial ownership includes voting or investment power with respect to securities and includes the shares issuable under stock options, warrants and convertible securities that are exercisable/convertible within sixty (60) days of August 1, 2021.  Those shares issuable under stock options, warrants and/or convertible securities are deemed outstanding for computing the percentage of each person holding options, warrants and/or convertible securities but are not deemed outstanding for computing the percentage of any other person.  The percentage of beneficial ownership schedule is based upon 43,416,001 shares outstanding as of August 1, 2022.  The address for those individuals for which an address is not otherwise provided is c/o Bion Environmental Technologies, c/o PO Box 323, Old Bethpage, NY 11804.  To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting power and investment power with respect to all shares of common stock listed as owned by them.

 

 

56 
 

 

Name and Address  Number   Percent of Class Outstanding   Entitled
To Vote
 
             

Centerpoint Corporation(1)

c/o PO Box 323

Old Bethpage, NY 11604

   704,309    1.6%   —   
                

Dominic Bassani (2)

64 Village Hills Drive

Dix Hills, NY 11746

   14,492,592    25.5%   25.8%
                

Mark A. Smith(3)

401 N. Riverside Beach #408

Pompano Beach, FL 33062

   9,699,447    18.0%   18.2%
                

Christopher B. Parlow(4)

23 Longbow Drive

Commack, NY 11725

   8,497,857    16.1%   16.3%
                
Danielle Lominy(5)
c/o Dominic Bassani
64 Village Hill Drive
Dix Hills, NY 11746
   8,487,854    16.1%   16.3%
                
Edward Schafer (6)
c/o PO Box 323
Old Bethpage, NY 11804
   2,934,383    6.3%   6.4%
                
William O’Neill (8)
107 12th Street E
St. Petersburg, FL 3371
   1,051,125    6.2%   2.4%
                
Craig Scott
3131 North Daffodil Dr.
Billings, MT 59102
   2,578,965    2.3%   5.7%
                
Jon Northrop (9)
59 Chestnut Street
Westfield, New York 14787
   613,135    5.6%   1.4%
                

Anthony Orphanos(7)

c/o Blacksmith Advisors, LLC

320 Park Avenue 18th Floor

New York, NY 10022

   2,767,032    6.2%   6.3%
All executive officers and directors as a group (6 persons)   31,369,647    44.4%   45.1%

 

(1)Centerpoint Corporation is currently majority owned by the Company. Under Colorado law, Centerpoint Corporation is not entitled to vote these shares unless otherwise ordered by a court. These shares of common stock may be distributed to the shareholders of Centerpoint Corporation at a future date pursuant to a dividend declared during July 2004. The shares distributed to Bion, if any, will be cancelled immediately upon receipt.

(2)Includes 62,201 shares, 3,025,000 shares underlying options and 965,000 shares underlying warrants held directly by Mr. Bassani; 354,342 shares and 250,000 shares underlying warrants held by Mr. Bassani’s wife; and, 839,933 shares held in IRA accounts of Mr. Bassani and his wife. Also included are the shares set forth below owned (directly and indirectly) by Mr. Bassani’s daughter, Danielle Lominy (formerly Danielle Bassani) who resides within his residence and are included in Mr. Bassani’s beneficial ownership for purposes of the calculation including: a) 570,000 shares directly  b) 646,458 shares underlying warrants owned directly; and  c) Danielle Lominy is the 50% beneficiary of the Dominic Bassani 2019 Irrevocable Trust (“2019Trust”) which owns: i) 3,000,000 warrants and 1,000,000 options  to purchase shares of the Company’s common stock and, as a result, Danielle Lominy is the beneficial owner of 1,500,000 shares underlying warrants and 500,000 shares underlying options and ii)  $2,255,500 principal amount of the Company’s 2020 Convertible Obligation (“CVObligation”) which is convertible into  4,511,000 shares and 3,008,837 warrants and,  as a result, Danielle Lominy is the beneficial owner of 2,255,500  shares underlying conversion of the CVObligation and 1,504,419 shares underlying the warrants issuable on conversion of the CVObligation. The total also includes: a) 699,398 and 466,499 underlying warrants that could be issued on the conversion (at the election of Bassani) by Mr. Bassani of convertible notes in the amount of $349,699, (@ $0.50 price) and   b) 466,957 shares of common stock that could be issued on the conversion (at the election of Bassani) by Mr. Bassani of convertible notes in the amount of $280,174 (@ $0.60 price) and c) 386,885 shares of common stock that could be issued on the conversion (at the election of Bassani) of deferred compensation in the amount of $413,966. Mr. Bassani disclaims ownership of 1,511,477 shares underlying warrants held by the Danielle Christine Bassani Trust, which is separately itemized herein. Mr. Bassani’s adult daughter Danielle Lominy (formerly Danielle Bassani), who resides within his residence, is the beneficiary of the Danielle Christine Bassani Trust and Mr. Bassani is not one of the trustees of the trust. Mr. Bassani further disclaims beneficial ownership of shares and warrants owned by various other family members (including Christopher Parlow who is itemized separately), none of whom live with him or are his dependents, and such shares are not included in this calculation.

 

57 
 

 

(3)Includes 324,077 shares held jointly by Mark A. Smith with his wife, 62,535 shares held by Mark Smith in an IRA; 2,425,000 shares underlying options held directly by Mr. Smith, 1,271,944 shares underlying warrants held directly by Mr. Smith; 53,756 shares held by his wife in her IRA, 12,681 shares of common stock held by LoTayLingKyur Foundation and 100,001 shares of common stock and 100,001 underlying warrants held by LoTayLingKyur LLC which is controlled by Mr. Smith and his wife. Also includes 2,664,726 shares and 2,664,726 warrants underlying units that could be issued on the conversion (at the election of Mr. Smith) by Mr. Smith of his 2020 Convertible Obligations in the aggregate amount of $1,332,363. Mr. Smith has the option to convert this amount into units with each unit consisting of 1 share of common stock and 1 warrant exercisable at $0.75 per share. The conversion price will be $0.50 per unit.  Also includes 20,000 shares of common stock that could be issued on the conversion (at the election of Mr. Smith) of deferred compensation in the amount of $10,000. Does not include shares and warrants owned by various family members of which Mr. Smith disclaims beneficial ownership. Mr. Smith is also the President of Centerpoint, although shares owned by Centerpoint are not entitled to a vote while held by Centerpoint.

(4)Includes 2,005 shares held directly by Christopher Parlow, 65,000 shares held jointly with wife, 250,000 shares owned by the Christopher Parlow Trust and 50,000 shares owned by Christopher Parlow’s minor daughters. Also includes 1,614,000 shares underlying warrants held by the Christopher Parlow Trust, 147,154 shares underlying warrants held jointly with wife, 150,000 warrants held directly by Mr. Parlow and 459,780 shares underlying warrants held by Mr. Parlow’s minor daughters. In addition, Christopher is the 50% beneficial owner of the Dominic Bassani 2019 Irrevocable Trust (“2019 Trust”) which owns 3,000,000 warrants to purchase shares of the Company’s common stock and 1,000,000 options and as a result, Christopher Parlow is the beneficial owner of 1,500,000 shares underlying exercise of the warrants and 500,000 shares underlying exercise of the options. Additionally, the 2019 Trust owns $2,255,500 principal amount of the Company’s 2020 Convertible Obligation (“CVObligation”) which is convertible @$0.50 into 4,511,000 shares and 3,008,837 warrants. As a result, Christopher Parlow is the beneficial owner of 2,255,500 shares underlying conversion of the CVObligation and 1,504,418 shares underlying the warrants issuable on conversion of the CVObligation.

(5)Includes 170,000 shares held directly by Danielle Lominy (formerly Danielle Bassani), 1,511,477 shares underlying warrants held by The Danielle Christine Bassani Trust, 400,000 shares owned by the Danielle Bassani Trust, 311,458 shares underlying warrants, 105,000 shares underlying warrants owned jointly with husband and 230,000 shares underlying warrants owned by Danielle Lominy’s daughter. In addition, Danielle is the 50% beneficial owner of the Dominic Bassani 2019 Irrevocable Trust (“2019 Trust”) which owns 3,000,000 warrants to purchase shares of the Company’s common stock and 1,000,000 options and, as a result Danielle Lominy is the beneficial owner of 1,500,000 shares underlying exercise of the warrants and 500,000 shares underlying exercise of the options. Additionally, the 2019 Trust owns $2,255,500 principal amount of the Company’s 2020 Convertible Obligation (“CVObligation”) which is convertible @ $0.50 into 4,511,000 shares and 3,008,837 warrants. As a result, Danielle Lominy is the beneficial owner of 2,255,500 shares underlying conversion of the CVObligation and 1,504,419 shares underlying the warrants issuable on conversion of the CVObligation.

(6)Includes 319,589 shares held directly by Mr. Orphanos; 156,750 shares underlying warrants held directly by Mr. Orphanos;120,263 shares held jointly with his wife; 1,425,374 shares held in IRA accounts; and 745,027 shares of common stock that could be issued on conversion of $447,016 convertible notes (.60 conversion price).  Not included are 1,450,878 common shares owned by certain clients of Blacksmith Advisors, over which Mr. Orphanos exercises discretionary authority (which shares include: 98,000 shares owned by Danielle Lominy (formerly Danielle Bassani). Mr. Orphanos disclaims beneficial ownership of the shares listed in the preceding sentences because he has no pecuniary interest in the shares.

(7)Includes 158,254 shares held directly by Mr. Schafer, options to purchase 1,215,000 shares and warrants to purchase 23,934 shares. Also includes 1,001,574 shares and 500,787 warrants underlying units that could be issued on the conversion by Mr. Schafer of a deferred compensation promissory note in the amount of $500,787 Mr. Schafer has the option to convert this amount into units with each unit consisting of 1 share of common stock and ½ warrant exercisable at $0.75 per share until December 31, 2024. The conversion price is $0.50 per unit. Also includes 34,834 shares of common stock that could be issued on the conversion (at the election of Mr. Schafer) by Mr. Schafer of a convertible note in the amount of $20,900. The conversion price will be $0.60 per share.

 

58 
 

 

(8)Includes 50,000 underlying warrants held directly by Mr. O’Neill, 1,125 shares held by Mr. O’Neill’s wife, and 1,000,000 underlying warrants held by Identifoods, LLC which is owned by Mr. O’Neill and his wife.

(9)Includes 504,894 shares, 1,470,000 shares underlying options and 573,747 shares underlying warrants held directly by Mr. Scott.  The total also includes 30,324 shares of common stock that could be issued on the conversion (at the election of Mr. Scott) of deferred compensation in the amount of $32,445.81.  Does not include shares and warrants owned by various family members of which Mr. Scott disclaims beneficial ownership.

(10)Includes 120,635 shares held directly by Jon Northrop and options to purchase 492,500 shares held by Jon Northrop. Does not include shares or options owned by the adult children of Jon Northrop nor his former wife.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

Other than the employment/consulting agreements, deferred compensation arrangements and conversions of debt described above in Item 1 Business and Item 11 Executive Compensation, there are no related party transactions except that:

 

No directors of the Company are considered to be independent directors.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

 

Audit Fees

 

In January 2017 the Company engaged Eide Bailly LLP as its independent registered public accounting firm.  The aggregate fees billed for the fiscal years ended June 30, 2022 and June 30, 2021 by Eide Bailly LLP for professional services rendered for the audit of the Company's annual financial statements and reviews of interim financial statements included in the Company's quarterly reports on Form 10-Q (and related matters) were $74,000 and $56,800, respectively.

 

Audit Related Fees

 

There were no fees billed by Eide Bailly LLP for audit-related fees in each of the last two fiscal years ended June 30, 2022 and June 30, 2021.

 

Tax Fees

 

The aggregate fees billed for tax services rendered by Eide Bailly LLP for tax compliance and related services for the two fiscal years ended June 30, 2022 and June 30, 2021 were nil and $3,600, respectively.

 

All Other Fees

 

None.

 

Audit Committee Pre-Approval Policy

 

Under provisions of the Sarbanes-Oxley Act of 2002, the Company's principal accountant may not be engaged to provide non-audit services that are prohibited by law or regulation to be provided by it, and the Board of Directors (which serves as the Company's audit committee) must pre-approve the engagement of the Company's principal accountant to provide audit and permissible non-audit services. The Company's Board has not established any policies or procedures other than those required by applicable laws and regulations.

 

59 
 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

 

(a) Exhibits 

 

Exhibit
Number
Description and Location
   
3.1

Amended and Restated Articles of Incorporation of Bion Environmental Technologies, Inc., filed with the Secretary of State of the State of Colorado on April 11, 2022. (Incorporated by reference to Exhibit 3.1 filed with Form 8-K filed on April 12, 2022).

3.2

Amended and Restated Bylaws. (Incorporated by reference to Exhibit 3.2 filed with Form 8-K filed on January 4, 2022).

10.1 Subscription Agreement dated January 10, 2002 between Bion Environmental Technologies, Inc. and Centerpoint Corporation regarding issuance of stock in exchange for cash and claims regarding Aprilia (Incorporated by reference to Exhibit 10.1 filed with Form 10SB12G on November 14, 2006).
10.2 Agreement dated March 15, 2002 and effective January 15, 2002 between Bion Environmental Technologies, Inc. and Centerpoint Corporation regarding purchase of warrant and management agreement (Incorporated by reference to Exhibit 10.2 filed with Form 10SB12G on November 14, 2006).
10.3 Agreement dated February 12, 2003 between Bion Environmental Technologies, Inc. and Centerpoint Corporation canceling provisions of the Subscription Agreement by and between Bion Environmental Technologies, Inc. and Centerpoint Corporation (Incorporated by reference to Exhibit 10.3 filed with Form 10SB12G on November 14, 2006).
10.4 Promissory Note and Security Agreement between Bion Environmental Technologies, Inc. and Bright Capital, LLC (Incorporated by reference to Exhibit 10.4 filed with Form 10SB12G on November 14, 2006).
10.5 Letter Agreement with Bright Capital, Ltd. (Incorporated by reference to Exhibit 10.8 filed with Form 10SB12G on November 14, 2006).
10.6 Amended Agreement with Centerpoint Corporation dated April 23, 2003  (Incorporated by reference to Exhibit 10.10 filed with Form 10SB12G on November 14, 2006).
10.7 Promissory Note and Conversion Agreement between Bion Environmental Technologies, Inc. and Mark A. Smith related to deferred compensation (Incorporated by reference to Exhibit 10.21 filed with Form 10SB12G on November 14, 2006).
10.8 Promissory Note and Conversion Agreement between Bion Environmental Technologies, Inc. and Bright Capital, Ltd. related to deferred compensation (Incorporated by reference to Exhibit 10.22 filed with Form 10SB12G on November 14, 2006).
10.9 Employment agreement with Mark A. Smith (Incorporated by reference to Exhibit 10.23 filed with Form 10SB12G on November 14, 2006).
10.10 Employment agreement with Bright Capital, Ltd. (Incorporated by reference to Exhibit 10.25 filed with Form 10SB12G on November 14, 2006).
10.11

Employment agreement with Jeff Kapell (Incorporated by reference to Exhibit 10.26 filed with Form 10SB12G on November 14, 2006).

10.12

Employment agreement with Jeremy Rowland (Incorporated by reference to Exhibit 10.27 filed with Form 10SB12G on November 14, 2006).

10.13

Office lease at 641 Lexington Avenue, 17th Floor, New York (Incorporated by reference to Exhibit 10.28 filed with Form 10SB12G on November 14, 2006).

10.14 2006 Consolidated Incentive Plan (Incorporated by reference to Exhibit 10.29 filed with Form 10SB12G on November 14, 2006).
10.15 Memo to Dominic Bassani & Bright Capital, Ltd. dated October 16, 2006 regarding Change in Title/Status of DB/Amendment to Brightcap Agreement (Incorporated by reference to Exhibit 10.30 filed with Form 10SB12G on November 14, 2006).
10.16 Promissory Note and Conversion Agreement for Mark Smith, dated January 1, 2007 (Incorporated by reference to Exhibit 10.31 filed with Form 10SB12G/A on February 1, 2007).
10.17 Promissory Note and Conversion Agreement for Bright Capital, Ltd., dated January 1, 2007 (Incorporated by reference to Exhibit 10.35 filed with Form 10SB12G/A on February 1, 2007).
10.18 Extension Agreement dated March 31, 2007 between the Company and Mark A Smith (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on April 3, 2007)

10.19 Form of Note dated March 31, 2007 in the amount of $151,645.89 in favor of Mark A. Smith (Incorporated by reference to Exhibit 10. 2 filed with Form 8-K filed on April 3, 2007)
10.20 Form of Note dated March 31, 2007 in the amount of $455.486.30 in favor of Bright Capital, Ltd. (Incorporated by reference to Exhibit 10.4 filed with Form 8-K filed on April 3, 2007)
10.21 Memorandum of Understanding with Kreider Farms (Incorporated by reference to Exhibit 99.1 filed with Form 8-K filed on February 27, 2008)
10.22 Subscription Agreement from Bright Capital, Ltd. (Incorporated by reference to Exhibit 99.1 filed with Form 8-K filed on June 3, 2008)

 

 

60 
 

 

   
10.23 Amendment to 2006 Consolidated Incentive Plan (Incorporated by reference to Exhibit 99.2 filed with Form 8-K filed on June 3, 2008)
10.24 Agreement between the Company and Mark A. Smith dated May 31, 2008 (Incorporated by reference to Exhibit 99.3 filed with Form 8-K filed on June 3, 2008).
10.25 2007 Series AB Convertible Promissory Note (Incorporated by reference to Exhibit 99.1 filed with Form 8-K filed on June 19, 2008).
10.26 Promissory Note between Bion Environmental Technologies, Inc. and Dominic Bassani (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on September 30, 2008).
10.27 Promissory Note between Anthony Orphanos and Bion dated October 30, 2008, Guaranteed by Dominic Bassani (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on November 13, 2008).
10.28 Addendum to Settlement Agreement and Release Stipulation from Bion, Bion Dairy and Mark Smith dated October 31, 2008 (Incorporated by reference to Exhibit 10.4 filed with Form 8-K filed on November 13, 2008).
10.29 Kreider Farms Agreement (September 25, 2008): REDACTED (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on November 14, 2008).
10.30 Amendment #3 to 2006 Consolidated Incentive Plan (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on January 6, 2009).
10.31 Agreement between Bright Capital, Ltd. and Dominic Bassani and Bion effective January 11, 2009 (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on January 15, 2009).
10.32 Agreement between Mark A. Smith and Bion effective January 12, 2009 (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on January 15, 2009).
10.33 Orphanos Extension Agreement dated January 13, 2009 (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on January 15, 2009).
10.34 Lease Agreement between Ronald Kreider and Kreider Farms and Bion PA 1 LLC dated June 26, 2009 (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on July 2, 2009).
10.35 Capitalization Agreement between Bion Companies and Bion PA 1 LLC dated June 30, 2009 (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on July 2, 2009).
10.36 Extension Agreement with Mark A. Smith. (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on August 18, 2010).
10.37 Agreement with Edward Schafer (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on August 18, 2010).
10.38 Accepted Funding Offer (base loan agreement) (without exhibits) with PENNVEST for Kreider Farms Project Loan -- effective November 3, 2010 (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on November 3, 2010).
10.39 Short Form Agreement (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on November 22, 2010).
10.40 Resume of William O’Neill. (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on November 22, 2010).
10.41 Loan & Security Agreement with Milestone Bank (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on December 6, 2010).
10.42 O'Neill Employment Agreement (dated December 22, 2010) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on December 6, 2010).
10.43 Schafer Employment Agreement (dated December 21, 2010) (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on December 6, 2010).
10.44 Biography of Edward T. Schafer (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on December 6, 2010).
10.45 Kreider Farms Clarification Agreement (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on March 16, 2011).
10.46 Resignation of William O’Neill (effective May 13, 2011) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on May 13, 2011).
10.47 PADEP Certification of Kreider Poultry Credits (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on June 1, 2011).
10.48 Bassani/Bright Capital Extension Agreement (executed August 31, 2011) (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on September 2, 2011).
10.49 Smith Extension Agreement (executed August 31, 2011) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on September 2, 2011).
10.50 Bloom Employment Agreement (executed September 30, 2011) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on October 4, 2011).

 

 

 

 

61 
 

 

10.51 Extension/Conversion Agreement with Smith and Bassani (dated March 31, 2012) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on April 4, 2012).
10.52 Memorialization of extension of Maturity of Bassani convertible deferred compensation (dated July 31, 2012) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on August 3, 2012).
10.53 Memorialization of Smith Extension Agreement (dated August 14, 2012) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on August 21, 2012).
10.54 Memorialization of Bassani Extension Agreement (dated August 14, 2012) (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on August 21, 2012).
10.55 Memorialization of Schafer Agreement (dated August 21, 2012) (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on August 21, 2012).
10.56 Board Ratification dated May 5, 2013 (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on May 14, 2013).
10.57 Demand Promissory Note dated May 13, 2013 (Incorporated by reference to Exhibit 10.2 filed with Form 10-Q filed on May 14, 2013).
10.58 Pennvest Demand Letter (dated September 25, 2014) (Incorporated by reference to Exhibit 10.92 filed with Form 10-K filed on September 26, 2014).
10.59 Extension Agreement with Mark A. Smith (w/o exhibits) (February 10, 2015) (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on February 11, 2015).
10.60 Extension Agreement with Dominic Bassani (w/o exhibits) (February 10, 2015) (Incorporated by reference to Exhibit 10.2 filed with Form 10-Q filed on February 11, 2015).
10.61 Agreement with Edward Schafer (w/o exhibits) (February 10, 2015) (Incorporated by reference to Exhibit 10.3 filed with Form 10-Q filed on February 11, 2015).
10.62 Convertible Promissory Note between the Company and Dominic Bassani dated September 8, 2015 (Incorporated by reference to Exhibit 10.96 filed with Form 10-K filed on September 22, 2015).
10.63 Convertible Promissory Note between the Company and Edward Schafer dated September 8, 2015 (Incorporated by reference to Exhibit 10.97 filed with Form 10-K filed on September 22, 2015).

10.64

Convertible Promissory Note between the Company and Anthony Orphanos dated September 8, 2015 (Incorporated by reference to Exhibit 10.98 filed with Form 10-K filed on September 22, 2015).
10.65 Kreider Poultry Joint Venture Agreement (May 5, 2016) (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on May 9, 2016).
10.66 Bassani Warrant Purchase effective August 1, 2018 (Incorporated by reference to Exhibit 10.100 filed with Form 10-K filed on September 24, 2019).
10.67 Smith Warrant Purchase effective August 1, 2018 (Incorporated by reference to Exhibit 10.101 filed with Form 10-K filed on September 24, 2019).
10.68 Amendment #9 to 2006 Consolidated Incentive Plan, as amended (Incorporated by reference to Exhibit 10.102 filed with Form 10-K filed on September 24, 2019).
10.69 Lease (executed September 23, 2021) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on September 29, 2021).
10.70 Subsidiaries of the Registrant (Incorporated by reference to Exhibit 21 filed with Form 10SB12G on November 14, 2006).
10.71

Buflovak/Hebeler Purchase Order (January 28, 2022)(without Technical Details and Standard Terms and Conditions) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on February 1, 2022)

10.72

Agreement with BioNTech SE re sale/purchase of domain name <biontech.com> (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on March 25, 2022)

10.73 Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan. (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on January 4, 2022).
10.74 William O’Neill Employment Agreement (effective May 1, 2022) (without exhibits). (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on May 3, 2022).
10.75 Letter of Intent with Ribbonwire Ranch (July 20, 2022). (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on July 272, 2022).
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically.
31.2 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically.
32.1 Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350. Furnished*
32.2 Certification of Principal Financial Officer Pursuant to Section 18 U.S.C. Section 1350. Furnished*
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

*This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

 

62 
 

 

(b) Financial Statement Schedules

 

Our consolidated financial statements being filed as part of this Form 10-K are filed on Item 8 of this Form 10-K. All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable, and therefore have been omitted.

 

   
   
Report of Independent Registered Public Accounting Firm (Eide Baily LLP; Denver, CO, PCAOB ID:  286)  F-2
   
Consolidated balance sheets     F-4
   
Consolidated statements of operations     F-5
   
Consolidated statements of changes in stockholders’ equity (deficit)  F-6
   
Consolidated statements of cash flows  F-7
   
Notes to consolidated financial statements  F-8 - F-32

 

 

 

F-1 
 

 

 

 

 

 

Report of Independent Registered Public Accounting Firm

 

 

To the Board of Directors and Stockholders
Bion Environmental Technologies, Inc.

Old Bethpage, New York

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Bion Environmental Technologies, Inc. (the “Company”) as of June 30, 2022 and 2021, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows, for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of Bion Environmental Technologies, Inc. as of June 30, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has not generated significant revenue and has suffered recurring losses from operations. These factors raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also discussed in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.

 

 

F-2 
 

Our audits included performing procedures to assess the risk of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Equity Transactions

 

As discussed in Note 7 to the financial statements, the Company has entered into various equity-based compensation agreements. These agreements include transactions, including the original issuance and subsequent modifications of warrants and stock options, that are required to be measured and accounted for at estimated fair value. These transactions resulted in recording of stock-based compensation expense of $419,370, modification of options of $-0-, warrant issuances of $30,000, and warrant modifications of $8,337 for the year ended June 30, 2022.

 

The Company’s determination of the estimated fair values involves the identification of related financial instruments and a clear understanding of the terms of the agreements. Auditing management’s estimates of fair value requires a high degree of auditor judgment and an increased extent of effort, including the need to carefully examine to understand the true nature of the related agreements.

 

The primary procedures we performed to address this critical audit matter included:

 

·We gained an understanding of management's process and methodology to develop the estimates
·We examined agreements and agreed terms utilized in calculations
·We evaluated the reasonableness of the inputs and assumptions used by management in developing the estimates
·We recalculated the amounts and compared to management’s calculation
·We evaluated the adequacy of the disclosures related to these fair value measurements.

 

 

 

We have served as Bion Environmental Technologies, Inc. auditor since 2017.

 

Denver, Colorado

September 27, 2022

 

 

 

 

F-3 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

       
   June 30,  June 30,
   2022  2021
       
ASSETS          
           
Current assets:          
Cash  $3,160,442   $4,216,321 
Prepaid expenses   157,550    124,049 
Deposits and other assets   1,000    1,000 
           
Total current assets   3,318,992    4,341,370 
           
Operating lease right-of-use asset   145,787       
Property and equipment, net (Note 3)   2,895,558    541 
           
Total assets  $6,360,337   $4,341,911 
           
LIABILITIES AND EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable and accrued expenses  $1,360,644   $570,050 
  Series B Redeemable Convertible Preferred stock, $0.01 par value,  50,000 shares authorized; 0 and 200 shares issued and outstanding, liquidation preference of $0 and $40,000, respectively (Note 7)         37,400 
Deferred compensation (Note 4)   594,798    479,208 
Loan payable and accrued interest (Note 5)         9,868,495 
           
Total current liabilities   1,955,442    10,955,153 
           
Operating lease liability   128,864       
Convertible notes payable - affiliates (Note 6)   5,170,610    4,793,097 
           
Total Liabilities   7,254,916    15,748,250 
           
Deficit:          
Bion's stockholders' equity (deficit):          
Series A Preferred stock, $0.01 par value, 10,000,000 and 50,000 shares authorized respectively, no shares issued and outstanding            
           
Series C Convertible Preferred stock, $0.01 par value,60,000 shares authorized; no shares issued and outstanding            
           
Common stock, no par value, 250,000,000 and 100,000,000 shares authorized respectively, 43,758,820 and 41,315,986 shares issued, respectively; 43,054,511 and 40,611,677 shares outstanding, respectively            
Additional paid-in capital   123,620,046    121,399,067 
Subscription receivable - affiliates (Note 8)   (504,650)   (504,650)
Accumulated deficit   (124,047,548)   (132,339,873)
           
Total Bion's stockholders’ deficit    (932,152)   (11,445,456)
           
Noncontrolling interest   37,573    39,117 
           
Total deficit   (894,579)   (11,406,339)
           
Total liabilities and deficit  $6,360,337   $4,341,911 

 

See notes to consolidated financial statements

F-4 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

YEARS ENDED JUNE 30, 2022 AND 2021

 

 

           
   2022  2021
       
Revenue  $       $     
       
       
Operating expenses:          
General and administrative (including stock-based compensation (Note 7))   2,348,324    2,078,248 
Depreciation   1,161    827 
Research and development (including stock-based compensation (Note 7))   200,691    748,545 
           
           
Total operating expenses   2,550,176    2,827,620 
           
Loss from operations   (2,550,176)   (2,827,620)
           
Other (income) expense:          
Forgiveness of debt         (34,800)
Interest income   (5,625)      
Interest expense   301,659    657,945 
Gain on sale of domain (Note 9)   (902,490)      
Gain on legal dissolution of subsidiary (Note 5)   (10,234,501)      
           
Total other expense   (10,840,957)   623,145 
           
Net income (loss)   8,290,781    (3,450,765)
           
Net loss attributable to the noncontrolling interest   1,544    2,785 
           
Net income (loss) applicable to Bion's common stockholders  $8,292,325   $(3,447,980)
           
Net income (loss) applicable to Bion's common stockholders          
per basic and diluted common share  $0.20   $(0.10)
           
Weighted-average number of common shares outstanding:          
Basic and diluted   41,962,302    33,068,832 

 

 

See notes to consolidated financial statements

 

 

 

F-5 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) 

YEARS ENDED JUNE 30, 2022 AND 2021

                                                        
   Bion's Stockholders'      
   Series A Preferred Stock  Series C Preferred Stock  Common Stock  Additional  Subscription Rec-  Accumulated  Noncontrolling  Total
   Shares  Amount  Shares  Amount  Shares  Amount  paid-in capital  -eivables for Shares  deficit  interest 

equity/

(deficit)

                                  
Balances, July 1, 2020        $           $      31,409,005   $      114,266,683   $(504,650)  $(128,891,893)  $41,902   $(15,087,958)
Sale of units   —            —            3,720,000          1,860,000                      1,860,000 
Commissions on sale of units   —            —            129,364          (164,537)                     (164,537)
Vesting of options for services   —            —            —            1,017,700                      1,017,700 
Modification of options   —            —            —            8,775                      8,775 
Modification of warrants   —            —            —            212,645                      212,645 
Issuance of warrants   —            —            —            2,500                      2,500 
Warrants exercised for common shares   —            —            4,065,988          3,049,490                      3,049,490 
Sale of common shares   —            —            300,000          300,000                      300,000 
Issuance of units for services   —            —            144,000          72,000                      72,000 
Conversion of debt and liabilities   —            —            1,547,629          773,811                      773,811 
Net loss   —            —            —                        (3,447,980)   (2,785)   (3,450,765)
Balances, June 30, 2021        $           $      41,315,986   $     $121,399,067   $(504,650)  $(132,339,873)  $39,117   $(11,406,339)
Warrants exercised for common shares   —            —            2,315,550          1,736,662                      1,736,662 
Commissions on warrant exercises   —            —            66,860          (18,601)                     (18,601)
Conversion of debt and liabilities   —            —            35,424          17,711                      17,711 
Issuance of units for services   —            —            25,000          27,500                    27,500 
Modification of warrants   —            —            —            8,337                      8,337 
Issuance of warrants   —            —            —            30,000                      30,000 
Vesting of options for services   —            —            —            419,370                      419,370 
Net income (loss)   —            —            —                        8,292,325    (1,544)   8,290,781 
Balances, June 30, 2022        $           $      43,758,820   $     $123,620,046   $(504,650)  $(124,047,548)  $37,573   $(894,579)

 

 

 

 

See notes to consolidated financial statements

 

 

F-6 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED JUNE 30, 2022 AND 2021

 

       
   2022  2021
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income (loss)  $8,290,781   $(3,450,765)
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Gain on legal dissolution of subsidiary   (10,234,501)      
Depreciation expense   1,161    827 
Forgiveness of debt         (34,800)
Accrued interest on loans payable, deferred compensation and other   319,523    694,793 
Stock-based compensation   346,846    1,126,481 
Decrease (increase) in prepaid expenses   (33,501)   (116,084)
Increase (decrease) in accounts payable and accrued expenses   366,629    (6,516)
Decrease in operating lease assets and liabilities   (16,923)      
Increase in deferred compensation   289,200    396,604 
           
Net cash used in operating activities   (670,785)   (1,389,460)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (2,062,155)      
           
Net cash used in investing activities   (2,062,155)      
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from exercise of warrants   1,736,662    3,049,490 
Commissions on exercise of warrants   (18,601)   (3,537)
Redemption of Preferred Series B shares and interest   (41,000)      
Proceeds from sale of units         1,860,000 
Commissions on sale of units         (161,000)
Proceeds from sale of common shares         300,000 
           
Net cash provided by financing activities   1,677,061    5,044,953 
           
Net increase (decrease) in cash   (1,055,879)   3,655,493 
           
Cash at beginning of year   4,216,321    560,828 
           
Cash at end of year  $3,160,442   $4,216,321 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $     $28 
           
Non-cash investing and financing transactions:          
Conversion of debt and liabilities into common units  $17,711   $773,811 
Warrants issued for unit commissions  $     $16,100 
Shares issued for warrant exercise commissions  $50,145   $97,023 
Purchase of property and equipment in accounts payable and accrued expenses  $666,375   $   
Non-cash compensation in property and equipment  $135,648   $   
Capitalized interest in property and equipment  $32,000      
Conversion of deferred compensation to notes payable  $190,000   $   

 

 

See notes to consolidated financial statements

 

 

 

F-7 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2022 AND 2021

 

1.ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. 

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business will be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022 Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will treat the waste stream and recover/refine valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity, organic fertilizer and potentially other products. We anticipate converting the Ribbonwire LOI into a definitive joint venture agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors before the end of calendar year 2022.

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef joint venture projects over the next twelve months while moving forward with the Initial Project (see below) and the Dalhart Project and pursuing other opportunities in the livestock industry enabled by our Gen3 Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.

 

 

F-8 
 

During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2nd quarter in 2023 and supports development of the Dalhart Project during 2023.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) development/construction of the Dalhart Project, iii) developing applications and markets for its low carbon organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During July 2022, the Company entered into a letter of intent with Ribbonwire Ranch (Dalhart, Texas) (“Ribbonwire LOI”) setting forth the parties’ intention to negotiate a joint venture agreement and enter into a joint venture to develop and operate an initial 15,000 head integrated, sustainable beef facility on RWR property (“Dalhart Project”) including:

 

a)innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,
b)‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

 

F-9 
 

 

c)a Bion GEN3 Tech module (which will utilize the recycled CO2 to increase ammonium bicarbonate recovery) for the production of ammonium bicarbonate fertilizer for use in organic crop production (plus residual organic solids and clean water),
d)which will produce verifiably sustainable beef products with USDA certified branding.

The Dalhart Project will include expansion capability up to 60,000 head of cattle, in aggregate, located at/around/contiguous to the initial facilities on Ribbonwire property.

The opportunity presented by the Ribbonwire LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation in Dalhart, TX a reality as soon as possible.

 

To place the Ribbonwire LOI and the Dalhart Project in the context of Company’s business plan (and our prior public disclosure), if the contemplated venture moves forward on the timelines set forth in the Ribbonwire LOI, active development of the Dalhart Project will commence early in the second quarter of 2023.

 

Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3 Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion 3G Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the Dalhart Project). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site targeted to commence during January 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart Project.

 

As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until sometime during January 2023. 3G1 has been moving forward with the development process of the Initial Project. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2023 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

  i. Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3technology platform.

 

 

F-10 
 

 

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

  iv. Produce sustainable beef products for initial test marketing efforts.

 

The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project, (coupled with obtaining organic certifications(s) for our for our solid ammonium bicarbonate fertilizer product line), Bion expects to be ready to move forward with its plans for development of much larger facilities including the Dalhart Project. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-12 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3 Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility will include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project. 

 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food & Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which is likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Organic Fertilizer Listing/Certification Process” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3 Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers is choosing food marketed as ‘sustainable’ and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

 

F-11 
 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and initially enjoyed steady sales growth until sales began flattening over the past 12-18 months. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence) plus a patina of initiatiatives invoking the vague term ‘regenerative’ agriculture. However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, segment which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad technical and economic challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost and timeline for availability remain very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium verifiably sustainable beef products that address these consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or sustainable organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, while providing the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water and air, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility (see diagram above) will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss to the atmosphere, as well as odors, thereby improving animal health and human working conditions while preventing air/soil/water pollution. The manure will be collected and moved directly to customized anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

 

F-12 
 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their harvest and production techniques, meat industry leaders have also announced their willingness to move forward with initiatives in this area. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2025) and 25% in five (5) years (end of 2027) (approximately 2,000,000 cattle annually). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2023. Our first commercial project is likely to be the Dalhart Project but we anticipate commencing additional sustainable beef projects during 2023 as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development/under construction during 2023 in three (3) different JVs with the initial barns being populated with livestock by fall/winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and populated by 2027-28 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

During this period, the Company also anticipates having Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

 

F-13 
 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for

the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Organic Fertilizer Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020.

 

 

 

F-14 
 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021), the Iowa Organic Program (“IOP”)(filed during March 2022) and the California Department of Food & Agriculture (“CDFA”)(filed during May 2022) and are each in the review process. The review processes are requiring extended periods of time and multiple procedural steps with each entity in part due to the novel nature of Bion’s Gen3Tech and our solid ammonium bicarbonate product in the context of organic certifications. The OMRI application has proceeded through multiple stages of review and rebuttal/appeal without receiving a positive result to date. The Company anticipates has recently filed a new appeal to the most recent determinations. The Company’s CDFA has received initial comments regarding our solid ammonium bicarbonate product line and we anticipate providing CDFA with the requested updated information and clarifications during the next 60 days. The Company’s product line is novel in part due to the fact that there is not a formal listing category for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this matter with one or more listings/certifications of this product line well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

Gen3 Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3 Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates that if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’. The Covid-19 pandemic has delayed legislative efforts needed to commence its development in Pennsylvania. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3 Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.

 

 

 

F-15 
 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

 

 

F-16 
 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

 

F-17 
 

 

Going concern and management’s plans:

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $3,451,000 during the year ended June 30, 2021. The Company has net income of $8,292,000 for the year ended June 30, 2022. The net income for the year is largely due to a one-time, non-cash event of the dissolution of PA-1 for a gain of approximately $10,235,000 (Note 5). Additionally, the Company realized a one-time gain of $902,490 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period (Note 9). There was an operating loss of approximately $2,550,000 for the year ended June 30, 2022. At June 30, 2022, the Company has working capital and a stockholders’ deficit of approximately $1,364,000 and $932,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the year ended June 30, 2021, the Company received gross proceeds of approximately $5,209,000, respectively, from the sale of its debt and equity securities.

 

During the year ended June 30, 2022, the Company received total proceeds of approximately $1,737,000 from the sale of its equity securities and paid approximately $19,000 in cash commissions.

 

During fiscal years 2022 and 2021, the Company has faced less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years except that during the first three months of the current fiscal year, the Company has raised equity funds at a rate materially lower than the average rate during fiscal years 2021 and 2022. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart Project), Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

 

F-18 
 

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2022 and 2021 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Projects such as consulting fees, internal salaries, benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

 

F-19 
 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of June 30, 2022 and 2021, there are no derivative financial instruments.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates. 

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

 

F-20 
 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheets at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income taxes:

The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, as well as net operating losses.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in the period in which the tax change occurs. A valuation allowance is provided to reduce the deferred tax assets by 100%, since the Company believes that at this time it is more likely than not that the deferred tax asset will not be realized.

The Company is no longer subject to U.S. federal and state tax examinations for fiscal years before 2009. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months.

The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of June 30, 2022, there were no penalties or accrued interest amounts associated with any unrecognized tax benefits, nor was any interest expense recognized during the years ended June 30, 2022 and 2021.

 

Income (loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

 

 

F-21 
 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   June 30,
2022
   June 30,
2021
 
Warrants   20,778,635    21,931,903 
Options   11,201,600    10,471,600 
Convertible debt   10,686,065    10,183,558 
Convertible preferred stock         20,000 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2022 and 2021:

 

          
   Year
Ended
June 30,
2022
   Year
Ended
June 30,
2021
 
Shares issued – beginning of period   41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,611,677    30,704,696 
Weighted average shares issued
    during the period
   1,350,625    2,364,136 
Basic and diluted weighted average shares –
    end of period
   41,962,302    33,068,832 

 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

 

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   June 30,
2022
   June 30,
2021
 
Machinery and equipment  $     $2,222,670 
Buildings and structures         401,470 
Computers and office equipment   13,598    171,485 
3G project construction in process   2,892,222       
Property and equipment, gross    2,905,820    2,795,625 
Less accumulated depreciation   (10,262)   (2,795,084)
Property and equipment, net   $2,895,558   $541 

 

The 3G project began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for 3G construction in process includes $32,000 for capitalized interest and $135,648 in non-cash compensation as of June 30, 2022.

 

Management has reviewed the remaining property and equipment for impairment as of June 30, 2022 and believes that no impairment exists.

 

Depreciation expense was $1,161 and $827 for the years ended June 30, 2022 and 2021, respectively.

 

 

F-22 
 

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $594,798 and $479,208 as of June 30, 2022 and 2021, respectively. Included in the deferred compensation balances as of June 30, 2022, are $437,508 and $10,000 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of June 30, 2021 was $399,971 and nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $74,790 and $6,738 as of June 30, 2022 and 2021, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.

 

Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until December 31, 2022 (which date has subsequently been extended to June 30, 2024) to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.

 

During the year ended June 30, 2022, Smith elected to convert $90,000 of deferred compensation into the 2020 Convertible Note.

 

The Company recorded interest expense of $16,390 ($15,537 with related parties) and $25,838 ($12,249 with related parties) for the years ended June 30, 2022 and 2021, respectively, related to deferred compensation.

 

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

 

F-23 
 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest, the remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.

 

 

F-24 
 

As of June 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $2,597,329, $1,328,040 and $499,274, respectively. As of June 30, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,502,880, $1,186,926 and $481,119, respectively.

 

During the year ended June 30, 2022, Smith elected to add $90,000 of his salary to his 2020 Convertible Obligations.

 

The Company recorded interest expense of $131,718 and $175,794 for the years ended June 30, 2022 and 2021, respectively. The Company capitalized $32,000 and nil related to the 3G project for the years ended June 30, 2022 and 2021, respectively.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani (now owned by Bassani Family Trusts), Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of June 30, 2022, including accrued interest owed Bassani Family Trusts, Schafer and Shareholder, are $279,366, $20,845 and $445,756, respectively. The balances of the September 2015 Convertible Notes as of June 30, 2021, including accrued interest, were $171,343, $20,190 and $430,639, respectively.

 

During the year ended June 30, 2022, Bassani elected to transfer $100,000 from deferred compensation to the 2015 convertible note.

 

The Company recorded interest expense of $23,796 and $21,462 for the years ended June 30, 2022 and 2021, respectively, on the September 2015 Convertible Notes.

 

7.       STOCKHOLDERS' EQUITY:

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

In April 2023, the Company amended the number of preferred stock shares from 50,000 to 10,000,000, having a $0.01 par value per share.

 

During the years ended June 30, 2022, and 2021, the Company declared dividends of $1,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

  

During April 2022, the Company amended the number of common stock shares from 100,000,000 to 250,000,000.

 

 

F-25 
 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the year ended June 30, 2022, Smith elected to convert accounts payable (based on his unreimbursed expenses) of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

During the year ended June 30, 2022, the Company issued 66,860 shares of the Company’s common stock to three brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a broker $18,601 in commissions for the warrant exercises.

During the year ended June 30, 2022, the Company issued 25,000 shares of the Company’s common stock to a marketing firm for services provided.

During the year ended June 30, 2021, the Company entered into subscription agreements, under three different offerings, to sell units for $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2021, and pursuant thereto, the Company issued 3,720,000 units for total proceeds of $1,860,000, net proceeds of $1,699,000 after commissions of $161,000. The Company allocated the proceeds from the 3,720,000 shares and the 3,720,000 warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be$0.05 per warrant. As a result, $114,148 was allocated to the warrants and $1,745,852 was allocated to the shares, and both were recorded as additional paid in capital.

 

During the year ended June 30, 2021, 300,000 share of the Company’s restricted company stock were sold to an investor for $300,000.

 

During the year ended June 30, 2021, Smith elected to convert deferred compensation and accounts payable of $128,039 and $52,361, respectively, into an aggregate 360,805 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, two consultants elected to convert deferred compensation of $593,411, into an aggregate 1,186,824 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2023.

 

During the year ended June 30, 2021, the Company issued 144,000 units to Smith for salary of $72,000, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024.

 

During the year ended June 30, 2021, 4,065,988 warrants were exercised to purchase 4,065,988 shares of the Company’s common stock at $0.75 per share for total proceeds of $3,049,490.

 

During the year ended June 30, 2021, the Company issued 129,364 shares of the Company’s common stock to a broker as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The company also paid a broker $3,537 in commissions for the warrant exercises.

 

Warrants:

 

As of June 30, 2022, the Company had approximately 20.8 million warrants outstanding, with exercise prices from $0.60 to $1.50 and expiring on various dates through April 31, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.75, and the weighted-average remaining contractual life as of June 30, 2022 is 2.6 years.

 

 

F-26 
 

During the year ended June 30, 2022, Smith elected to convert accounts payable (for unreimbursed expenses) of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2022, the Company approved the issuance of 75,000 warrants for two consultants for consulting services of $7,500. The warrants are exercisable at $1.50 and expire in November 2026.

During the year ended June 30, 2022, the Company approved the modification of existing warrants held by one former consultant and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $5,624 and interest expenses of $2,713.

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

During the year ended June 30, 2022, the Company issued 66,860 shares of the Company’s common stock to three brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The company also paid a broker $18,601 in commissions for the warrant exercises.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On February 11, 2022, the Company granted 10,000 options under the 2006 Plan to one consultant.

 

On April 29, 2022, the Company granted an aggregate of 720,000 options under the 2006 Plan to seven employees/consultants/directors including: i) 50,000 options each to Schafer and Northrop for service as directors, ii) 200,000 options to Bassani (now COO of the Company and formerly CEO) and iii) 200,000 options to Smith, the Company’s President, which new option grants are included in the presentation below.

 

The Company recorded compensation expense related to employee stock options of $419,370 and $1,107,700 for the years ended June 30, 2022 and 2021, respectively. The Company granted 730,000 and 960,000 fully vested options during the years ended June 30, 2022 and 2021, respectively.

 

The fair value of the options granted during the years ended June 30, 2022 and 2021 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

 

                    
   Weighted
Average,
June 30,
2022
   Range,
June 30,
2022
   Weighted
Average,
June 30,
2021
   Range,
June 30,
2021
 
Volatility   65%   65% -69%   65%   58%-65%
Dividend yield                        
Risk-free interest rate   2.99%   1.71% – 3.01%   0.79%   0.47%-0.82%
Expected term (years)   3.71    3.04 to 3.72    5.8    5.0 to 5.9 

 

The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

 

F-27 
 

A summary of option activity under the 2006 Plan for the years ended June 30, 2022 and 2021 is as follows:

                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2020    9,511,600   $.74    4.5   $   
   Granted    960,000    1.10           
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at June 30, 2021    10,471,600   $0.77    3.7   $6,064,335 
   Granted    730,000    1.00    3.7    —   
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at June 30, 2022    11,201,600   $0.80    2.7   $4,429,263 

 

 

The following table presents information relating to nonvested stock options as of June 30, 2022:

 

            
    Options   Weighted Average
Grant-Date Fair
Value
 
 Nonvested at July 1, 2021         $   
 Granted    730,000    .574 
 Vested    (730,000)   (.574)
 Nonvested at June 30, 2022         $   

 

The total fair value of stock options that vested during the years ended June 30, 2022 and 2021 was $419,370 and $1,017,700, respectively. As of June 30, 2022, the Company had no unrecognized compensation cost related to stock options.

 

Stock-based employee compensation charges in operating expenses in the Company’s consolidated financial statements for the years ended June 30, 2022 and 2021 are as follows:

          
   Year
ended
June 30,
2022
   Year
ended
June 30,
2021
 
General and administrative:          
  Change in fair value from modification of
    option terms
  $     $8,775 
Change in fair value from modification of
    warrant terms
   8,337    25,506 
  Fair value of stock options expensed   261,258    816,050 
     Total  $269,595   $850,331 
           
Research and development:          
  Fair value of stock options expensed  $22,464   $201,650 
     Total  $22,464   $201,650 

 

The Company capitalized $135,648 and nil in non-cash compensation related to the 3G project in June 30, 2022 and 2021, respectively.

 

 

F-28 
 

 

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of June 30, 2022, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($504,650, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of June 30, 2022, the Company has an interest bearing, secured promissory note for $30,000 ($34,688 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,011, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of June 30, 2022 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($55,009 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2022)(check with Kathy whether this was extended), and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 a month is deferred. For the years ended June 30, 2022 and 2021, Smith was paid $130,000 and $139,460, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani (now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, and subsequently extended until December 31, 2022 (which date has subsequently been extended to June 30, 2024). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2022, the principal and accrued interest was $348,643. For the years ended June 30, 2022 and 2021, Brightcap was paid $250,000 and $155,000, respectively, of cash compensation earned during the period.

 

William O’Neill (“O’Neill”) has been hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s GEN3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $25,000 cash and $10,000 deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  

 

 

F-29 
 

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of June 30, 2022, the execution/exercise bonuses ranging from 50-90% were applicable to 17,778,213 of the Company’s outstanding options and 17,778,213 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Purchase Order Agreement:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375)) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. On March 21, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375).  On June 6, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $1,996,125 as of the date of this report. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

 

 

F-30 
 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations werebeen subject disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

 

F-31 
 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest, the remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The following table summarized the supplemental cash flow information for the year ended June 30, 2022:

     
Cash paid for noncancelable operating lease included in the operating cash flows  $60,000 
Right of use assets obtained in exchange for operating lease liabilities  $180,586 

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2022:

 

     
Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (21,136)
Total  $128,864 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2022 were 3 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

 

F-32 
 

 

10.       INCOME TAXES:

The reconciliation between the expected federal income tax expense (benefit) computed by applying the Federal statutory rate to income (loss) before income taxes and the actual expense (benefit) for taxes on income (loss) for the years ended June 30, 2022 and 2021 is as follows:

          
   2022     2021 
Expected income tax expense (benefit) at statutory rate  $1,741,000   $(724,000)
State taxes, net of federal benefit   303,000    (126,000)
RTP – Excess Business Interest         115,000 
Permanent differences and other   8,000    8,000 
Expiration of net operating allowances   1,229,000    802,000 
Change in valuation allowance   (3,281,000)   (75,000)
Income tax expense (benefit)  $     $   

The Company has net operating loss carry-forwards (“NOLs”) for tax purposes of approximately $8,274,000 as of June 30, 2022. These NOLs expire on various dates through 2041.

The utilization of the NOLs may be limited under Section 382 of the Internal Revenue Code.

The Company’s deferred tax assets as of June 30, 2022 and 2021 are estimated as follows:

          
   2022   2021 
NOL carryforwards (Federal and State)  $8,274,000   $11,784,000 
Stock-based compensation   5,436,000    5,350,000 
Impairment   1,340,000    1,340,000 
Business interest   339,000    264,000 
Deferred compensation   1,054,000    986,000 
Gross deferred tax assets   16,443,000    19,724,000 
Valuation allowance   (16,443,000)   (19,724,000)
Net deferred tax assets  $     $   

 

The Company has provided a valuation allowance of 100% of its net deferred tax assets due to the uncertainty of generating future profits that would allow for the realization of such deferred tax assets.

 

11.       401(k) PLAN:

 

The Company has adopted the Bion Technologies, Inc. 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”), a defined contribution retirement plan for the benefit of its employees. The 401(k) Plan is currently a salary deferral only plan and at this time the Company does not match employee contributions. The 401(k) is open to all employees over 21 years of age and no service requirement is necessary.

 

12.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to June 30, 2022 for recognition and disclosure in the financial statements and notes to the financial statements.

 

On June 6, 2022 the Company received progress notice regarding completion of certain work in process on the core modules of the 3G1 core modules and an invoice from Buflovak for the third 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $1,996,125 as of the date of this report. 

 

During July 2022 the Company sold 320,000 Units containing 320,000 shares of the Company’s Common Stock and 320,000 warrants to purchase 320,000 restricted and legended shares of the Company’s Common stock exercisable at $1.25 until December 31, 2023 for the sum of $320,000 to two non-affiliated purchasers.

 

From July 1, 2022 through September 27, 2022 74,834 warrants were exercised for $56,126 and the Company issued 74,834 restricted common shares.

 

During the period from July 1, 2022 through September 27, 2022, Smith transferred $23,943 of unreimbursed expenses and $20,000 of deferred compensation to his 2020 Convertible Obligation and converted 50,000 of the initial principalbalance of his 2020 Convertible Obligation to 100,000 shares (60,000 of which were donated/gifted upon acquisition) and 100,000 warrants (all of which were donated/gifted upon acquisition).

 

On August 8, 2022 the Company extended the expiration of 300,000 warrants owned by a consultant until December 31, 2023.

 

On August 8, 2022, the Company extended the expiration of 1,286,824 warrants for three employees and contractors to December 31, 2024.

 

On September 9, 2022, the Company issued 50,000 shares to non-affiliated consultant for services.

 

During August and September 2022 the Company issued 150,000 warrants, in aggregate, to three (3) new members of its Advisory Group in connection with their commitment to the advisory role and/or for consulting services.

 

 

 

F-33 
 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunder duly authorized.

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC.

   
Dated:  September 27, 2022 By: /s/ Mark A. Smith
      Mark A. Smith, President and Chief
      Financial Officer (Principal Financial
      and Accounting Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

 

SIGNATURE   TITLE   DATE
         
         
         
/s/ Mark A. Smith   Executive Chairman,   September 27, 2022
Mark A. Smith  

President, Chief Financial Officer

and Director

   
         
         
         
/s/ William O’Neill   Chief Executive Officer   September 27, 2022
William O’Neill        
         
         
         
/s/ Jon Northrop   Secretary and Director   September 27, 2022
Jon Northrop        
         
         
         
/s/ Edward Schafer       September 27, 2022
Edward Schafer   Director    

 

 

 

 

 

 
 

EX-31.1 2 bion_ex31z1.htm EXHIBIT 31.1 Certification

Exhibit 31.1

 


SECTION 302 CERTIFICATION

 


I, Dominic Bassani, certify that:

 


1.   I have reviewed this annual report on Form 10-K of Bion Environmental Technologies, Inc.;

 


2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 


3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

 


4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 


(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 


(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 


(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 


(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 


5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 


(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 


(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 


Date:  September 27, 2022

 



/s/ Dominic Bassani

Dominic Bassani

Chief Executive Officer





EX-31.2 3 bion_ex31z2.htm EXHIBIT 31.2 Certification


Exhibit 31.2


SECTION 302 CERTIFICATION


I, Mark A. Smith, certify that:


1.   I have reviewed this annual report on Form 10-K of Bion Environmental Technologies, Inc.;


2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;


4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:  September 27, 2022




/s/ Mark A. Smith

Mark A. Smith

Executive Chairman, President and Chief Financial Officer




EX-32.1 4 bion_ex32z1.htm EXHIBIT 32.1 Certification


Exhibit 32.1

 


CERTIFICATION OF CEO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Form 10-K of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the fiscal year ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Dominic Bassani, Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

September 27, 2022 /s/ Dominic Bassani  
 

Dominic Bassani

Chief Executive Officer

 

 




This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 


A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



EX-32.2 5 bion_ex32z2.htm EXHIBIT 32.2 Certification


Exhibit 32.2

 


CERTIFICATION OF CFO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 


In connection with the Form 10-K of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the fiscal year ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark A. Smith, President (Executive Chairman) and Interim Chief Financial Officer (Principal Financial and  Accounting Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

       
Date: September 27, 2022   /s/ Mark A. Smith  
   

Mark A. Smith

Executive Chairman, President and

Interim Chief Financial Officer

 
       

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

GRAPHIC 6 image_002.jpg GRAPHIC begin 644 image_002.jpg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end GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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image_003.jpg GRAPHIC begin 644 image_003.jpg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bnet-20220630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DEFERRED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 401(k) PLAN link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - DEFERRED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details1) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bnet-20220630_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 bnet-20220630_def.xml XBRL DEFINITION FILE EX-101.LAB 12 bnet-20220630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Preferred Stock [Member] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Subscriptions Receivable [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Counterparty Name [Axis] Ribbonwire [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Ownership [Axis] Centerpoint [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Convertible Debt Securities [Member] Convertible Preferred Stock Antidilutive Securities [Member] Long-Lived Tangible Asset [Axis] Property, Plant and Equipment of PA1 [Member] Title of Individual [Axis] Chief Executive Officer [Member] Bassani [Member] Smith [Member] Consultants [Member] Nature of Expense [Axis] Interest Expense on Deferred Compensation Obligation [Member] Debt Instrument [Axis] Pennvest Loan [Member] Scenario [Axis] Years One Through Five [Member] Years Six Through Maturity [Member] Legal Entity [Axis] PA-1 [Member] The 2020 Convertible Obligations [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] President [Member] Executive Vice Chairman [Member] Receivable Type [Axis] Secured Promissory Note [Member] September 2015 Convertible Notes [Member] Related Party Transaction [Axis] Bassani Family Trusts [Member] Related Party [Axis] Schafer [Member] Shareholder [Member] Forecast [Member] Award Type [Axis] Restricted Stock [Member] An Investor [Member] Class of Warrant or Right [Axis] Warrants Related to the Conversion of Deferred Compensation and Accounts Payable into Units [Member] Two Consultants [Member] Sale of Stock [Axis] Sale of Units in Exchange for Salary [Member] Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member] Plan Name [Axis] Equity Incentive Plan [Member] Plan 2006 [Member] Northrop [Member] Financial Instrument [Axis] Options Held [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Project 3 G [Member] Weighted Average [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Research and Development Expense [Member] Warrants Issused, Subscription Receivable [Member] Smiths [Member] Former Employee [Member] Extension Bonus [Member] FY2016 Extension Agreement [Member] Warrants Expiring on December 31, 2025 [Member] Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Restricted And Legended Shares [Member] Two Non Affiliated Purchasers [Member] Three Employees And Contractors [Member] Non Affilated Consultant [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Name Auditor Firm ID Auditor Location Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Prepaid expenses Deposits and other assets Total current assets Operating lease right-of-use asset Property and equipment, net (Note 3) Total assets LIABILITIES AND EQUITY (DEFICIT) Current liabilities: Accounts payable and accrued expenses Preferred stock Deferred compensation (Note 4) Loan payable and accrued interest (Note 5) Total current liabilities Operating lease liability Convertible notes payable - affiliates (Note 6) Total Liabilities Deficit: Bion's stockholders' equity (deficit): Common stock, no par value, 250,000,000 and 100,000,000 shares authorized respectively, 43,758,820 and 41,315,986 shares issued, respectively; 43,054,511 and 40,611,677 shares outstanding, respectively Additional paid-in capital Subscription receivable - affiliates (Note 8) Accumulated deficit Total Bion's stockholders’ deficit  Noncontrolling interest Total deficit Total liabilities and deficit Preferred stock, par value (in dollars per share) Preferred stock, authorized (in shares) Preferred stock, issued (in shares) Preferred stock, outstanding (in shares) Preferred stock, liquidation Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Value, Outstanding Income Statement [Abstract] Revenue Operating expenses: General and administrative (including stock-based compensation (Note 7)) Depreciation Research and development (including stock-based compensation (Note 7)) Total operating expenses Loss from operations Other (income) expense: Forgiveness of debt Interest income Interest expense Gain on sale of domain (Note 9) Gain on legal dissolution of subsidiary (Note 5) Total other expense Net income (loss) Net loss attributable to the noncontrolling interest Net income (loss) applicable to Bion's common stockholders per basic and diluted common share Weighted-average number of common shares outstanding: Basic and diluted Beginning balance, value Beginning balance, shares Sale of units Sale of units (in shares) Commissions on sale of units Commissions on sale of units, shares Vesting of options for services Modification of options Modification of warrants Issuance of warrants Warrants exercised for common shares Warrants exercised for common shares, shares Commissions on warrant exercises Commissions on warrant exercises, shares Sale of common shares Sale of common shares, shares Issuance of units for services Issuance of units for services, shares Conversion of debt and liabilities Conversion of debt and liabilities, shares Net income (loss) Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Gain on legal dissolution of subsidiary Depreciation expense Forgiveness of debt Accrued interest on loans payable, deferred compensation and other Stock-based compensation Decrease (increase) in prepaid expenses Increase (decrease) in accounts payable and accrued expenses Decrease in operating lease assets and liabilities Increase in deferred compensation Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants Commissions on exercise of warrants Redemption of Preferred Series B shares and interest Proceeds from sale of units Commissions on sale of units Proceeds from sale of common shares Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of year Cash at end of year Supplemental disclosure of cash flow information: Cash paid for interest Non-cash investing and financing transactions: Conversion of debt and liabilities into common units Warrants issued for unit commissions Shares issued for warrant exercise commissions Purchase of property and equipment in accounts payable and accrued expenses Non-cash compensation in property and equipment Capitalized interest in property and equipment Conversion of deferred compensation to notes payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Share-Based Payment Arrangement [Abstract] DEFERRED COMPENSATION Debt Disclosure [Abstract] LOANS PAYABLE Convertible Notes Payable - Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Equity [Abstract] STOCKHOLDERS' EQUITY Subscription Receivable - Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] INCOME TAXES Retirement Benefits [Abstract] 401(k) PLAN Subsequent Events [Abstract] SUBSEQUENT EVENTS Principles of consolidation Cash and cash equivalents Property and equipment Patents Stock-based compensation Derivative Financial Instruments Options Warrants Concentrations of credit risk Noncontrolling interests Fair value measurements Lease Accounting Revenue Recognition Income taxes Income (loss) per share Use of estimates Recent Accounting Pronouncements Schedule of anti dilutive securities Schedule of earnings per share, basic and diluted Schedule of property and equipment Fair value of options assumptions Schedule of option activity Schedule of non vested stock options Condensed Financial Statement Schedule Of Cash Flow Supplemental Disclosure Schedule Of Future Minimum Lease Payment Schedule of effective income tax rate reconciliation Schedule of deferred tax assets and liabilities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Tech wastage Cattle per head Percentage of sustainable Cost in excess Description of kreider 2 poultry project Net Income (loss) Net income Gain on sale of domain Operating loss Working Capital (error) Proceeds from Issuance or Sale of Equity Commissions paid Deferred Compensation Liability, Amount Cancelled Capital Required for Capital Adequacy Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Shares issued – beginning of period Shares held by subsidiaries (Note 7) Shares outstanding – beginning of period Weighted average shares issued     during the period Basic and diluted weighted average shares –     end of period Noncontrolling interest, ownership percentage by parent Cash equivalents Derivative financial instruments Unrecognized tax positions term Accrued interest and penalties Unrecognized tax benefits Machinery and equipment Buildings and structures Computers and office equipment 3G project construction in process Property and equipment, gross  Less accumulated depreciation Property and equipment, net  Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Capitalized interest Non cash compensation Impairment of Long-Lived Assets Held-for-use Depreciation expense Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Deferred compensation liability Interest Rate on Deferred Compensation Deferred Compensation Consecutive Trading Days (Day) Deferred Compensation, Convertible to Common Stock Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) Interest Expense Interest Expense, Related Party Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Construction Loan Accrued Interest and Late Charges Payable Total assets Total liabilities Accounts payable and accrued liabilities Accounts payable Accrued Liabilities, Current Gain on legal dissolution of subsidiary Line of Credit Facility, Maximum Borrowing Capacity Debt Instrument, Interest Rate During Period Debt Instrument, Annual Principal Payment Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Interest Expense, Debt Loans as a liability Debt Instrument, Debt Default, Amount Realized from the asset sale Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage, Quarterly Conversion Price Per Unit (in dollars per share) Original conversion price Convertible Notes Payable, Noncurrent Accrued interest Salary paid Capitalized amount Financing Receivable, Interest Rate, Stated Percentage Convertible Notes Payable Deferred compensation Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Volatility Dividend yield Risk-free interest rate Expected term (Year) Options outstanding, beginning (in shares) Options outstanding, beginning weighted-average exercise price Outstanding, weighted-average remaining contractual life (Year) Outstanding, aggregate intrinsic value beginning Granted Granted, weighted-average exercise price Exercised, options (in shares) Exercised, weighted-average exercise price Forfeited, options (in shares) Forfeited, weighted-average exercise price Expired, options (in shares) Expired, weighted-average exercise price Granted, weighted-average remaining contractual life (Year) Options outstanding, ending (in shares) Options outstanding, ending weighted-average exercise price Outstanding, aggregate intrinsic value ending Nonvested options, beginning (in shares) Granted, options (in shares) Granted, weighted-average grant-date fair value Vested (in shares) Vested, weighted-average grant-date fair value Nonvested, weighted-average grant-date fair value, ending Change in fair value from modification of option terms Change in fair value from modification of warrant terms Allocated Share-based Compensation Expense Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred Stock, Shares Outstanding, Ending Balance (in shares) Par value Preferred Stock, Convertible Option Per Share (in dollars per share) Preferred Stock, Dividend Rate, Percentage Preferred Stock, Redemption Price Per Share (in dollars per share) Redemption of convertible Preferred stock Dividends Payable Preferred stock shares Dividends, Preferred Stock Common stock shares Shares Held by Subsidiaries (in shares) Converted to Units, Amount Accounts Payable Converted to Units, Shares Accounts Payable Converted to Units, Price Per Unit Warrants exercisable per share Class of Warrant or Right, Exercised During Period (in shares) Common Stock Shares Issued upon Exercise of Warrants (in shares) Warrants Exercised for Common Stock Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares) Payments of Commissions on Exercise of Warrants Number of shares issued Share price Expiry date Number of shares issued Total proceeds Net proceeds Commissions Proceeds from allocated shares Allocated to warrants Allocated to the sharea Number of shares sold Proceeds from Issuance of Common Stock Deferred Compensation, Converted to Units, Amount Accounts Payable, Converted to Units, Amount Deferred Compensation and Accounts Payable Converted to Units, Shares (in shares) Shares Issued, Price Per Share (in dollars per share) Sale of Units, Number Of Units Issued (in shares) Sale of Units in Exchange for Salary and Expense, Salary Amount Class of Warrant or Right, Outstanding (in shares) Weighted Average Exercise Price for Outstanding Warrants (in dollars per share) Weighted Average Remaining Contractual Life for Outstanding Warrants (Year) Share-based Payment Arrangement, Plan Modification, Incremental Cost Interest expenses Warrant Exercised for Common Stock Commissions on warrant exercises Number of shares issued Cancellation of warrants Exercise bonus Stock options, authorized (in shares) Number of shares granted Share-based Compensation, Granted Share-based Compensation, Granted Share-based Payment Arrangement, Expense Fair value of stock options Capitalized amount Financing Receivable, after Allowance for Credit Loss, Total Notes receivable interest Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Financing Receivable, Principal Amount Cash paid for noncancelable operating lease included in the operating cash flows Right of use assets obtained in exchange for operating lease liabilities Year ended June 30, 2023 Year ended June 30, 2024 Year ended June 30, 2025 Undiscounted cash flow Less imputed interest Total Loss Contingencies [Table] Loss Contingencies [Line Items] Monthly Officers' Cash Compensation Compensation increased Cash compensation paid Deferred Compensation, Maximum Convertible Amount Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share) Salaries and wages Additional paid amount Interest bearing secured promissory note Repayments of Long-term Debt, Total Warrants held by trust owned Warrants and Rights Outstanding Debt instrument paid amount Principal, interest Aggregate payment Sale of domain, description Loan related to construction Accrued interest Line of Credit, Current Gain (Loss) on Securitization of Financial Assets Weighted average remaining lease term Expected income tax expense (benefit) at statutory rate State taxes, net of federal benefit RTP – Excess Business Interest Permanent differences and other Expiration of net operating allowances Change in valuation allowance Income tax expense (benefit) NOL carryforwards (Federal and State) Stock-based compensation Impairment Business interest Deferred compensation Gross deferred tax assets Valuation allowance Net deferred tax assets Operating Loss Carryforwards, Total Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Subsequent Event [Table] Subsequent Event [Line Items] Debt Instrument, Periodic Payment Aggregate Payment Exercisable Sale of Stock, Consideration Received Per Transaction Number of shares exercised Stock Issued During Period, Value, Stock Options Exercised Number of shares issued [custom:UnreimbursedExpenses] Deferred Compensation Liability, Current Debt Conversion, Converted Instrument, Amount Debt Conversion, Converted Instrument, Shares Issued Issaunce of warrants Number of shares expired Stock Issued During Period, Shares, Issued for Services Represents the equity impact of units issued during the period. Represents the value of stock issued during the period for commissions on sale of units. This item represents the adjustment To additional paid in capital as a result of modification of options. This item represents the adjustment to additional paid in capital as a result of modification of warrants. Number of units issued pursuant to a subscription agreement. This item represents the capital available for operations for the Company. The amount of deferred compensation liability cancelled during the period. This item represents the separate legal entity of Centerpoint. This item represents the convertible preferred stock securities that have been excluded from the computation of earnings per share. Number of shares held by subsidiaries. Represents the weighted average number of additional shares issued during period. This item represents the gross amount computers and office equipment held by the Company. Represents the Property, Plant and Equipment of PA1. This item represents the interest rate that is accrued on deferred compensation. Number of specified trading days during the end of a month for which the share price of common stock during that period will be applied to deferred compensation if converted. Consultants of the Company. Represents the amount of deferred compensation liability convertible to shares of the entity's common stock as of the balance sheet date. Represents the price per share at which the deferred compensation liability is convertible to shares of the entity's common stock as of the balance sheet date. This item represents the obligation accrued for interest expense of deferred compensation. This item represents the Pennvest Loan. The carrying amount of accrued interest and late charges payable to lender. This item represents events that will occur during years one through five. This item represents events that occur during years six through loan maturity. Depicts the subsidiary PA-1. Represents 2020 Convertible Obligations (formerly January 2015 Convertible Notes) and 2019 Convertible Note. Represents quarterly stated percentage of debt instrument. Represents the conversion price on a per Unit basis of convertible debt instruments. Represents the Executive Vice Chairman. Contractual interest rate for financing receivable, under the agreement. Related to a secured promissory note. Represents information about the September 2015 convertible notes. The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is convertible to an option. The number of warrants or rights exercised during period. Represents warrants exercised for common stock shares. The number of shares issued during the period for commissions on sale of units and warrant exercises. The amount of cash outflow of commissions on exercise of warrants. Represents information about an investor. Represents the monetary amount of the Company's units into which deferred compensation was converted during the period. Represents the monetary amount of the Company's accounts payable converted into units during the period. Represents the number of the Company's units into which deferred compensation and accounts payable were converted during the period. Represents information pertaining to warrants related to the conversion of deferred compensation and accounts payable into units. Represents the information pertaining to two consultants. Represents information about sale of units in exchange for salary. Represents sale of units in exchange for salary and expense, salary amount. Represents information about warrants issued in connection with sale of units in exchange for salary. The amount of change in fair value of share-based payment awards due to modifications in warrants terms. The warrants issued in exchange for promissory notes. The principal amount of financing receivable. Represents former employee. Represents information about monthly officers' cash compensation. The maximum amount of deferred compensation that is deemed to be convertible. The price per share in which an individual can convert their deferred compensation. Represents information concerning warrants that expire on December 31, 2025. Information concerning the secured promissory note that was received as consideration toward the Bassani Warrants that expire on December 31, 2025. Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to RTP, excess business interest. Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit). Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of net operating allowance. Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business interest. Assets, Current Liabilities, Current Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Income, Operating OtherExpense Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding GainOnLegalDissolutionsOfSubsidiary ForgivenessOfDebt Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities CommissionsOnExerciseOfWarrants CommissionsOnSaleOfUnits Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Payment Arrangement [Policy Text Block] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Other, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Deferred Tax Assets, Valuation Allowance Stock Issued During Period, Shares, Restricted Stock Award, Gross EX-101.PRE 13 bnet-20220630_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2022
Aug. 01, 2022
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Annual Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2022  
Document Fiscal Period Focus FY  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --06-30  
Entity File Number 000-19333  
Entity Registrant Name BION ENVIRONMENTAL TECHNOLOGIES, INC.  
Entity Central Index Key 0000875729  
Entity Tax Identification Number 84-1176672  
Entity Incorporation, State or Country Code CO  
Entity Address, Address Line One 9 East Park Court  
Entity Address, City or Town Old Bethpage  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11804  
City Area Code (516)  
Local Phone Number 586-5643  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Public Float $ 35,500  
Entity Common Stock, Shares Outstanding   43,416,011
Auditor Name Eide Baily LLP  
Auditor Firm ID 286  
Auditor Location Colorado  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Current assets:    
Cash $ 3,160,442 $ 4,216,321
Prepaid expenses 157,550 124,049
Deposits and other assets 1,000 1,000
Total current assets 3,318,992 4,341,370
Operating lease right-of-use asset 145,787
Property and equipment, net (Note 3) 2,895,558 541
Total assets 6,360,337 4,341,911
Current liabilities:    
Accounts payable and accrued expenses 1,360,644 570,050
Deferred compensation (Note 4) 594,798 479,208
Loan payable and accrued interest (Note 5) 9,868,495
Total current liabilities 1,955,442 10,955,153
Operating lease liability 128,864
Convertible notes payable - affiliates (Note 6) 5,170,610 4,793,097
Total Liabilities 7,254,916 15,748,250
Bion's stockholders' equity (deficit):    
Common stock, no par value, 250,000,000 and 100,000,000 shares authorized respectively, 43,758,820 and 41,315,986 shares issued, respectively; 43,054,511 and 40,611,677 shares outstanding, respectively
Additional paid-in capital 123,620,046 121,399,067
Subscription receivable - affiliates (Note 8) (504,650) (504,650)
Accumulated deficit (124,047,548) (132,339,873)
Total Bion's stockholders’ deficit  (932,152) (11,445,456)
Noncontrolling interest 37,573 39,117
Total deficit (894,579) (11,406,339)
Total liabilities and deficit 6,360,337 4,341,911
Series B Preferred Stock [Member]    
Current liabilities:    
Preferred stock 37,400
Series A Preferred Stock [Member]    
Current liabilities:    
Preferred stock
Bion's stockholders' equity (deficit):    
Total deficit
Series C Preferred Stock [Member]    
Current liabilities:    
Preferred stock
Bion's stockholders' equity (deficit):    
Total deficit
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Common Stock, Par or Stated Value Per Share $ 0 $ 0
Common Stock, Shares Authorized 250,000,000 100,000,000
Common Stock, Shares, Issued 43,758,820 41,315,986
Common Stock, Value, Outstanding $ 43,054,511 $ 40,611,677
Series B Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 50,000 50,000
Preferred stock, issued (in shares) 0 200
Preferred stock, outstanding (in shares) 0 200
Preferred stock, liquidation $ 0 $ 40,000
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 10,000,000 50,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Series C Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 60,000 60,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]    
Revenue
Operating expenses:    
General and administrative (including stock-based compensation (Note 7)) 2,348,324 2,078,248
Depreciation 1,161 827
Research and development (including stock-based compensation (Note 7)) 200,691 748,545
Total operating expenses 2,550,176 2,827,620
Loss from operations (2,550,176) (2,827,620)
Other (income) expense:    
Forgiveness of debt (34,800)
Interest income (5,625)
Interest expense 301,659 657,945
Gain on sale of domain (Note 9) (902,490)
Gain on legal dissolution of subsidiary (Note 5) (10,234,501)
Total other expense (10,840,957) 623,145
Net income (loss) 8,290,781 (3,450,765)
Net loss attributable to the noncontrolling interest 1,544 2,785
Net income (loss) applicable to Bion's common stockholders $ 8,292,325 $ (3,447,980)
per basic and diluted common share $ 0.20 $ (0.10)
Weighted-average number of common shares outstanding:    
Basic and diluted 41,962,302 33,068,832
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Series A Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscriptions Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Jun. 30, 2020 $ 114,266,683 $ (504,650) $ (128,891,893) $ 41,902 $ (15,087,958)
Beginning balance, shares at Jun. 30, 2020 31,409,005          
Sale of units 1,860,000 1,860,000
Sale of units (in shares)     3,720,000          
Commissions on sale of units (164,537) (164,537)
Commissions on sale of units, shares     129,364          
Vesting of options for services 1,017,700 1,017,700
Modification of options 8,775 8,775
Modification of warrants 212,645 212,645
Issuance of warrants 2,500 2,500
Warrants exercised for common shares 3,049,490 3,049,490
Warrants exercised for common shares, shares     4,065,988          
Sale of common shares 300,000 300,000
Sale of common shares, shares     300,000          
Issuance of units for services 72,000 72,000
Issuance of units for services, shares     144,000          
Conversion of debt and liabilities 773,811 773,811
Conversion of debt and liabilities, shares     1,547,629          
Net income (loss) (3,447,980) (2,785) (3,450,765)
Ending balance, value at Jun. 30, 2021 121,399,067 (504,650) (132,339,873) 39,117 (11,406,339)
Ending balance, shares at Jun. 30, 2021 41,315,986          
Vesting of options for services 419,370 419,370
Modification of warrants 8,337 8,337
Issuance of warrants 30,000 30,000
Warrants exercised for common shares 1,736,662 1,736,662
Warrants exercised for common shares, shares     2,315,550          
Commissions on warrant exercises (18,601) (18,601)
Commissions on warrant exercises, shares     66,860          
Issuance of units for services 27,500     27,500
Issuance of units for services, shares     25,000          
Conversion of debt and liabilities 17,711 17,711
Conversion of debt and liabilities, shares     35,424          
Net income (loss) 8,292,325 (1,544) 8,290,781
Ending balance, value at Jun. 30, 2022 $ 123,620,046 $ (504,650) $ (124,047,548) $ 37,573 $ (894,579)
Ending balance, shares at Jun. 30, 2022 43,758,820          
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ 8,290,781 $ (3,450,765)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Gain on legal dissolution of subsidiary (10,234,501)
Depreciation expense 1,161 827
Forgiveness of debt (34,800)
Accrued interest on loans payable, deferred compensation and other 319,523 694,793
Stock-based compensation 346,846 1,126,481
Decrease (increase) in prepaid expenses (33,501) (116,084)
Increase (decrease) in accounts payable and accrued expenses 366,629 (6,516)
Decrease in operating lease assets and liabilities (16,923)
Increase in deferred compensation 289,200 396,604
Net cash used in operating activities (670,785) (1,389,460)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property and equipment (2,062,155)
Net cash used in investing activities (2,062,155)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from exercise of warrants 1,736,662 3,049,490
Commissions on exercise of warrants (18,601) (3,537)
Redemption of Preferred Series B shares and interest (41,000)
Proceeds from sale of units 1,860,000
Commissions on sale of units (161,000)
Proceeds from sale of common shares 300,000
Net cash provided by financing activities 1,677,061 5,044,953
Net increase (decrease) in cash (1,055,879) 3,655,493
Cash at beginning of year 4,216,321 560,828
Cash at end of year 3,160,442 4,216,321
Supplemental disclosure of cash flow information:    
Cash paid for interest 28
Non-cash investing and financing transactions:    
Conversion of debt and liabilities into common units 17,711 773,811
Warrants issued for unit commissions 16,100
Shares issued for warrant exercise commissions 50,145 97,023
Purchase of property and equipment in accounts payable and accrued expenses 666,375
Non-cash compensation in property and equipment 135,648
Capitalized interest in property and equipment 32,000
Conversion of deferred compensation to notes payable $ 190,000
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS
12 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS

 

1.ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. 

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business will be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022 Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will treat the waste stream and recover/refine valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity, organic fertilizer and potentially other products. We anticipate converting the Ribbonwire LOI into a definitive joint venture agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors before the end of calendar year 2022.

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef joint venture projects over the next twelve months while moving forward with the Initial Project (see below) and the Dalhart Project and pursuing other opportunities in the livestock industry enabled by our Gen3 Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.

 

During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2nd quarter in 2023 and supports development of the Dalhart Project during 2023.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) development/construction of the Dalhart Project, iii) developing applications and markets for its low carbon organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During July 2022, the Company entered into a letter of intent with Ribbonwire Ranch (Dalhart, Texas) (“Ribbonwire LOI”) setting forth the parties’ intention to negotiate a joint venture agreement and enter into a joint venture to develop and operate an initial 15,000 head integrated, sustainable beef facility on RWR property (“Dalhart Project”) including:

 

a)innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,
b)‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

c)a Bion GEN3 Tech module (which will utilize the recycled CO2 to increase ammonium bicarbonate recovery) for the production of ammonium bicarbonate fertilizer for use in organic crop production (plus residual organic solids and clean water),
d)which will produce verifiably sustainable beef products with USDA certified branding.

The Dalhart Project will include expansion capability up to 60,000 head of cattle, in aggregate, located at/around/contiguous to the initial facilities on Ribbonwire property.

The opportunity presented by the Ribbonwire LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation in Dalhart, TX a reality as soon as possible.

 

To place the Ribbonwire LOI and the Dalhart Project in the context of Company’s business plan (and our prior public disclosure), if the contemplated venture moves forward on the timelines set forth in the Ribbonwire LOI, active development of the Dalhart Project will commence early in the second quarter of 2023.

 

Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3 Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion 3G Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the Dalhart Project). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site targeted to commence during January 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart Project.

 

As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until sometime during January 2023. 3G1 has been moving forward with the development process of the Initial Project. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2023 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

  i. Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

  iv. Produce sustainable beef products for initial test marketing efforts.

 

The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project, (coupled with obtaining organic certifications(s) for our for our solid ammonium bicarbonate fertilizer product line), Bion expects to be ready to move forward with its plans for development of much larger facilities including the Dalhart Project. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-12 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3 Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility will include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project. 

 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food & Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which is likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Organic Fertilizer Listing/Certification Process” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3 Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers is choosing food marketed as ‘sustainable’ and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and initially enjoyed steady sales growth until sales began flattening over the past 12-18 months. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence) plus a patina of initiatiatives invoking the vague term ‘regenerative’ agriculture. However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, segment which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad technical and economic challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost and timeline for availability remain very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium verifiably sustainable beef products that address these consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or sustainable organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, while providing the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water and air, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility (see diagram above) will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss to the atmosphere, as well as odors, thereby improving animal health and human working conditions while preventing air/soil/water pollution. The manure will be collected and moved directly to customized anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their harvest and production techniques, meat industry leaders have also announced their willingness to move forward with initiatives in this area. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2025) and 25% in five (5) years (end of 2027) (approximately 2,000,000 cattle annually). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2023. Our first commercial project is likely to be the Dalhart Project but we anticipate commencing additional sustainable beef projects during 2023 as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development/under construction during 2023 in three (3) different JVs with the initial barns being populated with livestock by fall/winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and populated by 2027-28 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

During this period, the Company also anticipates having Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for

the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Organic Fertilizer Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021), the Iowa Organic Program (“IOP”)(filed during March 2022) and the California Department of Food & Agriculture (“CDFA”)(filed during May 2022) and are each in the review process. The review processes are requiring extended periods of time and multiple procedural steps with each entity in part due to the novel nature of Bion’s Gen3Tech and our solid ammonium bicarbonate product in the context of organic certifications. The OMRI application has proceeded through multiple stages of review and rebuttal/appeal without receiving a positive result to date. The Company anticipates has recently filed a new appeal to the most recent determinations. The Company’s CDFA has received initial comments regarding our solid ammonium bicarbonate product line and we anticipate providing CDFA with the requested updated information and clarifications during the next 60 days. The Company’s product line is novel in part due to the fact that there is not a formal listing category for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this matter with one or more listings/certifications of this product line well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

Gen3 Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3 Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates that if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’. The Covid-19 pandemic has delayed legislative efforts needed to commence its development in Pennsylvania. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3 Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going concern and management’s plans:

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $3,451,000 during the year ended June 30, 2021. The Company has net income of $8,292,000 for the year ended June 30, 2022. The net income for the year is largely due to a one-time, non-cash event of the dissolution of PA-1 for a gain of approximately $10,235,000 (Note 5). Additionally, the Company realized a one-time gain of $902,490 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period (Note 9). There was an operating loss of approximately $2,550,000 for the year ended June 30, 2022. At June 30, 2022, the Company has working capital and a stockholders’ deficit of approximately $1,364,000 and $932,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the year ended June 30, 2021, the Company received gross proceeds of approximately $5,209,000, respectively, from the sale of its debt and equity securities.

 

During the year ended June 30, 2022, the Company received total proceeds of approximately $1,737,000 from the sale of its equity securities and paid approximately $19,000 in cash commissions.

 

During fiscal years 2022 and 2021, the Company has faced less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years except that during the first three months of the current fiscal year, the Company has raised equity funds at a rate materially lower than the average rate during fiscal years 2021 and 2022. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart Project), Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2022 and 2021 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Projects such as consulting fees, internal salaries, benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of June 30, 2022 and 2021, there are no derivative financial instruments.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates. 

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheets at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income taxes:

The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, as well as net operating losses.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in the period in which the tax change occurs. A valuation allowance is provided to reduce the deferred tax assets by 100%, since the Company believes that at this time it is more likely than not that the deferred tax asset will not be realized.

The Company is no longer subject to U.S. federal and state tax examinations for fiscal years before 2009. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months.

The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of June 30, 2022, there were no penalties or accrued interest amounts associated with any unrecognized tax benefits, nor was any interest expense recognized during the years ended June 30, 2022 and 2021.

 

Income (loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   June 30,
2022
   June 30,
2021
 
Warrants   20,778,635    21,931,903 
Options   11,201,600    10,471,600 
Convertible debt   10,686,065    10,183,558 
Convertible preferred stock         20,000 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2022 and 2021:

 

          
   Year
Ended
June 30,
2022
   Year
Ended
June 30,
2021
 
Shares issued – beginning of period   41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,611,677    30,704,696 
Weighted average shares issued
    during the period
   1,350,625    2,364,136 
Basic and diluted weighted average shares –
    end of period
   41,962,302    33,068,832 

 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

 

XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT
12 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   June 30,
2022
   June 30,
2021
 
Machinery and equipment  $     $2,222,670 
Buildings and structures         401,470 
Computers and office equipment   13,598    171,485 
3G project construction in process   2,892,222       
Property and equipment, gross    2,905,820    2,795,625 
Less accumulated depreciation   (10,262)   (2,795,084)
Property and equipment, net   $2,895,558   $541 

 

The 3G project began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for 3G construction in process includes $32,000 for capitalized interest and $135,648 in non-cash compensation as of June 30, 2022.

 

Management has reviewed the remaining property and equipment for impairment as of June 30, 2022 and believes that no impairment exists.

 

Depreciation expense was $1,161 and $827 for the years ended June 30, 2022 and 2021, respectively.

 

XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED COMPENSATION
12 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
DEFERRED COMPENSATION

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $594,798 and $479,208 as of June 30, 2022 and 2021, respectively. Included in the deferred compensation balances as of June 30, 2022, are $437,508 and $10,000 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of June 30, 2021 was $399,971 and nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $74,790 and $6,738 as of June 30, 2022 and 2021, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.

 

Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until December 31, 2022 (which date has subsequently been extended to June 30, 2024) to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.

 

During the year ended June 30, 2022, Smith elected to convert $90,000 of deferred compensation into the 2020 Convertible Note.

 

The Company recorded interest expense of $16,390 ($15,537 with related parties) and $25,838 ($12,249 with related parties) for the years ended June 30, 2022 and 2021, respectively, related to deferred compensation.

 

XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOANS PAYABLE
12 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
LOANS PAYABLE

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest, the remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONVERTIBLE NOTES PAYABLE - AFFILIATES
12 Months Ended
Jun. 30, 2022
Convertible Notes Payable - Affiliates  
CONVERTIBLE NOTES PAYABLE - AFFILIATES

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.

 

As of June 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $2,597,329, $1,328,040 and $499,274, respectively. As of June 30, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,502,880, $1,186,926 and $481,119, respectively.

 

During the year ended June 30, 2022, Smith elected to add $90,000 of his salary to his 2020 Convertible Obligations.

 

The Company recorded interest expense of $131,718 and $175,794 for the years ended June 30, 2022 and 2021, respectively. The Company capitalized $32,000 and nil related to the 3G project for the years ended June 30, 2022 and 2021, respectively.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani (now owned by Bassani Family Trusts), Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of June 30, 2022, including accrued interest owed Bassani Family Trusts, Schafer and Shareholder, are $279,366, $20,845 and $445,756, respectively. The balances of the September 2015 Convertible Notes as of June 30, 2021, including accrued interest, were $171,343, $20,190 and $430,639, respectively.

 

During the year ended June 30, 2022, Bassani elected to transfer $100,000 from deferred compensation to the 2015 convertible note.

 

The Company recorded interest expense of $23,796 and $21,462 for the years ended June 30, 2022 and 2021, respectively, on the September 2015 Convertible Notes.

 

XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY
12 Months Ended
Jun. 30, 2022
Equity [Abstract]  
STOCKHOLDERS' EQUITY

7.       STOCKHOLDERS' EQUITY:

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

In April 2023, the Company amended the number of preferred stock shares from 50,000 to 10,000,000, having a $0.01 par value per share.

 

During the years ended June 30, 2022, and 2021, the Company declared dividends of $1,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

  

During April 2022, the Company amended the number of common stock shares from 100,000,000 to 250,000,000.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the year ended June 30, 2022, Smith elected to convert accounts payable (based on his unreimbursed expenses) of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

During the year ended June 30, 2022, the Company issued 66,860 shares of the Company’s common stock to three brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a broker $18,601 in commissions for the warrant exercises.

During the year ended June 30, 2022, the Company issued 25,000 shares of the Company’s common stock to a marketing firm for services provided.

During the year ended June 30, 2021, the Company entered into subscription agreements, under three different offerings, to sell units for $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2021, and pursuant thereto, the Company issued 3,720,000 units for total proceeds of $1,860,000, net proceeds of $1,699,000 after commissions of $161,000. The Company allocated the proceeds from the 3,720,000 shares and the 3,720,000 warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be$0.05 per warrant. As a result, $114,148 was allocated to the warrants and $1,745,852 was allocated to the shares, and both were recorded as additional paid in capital.

 

During the year ended June 30, 2021, 300,000 share of the Company’s restricted company stock were sold to an investor for $300,000.

 

During the year ended June 30, 2021, Smith elected to convert deferred compensation and accounts payable of $128,039 and $52,361, respectively, into an aggregate 360,805 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, two consultants elected to convert deferred compensation of $593,411, into an aggregate 1,186,824 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2023.

 

During the year ended June 30, 2021, the Company issued 144,000 units to Smith for salary of $72,000, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024.

 

During the year ended June 30, 2021, 4,065,988 warrants were exercised to purchase 4,065,988 shares of the Company’s common stock at $0.75 per share for total proceeds of $3,049,490.

 

During the year ended June 30, 2021, the Company issued 129,364 shares of the Company’s common stock to a broker as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The company also paid a broker $3,537 in commissions for the warrant exercises.

 

Warrants:

 

As of June 30, 2022, the Company had approximately 20.8 million warrants outstanding, with exercise prices from $0.60 to $1.50 and expiring on various dates through April 31, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.75, and the weighted-average remaining contractual life as of June 30, 2022 is 2.6 years.

 

During the year ended June 30, 2022, Smith elected to convert accounts payable (for unreimbursed expenses) of $17,711 into 35,424 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2022, the Company approved the issuance of 75,000 warrants for two consultants for consulting services of $7,500. The warrants are exercisable at $1.50 and expire in November 2026.

During the year ended June 30, 2022, the Company approved the modification of existing warrants held by one former consultant and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $5,624 and interest expenses of $2,713.

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662.

During the year ended June 30, 2022, the Company issued 66,860 shares of the Company’s common stock to three brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The company also paid a broker $18,601 in commissions for the warrant exercises.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On February 11, 2022, the Company granted 10,000 options under the 2006 Plan to one consultant.

 

On April 29, 2022, the Company granted an aggregate of 720,000 options under the 2006 Plan to seven employees/consultants/directors including: i) 50,000 options each to Schafer and Northrop for service as directors, ii) 200,000 options to Bassani (now COO of the Company and formerly CEO) and iii) 200,000 options to Smith, the Company’s President, which new option grants are included in the presentation below.

 

The Company recorded compensation expense related to employee stock options of $419,370 and $1,107,700 for the years ended June 30, 2022 and 2021, respectively. The Company granted 730,000 and 960,000 fully vested options during the years ended June 30, 2022 and 2021, respectively.

 

The fair value of the options granted during the years ended June 30, 2022 and 2021 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

 

                    
   Weighted
Average,
June 30,
2022
   Range,
June 30,
2022
   Weighted
Average,
June 30,
2021
   Range,
June 30,
2021
 
Volatility   65%   65% -69%   65%   58%-65%
Dividend yield                        
Risk-free interest rate   2.99%   1.71% – 3.01%   0.79%   0.47%-0.82%
Expected term (years)   3.71    3.04 to 3.72    5.8    5.0 to 5.9 

 

The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

A summary of option activity under the 2006 Plan for the years ended June 30, 2022 and 2021 is as follows:

                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2020    9,511,600   $.74    4.5   $   
   Granted    960,000    1.10           
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at June 30, 2021    10,471,600   $0.77    3.7   $6,064,335 
   Granted    730,000    1.00    3.7    —   
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at June 30, 2022    11,201,600   $0.80    2.7   $4,429,263 

 

 

The following table presents information relating to nonvested stock options as of June 30, 2022:

 

            
    Options   Weighted Average
Grant-Date Fair
Value
 
 Nonvested at July 1, 2021         $   
 Granted    730,000    .574 
 Vested    (730,000)   (.574)
 Nonvested at June 30, 2022         $   

 

The total fair value of stock options that vested during the years ended June 30, 2022 and 2021 was $419,370 and $1,017,700, respectively. As of June 30, 2022, the Company had no unrecognized compensation cost related to stock options.

 

Stock-based employee compensation charges in operating expenses in the Company’s consolidated financial statements for the years ended June 30, 2022 and 2021 are as follows:

          
   Year
ended
June 30,
2022
   Year
ended
June 30,
2021
 
General and administrative:          
  Change in fair value from modification of
    option terms
  $     $8,775 
Change in fair value from modification of
    warrant terms
   8,337    25,506 
  Fair value of stock options expensed   261,258    816,050 
     Total  $269,595   $850,331 
           
Research and development:          
  Fair value of stock options expensed  $22,464   $201,650 
     Total  $22,464   $201,650 

 

The Company capitalized $135,648 and nil in non-cash compensation related to the 3G project in June 30, 2022 and 2021, respectively.

 

XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSCRIPTION RECEIVABLE - AFFILIATES
12 Months Ended
Jun. 30, 2022
Subscription Receivable - Affiliates  
SUBSCRIPTION RECEIVABLE - AFFILIATES

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of June 30, 2022, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($504,650, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of June 30, 2022, the Company has an interest bearing, secured promissory note for $30,000 ($34,688 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,011, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of June 30, 2022 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($55,009 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2022)(check with Kathy whether this was extended), and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 a month is deferred. For the years ended June 30, 2022 and 2021, Smith was paid $130,000 and $139,460, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani (now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, and subsequently extended until December 31, 2022 (which date has subsequently been extended to June 30, 2024). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2022, the principal and accrued interest was $348,643. For the years ended June 30, 2022 and 2021, Brightcap was paid $250,000 and $155,000, respectively, of cash compensation earned during the period.

 

William O’Neill (“O’Neill”) has been hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s GEN3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $25,000 cash and $10,000 deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of June 30, 2022, the execution/exercise bonuses ranging from 50-90% were applicable to 17,778,213 of the Company’s outstanding options and 17,778,213 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Purchase Order Agreement:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375)) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. On March 21, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375).  On June 6, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $1,996,125 as of the date of this report. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations werebeen subject disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest, the remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The following table summarized the supplemental cash flow information for the year ended June 30, 2022:

     
Cash paid for noncancelable operating lease included in the operating cash flows  $60,000 
Right of use assets obtained in exchange for operating lease liabilities  $180,586 

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2022:

 

     
Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (21,136)
Total  $128,864 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2022 were 3 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES
12 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

10.       INCOME TAXES:

The reconciliation between the expected federal income tax expense (benefit) computed by applying the Federal statutory rate to income (loss) before income taxes and the actual expense (benefit) for taxes on income (loss) for the years ended June 30, 2022 and 2021 is as follows:

          
   2022     2021 
Expected income tax expense (benefit) at statutory rate  $1,741,000   $(724,000)
State taxes, net of federal benefit   303,000    (126,000)
RTP – Excess Business Interest         115,000 
Permanent differences and other   8,000    8,000 
Expiration of net operating allowances   1,229,000    802,000 
Change in valuation allowance   (3,281,000)   (75,000)
Income tax expense (benefit)  $     $   

The Company has net operating loss carry-forwards (“NOLs”) for tax purposes of approximately $8,274,000 as of June 30, 2022. These NOLs expire on various dates through 2041.

The utilization of the NOLs may be limited under Section 382 of the Internal Revenue Code.

The Company’s deferred tax assets as of June 30, 2022 and 2021 are estimated as follows:

          
   2022   2021 
NOL carryforwards (Federal and State)  $8,274,000   $11,784,000 
Stock-based compensation   5,436,000    5,350,000 
Impairment   1,340,000    1,340,000 
Business interest   339,000    264,000 
Deferred compensation   1,054,000    986,000 
Gross deferred tax assets   16,443,000    19,724,000 
Valuation allowance   (16,443,000)   (19,724,000)
Net deferred tax assets  $     $   

 

The Company has provided a valuation allowance of 100% of its net deferred tax assets due to the uncertainty of generating future profits that would allow for the realization of such deferred tax assets.

 

XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
401(k) PLAN
12 Months Ended
Jun. 30, 2022
Retirement Benefits [Abstract]  
401(k) PLAN

11.       401(k) PLAN:

 

The Company has adopted the Bion Technologies, Inc. 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”), a defined contribution retirement plan for the benefit of its employees. The 401(k) Plan is currently a salary deferral only plan and at this time the Company does not match employee contributions. The 401(k) is open to all employees over 21 years of age and no service requirement is necessary.

 

XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS
12 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

12.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to June 30, 2022 for recognition and disclosure in the financial statements and notes to the financial statements.

 

On June 6, 2022 the Company received progress notice regarding completion of certain work in process on the core modules of the 3G1 core modules and an invoice from Buflovak for the third 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $1,996,125 as of the date of this report. 

 

During July 2022 the Company sold 320,000 Units containing 320,000 shares of the Company’s Common Stock and 320,000 warrants to purchase 320,000 restricted and legended shares of the Company’s Common stock exercisable at $1.25 until December 31, 2023 for the sum of $320,000 to two non-affiliated purchasers.

 

From July 1, 2022 through September 27, 2022 74,834 warrants were exercised for $56,126 and the Company issued 74,834 restricted common shares.

 

During the period from July 1, 2022 through September 27, 2022, Smith transferred $23,943 of unreimbursed expenses and $20,000 of deferred compensation to his 2020 Convertible Obligation and converted 50,000 of the initial principalbalance of his 2020 Convertible Obligation to 100,000 shares (60,000 of which were donated/gifted upon acquisition) and 100,000 warrants (all of which were donated/gifted upon acquisition).

 

On August 8, 2022 the Company extended the expiration of 300,000 warrants owned by a consultant until December 31, 2023.

 

On August 8, 2022, the Company extended the expiration of 1,286,824 warrants for three employees and contractors to December 31, 2024.

 

On September 9, 2022, the Company issued 50,000 shares to non-affiliated consultant for services.

 

During August and September 2022 the Company issued 150,000 warrants, in aggregate, to three (3) new members of its Advisory Group in connection with their commitment to the advisory role and/or for consulting services.

 

XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Principles of consolidation

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

Cash and cash equivalents

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2022 and 2021 there are no cash equivalents.

 

Property and equipment

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Projects such as consulting fees, internal salaries, benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of June 30, 2022 and 2021, there are no derivative financial instruments.

 

Options

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates. 

 

Warrants

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheets at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income taxes

Income taxes:

The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, as well as net operating losses.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in the period in which the tax change occurs. A valuation allowance is provided to reduce the deferred tax assets by 100%, since the Company believes that at this time it is more likely than not that the deferred tax asset will not be realized.

The Company is no longer subject to U.S. federal and state tax examinations for fiscal years before 2009. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months.

The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of June 30, 2022, there were no penalties or accrued interest amounts associated with any unrecognized tax benefits, nor was any interest expense recognized during the years ended June 30, 2022 and 2021.

 

Income (loss) per share

Income (loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   June 30,
2022
   June 30,
2021
 
Warrants   20,778,635    21,931,903 
Options   11,201,600    10,471,600 
Convertible debt   10,686,065    10,183,558 
Convertible preferred stock         20,000 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2022 and 2021:

 

          
   Year
Ended
June 30,
2022
   Year
Ended
June 30,
2021
 
Shares issued – beginning of period   41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,611,677    30,704,696 
Weighted average shares issued
    during the period
   1,350,625    2,364,136 
Basic and diluted weighted average shares –
    end of period
   41,962,302    33,068,832 

 

 

Use of estimates

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

 

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Schedule of anti dilutive securities
          
   June 30,
2022
   June 30,
2021
 
Warrants   20,778,635    21,931,903 
Options   11,201,600    10,471,600 
Convertible debt   10,686,065    10,183,558 
Convertible preferred stock         20,000 
Schedule of earnings per share, basic and diluted
          
   Year
Ended
June 30,
2022
   Year
Ended
June 30,
2021
 
Shares issued – beginning of period   41,315,986    31,409,005 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   40,611,677    30,704,696 
Weighted average shares issued
    during the period
   1,350,625    2,364,136 
Basic and diluted weighted average shares –
    end of period
   41,962,302    33,068,832 

 

XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Tables)
12 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
          
   June 30,
2022
   June 30,
2021
 
Machinery and equipment  $     $2,222,670 
Buildings and structures         401,470 
Computers and office equipment   13,598    171,485 
3G project construction in process   2,892,222       
Property and equipment, gross    2,905,820    2,795,625 
Less accumulated depreciation   (10,262)   (2,795,084)
Property and equipment, net   $2,895,558   $541 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Fair value of options assumptions
                    
   Weighted
Average,
June 30,
2022
   Range,
June 30,
2022
   Weighted
Average,
June 30,
2021
   Range,
June 30,
2021
 
Volatility   65%   65% -69%   65%   58%-65%
Dividend yield                        
Risk-free interest rate   2.99%   1.71% – 3.01%   0.79%   0.47%-0.82%
Expected term (years)   3.71    3.04 to 3.72    5.8    5.0 to 5.9 
Schedule of option activity
                      
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2020    9,511,600   $.74    4.5   $   
   Granted    960,000    1.10           
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at June 30, 2021    10,471,600   $0.77    3.7   $6,064,335 
   Granted    730,000    1.00    3.7    —   
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at June 30, 2022    11,201,600   $0.80    2.7   $4,429,263 
Schedule of non vested stock options
            
    Options   Weighted Average
Grant-Date Fair
Value
 
 Nonvested at July 1, 2021         $   
 Granted    730,000    .574 
 Vested    (730,000)   (.574)
 Nonvested at June 30, 2022         $   
Condensed Financial Statement
          
   Year
ended
June 30,
2022
   Year
ended
June 30,
2021
 
General and administrative:          
  Change in fair value from modification of
    option terms
  $     $8,775 
Change in fair value from modification of
    warrant terms
   8,337    25,506 
  Fair value of stock options expensed   261,258    816,050 
     Total  $269,595   $850,331 
           
Research and development:          
  Fair value of stock options expensed  $22,464   $201,650 
     Total  $22,464   $201,650 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Tables)
12 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule Of Cash Flow Supplemental Disclosure
     
Cash paid for noncancelable operating lease included in the operating cash flows  $60,000 
Right of use assets obtained in exchange for operating lease liabilities  $180,586 
Schedule Of Future Minimum Lease Payment
     
Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (21,136)
Total  $128,864 
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES (Tables)
12 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Schedule of effective income tax rate reconciliation
          
   2022     2021 
Expected income tax expense (benefit) at statutory rate  $1,741,000   $(724,000)
State taxes, net of federal benefit   303,000    (126,000)
RTP – Excess Business Interest         115,000 
Permanent differences and other   8,000    8,000 
Expiration of net operating allowances   1,229,000    802,000 
Change in valuation allowance   (3,281,000)   (75,000)
Income tax expense (benefit)  $     $   
Schedule of deferred tax assets and liabilities
          
   2022   2021 
NOL carryforwards (Federal and State)  $8,274,000   $11,784,000 
Stock-based compensation   5,436,000    5,350,000 
Impairment   1,340,000    1,340,000 
Business interest   339,000    264,000 
Deferred compensation   1,054,000    986,000 
Gross deferred tax assets   16,443,000    19,724,000 
Valuation allowance   (16,443,000)   (19,724,000)
Net deferred tax assets  $     $   
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative)
12 Months Ended
Jun. 30, 2022
USD ($)
Decimal
Jun. 30, 2021
USD ($)
Jun. 30, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Tech wastage | Decimal 1,500    
Cattle per head | Decimal 300    
Percentage of sustainable 29.50%    
Cost in excess $ 50,000,000    
Description of kreider 2 poultry project Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).    
Net Income (loss) $ 8,292,000 $ 3,451,000  
Net income 10,235,000    
Gain on sale of domain 902,490    
Operating loss 2,550,000    
Working Capital 1,364,000    
(error) 932,152 11,445,456  
Proceeds from Issuance or Sale of Equity 1,737,000 $ 5,209,000  
Commissions paid 19,000    
Deferred Compensation Liability, Amount Cancelled     $ 2,404,000
Minimum [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Capital Required for Capital Adequacy 20,000,000    
Maximum [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Capital Required for Capital Adequacy $ 80,000,000    
Ribbonwire [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Tech wastage | Decimal 15,000    
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) - shares
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 20,778,635 21,931,903
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 11,201,600 10,471,600
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 10,686,065 10,183,558
Convertible Preferred Stock Antidilutive Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 20,000
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) - shares
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Accounting Policies [Abstract]    
Shares issued – beginning of period 41,315,986 31,409,005
Shares held by subsidiaries (Note 7) (704,309) (704,309)
Shares outstanding – beginning of period 40,611,677 30,704,696
Weighted average shares issued     during the period 1,350,625 2,364,136
Basic and diluted weighted average shares –     end of period 41,962,302 33,068,832
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash equivalents $ 0 $ 0
Derivative financial instruments $ 0 0
Unrecognized tax positions term 12 months  
Accrued interest and penalties $ 0  
Unrecognized tax benefits $ 0 $ 0
Centerpoint [Member]    
Noncontrolling interest, ownership percentage by parent 58.90%  
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Abstract]    
Machinery and equipment $ 2,222,670
Buildings and structures 401,470
Computers and office equipment 13,598 171,485
3G project construction in process 2,892,222
Property and equipment, gross  2,905,820 2,795,625
Less accumulated depreciation (10,262) (2,795,084)
Property and equipment, net  $ 2,895,558 $ 541
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Line Items]    
Capitalized interest $ 32,000  
Non cash compensation 135,648  
Depreciation expense 1,161 $ 827
Property, Plant and Equipment of PA1 [Member]    
Property, Plant and Equipment [Line Items]    
Impairment of Long-Lived Assets Held-for-use $ 0  
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED COMPENSATION (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability $ 594,798 $ 479,208
Interest Rate on Deferred Compensation 4.00%  
Deferred Compensation Consecutive Trading Days (Day) 10 days  
Interest Expense $ 301,659 657,945
Interest Expense on Deferred Compensation Obligation [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Interest Expense 16,390 25,838
Interest Expense, Related Party 15,537 12,249
Bassani [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability   399,971
Smith [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability   0
Deferred Compensation, Convertible to Common Stock 90,000  
Chief Executive Officer [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability 437,508 10,000
Deferred Compensation, Convertible to Common Stock $ 300,000  
Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) $ 0.75  
Consultants [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability $ 74,790 $ 6,738
Interest Rate on Deferred Compensation 3.00%  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOANS PAYABLE (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jun. 06, 2022
Jun. 15, 2022
Mar. 21, 2022
Jan. 28, 2022
Jun. 30, 2022
Jun. 30, 2021
Dec. 29, 2021
Sep. 30, 2021
Sep. 25, 2014
Short-Term Debt [Line Items]                  
Total assets         $ 6,360,337 $ 4,341,911 $ 0 $ 297  
Total liabilities         7,254,916 15,748,250 10,234,501 10,154,334  
Accounts payable and accrued liabilities         1,360,644 570,050 10,009,802 9,939,148  
Accounts payable             212,263 214,235  
Accrued Liabilities, Current             $ 12,436 $ 950  
Gain on legal dissolution of subsidiary         10,234,501        
Debt Instrument, Interest Rate During Period 25.00%   25.00% 25.00%          
Loans as a liability           9,868,495      
PA-1 [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Debt Default, Amount                 $ 8,137,117
Realized from the asset sale   $ 104,725              
Pennvest Loan [Member]                  
Short-Term Debt [Line Items]                  
Construction Loan         10,010,000        
Accrued Interest and Late Charges Payable         2,255,802        
Line of Credit Facility, Maximum Borrowing Capacity         7,754,000        
Debt Instrument, Annual Principal Payment         5,886,000        
Long-Term Debt, Maturity, Year Two         846,000        
Long-Term Debt, Maturity, Year Three         873,000        
Long-Term Debt, Maturity, Year Four         149,000        
Interest Expense, Debt         $ 123,444 $ 246,887      
Pennvest Loan [Member] | Years One Through Five [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Interest Rate During Period         2.547%        
Pennvest Loan [Member] | Years Six Through Maturity [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Interest Rate During Period         3.184%        
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Dec. 29, 2021
Sep. 30, 2021
Jan. 01, 2020
Defined Benefit Plan Disclosure [Line Items]          
Original conversion price $ 0.50        
Convertible Notes Payable, Noncurrent $ 5,170,610 $ 4,793,097      
Accrued interest     $ 12,436 $ 950  
Interest Expense 301,659 657,945      
Capitalized amount $ 32,000 0      
President [Member] | Secured Promissory Note [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Financing Receivable, Interest Rate, Stated Percentage 4.00%        
The 2020 Convertible Obligations [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Salary paid $ 90,000        
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage         4.00%
Debt Instrument, Interest Rate, Stated Percentage, Quarterly         4.00%
Conversion Price Per Unit (in dollars per share)         $ 0.50
Interest Expense 131,718 175,794      
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Convertible Notes Payable, Noncurrent 2,597,329 2,502,880      
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | President [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Convertible Notes Payable, Noncurrent   1,186,926      
Accrued interest 1,328,040        
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Executive Vice Chairman [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Convertible Notes Payable, Noncurrent   481,119      
Accrued interest 499,274        
September 2015 Convertible Notes [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Deferred compensation 100,000        
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Bassani Family Trusts [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Convertible Notes Payable   171,343      
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Bassani Family Trusts [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Convertible Notes Payable 279,366        
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member] | Shareholder [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Convertible Notes Payable 445,756 430,639      
September 2015 Convertible Notes [Member] | Consultants [Member] | Schafer [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Convertible Notes Payable 20,845 $ 20,190      
September 2015 Convertible Notes [Member] | Convertible Debt [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Conversion Price Per Unit (in dollars per share)   $ 0.60      
Interest Expense $ 23,796 $ 21,462      
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY (Details) - Share-Based Payment Arrangement, Option [Member]
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Dividend yield
Weighted Average [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 65.00% 65.00%
Dividend yield
Risk-free interest rate 2.99% 0.79%
Expected term (Year) 3 years 8 months 15 days 5 years 9 months 18 days
Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 65.00% 65.00%
Risk-free interest rate 3.01% 0.82%
Expected term (Year) 3 years 8 months 19 days 5 years 10 months 24 days
Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 69.00% 58.00%
Risk-free interest rate 1.71% 0.47%
Expected term (Year) 3 years 14 days 5 years
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Stock Options Activity (Details) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Equity [Abstract]      
Options outstanding, beginning (in shares) 10,471,600 9,511,600  
Options outstanding, beginning weighted-average exercise price $ 0.77 $ 0.74  
Outstanding, weighted-average remaining contractual life (Year) 2 years 8 months 12 days 3 years 8 months 12 days 4 years 6 months
Outstanding, aggregate intrinsic value beginning $ 6,064,335  
Granted 730,000 960,000  
Granted, weighted-average exercise price $ 1.00 $ 1.10  
Exercised, options (in shares)  
Exercised, weighted-average exercise price  
Forfeited, options (in shares)  
Forfeited, weighted-average exercise price  
Expired, options (in shares)  
Expired, weighted-average exercise price  
Granted, weighted-average remaining contractual life (Year) 3 years 8 months 12 days    
Options outstanding, ending (in shares) 11,201,600 10,471,600 9,511,600
Options outstanding, ending weighted-average exercise price $ 0.80 $ 0.77 $ 0.74
Outstanding, aggregate intrinsic value ending $ 4,429,263 $ 6,064,335
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)
12 Months Ended
Jun. 30, 2022
$ / shares
shares
Equity [Abstract]  
Nonvested options, beginning (in shares)
Granted, options (in shares) 730,000
Granted, weighted-average grant-date fair value | $ / shares $ 0.574
Vested (in shares) (730,000)
Vested, weighted-average grant-date fair value | $ / shares $ (0.574)
Nonvested, weighted-average grant-date fair value, ending
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Financial Statements (Details) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
General and Administrative Expense [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Change in fair value from modification of warrant terms $ 8,337 $ 25,506
Allocated Share-based Compensation Expense 269,595 850,331
Research and Development Expense [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Allocated Share-based Compensation Expense 22,464 201,650
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Change in fair value from modification of option terms 8,775
Allocated Share-based Compensation Expense 261,258 816,050
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Allocated Share-based Compensation Expense $ 22,464 $ 201,650
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Feb. 11, 2022
Jul. 01, 2014
Apr. 29, 2022
Jun. 30, 2022
Jun. 30, 2021
Apr. 30, 2023
May 01, 2022
Apr. 30, 2022
Jul. 03, 2014
Jul. 02, 2014
Class of Stock [Line Items]                    
Redemption of convertible Preferred stock       $ 41,000            
Common stock shares       43,758,820 41,315,986          
Shares Held by Subsidiaries (in shares)       704,309 704,309          
Warrants exercisable per share       $ 0.75 $ 0.75          
Class of Warrant or Right, Exercised During Period (in shares)       2,315,550 4,065,988          
Common Stock Shares Issued upon Exercise of Warrants (in shares)       2,315,550 4,065,988          
Warrants Exercised for Common Stock       $ 1,736,662 $ 3,049,490          
Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares)       66,860 129,364          
Payments of Commissions on Exercise of Warrants       $ 18,601 $ 3,537          
Share price         $ 0.50          
Total proceeds         $ 300,000          
Net proceeds       1,737,000 $ 5,209,000          
Commissions       19,000            
Proceeds from allocated shares         3,720,000          
Allocated to warrants       114,148            
Allocated to the sharea       1,745,852            
Proceeds from Issuance of Common Stock       $ 300,000          
Class of Warrant or Right, Outstanding (in shares)       20,800,000            
Weighted Average Exercise Price for Outstanding Warrants (in dollars per share)       $ 0.75            
Weighted Average Remaining Contractual Life for Outstanding Warrants (Year)       2 years 7 months 6 days            
Issuance of warrants       $ 30,000 2,500          
Interest expenses       301,659 $ 657,945          
Commissions on warrant exercises       $ 18,601            
Exercise bonus         75.00%          
Number of shares granted       730,000 960,000          
Share-based Compensation, Granted     720,000              
Share-based Compensation, Granted       730,000            
Fair value of stock options       $ 419,370 $ 1,017,700          
Capitalized amount       32,000            
Non cash compensation       135,648            
Project 3 G [Member]                    
Class of Stock [Line Items]                    
Capitalized amount       135,648            
Non cash compensation       $ 0            
Options Held [Member]                    
Class of Stock [Line Items]                    
Share-based Compensation, Granted       730,000 960,000          
Plan 2006 [Member]                    
Class of Stock [Line Items]                    
Number of shares granted 10,000                  
Smith [Member]                    
Class of Stock [Line Items]                    
Share price         $ 0.50          
Share-based Compensation, Granted     200,000              
Schafer [Member]                    
Class of Stock [Line Items]                    
Share-based Compensation, Granted     50,000              
Northrop [Member]                    
Class of Stock [Line Items]                    
Share-based Compensation, Granted     50,000              
Bassani [Member]                    
Class of Stock [Line Items]                    
Share-based Compensation, Granted     200,000              
Restricted Stock [Member]                    
Class of Stock [Line Items]                    
Share price         $ 0.75          
Expiry date         Dec. 31, 2021          
Number of shares issued         3,720,000          
Total proceeds         $ 1,860,000          
Net proceeds         1,699,000          
Commissions         161,000          
Share-Based Payment Arrangement, Option [Member]                    
Class of Stock [Line Items]                    
Stock options, authorized (in shares)       36,000,000            
Share-based Payment Arrangement, Expense       $ 419,370 $ 1,107,700          
Share-Based Payment Arrangement, Option [Member] | Equity Incentive Plan [Member]                    
Class of Stock [Line Items]                    
Stock options, authorized (in shares)       30,000,000            
Common Stock [Member]                    
Class of Stock [Line Items]                    
Warrants exercisable per share       $ 0.75            
Number of shares issued       25,000 144,000          
Number of shares issued         300,000          
Total proceeds                  
Sale of Units, Number Of Units Issued (in shares)         3,720,000          
Issuance of warrants                
Commissions on warrant exercises, shares       66,860            
Commissions on warrant exercises                  
Warrant [Member]                    
Class of Stock [Line Items]                    
Class of Warrant or Right, Exercised During Period (in shares)       2,315,550            
Common Stock Shares Issued upon Exercise of Warrants (in shares)       2,315,550            
Share price         $ 0.05          
Proceeds from allocated shares         3,720,000          
Issuance of warrants       $ 7,500            
Share-based Payment Arrangement, Plan Modification, Incremental Cost       5,624            
Interest expenses       2,713            
Warrant Exercised for Common Stock       1,736,662            
Additional Paid-in Capital [Member]                    
Class of Stock [Line Items]                    
Total proceeds         $ 300,000          
Issuance of warrants       30,000 2,500          
Commissions on warrant exercises       18,601            
President [Member]                    
Class of Stock [Line Items]                    
Converted to Units, Amount       $ 17,711            
Accounts Payable Converted to Units, Shares       35,424            
Accounts Payable Converted to Units, Price Per Unit       $ 0.50            
Warrants exercisable per share       0.75            
Deferred Compensation, Converted to Units, Amount         128,039          
Accounts Payable, Converted to Units, Amount         $ 52,361          
Deferred Compensation and Accounts Payable Converted to Units, Shares (in shares)         360,805          
President [Member] | Sale of Units in Exchange for Salary [Member]                    
Class of Stock [Line Items]                    
Sale of Units, Number Of Units Issued (in shares)         144,000          
Sale of Units in Exchange for Salary and Expense, Salary Amount         $ 72,000          
President [Member] | Warrants Related to the Conversion of Deferred Compensation and Accounts Payable into Units [Member]                    
Class of Stock [Line Items]                    
Warrants exercisable per share         $ 0.75          
President [Member] | Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member]                    
Class of Stock [Line Items]                    
Warrants exercisable per share       $ 0.75 0.75          
President [Member] | Common Stock [Member]                    
Class of Stock [Line Items]                    
Converted to Units, Amount       $ 17,711            
Accounts Payable Converted to Units, Shares       35,424            
An Investor [Member]                    
Class of Stock [Line Items]                    
Number of shares sold       300,000            
Proceeds from Issuance of Common Stock       $ 300,000            
Two Consultants [Member]                    
Class of Stock [Line Items]                    
Warrants exercisable per share         $ 0.75          
Deferred Compensation, Converted to Units, Amount         $ 593,411          
Deferred Compensation and Accounts Payable Converted to Units, Shares (in shares)         1,186,824          
Shares Issued, Price Per Share (in dollars per share)         $ 0.50          
Two Consultants [Member] | Warrant [Member]                    
Class of Stock [Line Items]                    
Warrants exercisable per share       $ 1.50            
Class of Warrant or Right, Exercised During Period (in shares)       75,000            
Chief Executive Officer [Member]                    
Class of Stock [Line Items]                    
Warrants exercisable per share             $ 1.00      
Number of shares issued             1,000,000      
Cancellation of warrants             700,000      
Exercise bonus             75.00%      
Minimum [Member]                    
Class of Stock [Line Items]                    
Common stock shares               100,000,000    
Warrants exercisable per share       $ 0.60            
Exercise bonus       50.00%            
Maximum [Member]                    
Class of Stock [Line Items]                    
Common stock shares               250,000,000    
Warrants exercisable per share       $ 1.50            
Exercise bonus       90.00%            
Forecast [Member]                    
Class of Stock [Line Items]                    
Par value           $ 0.01        
Forecast [Member] | Minimum [Member]                    
Class of Stock [Line Items]                    
Preferred stock shares           50,000        
Forecast [Member] | Maximum [Member]                    
Class of Stock [Line Items]                    
Preferred stock shares           10,000,000        
Series B Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       0 200         200
Par value       $ 0.01 $ 0.01         $ 0.01
Preferred Stock, Convertible Option Per Share (in dollars per share)                 $ 2.00  
Preferred Stock, Dividend Rate, Percentage   2.50%                
Preferred Stock, Redemption Price Per Share (in dollars per share)                   $ 100
Dividends Payable       $ 21,000            
Preferred stock shares       0 200          
Dividends, Preferred Stock       $ 1,000 $ 2,000          
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) - USD ($)
Jun. 30, 2022
May 01, 2022
Dec. 31, 2021
Jun. 30, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75     $ 0.75
Secured Promissory Note [Member] | Smiths [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Financing Receivable, after Allowance for Credit Loss, Total $ 35,011      
Financing Receivable, Principal Amount $ 30,000      
Chief Executive Officer [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 1.00    
Chief Executive Officer [Member] | Warrants Issused, Subscription Receivable [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 5,565,000      
Chief Executive Officer [Member] | Secured Promissory Note [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Financing Receivable, after Allowance for Credit Loss, Total $ 428,250      
Notes receivable interest $ 504,650      
President [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75      
President [Member] | Warrants Issused, Subscription Receivable [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 300,000   300,000  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.60      
President [Member] | Secured Promissory Note [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Financing Receivable, after Allowance for Credit Loss, Total $ 34,688      
Financing Receivable, Principal Amount $ 30,000      
Financing Receivable, Interest Rate, Stated Percentage 4.00%      
Former Employee [Member] | Warrants Issused, Subscription Receivable [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 928,000      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75      
Former Employee [Member] | Secured Promissory Note [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Financing Receivable, after Allowance for Credit Loss, Total $ 55,009      
Financing Receivable, Principal Amount $ 46,400      
Financing Receivable, Interest Rate, Stated Percentage 4.00%      
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details)
Jun. 30, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Cash paid for noncancelable operating lease included in the operating cash flows $ 60,000
Right of use assets obtained in exchange for operating lease liabilities $ 180,586
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details1)
Jun. 30, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Year ended June 30, 2023 $ 43,750
Year ended June 30, 2024 75,000
Year ended June 30, 2025 31,250
Undiscounted cash flow 150,000
Less imputed interest (21,136)
Total $ 128,864
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 05, 2022
Jun. 06, 2022
May 01, 2022
Oct. 10, 2016
Feb. 10, 2015
Mar. 31, 2023
Jun. 15, 2022
Mar. 23, 2022
Mar. 21, 2022
Jan. 28, 2022
Sep. 27, 2022
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 29, 2021
Sep. 30, 2021
Aug. 01, 2018
Feb. 28, 2018
Apr. 27, 2017
Oct. 31, 2016
Sep. 25, 2014
Loss Contingencies [Line Items]                                          
Warrants exercisable per share                       $ 0.75 $ 0.75                
Compensation increased     $ 25,000                                    
Cash compensation paid                       $ 346,846 $ 1,126,481                
Exercise bonus                         75.00%                
Warrants held by trust owned                         $ 3,000,000                
Warrants and Rights Outstanding                       17,778,213                  
Debt instrument paid amount                   $ 2,665,500                      
Debt Instrument, Interest Rate During Period   25.00%             25.00% 25.00%                      
Principal, interest   $ 666,375             $ 666,375 $ 666,375                      
Sale of domain, description               the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.                          
Loan related to construction                             $ 10,010,000            
Accrued interest                             2,255,802            
Total assets                       6,360,337 4,341,911   0 $ 297          
Total liabilities                       7,254,916 15,748,250   10,234,501 10,154,334          
Accounts payable and accrued liabilities                       1,360,644 570,050   10,009,802 9,939,148          
Accounts payable                             212,263 214,235          
Accrued Liabilities, Current                             $ 12,436 $ 950          
Gain on legal dissolution of subsidiary                       $ 10,234,501                  
Line of Credit, Current                         9,868,495                
Weighted average remaining lease term                       The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2022 were 3 years and 10%, respectively.                  
PA-1 [Member]                                          
Loss Contingencies [Line Items]                                          
Debt Instrument, Debt Default, Amount                                         $ 8,137,117
Gain (Loss) on Securitization of Financial Assets             $ 104,725                            
Pennvest Loan [Member]                                          
Loss Contingencies [Line Items]                                          
Line of Credit Facility, Maximum Borrowing Capacity                       $ 7,754,000                  
Debt Instrument, Annual Principal Payment                       5,886,000                  
Long-Term Debt, Maturity, Year Two                       846,000                  
Long-Term Debt, Maturity, Year Three                       873,000                  
Long-Term Debt, Maturity, Year Four                       149,000                  
Interest Expense, Debt                       $ 123,444 246,887                
Subsequent Event [Member]                                          
Loss Contingencies [Line Items]                                          
Debt instrument paid amount                     $ 50,000                    
Aggregate payment $ 1,996,125                                        
Minimum [Member]                                          
Loss Contingencies [Line Items]                                          
Warrants exercisable per share                       $ 0.60                  
Exercise bonus                       50.00%                  
Maximum [Member]                                          
Loss Contingencies [Line Items]                                          
Warrants exercisable per share                       $ 1.50                  
Exercise bonus                       90.00%                  
Years One Through Five [Member] | Pennvest Loan [Member]                                          
Loss Contingencies [Line Items]                                          
Debt Instrument, Interest Rate During Period                       2.547%                  
Years Six Through Maturity [Member] | Pennvest Loan [Member]                                          
Loss Contingencies [Line Items]                                          
Debt Instrument, Interest Rate During Period                       3.184%                  
Smith [Member]                                          
Loss Contingencies [Line Items]                                          
Cash compensation paid                       $ 130,000 $ 139,460                
President [Member]                                          
Loss Contingencies [Line Items]                                          
Monthly Officers' Cash Compensation       $ 18,000                                  
Warrants exercisable per share                       $ 0.75                  
President [Member] | Extension Bonus [Member] | FY2016 Extension Agreement [Member]                                          
Loss Contingencies [Line Items]                                          
Deferred Compensation, Maximum Convertible Amount                                     $ 300,000 $ 125,000  
Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)                                     $ 0.75 $ 0.75  
President [Member] | Warrants Issused, Subscription Receivable [Member]                                          
Loss Contingencies [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                       300,000   300,000              
Warrants exercisable per share                       $ 0.60                  
President [Member] | Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member]                                          
Loss Contingencies [Line Items]                                          
Warrants exercisable per share                       $ 0.75 $ 0.75                
Chief Executive Officer [Member]                                          
Loss Contingencies [Line Items]                                          
Monthly Officers' Cash Compensation         $ 31,000             $ 25,000                  
Warrants exercisable per share     $ 1.00                                    
Deferred Compensation, Maximum Convertible Amount                       10,000                  
Exercise bonus     75.00%                                    
Number of shares issued     1,000,000                                    
Cancellation of warrants     700,000                                    
Chief Executive Officer [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]                                          
Loss Contingencies [Line Items]                                          
Financing Receivable, after Allowance for Credit Loss, Total                       348,643                  
Repayments of Long-term Debt, Total                       $ 250,000 $ 155,000                
Chief Executive Officer [Member] | Warrants Issused, Subscription Receivable [Member]                                          
Loss Contingencies [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                       5,565,000                  
Chief Executive Officer [Member] | Warrants Expiring on December 31, 2025 [Member]                                          
Loss Contingencies [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                                 3,000,000        
Bassani [Member]                                          
Loss Contingencies [Line Items]                                          
Salaries and wages                                   $ 31,000      
Additional paid amount                                   $ 2,000      
Bassani [Member] | Forecast [Member]                                          
Loss Contingencies [Line Items]                                          
Interest bearing secured promissory note           $ 300,000                              
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES (Details) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Income Tax Disclosure [Abstract]    
Expected income tax expense (benefit) at statutory rate $ 1,741,000 $ (724,000)
State taxes, net of federal benefit 303,000 (126,000)
RTP – Excess Business Interest 115,000
Permanent differences and other 8,000 8,000
Expiration of net operating allowances 1,229,000 802,000
Change in valuation allowance (3,281,000) (75,000)
Income tax expense (benefit)
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES (Details 1) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Income Tax Disclosure [Abstract]    
NOL carryforwards (Federal and State) $ 8,274,000 $ 11,784,000
Stock-based compensation 5,436,000 5,350,000
Impairment 1,340,000 1,340,000
Business interest 339,000 264,000
Deferred compensation 1,054,000 986,000
Gross deferred tax assets 16,443,000 19,724,000
Valuation allowance (16,443,000) (19,724,000)
Net deferred tax assets
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES (Details Narrative)
12 Months Ended
Jun. 30, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Operating Loss Carryforwards, Total $ 8,274,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 100.00%
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 09, 2022
Aug. 08, 2022
Jul. 05, 2022
Jun. 06, 2022
Jul. 31, 2022
Mar. 21, 2022
Jan. 28, 2022
Sep. 27, 2022
Jun. 30, 2022
Jun. 30, 2021
Sep. 30, 2022
Aug. 31, 2022
Subsequent Event [Line Items]                        
Debt Instrument, Interest Rate During Period       25.00%   25.00% 25.00%          
Debt Instrument, Periodic Payment       $ 666,375   $ 666,375 $ 666,375          
Number of shares exercised                    
Deferred Compensation Liability, Current                 $ 594,798 $ 479,208    
Debt Conversion, Converted Instrument, Amount             $ 2,665,500          
Issaunce of warrants                 20,800,000      
Common Stock [Member]                        
Subsequent Event [Line Items]                        
Stock Issued During Period, Shares, Issued for Services                 25,000 144,000    
Subsequent Event [Member]                        
Subsequent Event [Line Items]                        
Aggregate Payment     $ 1,996,125                  
Number of shares sold         320,000              
Exercisable         $ 1.25              
Number of shares exercised               74,834        
Stock Issued During Period, Value, Stock Options Exercised               $ 56,126        
Number of shares issued               74,834        
[custom:UnreimbursedExpenses]               $ 23,943        
Deferred Compensation Liability, Current               20,000        
Debt Conversion, Converted Instrument, Amount               $ 50,000        
Debt Conversion, Converted Instrument, Shares Issued               100,000        
Issaunce of warrants               100,000     150,000 150,000
Subsequent Event [Member] | Two Non Affiliated Purchasers [Member]                        
Subsequent Event [Line Items]                        
Sale of Stock, Consideration Received Per Transaction         $ 320,000              
Subsequent Event [Member] | Consultants [Member]                        
Subsequent Event [Line Items]                        
Number of shares expired   300,000                    
Subsequent Event [Member] | Three Employees And Contractors [Member]                        
Subsequent Event [Line Items]                        
Number of shares expired   1,286,824                    
Subsequent Event [Member] | Non Affilated Consultant [Member]                        
Subsequent Event [Line Items]                        
Stock Issued During Period, Shares, Issued for Services 50,000                      
Subsequent Event [Member] | Restricted And Legended Shares [Member]                        
Subsequent Event [Line Items]                        
Number of shares sold         320,000              
Subsequent Event [Member] | Common Stock [Member]                        
Subsequent Event [Line Items]                        
Number of shares sold         320,000              
Subsequent Event [Member] | Warrant [Member]                        
Subsequent Event [Line Items]                        
Number of shares sold         320,000              
XML 60 bnet_10k-063022_htm.xml IDEA: XBRL DOCUMENT 0000875729 2021-07-01 2022-06-30 0000875729 2022-06-30 0000875729 2022-08-01 0000875729 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2020-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2020-06-30 0000875729 us-gaap:CommonStockMember 2020-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000875729 bnet:SubscriptionsReceivableMember 2020-06-30 0000875729 us-gaap:RetainedEarningsMember 2020-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2020-06-30 0000875729 2020-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2020-07-01 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 bnet:RibbonwireMember 2021-07-01 2022-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2022-06-30 0000875729 srt:MaximumMember 2022-06-30 0000875729 bnet:CenterpointMember 2022-06-30 0000875729 us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 us-gaap:WarrantMember 2020-07-01 2021-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2022-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2020-07-01 2021-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2022-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2020-07-01 2021-06-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-06-30 0000875729 bnet:BassaniMember 2021-06-30 0000875729 bnet:SmithMember 2021-06-30 0000875729 bnet:ConsultantsMember 2022-06-30 0000875729 bnet:ConsultantsMember 2021-06-30 0000875729 bnet:SmithMember 2022-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2022-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2020-07-01 2021-06-30 0000875729 bnet:PennvestLoanMember 2022-06-30 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-01 2022-06-15 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 bnet:The2020ConvertibleObligationsMember 2021-07-01 2022-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-07-01 2021-06-30 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-06-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2021-06-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2021-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2021-06-30 0000875729 bnet:September2015ConvertibleNotesMember 2021-07-01 2022-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-07-01 2021-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 srt:MinimumMember srt:ScenarioForecastMember 2023-04-30 0000875729 srt:MaximumMember srt:ScenarioForecastMember 2023-04-30 0000875729 srt:ScenarioForecastMember 2023-04-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2020-07-01 2021-06-30 0000875729 srt:MinimumMember 2022-04-30 0000875729 srt:MaximumMember 2022-04-30 0000875729 srt:PresidentMember us-gaap:CommonStockMember 2021-07-01 2022-06-30 0000875729 srt:PresidentMember 2022-06-30 0000875729 us-gaap:RestrictedStockMember 2021-06-30 0000875729 us-gaap:RestrictedStockMember 2020-07-01 2021-06-30 0000875729 us-gaap:WarrantMember 2020-07-01 2021-06-30 0000875729 us-gaap:WarrantMember 2021-06-30 0000875729 bnet:AnInvestorMember 2021-07-01 2022-06-30 0000875729 srt:PresidentMember 2020-07-01 2021-06-30 0000875729 srt:PresidentMember bnet:WarrantsRelatedToTheConversionOfDeferredCompensationAndAccountsPayableIntoUnitsMember 2021-06-30 0000875729 bnet:TwoConsultantsMember 2020-07-01 2021-06-30 0000875729 bnet:TwoConsultantsMember 2021-06-30 0000875729 srt:PresidentMember bnet:SaleOfUnitsInExchangeForSalaryMember 2020-07-01 2021-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2021-06-30 0000875729 srt:PresidentMember 2021-07-01 2022-06-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-06-30 0000875729 bnet:Plan2006Member 2022-02-01 2022-02-11 0000875729 2022-04-01 2022-04-29 0000875729 bnet:SchaferMember 2022-04-01 2022-04-29 0000875729 bnet:NorthropMember 2022-04-01 2022-04-29 0000875729 bnet:BassaniMember 2022-04-01 2022-04-29 0000875729 bnet:SmithMember 2022-04-01 2022-04-29 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000875729 us-gaap:OptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:OptionMember 2020-07-01 2021-06-30 0000875729 bnet:Project3GMember 2021-07-01 2022-06-30 0000875729 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000875729 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000875729 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000875729 2019-07-01 2020-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2021-06-30 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2021-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2021-06-30 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2022-06-30 0000875729 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2022-06-30 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2022-06-30 0000875729 2022-04-30 2022-05-01 0000875729 bnet:SmithMember 2021-07-01 2022-06-30 0000875729 bnet:SmithMember 2020-07-01 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 srt:ScenarioForecastMember bnet:BassaniMember 2023-03-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2020-07-01 2021-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-06-30 0000875729 2022-01-01 2022-01-28 0000875729 2022-03-02 2022-03-21 0000875729 us-gaap:SubsequentEventMember 2022-07-01 2022-07-05 0000875729 2022-03-02 2022-03-23 0000875729 2022-06-01 2022-06-06 0000875729 us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0000875729 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0000875729 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0000875729 bnet:RestrictedAndLegendedSharesMember us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0000875729 us-gaap:SubsequentEventMember 2022-07-31 0000875729 bnet:TwoNonAffiliatedPurchasersMember us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0000875729 us-gaap:SubsequentEventMember 2022-07-01 2022-09-27 0000875729 us-gaap:SubsequentEventMember 2022-09-27 0000875729 bnet:ConsultantsMember us-gaap:SubsequentEventMember 2022-08-01 2022-08-08 0000875729 bnet:ThreeEmployeesAndContractorsMember us-gaap:SubsequentEventMember 2022-08-01 2022-08-08 0000875729 bnet:NonAffilatedConsultantMember us-gaap:SubsequentEventMember 2022-09-01 2022-09-09 0000875729 us-gaap:SubsequentEventMember 2022-09-30 0000875729 us-gaap:SubsequentEventMember 2022-08-31 iso4217:USD shares iso4217:USD shares pure bnet:Decimal 0000875729 false 2022 FY No No Yes Yes 10-K true 2022-06-30 --06-30 false 000-19333 BION ENVIRONMENTAL TECHNOLOGIES, INC. CO 84-1176672 9 East Park Court Old Bethpage NY 11804 (516) 586-5643 Non-accelerated Filer true false false 35500000 43416011 Eide Baily LLP 286 Colorado 3160442 4216321 157550 124049 1000 1000 3318992 4341370 145787 2895558 541 6360337 4341911 1360644 570050 0.01 0.01 50000 50000 0 0 200 200 0 40000 37400 594798 479208 9868495 1955442 10955153 128864 5170610 4793097 7254916 15748250 0.01 0.01 10000000 50000 0 0 0 0 0.01 0.01 60000 60000 0 0 0 0 0 0 250000000 100000000 43758820 41315986 43054511 40611677 123620046 121399067 504650 504650 -124047548 -132339873 -932152 -11445456 37573 39117 -894579 -11406339 6360337 4341911 2348324 2078248 1161 827 200691 748545 2550176 2827620 -2550176 -2827620 -34800 5625 301659 657945 -902490 -10234501 -10840957 623145 8290781 -3450765 -1544 -2785 8292325 -3447980 0.20 -0.10 41962302 33068832 31409005 114266683 -504650 -128891893 41902 -15087958 3720000 1860000 1860000 129364 -164537 -164537 1017700 1017700 8775 8775 212645 212645 2500 2500 4065988 3049490 3049490 300000 300000 300000 144000 72000 72000 1547629 773811 773811 -3447980 -2785 -3450765 41315986 121399067 -504650 -132339873 39117 -11406339 2315550 1736662 1736662 66860 18601 18601 35424 17711 17711 25000 27500 27500 8337 8337 30000 30000 419370 419370 8292325 -1544 8290781 43758820 123620046 -504650 -124047548 37573 -894579 8290781 -3450765 10234501 1161 827 34800 319523 694793 346846 1126481 33501 116084 366629 -6516 -16923 289200 396604 -670785 -1389460 2062155 -2062155 1736662 3049490 18601 3537 -41000 1860000 -161000 300000 1677061 5044953 -1055879 3655493 4216321 560828 3160442 4216321 28 17711 773811 16100 50145 97023 666375 135648 32000 190000 <p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zSB50JvzL1Lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt"><b>1.</b></span></td><td><span style="font-size: 10pt"><b><span id="xdx_821_ze0iWq1Vg3Si">ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS</span>:</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Organization and nature of business: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business will be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the first half of 2022 Bion began marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022 Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will treat the waste stream and recover/refine valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity, organic fertilizer and potentially other products. We anticipate converting the Ribbonwire LOI into a definitive joint venture agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors before the end of calendar year 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef joint venture projects over the next twelve months while moving forward with the Initial Project (see below) and the Dalhart Project and pursuing other opportunities in the livestock industry enabled by our Gen3 Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2<sup>nd</sup> quarter in 2023 and supports development of the Dalhart Project during 2023.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) development/construction of the Dalhart Project, iii) developing applications and markets for its low carbon organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&amp;D activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><b>HISTORY, BACKGROUND AND CURRENT ACTIVITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product while raising sustainable livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During July 2022, the Company entered into a letter of intent with Ribbonwire Ranch (Dalhart, Texas) (“Ribbonwire LOI”) setting forth the parties’ intention to negotiate a joint venture agreement and enter into a joint venture to develop and operate an initial <span id="xdx_906_ecustom--TechWastage_uDecimal_c20210701__20220630__srt--CounterpartyNameAxis__custom--RibbonwireMember_z6msFKTFl8F9">15,000</span> head integrated, sustainable beef facility on RWR property (“Dalhart Project”) including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">a)</span></td><td style="text-align: justify"><span style="font-size: 10pt">innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,</span></td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">c)</span></td><td style="text-align: justify"><span style="font-size: 10pt">a Bion GEN3 Tech module (which will utilize the recycled CO2 to increase ammonium bicarbonate recovery) for the production of ammonium bicarbonate fertilizer for use in organic crop production (plus residual organic solids and clean water),</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">d)</span></td><td style="text-align: justify"><span style="font-size: 10pt">which will produce verifiably sustainable beef products with USDA certified branding.</span></td></tr></table> <p style="margin-top: 0; margin-bottom: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Dalhart Project will include expansion capability up to 60,000 head of cattle, in aggregate, located at/around/contiguous to the initial facilities on Ribbonwire property.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The opportunity presented by the Ribbonwire LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation in Dalhart, TX a reality as soon as possible.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To place the Ribbonwire LOI and the Dalhart Project in the context of Company’s business plan (and our prior public disclosure), if the contemplated venture moves forward on the timelines set forth in the Ribbonwire LOI, active development of the Dalhart Project will commence early in the second quarter of 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3 Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion 3G Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the Dalhart Project). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site targeted to commence during January 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately <span id="xdx_904_ecustom--CattlePerHead_uDecimal_c20210701__20220630_z5U5ns2Cj0L9" title="Cattle per head">300</span> head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately <span id="xdx_909_ecustom--TechWastage_uDecimal_c20210701__20220630_zMNEWCNBjGJ3" title="Tech wastage">1,500</span> head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until sometime during January 2023. 3G1 has been moving forward with the development process of the Initial Project. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2023 fiscal year).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Specifically, the Initial Project is being developed to provide and/or accomplish the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">i.</span></td> <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Proof of Gen3Tech platform scalability</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">-</span></td> <td><span style="font-size: 10pt">Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3technology platform.</span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">-</span></td> <td><span style="font-size: 10pt">Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">ii.</span></td> <td><span style="font-size: 10pt">Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">iii.</span></td> <td><span style="font-size: 10pt">Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">iv.</span></td> <td><span style="font-size: 10pt">Produce sustainable beef products for initial test marketing efforts.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completing the primary goals of phase 1 of the Initial Project, (coupled with obtaining organic certifications(s) for our for our solid ammonium bicarbonate fertilizer product line), Bion expects to be ready to move forward with its plans for development of much larger facilities including the Dalhart Project. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-12 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.</p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3 Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility will include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food &amp; Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which is likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “<b>Organic Fertilizer Listing/Certification Process</b>” below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘<b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Projec</span></b><span style="text-decoration: underline">t’</span> below as an example) in the swine, dairy and poultry industries utilizing our Gen3 Tech.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers is choosing food marketed as ‘sustainable’ and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is <span id="xdx_902_ecustom--PercentageOfSustainable_dp_c20210701__20220630_zhds4hfHvyuk" title="Percentage of sustainable">29.5</span> percent on average.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and initially enjoyed steady sales growth until sales began flattening over the past 12-18 months. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence) plus a patina of initiatiatives invoking the vague term ‘regenerative’ agriculture. However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, segment which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad technical and economic challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost and timeline for availability remain very uncertain at this point.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium verifiably sustainable beef products that address these consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or sustainable organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, while providing the superior taste and texture those consumers have grown to prefer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water and air, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Bion sustainable beef facility (see diagram above) will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss to the atmosphere, as well as odors, thereby improving animal health and human working conditions while preventing air/soil/water pollution. The manure will be collected and moved directly to customized anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their harvest and production techniques, meat industry leaders have also announced their willingness to move forward with initiatives in this area. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2025) and 25% in five (5) years (end of 2027) (approximately 2,000,000 cattle annually). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2023. Our first commercial project is likely to be the Dalhart Project but we anticipate commencing additional sustainable beef projects during 2023 as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development/under construction during 2023 in three (3) different JVs with the initial barns being populated with livestock by fall/winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and populated by 2027-28 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $<span id="xdx_90A_eus-gaap--CostsAndExpenses_pn3n3_dm_c20210701__20220630_zY03SPOVGkD8" title="Cost in excess">50</span> million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During this period, the Company also anticipates having Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Organic Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Organic Fertilizer Listing/Certification Process</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021), the Iowa Organic Program (“IOP”)(filed during March 2022) and the California Department of Food &amp; Agriculture (“CDFA”)(filed during May 2022) and are each in the review process. The review processes are requiring extended periods of time and multiple procedural steps with each entity in part due to the novel nature of Bion’s Gen3Tech and our solid ammonium bicarbonate product in the context of organic certifications. The OMRI application has proceeded through multiple stages of review and rebuttal/appeal without receiving a positive result to date. The Company anticipates has recently filed a new appeal to the most recent determinations. The Company’s CDFA has received initial comments regarding our solid ammonium bicarbonate product line and we anticipate providing CDFA with the requested updated information and clarifications during the next 60 days. The Company’s product line is novel in part due to the fact that there is not a formal listing category for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this matter with one or more listings/certifications of this product line well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.</p> <p style="font: 10pt/110% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Gen3 Tech Kreider 2 Poultry Project</span></b></p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_ecustom--DescriptionOfKreider2PoultryProject_c20210701__20220630">Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2<sup>nd</sup> generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).</span> Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3 Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates that if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’. The Covid-19 pandemic has delayed legislative efforts needed to commence its development in Pennsylvania. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3 Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.</p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Technology Deployment: Bion Gen3Tech</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">The Livestock Problem</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going concern and management’s plans:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $<span id="xdx_907_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20200701__20210630_zK4YGK3xei2b" title="Net Income (loss)">3,451,000</span> during the year ended June 30, 2021. The Company has net income of $<span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210701__20220630_pp0p0" title="Net Income (loss)">8,292,000</span> for the year ended June 30, 2022. The net income for the year is largely due to a one-time, non-cash event of the dissolution of PA-1 for a gain of approximately $<span id="xdx_906_eus-gaap--IncomeLossFromContinuingOperations_c20210701__20220630_pp0p0" title="Net income">10,235,000</span> (Note 5). Additionally, the Company realized a one-time gain of $<span id="xdx_903_ecustom--GainOnSaleOfDomainAmount_c20210701__20220630_pp0p0" title="Gain on sale of domain">902,490</span> from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period (Note 9). There was an operating loss of approximately $<span id="xdx_90F_ecustom--OperatingLoss_c20210701__20220630_pp0p0" title="Operating loss">2,550,000</span> for the year ended June 30, 2022. At June 30, 2022, the Company has working capital and a stockholders’ deficit of approximately $<span id="xdx_906_ecustom--WorkingCapital_c20220630_pp0p0" title="Working Capital">1,364,000</span> and $<span id="xdx_905_eus-gaap--StockholdersEquity_iNI_pp0p0_di_c20220630_zUcbNJuEDu2a" style="display: none" title="(error)">932,152</span>932,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company received gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200701__20210630_pp0p0" title="Proceeds from Issuance or Sale of Equity">5,209,000</span>, respectively, from the sale of its debt and equity securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the year ended June 30, 2022, the Company received total proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20210701__20220630_pp0p0" title="Proceeds from Issuance or Sale of Equity">1,737,000</span> from the sale of its equity securities and paid approximately $<span id="xdx_905_eus-gaap--PaymentsForCommissions_pp0p0_c20210701__20220630_zB5YcVreBqHd" title="Commissions paid">19,000</span> in cash commissions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal years 2022 and 2021, the Company has faced less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years except that during the first three months of the current fiscal year, the Company has raised equity funds at a rate materially lower than the average rate during fiscal years 2021 and 2022. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $<span id="xdx_90C_ecustom--DeferredCompensationLiabilityAmountCancelled_pp0p0_c20170701__20180630_z7jSq8txWVpj" title="Deferred Compensation Liability, Amount Cancelled">2,404,000</span>. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart Project), Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $<span id="xdx_90E_eus-gaap--CapitalRequiredForCapitalAdequacy_c20220630__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Capital Required for Capital Adequacy">20,000,000</span> to $<span id="xdx_901_eus-gaap--CapitalRequiredForCapitalAdequacy_c20220630__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Capital Required for Capital Adequacy">80,000,000</span> or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Covid-19 pandemic related matters:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 15000 300 1500 0.295 50000000 Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). 3451000 8292000 10235000 902490 2550000 1364000 -932152 5209000 1737000 19000 2404000 20000000 80000000 <p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zblxS49FQL3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2.       <span id="xdx_82A_zfoppNPgQ9P6">SIGNIFICANT ACCOUNTING POLICIES</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zb1iEN8A4gTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zqhA2MP0D5l2">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20220630__srt--OwnershipAxis__custom--CenterpointMember_ziuIr0m2Kckf" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zzxXAm7ch2Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zjvmc1AWMTV7">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2022 and 2021 there are <span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220630_znhHpg7WJ7cg" title="Cash equivalents"><span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20210630_zutSumQodtMa" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zHTFBCxOPKna" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zhwoBgch8Amf">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Projects such as consulting fees, internal salaries, benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zZHKJNB7zwji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zeaTJtfFl2Jh">Patents</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSDopoWARaP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zuUhwD8AAr07">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_z0FpY9I85Ip" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zBp89e15mlEl">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of June 30, 2022 and 2021, there are <span id="xdx_905_eus-gaap--DerivativeInstrumentsAndHedgesLiabilities_iI_do_c20220630_zHXHYMujWqXe" title="Derivative financial instruments"><span id="xdx_902_eus-gaap--DerivativeInstrumentsAndHedgesLiabilities_iI_do_c20210630_zhpgQp4545cl" title="Derivative financial instruments">no</span></span> derivative financial instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84F_ecustom--OptionsPolicyTextBlock_zLRVoGvP7V67" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zA1VDSYl88d5">Options</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zUUjvSADw9Yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zrpmBvr3djAk">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zvyG9Utw9Crk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_z6eNYKRI61Rk">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_ecustom--MinorityInterestPolicyPolicyTextBlock_z9FybU5795b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zLKwA09TZ0Xh">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zHlo6C50F8Ge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_z4c5hAoecJ14">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--LessorLeasesPolicyTextBlock_zn8qFWsmPra1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zfy5bnujV9b5">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheets at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zwE3YcsiyTYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zGkajYjtn337">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zXcBCZmsLsUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zNeZS21Foayg">Income taxes</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify; text-indent: 0in">The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, as well as net operating losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in the period in which the tax change occurs. A valuation allowance is provided to reduce the deferred tax assets by 100%, since the Company believes that at this time it is more likely than not that the deferred tax asset will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company is no longer subject to U.S. federal and state tax examinations for fiscal years before 2009. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next <span id="xdx_90B_ecustom--UnrecognizedTaxPositionsTerm_dtM_c20210701__20220630_zky5iPiKmnuk" title="Unrecognized tax positions term">12</span> months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of June 30, 2022, there were <span id="xdx_900_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20220630_zWYG4ytyz9yi" title="Accrued interest and penalties">no</span> penalties or accrued interest amounts associated with any unrecognized tax benefits, <span id="xdx_902_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20220630_zjofuKlO0shl" title="Unrecognized tax benefits"><span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20210630_zEcL9xbhy1Nf" title="Unrecognized tax benefits">no</span></span>r was any interest expense recognized during the years ended June 30, 2022 and 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zsVz7m3BWz6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zSuQOyMq3Hel">Income (loss) per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zl04jc4pSUn8" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify"><span id="xdx_8BA_zpVAd3KNHOWd" style="display: none">Schedule of anti dilutive securities</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">20,778,635</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgVo1ApO2EJl" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">21,931,903</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8FAUlPTgzj7" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zv6TrWssyEV4" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwQ8TOYIGdz3" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,686,065</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zVDwcV9xBpy5" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,183,558</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify">Convertible preferred stock</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0755">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_z1NKeaOHFuT4" style="font-size: 10pt; text-align: right" title="Antidilutive securities">20,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zmuqzTHP8Bk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX664YnRZ3m2" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8B7_z5PhvaFHQo46" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210701__20220630_zIzAnCeOHhe2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20200701__20210630_zxBymODxd2We" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Year <br/>Ended <br/>June 30, <br/>2022</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Year <br/>Ended <br/>June 30, <br/>2021</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0in"><span style="font-size: 10pt">Shares issued – beginning of period</span></td><td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">41,315,986</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">31,409,005</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--SharesHeldBySubsidiaries_iN_di_zbPFI4LFS6H4" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in"><span style="font-size: 10pt">Shares held by subsidiaries (Note 7)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(704,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(704,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in"><span style="font-size: 10pt">Shares outstanding – beginning of period</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">40,611,677</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">30,704,696</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--WeightedAverageNumberOfSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-size: 10pt">Weighted average shares issued <br/>    during the period</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,350,625</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">2,364,136</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zl1ei3bghTJf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-size: 10pt">Basic and diluted weighted average shares – <br/>    end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">41,962,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">33,068,832</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8AC_zSZcSdj9bBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--UseOfEstimates_zjeDOYKHORPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zjPMq1xcx096">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ1jXr1RjFug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zbcl1IlqrHpk">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zb1iEN8A4gTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zqhA2MP0D5l2">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20220630__srt--OwnershipAxis__custom--CenterpointMember_ziuIr0m2Kckf" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.589 <p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zzxXAm7ch2Tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zjvmc1AWMTV7">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2022 and 2021 there are <span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220630_znhHpg7WJ7cg" title="Cash equivalents"><span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20210630_zutSumQodtMa" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 0 0 <p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zHTFBCxOPKna" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zhwoBgch8Amf">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Projects such as consulting fees, internal salaries, benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zZHKJNB7zwji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zeaTJtfFl2Jh">Patents</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSDopoWARaP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zuUhwD8AAr07">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--DerivativesPolicyTextBlock_z0FpY9I85Ip" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zBp89e15mlEl">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of June 30, 2022 and 2021, there are <span id="xdx_905_eus-gaap--DerivativeInstrumentsAndHedgesLiabilities_iI_do_c20220630_zHXHYMujWqXe" title="Derivative financial instruments"><span id="xdx_902_eus-gaap--DerivativeInstrumentsAndHedgesLiabilities_iI_do_c20210630_zhpgQp4545cl" title="Derivative financial instruments">no</span></span> derivative financial instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0 0 <p id="xdx_84F_ecustom--OptionsPolicyTextBlock_zLRVoGvP7V67" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zA1VDSYl88d5">Options</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zUUjvSADw9Yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zrpmBvr3djAk">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zvyG9Utw9Crk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_z6eNYKRI61Rk">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_ecustom--MinorityInterestPolicyPolicyTextBlock_z9FybU5795b3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zLKwA09TZ0Xh">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zHlo6C50F8Ge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_z4c5hAoecJ14">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--LessorLeasesPolicyTextBlock_zn8qFWsmPra1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zfy5bnujV9b5">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheets at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zwE3YcsiyTYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zGkajYjtn337">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zXcBCZmsLsUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zNeZS21Foayg">Income taxes</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify; text-indent: 0in">The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, as well as net operating losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in the period in which the tax change occurs. A valuation allowance is provided to reduce the deferred tax assets by 100%, since the Company believes that at this time it is more likely than not that the deferred tax asset will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company is no longer subject to U.S. federal and state tax examinations for fiscal years before 2009. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next <span id="xdx_90B_ecustom--UnrecognizedTaxPositionsTerm_dtM_c20210701__20220630_zky5iPiKmnuk" title="Unrecognized tax positions term">12</span> months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of June 30, 2022, there were <span id="xdx_900_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20220630_zWYG4ytyz9yi" title="Accrued interest and penalties">no</span> penalties or accrued interest amounts associated with any unrecognized tax benefits, <span id="xdx_902_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20220630_zjofuKlO0shl" title="Unrecognized tax benefits"><span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20210630_zEcL9xbhy1Nf" title="Unrecognized tax benefits">no</span></span>r was any interest expense recognized during the years ended June 30, 2022 and 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> P12M 0 0 0 <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zsVz7m3BWz6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zSuQOyMq3Hel">Income (loss) per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zl04jc4pSUn8" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify"><span id="xdx_8BA_zpVAd3KNHOWd" style="display: none">Schedule of anti dilutive securities</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">20,778,635</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgVo1ApO2EJl" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">21,931,903</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8FAUlPTgzj7" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zv6TrWssyEV4" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwQ8TOYIGdz3" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,686,065</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zVDwcV9xBpy5" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,183,558</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify">Convertible preferred stock</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0755">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_z1NKeaOHFuT4" style="font-size: 10pt; text-align: right" title="Antidilutive securities">20,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zmuqzTHP8Bk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX664YnRZ3m2" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8B7_z5PhvaFHQo46" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210701__20220630_zIzAnCeOHhe2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20200701__20210630_zxBymODxd2We" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Year <br/>Ended <br/>June 30, <br/>2022</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Year <br/>Ended <br/>June 30, <br/>2021</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0in"><span style="font-size: 10pt">Shares issued – beginning of period</span></td><td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">41,315,986</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">31,409,005</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--SharesHeldBySubsidiaries_iN_di_zbPFI4LFS6H4" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in"><span style="font-size: 10pt">Shares held by subsidiaries (Note 7)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(704,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(704,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in"><span style="font-size: 10pt">Shares outstanding – beginning of period</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">40,611,677</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">30,704,696</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--WeightedAverageNumberOfSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-size: 10pt">Weighted average shares issued <br/>    during the period</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,350,625</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">2,364,136</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zl1ei3bghTJf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-size: 10pt">Basic and diluted weighted average shares – <br/>    end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">41,962,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">33,068,832</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8AC_zSZcSdj9bBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zl04jc4pSUn8" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify"><span id="xdx_8BA_zpVAd3KNHOWd" style="display: none">Schedule of anti dilutive securities</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">20,778,635</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgVo1ApO2EJl" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">21,931,903</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8FAUlPTgzj7" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zv6TrWssyEV4" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwQ8TOYIGdz3" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,686,065</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zVDwcV9xBpy5" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,183,558</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: justify">Convertible preferred stock</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0755">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_z1NKeaOHFuT4" style="font-size: 10pt; text-align: right" title="Antidilutive securities">20,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> 20778635 21931903 11201600 10471600 10686065 10183558 20000 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX664YnRZ3m2" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; text-indent: 0in"><span id="xdx_8B7_z5PhvaFHQo46" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20210701__20220630_zIzAnCeOHhe2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20200701__20210630_zxBymODxd2We" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Year <br/>Ended <br/>June 30, <br/>2022</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Year <br/>Ended <br/>June 30, <br/>2021</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0in"><span style="font-size: 10pt">Shares issued – beginning of period</span></td><td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">41,315,986</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 14%; text-align: right"><span style="font-size: 10pt">31,409,005</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_ecustom--SharesHeldBySubsidiaries_iN_di_zbPFI4LFS6H4" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in"><span style="font-size: 10pt">Shares held by subsidiaries (Note 7)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(704,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(704,309</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in"><span style="font-size: 10pt">Shares outstanding – beginning of period</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">40,611,677</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">30,704,696</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--WeightedAverageNumberOfSharesIssuedDuringPeriod_i_pdd" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"><span style="font-size: 10pt">Weighted average shares issued <br/>    during the period</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,350,625</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">2,364,136</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zl1ei3bghTJf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"><span style="font-size: 10pt">Basic and diluted weighted average shares – <br/>    end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">41,962,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">33,068,832</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 41315986 31409005 704309 704309 40611677 30704696 1350625 2364136 41962302 33068832 <p id="xdx_842_eus-gaap--UseOfEstimates_zjeDOYKHORPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zjPMq1xcx096">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ1jXr1RjFug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_zbcl1IlqrHpk">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zfWrir02f7bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>3.  <span id="xdx_826_ziO4DjSPBRS4">PROPERTY AND EQUIPMENT</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqcTP6Xb42Wj" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8BF_z3fVOtd9Smbh" style="display: none">Schedule of property and equipment</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49A_20220630_zVwsSW7OmzZ1" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_494_20210630_zNbsPjudBoZ3" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/>2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr id="xdx_40D_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGza6i_zEVyJj5ti79h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Machinery and equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">—</span>  </td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">2,222,670</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BuildingsAndImprovementsGross_iI_pp0p0_maPPAEGza6i_zCEn2f5I5SJ" style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left">Buildings and structures</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">401,470</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ComputersAndOfficeEquipmentGross_iI_pp0p0_maPPAEGza6i_zRjfbFXviGP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Computers and office equipment</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">13,598</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">171,485</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGza6i_zGrzLULTdnt4" style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">3G project construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,892,222</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGza6i_maPPAEOzNlp_zfLVKDLbxsk2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255)">Property and equipment, gross </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,905,820</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,795,625</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzNlp_zXIQCvEbKq9f" style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,262</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,795,084</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzNlp_zvbzWqUaOKab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); padding-bottom: 2.5pt">Property and equipment, net </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,895,558</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">541</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 3G project began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for 3G construction in process includes $<span id="xdx_90B_eus-gaap--InterestCostsCapitalized_c20210701__20220630_zaisxSKXwcE1" title="Capitalized interest">32,000</span> for capitalized interest and $<span id="xdx_90E_ecustom--NonCashCompensation_c20210701__20220630_zU0bRkrTeiki" title="Non cash compensation">135,648</span> in non-cash compensation as of June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has reviewed the remaining property and equipment for impairment as of June 30, 2022 and believes that <span id="xdx_903_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PropertyPlantAndEquipmentOfPA1Member_zk5CRMCsNFR" title="Impairment of Long-Lived Assets Held-for-use">no</span> impairment exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense was $<span id="xdx_90C_eus-gaap--Depreciation_pp0p0_c20210701__20220630_zcC6ANdVCeX4" title="Depreciation expense">1,161</span> and $<span id="xdx_90E_eus-gaap--Depreciation_pp0p0_c20200701__20210630_zt0x983oKQ83" title="Depreciation expense">827</span> for the years ended June 30, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqcTP6Xb42Wj" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8BF_z3fVOtd9Smbh" style="display: none">Schedule of property and equipment</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49A_20220630_zVwsSW7OmzZ1" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_494_20210630_zNbsPjudBoZ3" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/>2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">June 30, <br/> 2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr id="xdx_40D_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGza6i_zEVyJj5ti79h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Machinery and equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">—</span>  </td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">2,222,670</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BuildingsAndImprovementsGross_iI_pp0p0_maPPAEGza6i_zCEn2f5I5SJ" style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left">Buildings and structures</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">401,470</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--ComputersAndOfficeEquipmentGross_iI_pp0p0_maPPAEGza6i_zRjfbFXviGP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Computers and office equipment</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">13,598</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">171,485</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGza6i_zGrzLULTdnt4" style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">3G project construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,892,222</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGza6i_maPPAEOzNlp_zfLVKDLbxsk2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255)">Property and equipment, gross </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,905,820</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,795,625</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzNlp_zXIQCvEbKq9f" style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,262</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,795,084</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzNlp_zvbzWqUaOKab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); padding-bottom: 2.5pt">Property and equipment, net </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,895,558</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">541</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 2222670 401470 13598 171485 2892222 2905820 2795625 10262 2795084 2895558 541 32000 135648 0 1161 827 <p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zgl34TTEtG54" style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify"><b>4.       <span id="xdx_829_zG6K6TKncqeg">DEFERRED COMPENSATION</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owes deferred compensation to various employees, former employees and consultants totaling $<span id="xdx_900_eus-gaap--DeferredCompensationLiabilityCurrent_c20220630_pp0p0" title="Deferred compensation liability">594,798</span> and $<span id="xdx_901_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210630_z14NquxGqwT5" title="Deferred compensation liability">479,208</span> as of June 30, 2022 and 2021, respectively. Included in the deferred compensation balances as of June 30, 2022, are $<span id="xdx_90A_eus-gaap--DeferredCompensationLiabilityCurrent_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred compensation liability">437,508</span> and $<span id="xdx_901_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwCQepwZEm5k" title="Deferred compensation liability">10,000</span> owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at <span id="xdx_908_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20220630_zfSe68wkuseh" title="Interest Rate on Deferred Compensation">4</span>% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last <span id="xdx_904_ecustom--DeferredCompensationConsecutiveTradingDays_dtD_c20210701__20220630_z3Ck2SvdjDBe" title="Deferred Compensation Consecutive Trading Days (Day)">10</span> trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of June 30, 2021 was $<span id="xdx_905_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210630__srt--CounterpartyNameAxis__custom--BassaniMember_zbmZWEUZEuj2" title="Deferred compensation liability">399,971</span> and <span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210630__srt--CounterpartyNameAxis__custom--SmithMember_z2zCzddFbmM2" style="display: none" title="Deferred compensation liability">0</span> nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $<span id="xdx_90C_eus-gaap--DeferredCompensationLiabilityCurrent_c20220630__srt--TitleOfIndividualAxis__custom--ConsultantsMember_pp0p0" title="Deferred compensation liability">74,790</span> and $<span id="xdx_90A_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__custom--ConsultantsMember_ztqtUnkdh1Oj" title="Deferred compensation liability">6,738</span> as of June 30, 2022 and 2021, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at <span id="xdx_908_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20220630__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zxDuw6JbPQgj" title="Interest Rate on Deferred Compensation">3</span>% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bassani and Smith have each been granted the right to convert up to $<span id="xdx_90C_ecustom--DeferredCompensationConvertibleToCommonStock_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred Compensation, Convertible to Common Stock">300,000</span> of deferred compensation balances at a price of $<span id="xdx_901_ecustom--DeferredCompensationConvertibleToCommonStockPricePerShare_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)">0.75</span> per share until December 31, 2022 (which date has subsequently been extended to June 30, 2024) to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2022, Smith elected to convert $<span id="xdx_90E_ecustom--DeferredCompensationConvertibleToCommonStock_iI_pp0p0_c20220630__srt--CounterpartyNameAxis__custom--SmithMember_zh0KwlvtqKd6" title="Deferred Compensation, Convertible to Common Stock">90,000</span> of deferred compensation into the 2020 Convertible Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_906_eus-gaap--InterestExpense_pp0p0_c20210701__20220630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zMHNmTP93cA2" title="Interest Expense">16,390</span> ($<span id="xdx_90A_eus-gaap--InterestExpenseRelatedParty_pp0p0_c20210701__20220630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zGxkMcf4N8H4" title="Interest Expense, Related Party">15,537</span> with related parties) and $<span id="xdx_90B_eus-gaap--InterestExpense_pp0p0_c20200701__20210630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zte5mDhdx3j4" title="Interest Expense">25,838</span> ($<span id="xdx_90A_eus-gaap--InterestExpenseRelatedParty_pp0p0_c20200701__20210630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zZ0ZIzIqZpDc" title="Interest Expense, Related Party">12,249</span> with related parties) for the years ended June 30, 2022 and 2021, respectively, related to deferred compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 594798 479208 437508 10000 0.04 P10D 399971 0 74790 6738 0.03 300000 0.75 90000 16390 15537 25838 12249 <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zvJDxaRNlnme" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b/></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>5.       <span id="xdx_828_zRezwBAQ9ek4">LOANS PAYABLE</span>:</b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_906_eus-gaap--ConstructionLoan_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Construction Loan">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_907_ecustom--AccruedInterestAndLateChargesPayable_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Accrued Interest and Late Charges Payable">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $<span id="xdx_90F_eus-gaap--Assets_iI_c20210930_zXSCxTtiJozk" title="Total assets">297</span> and its total liabilities were $<span id="xdx_90F_eus-gaap--Liabilities_iI_c20210930_zYHmQt5eAMd9" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_902_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20210930_zG77zjJXjASg" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_909_eus-gaap--AccountsPayableCurrent_iI_c20210930_zYxdfS240jz2" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_c20210930_zKVx3BztfA52" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil <span id="xdx_907_eus-gaap--Assets_iI_c20211229_zjnXbLYu4Mb4" style="display: none">0</span> and its total liabilities were $<span id="xdx_907_eus-gaap--Liabilities_iI_c20211229_zyuLudaAKgUj">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_906_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20211229_zApBeQRE9OB" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_90A_eus-gaap--AccountsPayableCurrent_iI_c20211229_zzBeDzeukqAd" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrent_iI_c20211229_z5bCM4D24nK9" title="Accrued Liabilities, Current">12,436</span>. The net amount of $<span id="xdx_90C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210701__20220630_zDAer0b7sRKc" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_907_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20220630__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zWjXYw6viu1d" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20220630__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zHGqmqss5hJc" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_900_eus-gaap--DebtInstrumentAnnualPrincipalPayment_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_90F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_90F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_90B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zrGFlN14wBud" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_907_eus-gaap--InterestExpenseDebt_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_ztj13Y6hia1l" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_908_eus-gaap--LinesOfCreditCurrent_iI_c20210630_zVXeVegkdyeb" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pp0p0_c20140925__dei--LegalEntityAxis__custom--PA1Member_z1e7Jc30rRu9" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_905_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_c20220601__20220615__dei--LegalEntityAxis__custom--PA1Member_zMDuMpv4Cj5f" title="Realized from the asset sale">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest, the remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 10010000 2255802 297 10154334 9939148 214235 950 0 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 <p id="xdx_807_ecustom--ConvertibleDebtTextBlock_zhT6lbQZOgWl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>6.       <span id="xdx_82C_zOD7lGtE3WAb">CONVERTIBLE NOTES PAYABLE - AFFILIATES</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2020 Convertible Obligations </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Convertible Obligations, which accrue interest at either <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zNk7XUCCu8B4" title="Debt Instrument, Interest Rate, Stated Percentage">4</span>% per annum or <span id="xdx_900_ecustom--DebtInstrumentInterestRateStatedPercentageQuarterly_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zVp2ytJDyw19" title="Debt Instrument, Interest Rate, Stated Percentage, Quarterly">4</span>% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $<span id="xdx_907_ecustom--ConversionPricePerUnit_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" title="Conversion Price Per Unit (in dollars per share)">0.50</span> per Unit until July 1, 2024. The original conversion price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220630_zVBO4vnrdDRg" title="Original conversion price">0.50</span> per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $<span id="xdx_908_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zP72mut88yYj" title="Convertible Notes Payable, Noncurrent">2,597,329</span>, $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zoc79f1DWnh9" title="Accrued interest">1,328,040</span> and $<span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcz6kdzRPkh7" title="Accrued interest">499,274</span>, respectively. As of June 30, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $<span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zen7bcB76c58" title="Convertible Notes Payable, Noncurrent">2,502,880</span>, $<span id="xdx_906_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZdOIeXg87gl" title="Convertible Notes Payable, Noncurrent">1,186,926</span> and $<span id="xdx_90F_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zepYP8SblNUh" title="Convertible Notes Payable, Noncurrent">481,119</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2022, Smith elected to add $<span id="xdx_90C_eus-gaap--SalariesAndWages_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_z3xm30vmwS4c" title="Salary paid">90,000</span> of his salary to his 2020 Convertible Obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_90C_eus-gaap--InterestExpense_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zSOdPDnpFla5" title="Interest Expense">131,718</span> and $<span id="xdx_909_eus-gaap--InterestExpense_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zkVzMTiMhpqa" title="Interest Expense">175,794</span> for the years ended June 30, 2022 and 2021, respectively. The Company capitalized $<span id="xdx_905_eus-gaap--CostsIncurredDevelopmentCosts_c20210701__20220630_ze0Lu24YOQOh" title="Capitalized amount">32,000</span> and nil <span id="xdx_904_eus-gaap--CostsIncurredDevelopmentCosts_c20200701__20210630_zpbZkg4JRw7k" style="display: none">0</span> related to the 3G project for the years ended June 30, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani (now owned by Bassani Family Trusts), Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at <span id="xdx_909_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zL5OSWs1Ujjd" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_901_ecustom--ConversionPricePerUnit_iI_c20210630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zwIIOUaqlbol" title="Conversion Price Per Unit (in dollars per share)">0.60</span> per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balances of the September 2015 Convertible Notes as of June 30, 2022, including accrued interest owed Bassani Family Trusts, Schafer and Shareholder, are $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_z8YCCImjmXT7" title="Convertible Notes Payable">279,366</span>, $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchaferMember_zoEgY3dBQPNa" title="Convertible Notes Payable">20,845</span> and $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zicAO27nnAa7" title="Convertible Notes Payable">445,756</span>, respectively. The balances of the September 2015 Convertible Notes as of June 30, 2021, including accrued interest, were $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BassaniFamilyTrustsMember_zWTANBn4ICvk" title="Convertible Notes Payable">171,343</span>, $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SchaferMember_zzyHeXLc3HA2" title="Convertible Notes Payable">20,190</span> and $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zXs19AVddgsg" title="Convertible Notes Payable">430,639</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2022, Bassani elected to transfer $<span id="xdx_908_eus-gaap--DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_pp0p0" title="Deferred compensation">100,000</span> from deferred compensation to the 2015 convertible note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_909_eus-gaap--InterestExpense_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zzpEGKVdUZqe" title="Interest Expense">23,796</span> and $<span id="xdx_904_eus-gaap--InterestExpense_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zoILw2TjK7qj" title="Interest Expense">21,462</span> for the years ended June 30, 2022 and 2021, respectively, on the September 2015 Convertible Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.04 0.04 0.50 0.50 2597329 1328040 499274 2502880 1186926 481119 90000 131718 175794 32000 0 0.04 0.60 279366 20845 445756 171343 20190 430639 100000 23796 21462 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z4MU6nuwS7pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7.       <span id="xdx_820_zpjrfvm8uJC">STOCKHOLDERS' EQUITY</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series B Preferred stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since July 1, 2014, the Company had <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding, Ending Balance (in shares)">200</span> shares of Series B redeemable convertible Preferred stock outstanding with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Par or Stated Value Per Share (in dollars per share)">0.01</span> per share, convertible at the option of the holder at $<span id="xdx_909_ecustom--PreferredStockConvertibleOptionPerShare_c20140703__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Convertible Option Per Share (in dollars per share)">2.00</span> per share, with dividends accrued and payable at <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_dp_c20140625__20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwULsQALPug3" title="Preferred Stock, Dividend Rate, Percentage">2.5</span>% per quarter. The Series B Preferred stock is mandatorily redeemable at $<span id="xdx_901_eus-gaap--PreferredStockRedemptionPricePerShare_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Redemption Price Per Share (in dollars per share)">100</span> per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $<span id="xdx_90E_ecustom--RedemptionOfConvertiblePreferredStock_c20210701__20220630_pp0p0" title="Redemption of convertible Preferred stock">41,000</span>, which included the $<span id="xdx_90F_eus-gaap--DividendsPayableCurrentAndNoncurrent_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p0" title="Dividends Payable">21,000</span> in accrued dividend payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2023, the Company amended the number of preferred stock shares from <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20230430__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MinimumMember_zyPkugXBob2d" title="Preferred stock shares">50,000</span> to <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20230430__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--RangeAxis__srt--MaximumMember_zwCYnyBetmP3">10,000,000</span>, having a $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230430__srt--StatementScenarioAxis__srt--ScenarioForecastMember_ztswCvYMsCqi" title="Par value">0.01</span> par value per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2022, and 2021, the Company declared dividends of $<span id="xdx_90F_eus-gaap--DividendsPreferredStock_pp0p0_c20210701__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRrEdcHfHbYc" title="Dividends, Preferred Stock">1,000</span> and $<span id="xdx_90F_eus-gaap--DividendsPreferredStock_pp0p0_c20200701__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjAMFB14kWvh" title="Dividends, Preferred Stock">2,000</span> respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"> During April 2022, the Company amended the number of common stock shares from <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20220430__srt--RangeAxis__srt--MinimumMember_zBbl6P3i53U8" title="Common stock shares">100,000,000</span> to <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20220430__srt--RangeAxis__srt--MaximumMember_z3lyUhwk1o1h">250,000,000</span>.</p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Centerpoint holds <span id="xdx_90C_ecustom--SharesHeldBySubsidiaries_c20210701__20220630_pdd" title="Shares Held by Subsidiaries (in shares)">704,309</span> shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2022, Smith elected to convert accounts payable (based on his unreimbursed expenses) of $<span id="xdx_901_ecustom--ConvertedToUnitsAmount_c20210701__20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" title="Converted to Units, Amount">17,711</span> into <span id="xdx_90B_ecustom--AccountsPayableConvertedToUnitsShares_c20210701__20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Accounts Payable Converted to Units, Shares">35,424</span> units at $<span id="xdx_907_ecustom--AccountsPayableConvertedToUnitsPricePerUnit_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember_pdd" title="Accounts Payable Converted to Units, Price Per Unit">0.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember_zcNo9K9ytCNl" title="Warrants exercisable per share">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the year ended June 30, 2022, <span id="xdx_908_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20210701__20220630_pdd" title="Class of Warrant or Right, Exercised During Period (in shares)">2,315,550</span> warrants were exercised to purchase <span id="xdx_902_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20210701__20220630_pdd" title="Common Stock Shares Issued upon Exercise of Warrants (in shares)">2,315,550</span> shares of the Company’s common stock at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXvSOnLF8qjg" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.75</span> per share for total proceeds of $<span id="xdx_907_ecustom--WarrantsExercisedForCommonStock_c20210701__20220630_zLMZOoXChwAe" title="Warrant Exercised for Common Stock">1,736,662</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesCommissionOnSaleOfUnitsAndWarrantExercises_c20210701__20220630_pdd" title="Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares)">66,860</span> shares of the Company’s common stock to three brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The Company also paid a broker $<span id="xdx_901_ecustom--PaymentsOfCommissionsOnExerciseOfWarrants_c20210701__20220630_pp0p0" title="Payments of Commissions on Exercise of Warrants">18,601</span> in commissions for the warrant exercises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsJuMzymnOS2" title="Number of shares issued">25,000</span> shares of the Company’s common stock to a marketing firm for services provided.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company entered into subscription agreements, under three different offerings, to sell units for $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20210630_z5m6Oxvo64I3" title="Sell units">0.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxInTla41sTg">0.75</span> per share with an expiry date of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDWpMaag0gDa" title="Expiry date">December 31, 2021</span>, and pursuant thereto, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwChlmzfPicg" title="Number of shares issued">3,720,000</span> units for total proceeds of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOMoPrFmLkEb" title="Total proceeds">1,860,000</span>, net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjsbmBDPDnw" title="Net proceeds">1,699,000</span> after commissions of $<span id="xdx_909_eus-gaap--PaymentsForCommissions_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxtIX9vvowY9" title="Commissions">161,000</span>. The Company allocated the proceeds from the <span id="xdx_90B_ecustom--ProceedsFromAllocatedShares_c20200701__20210630_zdwUyljwrVZ6" title="Proceeds from allocated shares">3,720,000</span> shares and the <span id="xdx_905_ecustom--ProceedsFromAllocatedShares_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSdEyWXBSz4b">3,720,000</span> warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be$<span id="xdx_90A_eus-gaap--SharePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1tkdjKkKrYc" title="Share price">0.05</span> per warrant. As a result, $<span id="xdx_904_ecustom--AllocatedToWarrants_c20210701__20220630_zX9BoxbGbsRg" title="Allocated to warrants">114,148</span> was allocated to the warrants and $<span id="xdx_90E_ecustom--AllocatedToSharea_c20210701__20220630_zQNj29TDCxLi" title="Allocated to the sharea">1,745,852</span> was allocated to the shares, and both were recorded as additional paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210701__20220630__srt--TitleOfIndividualAxis__custom--AnInvestorMember_zAZMWzyV5lu9" title="Number of shares sold">300,000</span> share of the Company’s restricted company stock were sold to an investor for $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pdp0_c20210701__20220630__srt--TitleOfIndividualAxis__custom--AnInvestorMember_zUIke1hA7cX" title="Proceeds from Issuance of Common Stock">300,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, Smith elected to convert deferred compensation and accounts payable of $<span id="xdx_900_ecustom--DeferredCompensationConvertedToUnitsAmount_pdp0_c20200701__20210630__srt--TitleOfIndividualAxis__srt--PresidentMember_zBjUimNMZ2mf" title="Deferred Compensation, Converted to Units, Amount">128,039</span> and $<span id="xdx_901_ecustom--AccountsPayableConvertedToUnitsAmount_pdp0_c20200701__20210630__srt--TitleOfIndividualAxis__srt--PresidentMember_z9srbTHV7KOk" title="Accounts Payable, Converted to Units, Amount">52,361</span>, respectively, into an aggregate <span id="xdx_90E_ecustom--DeferredCompensationAndAccountsPayableConvertedToUnitsShares_c20200701__20210630__srt--TitleOfIndividualAxis__srt--PresidentMember_zJVWT4CiRBC6" title="Deferred Compensation and Accounts Payable Converted to Units, Shares (in shares)">360,805</span> units at $<span id="xdx_901_eus-gaap--SharePrice_iI_c20210630__srt--CounterpartyNameAxis__custom--SmithMember_z4Z5OAAs7vRk" title="Share price">0.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsRelatedToTheConversionOfDeferredCompensationAndAccountsPayableIntoUnitsMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zDMziutQXWLg" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, two consultants elected to convert deferred compensation of $<span id="xdx_90E_ecustom--DeferredCompensationConvertedToUnitsAmount_pdp0_c20200701__20210630__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zrYigTR7fKaf" title="Deferred Compensation, Converted to Units, Amount">593,411</span>, into an aggregate <span id="xdx_900_ecustom--DeferredCompensationAndAccountsPayableConvertedToUnitsShares_c20200701__20210630__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zQWZXHWRhMzg" title="Deferred Compensation and Accounts Payable Converted to Units, Shares (in shares)">1,186,824</span> units at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20210630__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zf6ewG8FDhL9" title="Shares Issued, Price Per Share (in dollars per share)">0.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210630__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zLB8afZm7B3g">0.75</span> per share until December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company issued <span id="xdx_90C_ecustom--SaleOfUnitsNumberOfUnitsIssued_c20200701__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--SaleOfUnitsInExchangeForSalaryMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zQUQuLU4jhSd" title="Sale of Units, Number Of Units Issued (in shares)">144,000</span> units to Smith for salary of $<span id="xdx_906_ecustom--SaleOfUnitsInExchangeForSalaryAndExpenseSalaryAmount_pdp0_c20200701__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--SaleOfUnitsInExchangeForSalaryMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zI5LpdOWiMsk" title="Sale of Units in Exchange for Salary and Expense, Salary Amount">72,000</span>, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember_zk1YCXAymmV3" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> per share with an expiry date of December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, <span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20200701__20210630_ztlRZdUEylgi" title="Class of Warrant or Right, Exercised During Period (in shares)">4,065,988</span> warrants were exercised to purchase <span id="xdx_905_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20200701__20210630_zOdSi5TcHTN4" title="Common Stock Shares Issued upon Exercise of Warrants (in shares)">4,065,988</span> shares of the Company’s common stock at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210630_zaq9pFwvxqdb" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> per share for total proceeds of $<span id="xdx_901_ecustom--WarrantsExercisedForCommonStock_pdp0_c20200701__20210630_zDwW7WhrsXJ9" title="Warrants Exercised for Common Stock">3,049,490</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company issued <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesCommissionOnSaleOfUnitsAndWarrantExercises_c20200701__20210630_zuN7wkGM3SJ3" title="Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares)">129,364</span> shares of the Company’s common stock to a broker as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The company also paid a broker $<span id="xdx_903_ecustom--PaymentsOfCommissionsOnExerciseOfWarrants_pdp0_c20200701__20210630_zgxE6gzJlve5" title="Payments of Commissions on Exercise of Warrants">3,537</span> in commissions for the warrant exercises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2022, the Company had approximately <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn3n3_dm_c20220630_z0Yzc335Lm18" title="Class of Warrant or Right, Outstanding (in shares)">20.8</span> million warrants outstanding, with exercise prices from $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__srt--RangeAxis__srt--MinimumMember_zvwVGxuLKchh" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.60</span> to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__srt--RangeAxis__srt--MaximumMember_zriFtjwRNJv2" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.50</span> and expiring on various dates through April 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted-average exercise price for the outstanding warrants is $<span id="xdx_90E_ecustom--WeightedAverageExercisePriceForOutstandingWarrants_c20210701__20220630_pdd" title="Weighted Average Exercise Price for Outstanding Warrants (in dollars per share)">0.75</span>, and the weighted-average remaining contractual life as of June 30, 2022 is <span id="xdx_90C_ecustom--WeightedAverageRemainingContractualLifeForOutstandingWarrants_dtY_c20210701__20220630_zAlhcxRuxiy" title="Weighted Average Remaining Contractual Life for Outstanding Warrants (Year)">2.6</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2022, Smith elected to convert accounts payable (for unreimbursed expenses) of $<span id="xdx_903_ecustom--ConvertedToUnitsAmount_pp0p0_c20210701__20220630__srt--TitleOfIndividualAxis__srt--PresidentMember_ze8Y5UXCyDQ9" title="Converted to Units, Amount">17,711</span> into <span id="xdx_908_ecustom--AccountsPayableConvertedToUnitsShares_c20210701__20220630__srt--TitleOfIndividualAxis__srt--PresidentMember_z9z3CmwOF7w" title="Accounts Payable Converted to Units, Shares">35,424</span> units at $<span id="xdx_903_ecustom--AccountsPayableConvertedToUnitsPricePerUnit_iI_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember_zEm1M1yGQx28" title="Accounts Payable Converted to Units, Price Per Unit">0.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember_zmk8xyfR6MYf" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2022, the Company approved the issuance of <span id="xdx_902_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20210701__20220630__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlYePWiPcTX" title="Class of Warrant or Right, Exercised During Period (in shares)">75,000</span> warrants for two consultants for consulting services of $<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfJKsBNa14Th" title="Issuance of warrants">7,500</span>. The warrants are exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJq2isSxYnZk" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.50</span> and expire in November 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the year ended June 30, 2022, the Company approved the modification of existing warrants held by one former consultant and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2Qdct7VIGVi" title="Share-based Payment Arrangement, Plan Modification, Incremental Cost">5,624</span> and interest expenses of $<span id="xdx_903_eus-gaap--InterestExpense_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqZw4y6K0f21" title="Interest expenses">2,713</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the year ended June 30, 2022, <span id="xdx_90C_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztsP6G8d3eC7" title="Class of Warrant or Right, Exercised During Period (in shares)">2,315,550</span> warrants were exercised to purchase <span id="xdx_90A_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Common Stock Shares Issued upon Exercise of Warrants (in shares)">2,315,550</span> shares of the Company’s common stock at $0.75 per share for total proceeds of $<span id="xdx_90B_ecustom--WarrantExercisedForCommonStock_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWQCEoEKXNJb" title="Warrant Exercised for Common Stock">1,736,662</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_90F_ecustom--CommissionsOnWarrantExercisesShares_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Commissions on warrant exercises, shares">66,860</span> shares of the Company’s common stock to three brokers as commissions for the warrant exercises. As the issuance was both a reduction and addition to additional paid in capital there was no impact to the financial statements. The company also paid a broker $<span id="xdx_90E_ecustom--CommissionsOnWarrantExercises_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjhuIBXmGu86" title="Commissions on warrant exercises">18,601</span> in commissions for the warrant exercises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued <span id="xdx_90F_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrUT6bvnx9Qk" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zt8DAv4Ny5wd" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_906_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zPjG4hdfjEPh" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_901_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z7rea0NSKLr6" title="Exercise bonus">75</span>% exercise bonus if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock options: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “<span style="text-decoration: underline">Equity Plan</span>”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_pdd" title="Stock options, authorized (in shares)">30,000,000</span> shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock options, authorized (in shares)">36,000,000</span> shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2022, the Company granted <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220201__20220211__us-gaap--PlanNameAxis__custom--Plan2006Member_zArwkxMn9eAa" title="Number of shares granted">10,000</span> options under the 2006 Plan to one consultant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 29, 2022, the Company granted an aggregate of <span id="xdx_905_ecustom--SharebasedCompensationGranted_c20220401__20220429_zOx0ZDjoIsxc" title="Share-based Compensation, Granted">720,000</span> options under the 2006 Plan to seven employees/consultants/directors including: i) <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--SchaferMember_zxCcEtGrRsfj" title="Share-based Compensation, Granted"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--NorthropMember_znZs4ucYi334" title="Share-based Compensation, Granted">50,000</span></span> options each to Schafer and Northrop for service as directors, ii) <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--BassaniMember_zpeyvOtCFBWa" title="Share-based Compensation, Granted">200,000</span> options to Bassani (now COO of the Company and formerly CEO) and iii) <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--SmithMember_zuNkHKJ6GRTb" title="Share-based Compensation, Granted">200,000</span> options to Smith, the Company’s President, which new option grants are included in the presentation below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded compensation expense related to employee stock options of $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBNi8uzYWd62" title="Share-based Payment Arrangement, Expense">419,370</span> and $<span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zriixYmlrrA1" title="Share-based Payment Arrangement, Expense">1,107,700</span> for the years ended June 30, 2022 and 2021, respectively. The Company granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20220630__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_z5qADpM9ljld" title="Share-based Compensation, Granted">730,000</span> and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200701__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zLRPO8YovtHa" title="Share-based Compensation, Granted">960,000</span> fully vested options during the years ended June 30, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the options granted during the years ended June 30, 2022 and 2021 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zyvpQKFtZAsi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B2_zEoK86GNqrL5" style="display: none">Fair value of options assumptions</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/> Average, <br/> June 30, <br/> 2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Range, <br/> June 30, <br/> 2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/> Average, <br/> June 30, <br/> 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Range, <br/> June 30, <br/> 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_z3mfoybIfNy6" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zJ8qrGxIU8Hd" title="Volatility">65</span>% -<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zbxUOZjpmy41" title="Volatility">69</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zjXOg9PzYGGl" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zZsTq6eDJHk4" title="Volatility">58</span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z5oOLDqMPY9l" title="Volatility">65</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1162">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1164">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1166">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1168">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zudZ101BSMie" title="Risk-free interest rate">2.99</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqaDLKOAXHTa" title="Risk-free interest rate">1.71</span>% – <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziWHdCaw6NG6" title="Risk-free interest rate">3.01</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zWTSbx1udhz8" title="Risk-free interest rate">0.79</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zuzmd6CIG9Vh" title="Risk-free interest rate">0.47</span>%-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z05pZBPojQti" title="Risk-free interest rate">0.82</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_z0uscb1GcgH2" title="Expected term (Year)">3.71</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zl6tyS6RmsC" title="Expected term (Year)">3.04</span> to <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zq96nheR9Xld" title="Expected term (Year)">3.72</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zAcJ221jPzp6" title="Expected term (Year)">5.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQw9QOkbFZ35" title="Expected term (Year)">5.0</span> to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zsNLDM2oZFVi" title="Expected term (Year)">5.9</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zOqRmrXIu5o1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt">A summary of option activity under the 2006 Plan for the years ended June 30, 2022 and 2021 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zaynPlz5h51l" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span id="xdx_8B2_zQ8DTvlqAaI1" style="display: none">Schedule of option activity</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; vertical-align: top"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Options</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted- <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 1%; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; width: 32%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2020</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20210630_zRaUZFDwb728" style="width: 13%; font-size: 10pt; text-align: right" title="Options outstanding, beginning (in shares)">9,511,600</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200701__20210630_zbrNgD3Ve4n7" style="width: 13%; font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">.74</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190701__20200630_zxLdtkEqjvv4" title="Outstanding, weighted-average remaining contractual life (Year)">4.5</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20200701__20210630_z1xOoOTykeW1" style="width: 13%; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning"><span style="-sec-ix-hidden: xdx2ixbrl1204">—</span>  </td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200701__20210630_znhIvvbZB1kd" style="font-size: 10pt; text-align: right" title="Granted">960,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200701__20210630_zhahUNiwfDFf" style="font-size: 10pt; text-align: right" title="Granted, weighted-average exercise price">1.10</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200701__20210630_zhTVL5k3rSv9" style="font-size: 10pt; text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1210">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200701__20210630_zdh8nTX1I0u" style="font-size: 10pt; text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200701__20210630_zJT3gww6n29e" style="font-size: 10pt; text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1214">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200701__20210630_zra7kmzhLMre" style="font-size: 10pt; text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1216">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20200701__20210630_zYSsyb6iOACb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1218">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200701__20210630_zQkRVsOVUNE" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1220">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at June 30, 2021</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20220630_zPIKn1wsslv8" style="font-size: 10pt; text-align: right" title="Options outstanding, beginning (in shares)">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20220630_zU1Jek0MgCc3" style="font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630_zug5jkXFdWd9" title="Outstanding, weighted-average remaining contractual life (Year)">3.7</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210701__20220630_zOs2lJz5lhZe" style="font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning">6,064,335</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Granted">730,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Granted, weighted-average exercise price">1.00</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_z3pm2iu0bUT7" title="Granted, weighted-average remaining contractual life (Year)">3.7</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">—  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1236">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1238">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1240">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1242">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20220630_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1244">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1246">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at June 30, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20220630_zItlnnTBRy8i" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending (in shares)">11,201,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20220630_zL9B8qrqgyeh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.80</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_zcbw8FDSE98" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210701__20220630_zhznFuRypmk6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value ending">4,429,263</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zcrqN8S3OIFi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information relating to nonvested stock options as of June 30, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z4zX98SCbwp5" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span id="xdx_8BF_zKO2TS15iSC" style="display: none">Schedule of non vested stock options</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; vertical-align: top"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Options</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted Average <br/> Grant-Date Fair <br/> Value</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Nonvested at July 1, 2021</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20210701__20220630_zdWMjSkZSDCb" style="font-size: 10pt; text-align: right" title="Nonvested options, beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1258">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20210701__20220630_z4Jm5AnjXhkg" style="font-size: 10pt; text-align: right" title="Nonvested options, beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1260">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; width: 1%; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; width: 65%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20220630_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Granted, options (in shares)">730,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210701__20220630_z1QYiNIXonk6" style="width: 14%; font-size: 10pt; text-align: right" title="Granted, weighted-average grant-date fair value">.574</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20210701__20220630_zcZxOb5WR6db" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vested (in shares)">(730,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_iN_di_c20210701__20220630_zKq3QBcZumnl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vested, weighted-average grant-date fair value">(.574</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Nonvested at June 30, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210701__20220630_z7WOy7MNtSOi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Nonvested, weighted-average grant-date fair value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1270">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210701__20220630_z7EKnDfQjXLk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Nonvested, weighted-average grant-date fair value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1272">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zfEayGwcj4k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total fair value of stock options that vested during the years ended June 30, 2022 and 2021 was $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210701__20220630_z5nrYf9Bv252" title="Fair value of stock options">419,370</span> and $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20200701__20210630_zVM7Ygl0dsW3" title="Fair value of stock options">1,017,700</span>, respectively. As of June 30, 2022, the Company had no unrecognized compensation cost related to stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt">Stock-based employee compensation charges in operating expenses in the Company’s consolidated financial statements for the years ended June 30, 2022 and 2021 are as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_893_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zcUmPRe0omSd" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B1_z8HxhsdOJUy1" style="display: none">Condensed Financial Statement</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Year <br/>ended <br/>June 30, <br/>2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Year <br/>ended <br/>June 30, <br/>2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">General and administrative:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">  Change in fair value from modification of <br/>    option terms</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Change in fair value from modification of option terms"><span style="-sec-ix-hidden: xdx2ixbrl1280">—</span>  </td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zNVcUXZfzMc" style="width: 14%; font-size: 10pt; text-align: right" title="Change in fair value from modification of option terms">8,775</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Change in fair value from modification of <br/>    warrant terms</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_c20210701__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="font-size: 10pt; text-align: right" title="Change in fair value from modification of warrant terms">8,337</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pp0p0_c20200701__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqaWrKXO4cAl" style="font-size: 10pt; text-align: right" title="Change in fair value from modification of warrant terms">25,506</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">261,258</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zItts4WMvVil" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">816,050</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">269,595</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTTxOBZmsiV3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">850,331</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Research and development:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">22,464</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmgCbJafEHEj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">201,650</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">22,464</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zeXfy9o9vSW2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">201,650</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zRde9ATfklAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company capitalized $<span id="xdx_90C_eus-gaap--InterestCostsCapitalized_c20210701__20220630__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--Project3GMember_zKVcfR79wXS7" title="Capitalized amount">135,648</span> and nil <span id="xdx_90B_ecustom--NonCashCompensation_c20210701__20220630__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--Project3GMember_zH53Zt6yM9bd" style="display: none" title="Non cash compensation">0</span> in non-cash compensation related to the 3G project in June 30, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 200 0.01 2.00 0.025 100 41000 21000 50000 10000000 0.01 1000 2000 100000000 250000000 704309 17711 35424 0.50 0.75 2315550 2315550 0.75 1736662 66860 18601 25000 0.50 0.75 2021-12-31 3720000 1860000 1699000 161000 3720000 3720000 0.05 114148 1745852 300000 300000 128039 52361 360805 0.50 0.75 593411 1186824 0.50 0.75 144000 72000 0.75 4065988 4065988 0.75 3049490 129364 3537 20800000 0.60 1.50 0.75 P2Y7M6D 17711 35424 0.50 0.75 75000 7500 1.50 5624 2713 2315550 2315550 1736662 66860 18601 1000000 1.00 700000 0.75 30000000 36000000 10000 720000 50000 50000 200000 200000 419370 1107700 730000 960000 <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zyvpQKFtZAsi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8B2_zEoK86GNqrL5" style="display: none">Fair value of options assumptions</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/> Average, <br/> June 30, <br/> 2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Range, <br/> June 30, <br/> 2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/> Average, <br/> June 30, <br/> 2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Range, <br/> June 30, <br/> 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_z3mfoybIfNy6" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zJ8qrGxIU8Hd" title="Volatility">65</span>% -<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zbxUOZjpmy41" title="Volatility">69</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zjXOg9PzYGGl" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zZsTq6eDJHk4" title="Volatility">58</span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z5oOLDqMPY9l" title="Volatility">65</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1162">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1164">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1166">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1168">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zudZ101BSMie" title="Risk-free interest rate">2.99</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqaDLKOAXHTa" title="Risk-free interest rate">1.71</span>% – <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_ziWHdCaw6NG6" title="Risk-free interest rate">3.01</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zWTSbx1udhz8" title="Risk-free interest rate">0.79</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zuzmd6CIG9Vh" title="Risk-free interest rate">0.47</span>%-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z05pZBPojQti" title="Risk-free interest rate">0.82</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_z0uscb1GcgH2" title="Expected term (Year)">3.71</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zl6tyS6RmsC" title="Expected term (Year)">3.04</span> to <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zq96nheR9Xld" title="Expected term (Year)">3.72</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zAcJ221jPzp6" title="Expected term (Year)">5.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQw9QOkbFZ35" title="Expected term (Year)">5.0</span> to <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zsNLDM2oZFVi" title="Expected term (Year)">5.9</span></span></td><td style="text-align: left"> </td></tr> </table> 0.65 0.65 0.69 0.65 0.58 0.65 0.0299 0.0171 0.0301 0.0079 0.0047 0.0082 P3Y8M15D P3Y14D P3Y8M19D P5Y9M18D P5Y P5Y10M24D <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zaynPlz5h51l" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span id="xdx_8B2_zQ8DTvlqAaI1" style="display: none">Schedule of option activity</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; vertical-align: top"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Options</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted- <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 1%; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; width: 32%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2020</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20210630_zRaUZFDwb728" style="width: 13%; font-size: 10pt; text-align: right" title="Options outstanding, beginning (in shares)">9,511,600</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200701__20210630_zbrNgD3Ve4n7" style="width: 13%; font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">.74</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190701__20200630_zxLdtkEqjvv4" title="Outstanding, weighted-average remaining contractual life (Year)">4.5</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20200701__20210630_z1xOoOTykeW1" style="width: 13%; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning"><span style="-sec-ix-hidden: xdx2ixbrl1204">—</span>  </td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200701__20210630_znhIvvbZB1kd" style="font-size: 10pt; text-align: right" title="Granted">960,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200701__20210630_zhahUNiwfDFf" style="font-size: 10pt; text-align: right" title="Granted, weighted-average exercise price">1.10</td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200701__20210630_zhTVL5k3rSv9" style="font-size: 10pt; text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1210">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200701__20210630_zdh8nTX1I0u" style="font-size: 10pt; text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200701__20210630_zJT3gww6n29e" style="font-size: 10pt; text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1214">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200701__20210630_zra7kmzhLMre" style="font-size: 10pt; text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1216">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20200701__20210630_zYSsyb6iOACb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1218">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200701__20210630_zQkRVsOVUNE" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1220">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at June 30, 2021</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20220630_zPIKn1wsslv8" style="font-size: 10pt; text-align: right" title="Options outstanding, beginning (in shares)">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20220630_zU1Jek0MgCc3" style="font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.77</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630_zug5jkXFdWd9" title="Outstanding, weighted-average remaining contractual life (Year)">3.7</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210701__20220630_zOs2lJz5lhZe" style="font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning">6,064,335</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Granted">730,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Granted, weighted-average exercise price">1.00</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_z3pm2iu0bUT7" title="Granted, weighted-average remaining contractual life (Year)">3.7</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">—  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1236">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1238">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1240">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1242">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20220630_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1244">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20220630_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1246">—</span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at June 30, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20220630_zItlnnTBRy8i" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending (in shares)">11,201,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20220630_zL9B8qrqgyeh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.80</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_zcbw8FDSE98" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210701__20220630_zhznFuRypmk6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value ending">4,429,263</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 9511600 0.74 P4Y6M 960000 1.10 10471600 0.77 P3Y8M12D 6064335 730000 1.00 P3Y8M12D 11201600 0.80 P2Y8M12D 4429263 <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z4zX98SCbwp5" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span id="xdx_8BF_zKO2TS15iSC" style="display: none">Schedule of non vested stock options</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; vertical-align: top"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Options</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Weighted Average <br/> Grant-Date Fair <br/> Value</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Nonvested at July 1, 2021</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20210701__20220630_zdWMjSkZSDCb" style="font-size: 10pt; text-align: right" title="Nonvested options, beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1258">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20210701__20220630_z4Jm5AnjXhkg" style="font-size: 10pt; text-align: right" title="Nonvested options, beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1260">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; width: 1%; font-size: 10pt; text-align: left"> </td><td style="vertical-align: top; width: 65%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20220630_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Granted, options (in shares)">730,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210701__20220630_z1QYiNIXonk6" style="width: 14%; font-size: 10pt; text-align: right" title="Granted, weighted-average grant-date fair value">.574</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20210701__20220630_zcZxOb5WR6db" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vested (in shares)">(730,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_iN_di_c20210701__20220630_zKq3QBcZumnl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Vested, weighted-average grant-date fair value">(.574</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; vertical-align: top; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Nonvested at June 30, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210701__20220630_z7WOy7MNtSOi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Nonvested, weighted-average grant-date fair value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1270">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210701__20220630_z7EKnDfQjXLk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Nonvested, weighted-average grant-date fair value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1272">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 730000 0.574 730000 0.574 419370 1017700 <table cellpadding="0" cellspacing="0" id="xdx_893_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zcUmPRe0omSd" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B1_z8HxhsdOJUy1" style="display: none">Condensed Financial Statement</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Year <br/>ended <br/>June 30, <br/>2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Year <br/>ended <br/>June 30, <br/>2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">General and administrative:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">  Change in fair value from modification of <br/>    option terms</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Change in fair value from modification of option terms"><span style="-sec-ix-hidden: xdx2ixbrl1280">—</span>  </td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zNVcUXZfzMc" style="width: 14%; font-size: 10pt; text-align: right" title="Change in fair value from modification of option terms">8,775</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Change in fair value from modification of <br/>    warrant terms</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_c20210701__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="font-size: 10pt; text-align: right" title="Change in fair value from modification of warrant terms">8,337</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms_pp0p0_c20200701__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqaWrKXO4cAl" style="font-size: 10pt; text-align: right" title="Change in fair value from modification of warrant terms">25,506</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">261,258</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zItts4WMvVil" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">816,050</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">269,595</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTTxOBZmsiV3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">850,331</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Research and development:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">  Fair value of stock options expensed</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">22,464</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmgCbJafEHEj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">201,650</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">     Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">22,464</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zeXfy9o9vSW2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Allocated Share-based Compensation Expense">201,650</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 8775 8337 25506 261258 816050 269595 850331 22464 201650 22464 201650 135648 0 <p id="xdx_80D_ecustom--SubscriptionReceivableTextBlock_zAk6zKNXZj0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8.       <span id="xdx_82B_zs0R01kDb8Lb">SUBSCRIPTION RECEIVABLE - AFFILIATES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2022, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_902_eus-gaap--NotesReceivableNet_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">428,250</span> ($<span id="xdx_90C_ecustom--NotesReceivableInterest_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Notes receivable interest">504,650</span>, including interest) from Bassani which were received as consideration for purchases of warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">5,565,000</span> shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2022, the Company has an interest bearing, secured promissory note for $<span id="xdx_901_ecustom--FinancingReceivablePrincipalAmount_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_904_eus-gaap--NotesReceivableNet_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">34,688</span> including interest) from Smith as consideration to purchase warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.60</span> and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at <span id="xdx_90C_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z7RCNqbJWRld" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, and is secured by $<span id="xdx_90E_ecustom--FinancingReceivablePrincipalAmount_c20220630__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_90F_eus-gaap--NotesReceivableNet_c20220630__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">35,011</span>, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">As of June 30, 2022 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_90F_ecustom--FinancingReceivablePrincipalAmount_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zrWnKySDftw5" title="Financing Receivable, Principal Amount">46,400</span> ($<span id="xdx_90F_eus-gaap--NotesReceivableNet_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zBPKiOUKQA2g" title="Financing Receivable, after Allowance for Credit Loss, Total">55,009</span> including interest) from two former employees as consideration to purchase warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_z9kBm6SPF5ug" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">928,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zMop4bAPhVr" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at <span id="xdx_907_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20220630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zHQGM8fNqkYb" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.</p> 428250 504650 5565000 0.75 30000 34688 300000 0.60 0.04 30000 35011 46400 55009 928000 0.75 0.04 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zFmmIcnHikrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9.       <span id="xdx_82F_zOE3HBVzVnw8">COMMITMENTS AND CONTINGENCIES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employment and consulting agreements:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $<span id="xdx_902_ecustom--MonthlyOfficersCashCompensation_c20161001__20161010__srt--TitleOfIndividualAxis__srt--PresidentMember_pp0p0" title="Monthly Officers' Cash Compensation">18,000</span> until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember_pdd" title="Warrants exercisable per share">0.75</span> per share, until December 31, 2022)(check with Kathy whether this was extended), and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $<span id="xdx_903_ecustom--CompensationIncreased_c20220430__20220501_zUCW5oGZRZfb" title="Compensation increased">25,000</span> per month of which $5,000 a month is deferred. For the years ended June 30, 2022 and 2021, Smith was paid $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20210701__20220630__srt--CounterpartyNameAxis__custom--SmithMember_zwHGwtXOvM7c" title="Cash compensation paid">130,000</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20200701__20210630__srt--CounterpartyNameAxis__custom--SmithMember_zku2pF47sQa">139,460</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani (now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($<span id="xdx_907_ecustom--MonthlyOfficersCashCompensation_c20150203__20150210__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Monthly Officers' Cash Compensation">31,000</span> per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $<span id="xdx_90A_ecustom--DeferredCompensationMaximumConvertibleAmount_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pp0p0" title="Deferred Compensation, Maximum Convertible Amount">125,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_90C_ecustom--DeferredCompensationStockConversionPricePerShare_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pdd" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $<span id="xdx_902_ecustom--DeferredCompensationMaximumConvertibleAmount_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pp0p0" title="Deferred Compensation, Maximum Convertible Amount">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_906_ecustom--DeferredCompensationStockConversionPricePerShare_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pdd" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, and subsequently extended until December 31, 2022 (which date has subsequently been extended to June 30, 2024). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $<span id="xdx_90C_eus-gaap--AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Salaries and wages">31,000</span> per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $<span id="xdx_90D_eus-gaap--OtherAdditionalCapital_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Additional paid amount">2,000</span> per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $<span id="xdx_90A_ecustom--InterestBearingSecuredPromissoryNote_c20230301__20230331__srt--TitleOfIndividualAxis__custom--BassaniMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_pp0p0" title="Interest bearing secured promissory note">300,000</span> from Bassani as consideration to purchase warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20180801__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsExpiringOnDecember312025Member_z02hoYPJQJX7" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">3,000,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2022, the principal and accrued interest was $<span id="xdx_90D_eus-gaap--NotesReceivableNet_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">348,643</span>. For the years ended June 30, 2022 and 2021, Brightcap was paid $<span id="xdx_90D_eus-gaap--RepaymentsOfLongTermDebt_c20210701__20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_pp0p0" title="Repayments of Long-term Debt, Total">250,000</span> and $<span id="xdx_90A_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20200701__20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zwwjAdu9qb14" title="Repayments of Long-term Debt, Total">155,000</span>, respectively, of cash compensation earned during the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">William O’Neill (“O’Neill”) has been hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s GEN3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $<span id="xdx_903_ecustom--MonthlyOfficersCashCompensation_c20210701__20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Monthly Officers' Cash Compensation">25,000</span> cash and $<span id="xdx_901_ecustom--DeferredCompensationMaximumConvertibleAmount_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred Compensation, Maximum Convertible Amount">10,000</span> deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Execution/exercise bonuses:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company added a <span id="xdx_904_ecustom--ExerciseBonus_iI_dp_c20210630_zxEbFYt1ypCa" title="Exercise bonus">75</span>% execution/exercise bonus to the terms of <span id="xdx_90A_ecustom--WarrantsHeldByTrustOwned_pp0p0_c20200701__20210630_z45rYmLrBsKg" title="Warrants held by trust owned">3,000,000</span> warrants held by a trust owned by Bassani.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2022, the execution/exercise bonuses ranging from <span id="xdx_90B_ecustom--ExerciseBonus_iI_dp_c20220630__srt--RangeAxis__srt--MinimumMember_zCFs7RCR3CX3" title="Exercise bonus">50</span>-<span id="xdx_903_ecustom--ExerciseBonus_iI_dp_c20220630__srt--RangeAxis__srt--MaximumMember_zkqVMdAbyWsl" title="Exercise bonus">90</span>% were applicable to 17,778,213 of the Company’s outstanding options and <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_c20220630_pp0p0" title="Warrants and Rights Outstanding">17,778,213</span> of the Company’s outstanding warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with O’Neill was issued <span id="xdx_908_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCF5dhVqXXxj" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zF0j5ypsJPVl" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_901_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwCfvAFKkOId" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_907_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5x0E5YuI3e7" title="Exercise bonus">75</span>% exercise bonus if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Purchase Order Agreement:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220101__20220128_pp0p0" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220101__20220128_zwsdbV56tO46" title="Debt instrument rate">25</span>% payment ($<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20220128_pp0p0" title="Principal, interest">666,375</span>)) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. On March 21, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220302__20220321_zETYn6NVx8ig" title="Debt instrument rate">25</span>% payment ($<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20220302__20220321_pp0p0" title="Principal, interest">666,375</span>).  On June 6, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $<span id="xdx_90C_ecustom--AggregatePayment_c20220701__20220705__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXVdo7uPORH1" title="Aggregate payment">1,996,125</span> as of the date of this report. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Litigation:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #222222"><b><span style="text-decoration: underline">A: Website: Domain Sale/Resolved Litigation/Hacking/Theft</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt/12.6pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On March 23, 2022 <span id="xdx_907_ecustom--SaleOfDomainDescription_c20220302__20220323" title="Sale of domain, description">the Company entered into an agreement to sell domain name &lt;biontech.com&gt; and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.</span> The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name &lt;biontech.com&gt; no longer represented a core asset of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the &lt;biontech.com&gt; domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name &lt;biontech.com&gt; ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name &lt;biontech.com&gt; to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations werebeen subject disruption and expenses were incurred related to the matter including legal fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #222222"><b><span style="text-decoration: underline">B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_903_eus-gaap--LongTermConstructionLoanCurrent_iI_c20211229_zGJi6eg7caFd" title="Loan related to construction">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20211229_zD7v8vE58dS3" title="Accrued interest">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $<span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20210930_z8KMzId2kGHl" title="Total assets">297</span> and its total liabilities were $<span id="xdx_90E_eus-gaap--Liabilities_iI_pp0p0_c20210930_zt7tPW4z5YN4" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_907_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zGr9WpqVho7i" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_907_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zvWnctaWUHGd" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zHaqhrLUqXqj" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $<span id="xdx_909_eus-gaap--Liabilities_c20211229_pp0p0" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_c20211229_pp0p0" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accrued Liabilities, Current">12,436</span>. The net amount of $<span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210701__20220630_pp0p0" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zcbPtcimy4W3" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20220630__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zMJXMcPgIQgf" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20220630__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zZWOCmGbNF51" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_906_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zX3Qy0sg7Iw5" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_90E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zWTG7GP647lf" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zHPqxVr8vBh" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_907_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_c20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zhsWOpkRjeLc" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_907_eus-gaap--InterestExpenseDebt_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z1FGE22oH75j" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_908_eus-gaap--LinesOfCreditCurrent_iI_c20210630_zkWSUrW9t5Ad">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtAmount_c20140925__dei--LegalEntityAxis__custom--PA1Member_pp0p0" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_905_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_c20220601__20220615__dei--LegalEntityAxis__custom--PA1Member_zAFNcZbxVNe3">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest, the remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company currently is not involved in any other material litigation or similar events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Lease:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarized the supplemental cash flow information for the year ended June 30, 2022:</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zmrpMTvTErC9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BF_z2Lrk13TXLz2" style="display: none">Schedule Of Cash Flow Supplemental Disclosure</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220630_zGPah0d6acd6" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlows_iI_pp0p0_zvElKSUv7MKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash paid for noncancelable operating lease included in the operating cash flows</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">60,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_iI_pp0p0_zh4CXSgoVvh5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right of use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">180,586</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_ziaGXPRLRMz8" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfFutureMinimumLeasePaymentTableTextBlock_zkbgXWxanz8k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details1)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BA_zudjg6lxVfFl" style="display: none">Schedule Of Future Minimum Lease Payment</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20220630_z3HnQe4fG4w4" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Year ended June 30, 2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">43,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td>Year ended June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInFourYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Year ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,250</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--UndiscountedCashFlow_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,136</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zd95lBcK7lMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_901_ecustom--WeightedAverageRemainingLeaseTermDescription_c20210701__20220630" title="Weighted average remaining lease term">The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2022 were 3 years and 10%, respectively.</span> The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 18000 300000 0.75 25000 130000 139460 31000 125000 0.75 300000 0.75 31000 2000 300000 3000000 348643 250000 155000 25000 10000 0.75 3000000 0.50 0.90 17778213 1000000 1.00 700000 0.75 2665500 0.25 666375 0.25 666375 1996125 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. 10010000 2255802 297 10154334 9939148 214235 950 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zmrpMTvTErC9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BF_z2Lrk13TXLz2" style="display: none">Schedule Of Cash Flow Supplemental Disclosure</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220630_zGPah0d6acd6" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlows_iI_pp0p0_zvElKSUv7MKl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash paid for noncancelable operating lease included in the operating cash flows</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">60,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_iI_pp0p0_zh4CXSgoVvh5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right of use assets obtained in exchange for operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">180,586</td><td style="text-align: left"> </td></tr> </table> 60000 180586 <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfFutureMinimumLeasePaymentTableTextBlock_zkbgXWxanz8k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details1)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BA_zudjg6lxVfFl" style="display: none">Schedule Of Future Minimum Lease Payment</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20220630_z3HnQe4fG4w4" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Year ended June 30, 2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">43,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td>Year ended June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInFourYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Year ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">31,250</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--UndiscountedCashFlow_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,136</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,864</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 43750 75000 31250 150000 -21136 128864 The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2022 were 3 years and 10%, respectively. <p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_z6Ts6RbHi4O7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10.       <span id="xdx_820_zPiUsaGXPZel">INCOME TAXES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The reconciliation between the expected federal income tax expense (benefit)<span style="font-size: 8pt"> </span>c<span style="font-size: 10pt">omputed by applying the Federal statutory rate to income (loss) before income taxes and the actual expense (benefit)</span><span style="font-size: 8pt"> </span><span style="font-size: 10pt">for taxes on income (loss)</span><span style="font-size: 8pt"> </span><span style="font-size: 10pt">for the years ended June 30, 2022 and 2021 is as follows:</span></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zr7VMMi0aJo8" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt"><span id="xdx_8B2_zzpI7B2PbPp1" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49E_20210701__20220630_zDmKX3wbAq9h" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_498_20200701__20210630_zGN4gTq010sk" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">2022</span><span style="font-size: 8pt">  </span></td><td style="padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maDOTEOz2es_zr2SuKsuTqwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify; padding-left: 5.4pt">Expected income tax expense (benefit) at statutory rate</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">1,741,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(724,000</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maDOTEOz2es_zmRRqcBqfCWl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">State taxes, net of federal benefit</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">303,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(126,000</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationRTPExcessBusinessInterestAmount_maDOTEOz2es_zTwsA4bVYZh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">RTP – Excess Business Interest</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">115,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationPermanentDifferences_maDOTEOz2es_z94rqa1EoF17" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Permanent differences and other</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount_maDOTEOz2es_ztegV41YQ3Tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Expiration of net operating allowances</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,229,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">802,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maDOTEOz2es_zexY1WALEFuk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,281,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(75,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iT_pp0p0_mtDOTEOz2es_z4QLTpW1upHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Income tax expense (benefit)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1518">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1519">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company has net operating loss carry-forwards (“NOLs”) for tax purposes of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_c20220630_pdp0" title="Operating Loss Carryforwards, Total">8,274,000</span> as of June 30, 2022. These NOLs expire on various dates through 2041.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The utilization of the NOLs may be limited under Section 382 of the Internal Revenue Code.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company’s deferred tax assets as of June 30, 2022 and 2021 are estimated as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zWBURKyVN10j" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt"><span id="xdx_8BF_zNn9zsdTqhc7" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_496_20220630_zkGBXdzZhCxl" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49C_20210630_zXrh20UeBd4" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify; padding-left: 5.4pt">NOL carryforwards (Federal and State)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">8,274,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">11,784,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Stock-based compensation</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,436,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,350,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Impairment</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,340,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,340,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsBusinessInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Business interest</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">339,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">264,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Deferred compensation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,054,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">986,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Gross deferred tax assets</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">16,443,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">19,724,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zea1uZdyNdsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(16,443,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(19,724,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_z64MwRzgQ1x1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Net deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1546">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1547">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zD7ph9EOXb4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has provided a valuation allowance of <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pip0_dp_c20210701__20220630_zXxWiS6VsGCe" title="Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent">100</span>% of its net deferred tax assets due to the uncertainty of generating future profits that would allow for the realization of such deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zr7VMMi0aJo8" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt"><span id="xdx_8B2_zzpI7B2PbPp1" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49E_20210701__20220630_zDmKX3wbAq9h" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_498_20200701__20210630_zGN4gTq010sk" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">2022</span><span style="font-size: 8pt">  </span></td><td style="padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maDOTEOz2es_zr2SuKsuTqwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify; padding-left: 5.4pt">Expected income tax expense (benefit) at statutory rate</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">1,741,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(724,000</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maDOTEOz2es_zmRRqcBqfCWl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">State taxes, net of federal benefit</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">303,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(126,000</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationRTPExcessBusinessInterestAmount_maDOTEOz2es_zTwsA4bVYZh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">RTP – Excess Business Interest</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1506">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">115,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationPermanentDifferences_maDOTEOz2es_z94rqa1EoF17" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Permanent differences and other</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">8,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount_maDOTEOz2es_ztegV41YQ3Tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Expiration of net operating allowances</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,229,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">802,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maDOTEOz2es_zexY1WALEFuk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,281,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(75,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iT_pp0p0_mtDOTEOz2es_z4QLTpW1upHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Income tax expense (benefit)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1518">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1519">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 1741000 -724000 303000 -126000 115000 8000 8000 1229000 802000 -3281000 -75000 8274000 <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zWBURKyVN10j" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt"><span id="xdx_8BF_zNn9zsdTqhc7" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_496_20220630_zkGBXdzZhCxl" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49C_20210630_zXrh20UeBd4" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2022</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2021</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify; padding-left: 5.4pt">NOL carryforwards (Federal and State)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">8,274,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">11,784,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Stock-based compensation</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,436,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">5,350,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Impairment</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,340,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,340,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsBusinessInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Business interest</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">339,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">264,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Deferred compensation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,054,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">986,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-left: 5.4pt">Gross deferred tax assets</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">16,443,000</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">19,724,000</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zea1uZdyNdsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(16,443,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(19,724,000</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_z64MwRzgQ1x1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">Net deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1546">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1547">—</span>  </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 8274000 11784000 5436000 5350000 1340000 1340000 339000 264000 1054000 986000 16443000 19724000 16443000 19724000 1 <p id="xdx_80F_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z6ur4qPFUzI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>11.       <span id="xdx_828_zRyZdMSZcHf4">401(k) PLAN</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the Bion Technologies, Inc. 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”), a defined contribution retirement plan for the benefit of its employees. The 401(k) Plan is currently a salary deferral only plan and at this time the Company does not match employee contributions. The 401(k) is open to all employees over 21 years of age and no service requirement is necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zaxvmuzCDLG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>12.        <span id="xdx_82C_zMUpztWMbKzb">SUBSEQUENT EVENTS</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events that occurred subsequent to June 30, 2022 for recognition and disclosure in the financial statements and notes to the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #222222">On June 6, 2022 the Company received progress notice regarding completion of certain work in process on the core modules of the 3G1 core modules and an invoice from Buflovak for the third <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220601__20220606_zySid0eVOcSd">25</span>% payment ($<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220601__20220606_zdkz8RkVKCrk">666,375</span>) which was paid on July 5, 2022 bringing the aggregate payments to </span><span style="background-color: white">$<span id="xdx_906_ecustom--AggregatePayment_c20220701__20220705__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaTh7Dzrc8Mi" title="Aggregate Payment">1,996,125</span> as <span style="color: #222222">of the date of this report. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">During July 2022 the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20220731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvFic1hgv8O5" title="Number of shares sold">320,000</span> Units containing <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20220731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zffcrxAZrDe8">320,000</span> shares of the Company’s Common Stock and <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20220731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCJfuCKLBJOd">320,000</span> warrants to purchase <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20220731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--RestrictedAndLegendedSharesMember_z7giRvbNYQB">320,000</span> restricted and legended shares of the Company’s Common stock exercisable at $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1YrlanBMThd" title="Exercisable">1.25</span> until December 31, 2023 for the sum of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20220701__20220731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--TwoNonAffiliatedPurchasersMember_z9ityy7GajN8">320,000</span> to two non-affiliated purchasers. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">From July 1, 2022 through September 27, 2022 <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220701__20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOWjm6HVP8qk" title="Number of shares exercised">74,834</span> warrants were exercised for $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20220701__20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNq81xj0yQe5">56,126</span> and the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220701__20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDkcV1TT1IG" title="Number of shares issued">74,834</span> restricted common shares.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">During the period from July 1, 2022 through September 27, 2022, Smith transferred $<span id="xdx_905_ecustom--UnreimbursedExpenses_c20220701__20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDqNsiAmoeDj">23,943 </span></span><span style="background-color: white">of unreimbursed expenses and $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zS5XVlVDSwF3">20,000 </span></span><span style="background-color: white">of deferred compensation to his 2020 Convertible Obligation and converted <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zblqvkXWA759">50,000 </span></span><span style="background-color: white">of the initial principalbalance of his 2020 Convertible Obligation to <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyZUXO4znnv2">100,000</span> shares (60,000 of which were donated/gifted upon acquisition) and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220927__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzAUOrsfXHu6">100,000</span> warrants (all of which were donated/gifted upon acquisition).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">On August 8, 2022 the Company extended the expiration of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220801__20220808__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--ConsultantsMember_ze35GzUOkj4i" title="Number of shares expired">300,000</span> warrants owned by a consultant until December 31, 2023. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">On August 8, 2022, the Company extended the expiration of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20220801__20220808__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--ThreeEmployeesAndContractorsMember_zsH9SaE1ToWf">1,286,824</span> warrants for three employees and contractors to December 31, 2024. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">On September 9, 2022, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220901__20220909__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--NonAffilatedConsultantMember_zjanXTVPnd4d">50,000</span> shares to non-affiliated consultant for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">During August and September 2022 the Company issued <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfchWuzvFQZh" title="Issaunce of warrants"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220831__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zs3ZXPFSngDa">150,000</span></span> warrants, in aggregate, to three (3) new members of its Advisory Group in connection with their commitment to the advisory role and/or for consulting services. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> 0.25 666375 1996125 320000 320000 320000 320000 1.25 320000 74834 56126 74834 23943 20000 50000 100000 100000 300000 1286824 50000 150000 150000 EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

0_NO8_"]7LJW/P7;_P;4$L#!!0 ( $-V.U67BKL

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

&J1 M;Z,+9;^$%AM2B8WLDI!I3$HR_V.7"3*'C:P.;VA?/+P@\;PC7!ORA(TM"CWE M]"+08TGHLAU1$PQR@XTL!]!@GQT3$]*$C>P)&-,UM]&0,1QD8_2KEESH_*CD MS0L3$W*(@^R0ON#<"PGF).A)"1#^R(6)"WX7T"5>Y*!NS-@*9QT4V3V\B]9.2F)B0>5QD\W12JF<\EDNI;]Z; MF)![7/R"V.^3K$[<=,&*&'8BT^OQ'YUJ2LB%).0B2ZB7\B5)55T\D&AG8D(2 MU%7A:Q).WA6!CV+MMJSOJQ+ /=%E7S.E^=OM*>OC"_ M^Q=02P,$% @ 0W8[5?TLU:6N 0 P1L !H !X;"]?/L@*.!8*=*@/96UMCS^&W^RUK.O4)7I4)_C_M#$WN54G>.\V*?4?#@7U_MP M*F._;L+Y=F5;MZZ-N$_$^OM]K . MG_7Z^Q3.Z8_![J=NCW$?0BIZJ[+=A30OW*5ZGH[N?I#^;7+16V[F1;O<2.%R M!RD$:?X@@R#+'^0AR.BOJK01Z*^JM!'HKZJT$>BOJ MK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'I;9[.$0&]#O8U ;T.]C4!O0[V-0&]# MO8U ;T.]C4!O0[V-0&^/>GL"O3WJ[0GT]JBW)]#;H]Z>0&_?V>PFT-NCWIY M;X]Z^W?J'=.U"O'9\UCC\]])=;K=&YZ/OR\?)SOO^!UG!W_L%K]02P,$% M @ 0W8[52;ZAZ>U 0 W!L !, !;0V]N=&5N=%]4>7!E&ULS9G- M;L(P$(1?!>6*B+&=TA\!E[;7ED-?P$TV)"*)+=M0>/LZX4=J1:,B*G4NL1+O MSHR]TG?)]&UGR VV==6X651X;QX8#QAJ6X\-7[D6XUH/GVB7*TK/WC>AL^NU,TLLE2Y:/"X+VR]9I$RIBI3Y<,^ MVS39-Y?1P2$.G5V-*TKCAJ$@8F<=VIV?#0Y]KQNRMLQHL%#6OZ@Z5+%MQ9S? M5>3B?HDS&76>EREE.EW7H25VQI+*7$'DZRK>BP[[G7VX8=H_^=7^G4R?8:A< M6&U) _?7_IG:-:U4V1W_6_=2;?P)02P$"% ,4 " !#=CM5 M!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM M;%!+ 0(4 Q0 ( $-V.U7&U-1[\ "L" 1 " :\ M !D;V-0&UL4$L! A0# M% @ 0W8[5;K'M(&PO=V]R:W-H965T&UL4$L! A0#% @ 0W8[53)L=CM8 M!0 K!0 !@ ("!R!D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0W8[52?B54EF,0 9X@ !@ M ("!\S 'AL+W=O,OQ;P# &" & M @(&==@ >&PO=V]R:W-H965T&UL4$L! A0# M% @ 0W8[5=R2_)+^ @ 6 8 !D ("!CWH 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 0W8[526Z M*5'0"@ KAT !D ("!6(H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0W8[5=K^)8R:! BPH !D M ("!U:P 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 0W8[5<] >0@<%0 M3\ !D ("! MV;@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 0W8[55TQ! 5B! L0L !D ("!ZM0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0W8[50CW@BP: P ;0D !D M ("!FO 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 0W8[5>%YTCH@!0 ;!P !D ("!G/H M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M0W8[50\)MI@&PO=V]R:W-H965T&UL4$L! A0#% @ 0W8[546E?BOT P M\1$ !D ("!P1X! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 0W8[58H4YLIR @ &@4 !D M ("!'DP! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 0W8[5=)G,(EC P 3 H !D ("!8W0! 'AL M+W=O&UL4$L! A0#% @ 0W8[ M5<'/?E)N# HK8 !D ("!!GX! 'AL+W=O&PO / " ?:. 0!X;"]W;W)K M8F]O:RYX;6Q02P$"% ,4 " !#=CM5_2S5I:X! #!&P &@ M @ % DP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" !#=CM5)OJ'I[4! #<&P $P @ $FE0$ 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 -@ V +$. ,EP$ ! end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 192 350 1 false 68 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://biontech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://biontech.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://biontech.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://biontech.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://biontech.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://biontech.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 9 false false R10.htm 00000010 - Disclosure - DEFERRED COMPENSATION Sheet http://biontech.com/role/DeferredCompensation DEFERRED COMPENSATION Notes 10 false false R11.htm 00000011 - Disclosure - LOANS PAYABLE Sheet http://biontech.com/role/LoansPayable LOANS PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes http://biontech.com/role/ConvertibleNotesPayable-Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://biontech.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES Sheet http://biontech.com/role/SubscriptionReceivable-Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://biontech.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - INCOME TAXES Sheet http://biontech.com/role/IncomeTaxes INCOME TAXES Notes 16 false false R17.htm 00000017 - Disclosure - 401(k) PLAN Sheet http://biontech.com/role/KPlan 401(k) PLAN Notes 17 false false R18.htm 00000018 - Disclosure - SUBSEQUENT EVENTS Sheet http://biontech.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biontech.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biontech.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biontech.com/role/SignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://biontech.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://biontech.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://biontech.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://biontech.com/role/StockholdersEquity 22 false false R23.htm 00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://biontech.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://biontech.com/role/CommitmentsAndContingencies 23 false false R24.htm 00000024 - Disclosure - INCOME TAXES (Tables) Sheet http://biontech.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://biontech.com/role/IncomeTaxes 24 false false R25.htm 00000025 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans 25 false false R26.htm 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Details 26 false false R27.htm 00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Details 27 false false R28.htm 00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://biontech.com/role/SignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) Sheet http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT - Property and Equipment (Details) Details 29 false false R30.htm 00000030 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://biontech.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://biontech.com/role/PropertyAndEquipmentTables 30 false false R31.htm 00000031 - Disclosure - DEFERRED COMPENSATION (Details Narrative) Sheet http://biontech.com/role/DeferredCompensationDetailsNarrative DEFERRED COMPENSATION (Details Narrative) Details http://biontech.com/role/DeferredCompensation 31 false false R32.htm 00000032 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://biontech.com/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://biontech.com/role/LoansPayable 32 false false R33.htm 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Notes http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/ConvertibleNotesPayable-Affiliates 33 false false R34.htm 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://biontech.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://biontech.com/role/StockholdersEquityTables 34 false false R35.htm 00000035 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details) Sheet http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails STOCKHOLDERS' EQUITY - Stock Options Activity (Details) Details 35 false false R36.htm 00000036 - Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details) Sheet http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details) Details 36 false false R37.htm 00000037 - Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details) Sheet http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails STOCKHOLDERS' EQUITY - Financial Statements (Details) Details 37 false false R38.htm 00000038 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://biontech.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://biontech.com/role/StockholdersEquityTables 38 false false R39.htm 00000039 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Sheet http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/SubscriptionReceivable-Affiliates 39 false false R40.htm 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://biontech.com/role/CommitmentsAndContingenciesTables 40 false false R41.htm 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details1) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetails1 COMMITMENTS AND CONTINGENCIES (Details1) Details http://biontech.com/role/CommitmentsAndContingenciesTables 41 false false R42.htm 00000042 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://biontech.com/role/CommitmentsAndContingenciesTables 42 false false R43.htm 00000043 - Disclosure - INCOME TAXES (Details) Sheet http://biontech.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://biontech.com/role/IncomeTaxesTables 43 false false R44.htm 00000044 - Disclosure - INCOME TAXES (Details 1) Sheet http://biontech.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://biontech.com/role/IncomeTaxesTables 44 false false R45.htm 00000045 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://biontech.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://biontech.com/role/IncomeTaxesTables 45 false false R46.htm 00000046 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://biontech.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://biontech.com/role/SubsequentEvents 46 false false All Reports Book All Reports bnet_10k-063022.htm bion_ex31z1.htm bion_ex31z2.htm bion_ex32z1.htm bion_ex32z2.htm bnet-20220630.xsd bnet-20220630_cal.xml bnet-20220630_def.xml bnet-20220630_lab.xml bnet-20220630_pre.xml image_001.jpg image_002.jpg image_003.jpg http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bnet_10k-063022.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 192, "dts": { "calculationLink": { "local": [ "bnet-20220630_cal.xml" ] }, "definitionLink": { "local": [ "bnet-20220630_def.xml" ] }, "inline": { "local": [ "bnet_10k-063022.htm" ] }, "labelLink": { "local": [ "bnet-20220630_lab.xml" ] }, "presentationLink": { "local": [ "bnet-20220630_pre.xml" ] }, "schema": { "local": [ "bnet-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 543, "entityCount": 1, "hidden": { "http://biontech.com/20220630": 63, "http://fasb.org/us-gaap/2022": 124, "http://xbrl.sec.gov/dei/2022": 8, "total": 195 }, "keyCustom": 103, "keyStandard": 247, "memberCustom": 40, "memberStandard": 22, "nsprefix": "bnet", "nsuri": "http://biontech.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biontech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - DEFERRED COMPENSATION", "role": "http://biontech.com/role/DeferredCompensation", "shortName": "DEFERRED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - LOANS PAYABLE", "role": "http://biontech.com/role/LoansPayable", "shortName": "LOANS PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES", "role": "http://biontech.com/role/ConvertibleNotesPayable-Affiliates", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://biontech.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES", "role": "http://biontech.com/role/SubscriptionReceivable-Affiliates", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://biontech.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - INCOME TAXES", "role": "http://biontech.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - 401(k) PLAN", "role": "http://biontech.com/role/KPlan", "shortName": "401(k) PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS", "role": "http://biontech.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://biontech.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://biontech.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://biontech.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://biontech.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://biontech.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://biontech.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - INCOME TAXES (Tables)", "role": "http://biontech.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:TechWastage", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:TechWastage", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "role": "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "role": "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "role": "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-012022-06-30_custom_PropertyPlantAndEquipmentOfPA1Member", "decimals": "0", "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - DEFERRED COMPENSATION (Details Narrative)", "role": "http://biontech.com/role/DeferredCompensationDetailsNarrative", "shortName": "DEFERRED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "lang": null, "name": "bnet:InterestRateOnDeferredCompensation", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - LOANS PAYABLE (Details Narrative)", "role": "http://biontech.com/role/LoansPayableDetailsNarrative", "shortName": "LOANS PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30_custom_PennvestLoanMember", "decimals": "0", "lang": null, "name": "us-gaap:ConstructionLoan", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "role": "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_EmployeeStockOptionMember_srt_WeightedAverageMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "role": "http://biontech.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS' EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_EmployeeStockOptionMember_srt_WeightedAverageMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options Activity (Details)", "role": "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)", "role": "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Nonvested Share Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "0", "first": true, "lang": null, "name": "bnet:SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - STOCKHOLDERS' EQUITY - Financial Statements (Details)", "role": "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "shortName": "STOCKHOLDERS' EQUITY - Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "0", "first": true, "lang": null, "name": "bnet:SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:RedemptionOfConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)", "role": "http://biontech.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS' EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:RedemptionOfConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "role": "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30_custom_SmithsMember_custom_SecuredPromissoryNoteMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://biontech.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlows", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlows", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "bnet:ScheduleOfFutureMinimumLeasePaymentTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details1)", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetails1", "shortName": "COMMITMENTS AND CONTINGENCIES (Details1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "bnet:ScheduleOfFutureMinimumLeasePaymentTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2022-04-302022-05-01", "decimals": "0", "lang": null, "name": "bnet:CompensationIncreased", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - INCOME TAXES (Details)", "role": "http://biontech.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - INCOME TAXES (Details 1)", "role": "http://biontech.com/role/IncomeTaxesDetails1", "shortName": "INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://biontech.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2022-06-012022-06-06", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://biontech.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2022-07-012022-07-31_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "role": "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "lang": null, "name": "bnet:GainOnLegalDissolutionsOfSubsidiary", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://biontech.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://biontech.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bnet_10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "bnet_AccountsPayableConvertedToUnitsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of the Company's accounts payable converted into units during the period.", "label": "Accounts Payable, Converted to Units, Amount" } } }, "localname": "AccountsPayableConvertedToUnitsAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AccountsPayableConvertedToUnitsPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable Converted to Units, Price Per Unit" } } }, "localname": "AccountsPayableConvertedToUnitsPricePerUnit", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_AccountsPayableConvertedToUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable Converted to Units, Shares" } } }, "localname": "AccountsPayableConvertedToUnitsShares", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_AccruedInterestAndLateChargesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of accrued interest and late charges payable to lender.", "label": "Accrued Interest and Late Charges Payable" } } }, "localname": "AccruedInterestAndLateChargesPayable", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the adjustment to additional paid in capital as a result of modification of warrants.", "label": "Modification of warrants" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfoptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the adjustment To additional paid in capital as a result of modification of options.", "label": "Modification of options" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfoptions", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_AggregatePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate payment", "verboseLabel": "Aggregate Payment" } } }, "localname": "AggregatePayment", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AllocatedToSharea": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Allocated to the sharea" } } }, "localname": "AllocatedToSharea", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AllocatedToWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Allocated to warrants" } } }, "localname": "AllocatedToWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AnInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about an investor.", "label": "An Investor [Member]" } } }, "localname": "AnInvestorMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_BasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted" } } }, "localname": "BasicAndDiluted", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "bnet_BassaniFamilyTrustsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bassani Family Trusts [Member]" } } }, "localname": "BassaniFamilyTrustsMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_BassaniMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bassani [Member]" } } }, "localname": "BassaniMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_BionsStockholdersEquityDeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bion's stockholders' equity (deficit):" } } }, "localname": "BionsStockholdersEquityDeficitAbstract", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "bnet_CancellationOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation of warrants" } } }, "localname": "CancellationOfWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CapitalizedInterestInPropertyAndEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Capitalized interest in property and equipment" } } }, "localname": "CapitalizedInterestInPropertyAndEquipment", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlows": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash paid for noncancelable operating lease included in the operating cash flows" } } }, "localname": "CashPaidForNoncancelableOperatingLeaseIncludedInOperatingCashFlows", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_CattlePerHead": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cattle per head" } } }, "localname": "CattlePerHead", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_CenterpointMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the separate legal entity of Centerpoint.", "label": "Centerpoint [Member]" } } }, "localname": "CenterpointMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during period.", "label": "Class of Warrant or Right, Exercised During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CommissionsOnExerciseOfWarrants": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "CommissionsOnExerciseOfWarrants", "negatedLabel": "Commissions on exercise of warrants" } } }, "localname": "CommissionsOnExerciseOfWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnSaleOfUnits": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "CommissionsOnSaleOfUnits", "verboseLabel": "Commissions on sale of units" } } }, "localname": "CommissionsOnSaleOfUnits", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnWarrantExercises": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises", "negatedLabel": "Commissions on warrant exercises" } } }, "localname": "CommissionsOnWarrantExercises", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnWarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises, shares" } } }, "localname": "CommissionsOnWarrantExercisesShares", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CommonStockSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants exercised for common stock shares.", "label": "Common Stock Shares Issued upon Exercise of Warrants (in shares)" } } }, "localname": "CommonStockSharesIssuedUponExerciseOfWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CompensationIncreased": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Compensation increased" } } }, "localname": "CompensationIncreased", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_ComputersAndOfficeEquipmentGross": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the gross amount computers and office equipment held by the Company.", "label": "Computers and office equipment" } } }, "localname": "ComputersAndOfficeEquipmentGross", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "bnet_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultants of the Company.", "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConversionOfDebtAndLiabilitiesIntoCommonUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into common units" } } }, "localname": "ConversionOfDebtAndLiabilitiesIntoCommonUnits", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionOfDeferredCompensationToNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of deferred compensation to notes payable" } } }, "localname": "ConversionOfDeferredCompensationToNotePayable", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the conversion price on a per Unit basis of convertible debt instruments.", "label": "Conversion Price Per Unit (in dollars per share)" } } }, "localname": "ConversionPricePerUnit", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_ConvertedToUnitsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Converted to Units, Amount" } } }, "localname": "ConvertedToUnitsAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_ConvertibleDebtTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE - AFFILIATES" } } }, "localname": "ConvertibleDebtTextBlock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_ConvertiblePreferredStockAntidilutiveSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the convertible preferred stock securities that have been excluded from the computation of earnings per share.", "label": "Convertible Preferred Stock Antidilutive Securities [Member]" } } }, "localname": "ConvertiblePreferredStockAntidilutiveSecuritiesMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "bnet_DebtInstrumentInterestRateStatedPercentageQuarterly": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents quarterly stated percentage of debt instrument.", "label": "Debt Instrument, Interest Rate, Stated Percentage, Quarterly" } } }, "localname": "DebtInstrumentInterestRateStatedPercentageQuarterly", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_DeferredCompensationAndAccountsPayableConvertedToUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of the Company's units into which deferred compensation and accounts payable were converted during the period.", "label": "Deferred Compensation and Accounts Payable Converted to Units, Shares (in shares)" } } }, "localname": "DeferredCompensationAndAccountsPayableConvertedToUnitsShares", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_DeferredCompensationConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of specified trading days during the end of a month for which the share price of common stock during that period will be applied to deferred compensation if converted.", "label": "Deferred Compensation Consecutive Trading Days (Day)" } } }, "localname": "DeferredCompensationConsecutiveTradingDays", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "bnet_DeferredCompensationConvertedToUnitsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of the Company's units into which deferred compensation was converted during the period.", "label": "Deferred Compensation, Converted to Units, Amount" } } }, "localname": "DeferredCompensationConvertedToUnitsAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationConvertibleToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred compensation liability convertible to shares of the entity's common stock as of the balance sheet date.", "label": "Deferred Compensation, Convertible to Common Stock" } } }, "localname": "DeferredCompensationConvertibleToCommonStock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationConvertibleToCommonStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the price per share at which the deferred compensation liability is convertible to shares of the entity's common stock as of the balance sheet date.", "label": "Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationConvertibleToCommonStockPricePerShare", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeferredCompensationLiabilityAmountCancelled": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred compensation liability cancelled during the period.", "label": "Deferred Compensation Liability, Amount Cancelled" } } }, "localname": "DeferredCompensationLiabilityAmountCancelled", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationMaximumConvertibleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of deferred compensation that is deemed to be convertible.", "label": "Deferred Compensation, Maximum Convertible Amount" } } }, "localname": "DeferredCompensationMaximumConvertibleAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The price per share in which an individual can convert their deferred compensation.", "label": "Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationStockConversionPricePerShare", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeferredTaxAssetsBusinessInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business interest.", "label": "Business interest" } } }, "localname": "DeferredTaxAssetsBusinessInterest", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "bnet_DeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deficit:" } } }, "localname": "DeficitAbstract", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "bnet_DescriptionOfKreider2PoultryProject": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of kreider 2 poultry project" } } }, "localname": "DescriptionOfKreider2PoultryProject", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_DisclosureConvertibleNotesPayableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Affiliates" } } }, "localname": "DisclosureConvertibleNotesPayableAffiliatesAbstract", "nsuri": "http://biontech.com/20220630", "xbrltype": "stringItemType" }, "bnet_DisclosureSubscriptionReceivableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscription Receivable - Affiliates" } } }, "localname": "DisclosureSubscriptionReceivableAffiliatesAbstract", "nsuri": "http://biontech.com/20220630", "xbrltype": "stringItemType" }, "bnet_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount": { "auth_ref": [], "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of net operating allowance.", "label": "Expiration of net operating allowances" } } }, "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_EffectiveIncomeTaxRateReconciliationRTPExcessBusinessInterestAmount": { "auth_ref": [], "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to RTP, excess business interest.", "label": "RTP \u2013 Excess Business Interest" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRTPExcessBusinessInterestAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan [Member]" } } }, "localname": "EquityIncentivePlanMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_EquityIssuancesWarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "EquityIssuancesWarrantsPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_ExecutiveViceChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Executive Vice Chairman.", "label": "Executive Vice Chairman [Member]" } } }, "localname": "ExecutiveViceChairmanMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ExerciseBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise bonus" } } }, "localname": "ExerciseBonus", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_ExtensionBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Extension Bonus [Member]" } } }, "localname": "ExtensionBonusMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_FinancingReceivableInterestRateStatedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for financing receivable, under the agreement.", "label": "Financing Receivable, Interest Rate, Stated Percentage" } } }, "localname": "FinancingReceivableInterestRateStatedPercentage", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_FinancingReceivablePrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The principal amount of financing receivable.", "label": "Financing Receivable, Principal Amount" } } }, "localname": "FinancingReceivablePrincipalAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_ForgivenessOfDebt": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "ForgivenessOfDebt", "negatedLabel": "Forgiveness of debt" } } }, "localname": "ForgivenessOfDebt", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ForgivenessOfDebts": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "bnet_OtherExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Forgiveness of debt" } } }, "localname": "ForgivenessOfDebts", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_FormerEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents former employee.", "label": "Former Employee [Member]" } } }, "localname": "FormerEmployeeMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_Fy2016ExtensionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FY2016 Extension Agreement [Member]" } } }, "localname": "Fy2016ExtensionAgreementMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_GainOnLegalDissolutionOfSubsidiary": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "bnet_OtherExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on legal dissolution of subsidiary (Note 5)" } } }, "localname": "GainOnLegalDissolutionOfSubsidiary", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_GainOnLegalDissolutionsOfSubsidiary": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainOnLegalDissolutionsOfSubsidiary", "negatedLabel": "Gain on legal dissolution of subsidiary" } } }, "localname": "GainOnLegalDissolutionsOfSubsidiary", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_GainOnSaleOfDomainAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on sale of domain" } } }, "localname": "GainOnSaleOfDomainAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_GainOnSaleOfDomainAmounts": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "bnet_OtherExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on sale of domain (Note 9)" } } }, "localname": "GainOnSaleOfDomainAmounts", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_ImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less imputed interest" } } }, "localname": "ImputedInterest", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "bnet_IncomeTaxReconciliationPermanentDifferences": { "auth_ref": [], "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Permanent differences and other" } } }, "localname": "IncomeTaxReconciliationPermanentDifferences", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_InterestBearingSecuredPromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest bearing secured promissory note" } } }, "localname": "InterestBearingSecuredPromissoryNote", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestExpenseOnDeferredCompensationObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the obligation accrued for interest expense of deferred compensation.", "label": "Interest Expense on Deferred Compensation Obligation [Member]" } } }, "localname": "InterestExpenseOnDeferredCompensationObligationMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_InterestRateOnDeferredCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the interest rate that is accrued on deferred compensation.", "label": "Interest Rate on Deferred Compensation" } } }, "localname": "InterestRateOnDeferredCompensation", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_LoanPayableAndAccruedInterest": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loan payable and accrued interest (Note 5)" } } }, "localname": "LoanPayableAndAccruedInterest", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bnet_MinorityInterestPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling interests" } } }, "localname": "MinorityInterestPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_MonthlyOfficersCashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents information about monthly officers' cash compensation.", "label": "Monthly Officers' Cash Compensation" } } }, "localname": "MonthlyOfficersCashCompensation", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NetIncomeLossApplicableToBionsCommonStockholdersPerBasicAndDilutedCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "per basic and diluted common share" } } }, "localname": "NetIncomeLossApplicableToBionsCommonStockholdersPerBasicAndDilutedCommonShare", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "bnet_NonAffilatedConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Affilated Consultant [Member]" } } }, "localname": "NonAffilatedConsultantMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_NonCashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non cash compensation" } } }, "localname": "NonCashCompensation", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NoncashCompensationInPropertyAndEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Non-cash compensation in property and equipment" } } }, "localname": "NoncashCompensationInPropertyAndEquipment", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_NorthropMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Northrop [Member]" } } }, "localname": "NorthropMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_NotesReceivableInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Notes receivable interest" } } }, "localname": "NotesReceivableInterest", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_OperatingLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating loss" } } }, "localname": "OperatingLoss", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_OptionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options" } } }, "localname": "OptionsPolicyTextBlock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_OtherExpense": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "OtherExpense", "totalLabel": "Total other expense" } } }, "localname": "OtherExpense", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "bnet_PA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depicts the subsidiary PA-1.", "label": "PA-1 [Member]" } } }, "localname": "PA1Member", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PaymentsOfCommissionsOnExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow of commissions on exercise of warrants.", "label": "Payments of Commissions on Exercise of Warrants" } } }, "localname": "PaymentsOfCommissionsOnExerciseOfWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_PennvestLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the Pennvest Loan.", "label": "Pennvest Loan [Member]" } } }, "localname": "PennvestLoanMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PercentageOfSustainable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of sustainable" } } }, "localname": "PercentageOfSustainable", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_Plan2006Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plan 2006 [Member]" } } }, "localname": "Plan2006Member", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PreferredStockConvertibleOptionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is convertible to an option.", "label": "Preferred Stock, Convertible Option Per Share (in dollars per share)" } } }, "localname": "PreferredStockConvertibleOptionPerShare", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_ProceedsFromAllocatedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from allocated shares" } } }, "localname": "ProceedsFromAllocatedShares", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_ProceedsFromSaleOfUnits": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from sale of units" } } }, "localname": "ProceedsFromSaleOfUnits", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_Project3GMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Project 3 G [Member]" } } }, "localname": "Project3GMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PropertyPlantAndEquipmentOfPA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Property, Plant and Equipment of PA1.", "label": "Property, Plant and Equipment of PA1 [Member]" } } }, "localname": "PropertyPlantAndEquipmentOfPA1Member", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Purchase of property and equipment in accounts payable and accrued expenses" } } }, "localname": "PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_RedemptionOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of convertible Preferred stock" } } }, "localname": "RedemptionOfConvertiblePreferredStock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_RedemptionOfPreferredSeriesBSharesAndInterest": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of Preferred Series B shares and interest" } } }, "localname": "RedemptionOfPreferredSeriesBSharesAndInterest", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_RestrictedAndLegendedSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted And Legended Shares [Member]" } } }, "localname": "RestrictedAndLegendedSharesMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_RibbonwireMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ribbonwire [Member]" } } }, "localname": "RibbonwireMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Right of use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_SaleOfDomainDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of domain, description" } } }, "localname": "SaleOfDomainDescription", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_SaleOfUnitsInExchangeForSalaryAndExpenseSalaryAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents sale of units in exchange for salary and expense, salary amount.", "label": "Sale of Units in Exchange for Salary and Expense, Salary Amount" } } }, "localname": "SaleOfUnitsInExchangeForSalaryAndExpenseSalaryAmount", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_SaleOfUnitsInExchangeForSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about sale of units in exchange for salary.", "label": "Sale of Units in Exchange for Salary [Member]" } } }, "localname": "SaleOfUnitsInExchangeForSalaryMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SaleOfUnitsNumberOfUnitsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of units issued pursuant to a subscription agreement.", "label": "Sale of units (in shares)", "verboseLabel": "Sale of Units, Number Of Units Issued (in shares)" } } }, "localname": "SaleOfUnitsNumberOfUnitsIssued", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_SaleOfUnitsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the equity impact of units issued during the period.", "label": "Sale of units" } } }, "localname": "SaleOfUnitsValue", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_SchaferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schafer [Member]" } } }, "localname": "SchaferMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ScheduleOfFutureMinimumLeasePaymentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Future Minimum Lease Payment" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentTableTextBlock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "bnet_SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information concerning the secured promissory note that was received as consideration toward the Bassani Warrants that expire on December 31, 2025.", "label": "Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]" } } }, "localname": "SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to a secured promissory note.", "label": "Secured Promissory Note [Member]" } } }, "localname": "SecuredPromissoryNoteMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_September2015ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about the September 2015 convertible notes.", "label": "September 2015 Convertible Notes [Member]" } } }, "localname": "September2015ConvertibleNotesMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of change in fair value of share-based payment awards due to modifications in warrants terms.", "label": "Change in fair value from modification of warrant terms" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPlanModificationModificationOfWarrantTerms", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "bnet_SharebasedCompensationGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Granted" } } }, "localname": "SharebasedCompensationGranted", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SharesHeldBySubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares held by subsidiaries.", "label": "Shares Held by Subsidiaries (in shares)", "negatedLabel": "Shares held by subsidiaries (Note 7)" } } }, "localname": "SharesHeldBySubsidiaries", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued \u2013 beginning of period" } } }, "localname": "SharesIssuedBeginningOfPeriod", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedForWarrantExerciseCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for warrant exercise commissions" } } }, "localname": "SharesIssuedForWarrantExerciseCommissions", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_SharesOutstandingBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares outstanding \u2013 beginning of period" } } }, "localname": "SharesOutstandingBeginningOfPeriod", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_SmithMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Smith [Member]" } } }, "localname": "SmithMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SmithsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Smiths [Member]" } } }, "localname": "SmithsMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_StockIssuedDuringPeriodSharesCommissionOnSaleOfUnitsAndWarrantExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period for commissions on sale of units and warrant exercises.", "label": "Stock Issued During Period, Shares, Commission on Sale of Units and Warrant Exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommissionOnSaleOfUnitsAndWarrantExercises", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_StockIssuedDuringPeriodSharesCommissionsOnSaleOfUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commissions on sale of units, shares" } } }, "localname": "StockIssuedDuringPeriodSharesCommissionsOnSaleOfUnits", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the value of stock issued during the period for commissions on sale of units.", "label": "Commissions on sale of units" } } }, "localname": "StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_SubscriptionReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSCRIPTION RECEIVABLE - AFFILIATES" } } }, "localname": "SubscriptionReceivableTextBlock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_SubscriptionsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscriptions Receivable [Member]" } } }, "localname": "SubscriptionsReceivableMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "bnet_TechWastage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tech wastage" } } }, "localname": "TechWastage", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_The2020ConvertibleObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents 2020 Convertible Obligations (formerly January 2015 Convertible Notes) and 2019 Convertible Note.", "label": "The 2020 Convertible Obligations [Member]" } } }, "localname": "The2020ConvertibleObligationsMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ThreeEmployeesAndContractorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Employees And Contractors [Member]" } } }, "localname": "ThreeEmployeesAndContractorsMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_TwoConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to two consultants.", "label": "Two Consultants [Member]" } } }, "localname": "TwoConsultantsMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_TwoNonAffiliatedPurchasersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Non Affiliated Purchasers [Member]" } } }, "localname": "TwoNonAffiliatedPurchasersMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_UndiscountedCashFlow": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Undiscounted cash flow" } } }, "localname": "UndiscountedCashFlow", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "bnet_UnrecognizedTaxPositionsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrecognized tax positions term" } } }, "localname": "UnrecognizedTaxPositionsTerm", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "bnet_UnreimbursedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[custom:UnreimbursedExpenses]" } } }, "localname": "UnreimbursedExpenses", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantExercisedForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant Exercised for Common Stock" } } }, "localname": "WarrantExercisedForCommonStock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExercisedForCommonShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares" } } }, "localname": "WarrantsExercisedForCommonShares", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExercisedForCommonSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares, shares" } } }, "localname": "WarrantsExercisedForCommonSharesShares", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_WarrantsExercisedForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants Exercised for Common Stock" } } }, "localname": "WarrantsExercisedForCommonStock", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information concerning warrants that expire on December 31, 2025.", "label": "Warrants Expiring on December 31, 2025 [Member]" } } }, "localname": "WarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsHeldByTrustOwned": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrants held by trust owned" } } }, "localname": "WarrantsHeldByTrustOwned", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsIssuedForUnitCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants issued for unit commissions" } } }, "localname": "WarrantsIssuedForUnitCommissions", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about warrants issued in connection with sale of units in exchange for salary.", "label": "Warrants Issued in Connection with Sale of Units in Exchange for Salary [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsIssusedSubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrants issued in exchange for promissory notes.", "label": "Warrants Issused, Subscription Receivable [Member]" } } }, "localname": "WarrantsIssusedSubscriptionReceivableMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsRelatedToTheConversionOfDeferredCompensationAndAccountsPayableIntoUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrants related to the conversion of deferred compensation and accounts payable into units.", "label": "Warrants Related to the Conversion of Deferred Compensation and Accounts Payable into Units [Member]" } } }, "localname": "WarrantsRelatedToTheConversionOfDeferredCompensationAndAccountsPayableIntoUnitsMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WeightedAverageExercisePriceForOutstandingWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price for Outstanding Warrants (in dollars per share)" } } }, "localname": "WeightedAverageExercisePriceForOutstandingWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_WeightedAverageNumberOfSharesIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average number of additional shares issued during period.", "label": "Weighted average shares issued \u00a0\u00a0\u00a0\u00a0during the period" } } }, "localname": "WeightedAverageNumberOfSharesIssuedDuringPeriod", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_WeightedAverageRemainingContractualLifeForOutstandingWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life for Outstanding Warrants (Year)" } } }, "localname": "WeightedAverageRemainingContractualLifeForOutstandingWarrants", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "bnet_WeightedAverageRemainingLeaseTermDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term" } } }, "localname": "WeightedAverageRemainingLeaseTermDescription", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_WeightedaverageNumberOfCommonSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedaverageNumberOfCommonSharesOutstandingAbstract", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "bnet_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the capital available for operations for the Company.", "label": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_YearsOneThroughFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents events that will occur during years one through five.", "label": "Years One Through Five [Member]" } } }, "localname": "YearsOneThroughFiveMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_YearsSixThroughMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents events that occur during years six through loan maturity.", "label": "Years Six Through Maturity [Member]" } } }, "localname": "YearsSixThroughMaturityMember", "nsuri": "http://biontech.com/20220630", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r560", "r562", "r563" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r560", "r562", "r563" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r560", "r562", "r563" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r560", "r562", "r563" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief executive officer.", "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r43", "r45", "r91", "r92", "r221", "r261", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r194", "r196", "r197", "r198", "r220", "r260", "r311", "r313", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r532", "r533", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r194", "r196", "r197", "r198", "r220", "r260", "r311", "r313", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r532", "r533", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of president.", "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r186", "r194", "r196", "r197", "r198", "r220", "r260", "r291", "r311", "r313", "r349", "r350", "r351", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r532", "r533", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r186", "r194", "r196", "r197", "r198", "r220", "r260", "r291", "r311", "r313", "r349", "r350", "r351", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r532", "r533", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r44", "r45", "r91", "r92", "r221", "r261" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r104", "r312", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r104", "r108", "r192", "r312" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": { "auth_ref": [ "r94", "r574" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.", "label": "Condensed Financial Statement" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r104", "r108", "r192", "r312", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r155", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r464", "r466", "r469", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Average of a range of values, calculated with consideration of proportional relevance.", "label": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to underwriters, promoters, and employees excluding salaries, wages and amount to related party, classified as current.", "label": "Salaries and wages" } } }, "localname": "AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued interest" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r510", "r529" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued interest" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r12", "r181" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r453" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r96", "r97", "r98", "r359", "r360", "r361", "r421" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r316", "r363", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Vesting of options for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r216", "r274", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r89", "r141", "r144", "r150", "r163", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r401", "r407", "r423", "r451", "r453", "r504", "r522" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r28", "r89", "r163", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r401", "r407", "r423", "r451", "r453" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r344", "r345", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r180" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and structures" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesContingentRentalPaymentsDue": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due based upon the occurrence of an event specified in the contractual terms.", "label": "Total" } } }, "localname": "CapitalLeasesContingentRentalPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalRequiredForCapitalAdequacy": { "auth_ref": [ "r518", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework.", "label": "Capital Required for Capital Adequacy" } } }, "localname": "CapitalRequiredForCapitalAdequacy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r10", "r453", "r539", "r540" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r68", "r75", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of year", "periodStartLabel": "Cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r68", "r424" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r10" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r18", "r19", "r20", "r86", "r89", "r112", "r113", "r118", "r121", "r122", "r127", "r128", "r129", "r163", "r204", "r208", "r209", "r210", "r213", "r214", "r258", "r259", "r263", "r267", "r274", "r423", "r565" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r283", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercisable per share", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding (in shares)", "verboseLabel": "Issaunce of warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r188", "r189", "r190", "r199", "r542" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r96", "r97", "r421" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "auth_ref": [ "r20" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription receivable from investors who have been allocated common stock.", "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "negatedLabel": "Subscription receivable - affiliates (Note 8)" } } }, "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r453" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, no par value, 250,000,000 and 100,000,000 shares authorized respectively, 43,758,820 and 41,315,986 shares issued, respectively; 43,054,511 and 40,611,677 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r132", "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r82", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r180" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "3G project construction in process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionLoan": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.", "label": "Construction Loan" } } }, "localname": "ConstructionLoan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r215", "r217", "r218", "r220", "r230", "r231", "r232", "r236", "r237", "r238", "r239", "r240", "r247", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r37" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable - affiliates (Note 6)", "verboseLabel": "Convertible Notes Payable, Noncurrent" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r16", "r507", "r524", "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Cost in excess" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsIncurredDevelopmentCosts": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.", "label": "Capitalized amount" } } }, "localname": "CostsIncurredDevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r78", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt instrument paid amount", "verboseLabel": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt Instrument, Debt Default, Amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r85", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r234", "r241", "r242", "r244", "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "LOANS PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r88", "r94", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r230", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r247", "r248", "r249", "r250", "r436", "r505", "r507", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r219", "r245" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Original conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r36", "r237", "r434" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r36", "r218" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r37", "r88", "r94", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r230", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r247", "r248", "r249", "r250", "r436" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r37", "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Principal, interest", "verboseLabel": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r288", "r290" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation (Note 4)", "terseLabel": "Deferred Compensation Liability, Current", "verboseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r384", "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "NOL carryforwards (Federal and State)" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Impairment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r384", "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "verboseLabel": "Deferred compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r384", "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "verboseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits and other assets" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r73", "r179" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r73", "r179" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgesLiabilities": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.", "label": "Derivative financial instruments" } } }, "localname": "DerivativeInstrumentsAndHedgesLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r93", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r319", "r320", "r354", "r355", "r357", "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "DEFERRED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": { "auth_ref": [ "r2", "r3", "r4", "r392" ], "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation", "totalLabel": "Income tax expense (benefit)" } } }, "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r15", "r17", "r506", "r523" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r282", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Income (loss) per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r372", "r390" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Share-based Payment Arrangement, Expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r96", "r97", "r98", "r100", "r105", "r107", "r126", "r164", "r274", "r282", "r359", "r360", "r361", "r387", "r388", "r421", "r425", "r426", "r427", "r428", "r429", "r430", "r446", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r165", "r166", "r167", "r168", "r170", "r171", "r172", "r173", "r174", "r243", "r272", "r419", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r565", "r566", "r567", "r568", "r569", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnSecuritizationOfFinancialAssets": { "auth_ref": [ "r55", "r56", "r73", "r460", "r511", "r531" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A gain (loss) realized on a transfer, accounted for as a sale, of all or a portion of financial assets in which the transferor surrenders control and receives consideration other than a beneficial interest in the assets transferred. Reflects the amount of sales proceeds in excess of, or deficient from, the sum of the carrying amounts of transferred financial assets plus transaction costs.", "label": "Realized from the asset sale", "verboseLabel": "Gain (Loss) on Securitization of Financial Assets" } } }, "localname": "GainLossOnSecuritizationOfFinancialAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r73", "r251", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on legal dissolution of subsidiary" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative (including stock-based compensation (Note 7))" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Patents" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r73", "r178", "r183" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r59", "r74", "r101", "r102", "r103", "r104", "r119", "r122", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Net income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r184", "r187" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r90", "r373", "r376", "r382", "r389", "r391", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Accrued interest and penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r48", "r370", "r371", "r376", "r377", "r381", "r386" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r372" ], "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r372" ], "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Expected income tax expense (benefit) at statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r372" ], "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (decrease) in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase in deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r72", "r441" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Decrease in operating lease assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r72" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Decrease (increase) in prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r433" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Capitalized interest", "verboseLabel": "Capitalized amount" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r52", "r140", "r432", "r435", "r513" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "bnet_OtherExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense", "terseLabel": "Interest expenses", "verboseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r61", "r238", "r246", "r249", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r58" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "bnet_OtherExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r66", "r69", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r442", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lease Accounting" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r89", "r145", "r163", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r402", "r407", "r408", "r423", "r451", "r452" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r89", "r163", "r423", "r453", "r509", "r527" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r35", "r89", "r163", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r402", "r407", "r408", "r423", "r451", "r452", "r453" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r14", "r505" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Loans as a liability", "verboseLabel": "Line of Credit, Current" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermConstructionLoanCurrent": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.", "label": "Loan related to construction" } } }, "localname": "LongTermConstructionLoanCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r94", "r202", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r94", "r202", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r94", "r202", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r37", "r203" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r191", "r193", "r194", "r195", "r196", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r180" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r42", "r89", "r163", "r204", "r208", "r209", "r210", "r213", "r214", "r423", "r508", "r526" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r71", "r74" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r46", "r47", "r51", "r53", "r74", "r89", "r99", "r101", "r102", "r103", "r104", "r106", "r107", "r119", "r141", "r143", "r146", "r149", "r151", "r163", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r422", "r423", "r512", "r530" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r46", "r47", "r51", "r106", "r107", "r405", "r410" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to the noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r101", "r102", "r103", "r104", "r109", "r110", "r120", "r122", "r141", "r143", "r146", "r149", "r151" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss) applicable to Bion's common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r111", "r114", "r115", "r116", "r117", "r120", "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r96", "r97", "r98", "r282", "r397" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r156", "r169" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss, Total" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r141", "r143", "r146", "r149", "r151" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r440" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r439" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears": { "auth_ref": [ "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the fourth year from the balance sheet date under an operating lease.", "label": "Year ended June 30, 2025" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears": { "auth_ref": [ "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the third year from the balance sheet date under an operating lease.", "label": "Year ended June 30, 2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears": { "auth_ref": [ "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the second year from the balance sheet date under an operating lease.", "label": "Year ended June 30, 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r41", "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Additional paid amount" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "localname": "OtherExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r74" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Accrued interest on loans payable, deferred compensation and other" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Commissions paid", "verboseLabel": "Commissions" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r291", "r293", "r294", "r296", "r298", "r299", "r300", "r301", "r302", "r307", "r308", "r309", "r310", "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "401(k) PLAN" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/KPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r344", "r345", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r344", "r345", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r86", "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred stock, liquidation" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r258" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "verboseLabel": "Par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r257", "r275", "r277" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred Stock, Redemption Price Per Share (in dollars per share)" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19", "r258" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)", "verboseLabel": "Preferred stock shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)", "verboseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r26", "r175", "r176" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r64" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common shares", "verboseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r64" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r46", "r47", "r51", "r67", "r89", "r99", "r106", "r107", "r141", "r143", "r146", "r149", "r151", "r163", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r400", "r404", "r406", "r410", "r411", "r422", "r423", "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r185", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r11", "r180" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r182", "r453", "r515", "r528" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net (Note 3)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r182", "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r297", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r297", "r447", "r448", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r297", "r447", "r450", "r491", "r492", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r366", "r489", "r548" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development (including stock-based compensation (Note 7))" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r282", "r453", "r525", "r537", "r538" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r96", "r97", "r98", "r100", "r105", "r107", "r164", "r359", "r360", "r361", "r387", "r388", "r421", "r534", "r536" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r138", "r139", "r142", "r147", "r148", "r152", "r153", "r154", "r285", "r286", "r490" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary paid" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of Stock, Consideration Received Per Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Number of shares sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of anti dilutive securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Fair value of options assumptions" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule Of Cash Flow Supplemental Disclosure" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r287", "r289" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r303", "r304", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of non vested stock options" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r315", "r317", "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r344", "r345", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r324", "r340", "r343" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r18", "r19", "r20", "r86", "r127", "r128", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r263", "r267", "r272", "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r18", "r19", "r274" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r18", "r19", "r274" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r18", "r19", "r274" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Cash compensation paid" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Expiry date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Stock options, authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Expired, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Number of shares expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Forfeited, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Granted", "verboseLabel": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, options (in shares)", "verboseLabel": "Share-based Compensation, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Granted, weighted-average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding, aggregate intrinsic value ending", "periodStartLabel": "Outstanding, aggregate intrinsic value beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, ending (in shares)", "periodStartLabel": "Options outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, ending weighted-average exercise price", "periodStartLabel": "Options outstanding, beginning weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Change in fair value from modification of option terms", "verboseLabel": "Share-based Payment Arrangement, Plan Modification, Incremental Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r320", "r321", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r344", "r345", "r348", "r349", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquity-FinancialStatementsDetails", "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r323", "r346", "r347", "r348", "r349", "r352", "r362", "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Nonvested, weighted-average grant-date fair value, ending", "periodStartLabel": "Nonvested options, beginning (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Fair value of stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "negatedLabel": "Vested, weighted-average grant-date fair value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-NonvestedShareActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Granted, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Number of shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r81", "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r18", "r19", "r20", "r86", "r89", "r112", "r113", "r118", "r121", "r122", "r127", "r128", "r129", "r163", "r204", "r208", "r209", "r210", "r213", "r214", "r258", "r259", "r263", "r267", "r274", "r423", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r39", "r49", "r50", "r51", "r96", "r97", "r98", "r100", "r105", "r107", "r126", "r164", "r274", "r282", "r359", "r360", "r361", "r387", "r388", "r421", "r425", "r426", "r427", "r428", "r429", "r430", "r446", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r96", "r97", "r98", "r126", "r490" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r38", "r235", "r274", "r275", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of debt and liabilities, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of units for services, shares", "terseLabel": "Stock Issued During Period, Shares, Issued for Services", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r274", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Sale of common shares, shares", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r274", "r282" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r274", "r282", "r330" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised, options (in shares)", "verboseLabel": "Number of shares exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionsActivityDetails", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r39", "r274", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of debt and liabilities" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of units for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r274", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Sale of common shares", "verboseLabel": "Total proceeds" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r39", "r274", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r23", "r24", "r89", "r157", "r163", "r423", "r453" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "negatedLabel": "(error)", "totalLabel": "Total Bion's stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r50", "r89", "r96", "r97", "r98", "r100", "r105", "r163", "r164", "r282", "r359", "r360", "r361", "r387", "r388", "r397", "r398", "r409", "r421", "r423", "r425", "r426", "r430", "r446", "r535", "r536" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r87", "r259", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r282", "r284", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r431", "r455" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r431", "r455" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r431", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r431", "r455" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r454", "r457" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r243", "r272", "r419", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r565", "r566", "r567", "r568", "r569", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r369", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r130", "r131", "r133", "r134", "r135", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r122" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Basic and diluted weighted average shares \u2013 \u00a0\u00a0\u00a0\u00a0end of period" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r457": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62014-109447" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958570-112826" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r549": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r550": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r551": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r552": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r553": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r554": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r555": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r556": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r557": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r558": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r559": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r560": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r561": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r562": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r563": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r564": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r565": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r566": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r567": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r569": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r572": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r573": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r574": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r575": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r576": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r577": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r578": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868742-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 67 0001079973-22-001171-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-22-001171-xbrl.zip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�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�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end